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Abstract 
 
The transporter hypothesis has been postulated to explain pharmacoresistance in 
epilepsy.  Despite over a decade of research surrounding the drug transporter 
hypothesis, the role that solute carrier (SLC) transporters might play in this theory 
remains largely unaddressed.  Hence, the major focus of this thesis was to investigate 
and identify SLC transporter systems of interest that are expressed at the blood-brain 
barrier (BBB) and to determine which, if any, of commonly prescribed antiepileptic 
drugs (AEDs) are substrates for such transporter systems. 
   
Characterisation of AED transport was undertaken using widely reported model systems 
such as Xenopus laevis oocytes and the human cerebral microvascular endothelial cell 
line (hCMEC/D3), together with novel stably-transfected MDCK II cell lines. Organic 
anion transporter 1A2 (OATP1A2), the monocarboxylate transporter (MCT) family and 
the organic anion transporter (OAT) family were specifically selected for investigation.  
Valproic acid and gabapentin showed the greatest evidence for SLC-mediated transport 
by OAT1/OAT3 and MCT1 respectively, while other compounds were largely 
unremarkable in this respect.  Valproic acid transport increased OAT1 overexpressing 
cells compared to control but decreased in OAT3 overexpressing cells. Gabapentin 
uptake increased in MCT1 transfected Xenopus laevis oocytes and was shown to 
decrease in hCMEC/D3 cells in the presence of a panel of MCT inhibitors.   
    
The induction/suppression of expression of SLC transporters by AEDs was explored in 
the hCMEC/D3 cell line, in an attempt to understand how AEDs might influence the 
functionality of endogenous transport pathways.  A number of AEDs were observed to 
induce/suppress expression of transporter genes involved in transport and detoxification 
 
A further study explored the fundamental physiochemical properties of AEDs, which is 
relevant to their penetration into the brain.  A number of AEDs, including lamotrigine, 
gabapentin and topiramate, observe adequate uptake in the hCMEC/D3 model of the 
BBB despite having physiochemical properties, such as a high polar surface area and 
negative log D value which may limit passive entry into the brain.  This would suggest 
that a carrier mediated system may be involved in the uptake of these drugs into the 
brain.   
 
The work described in this thesis has shown that a number of AEDs may be subject to 
carrier mediated uptake into the brain.  Individual differences in transporter expression 
at the BBB may be responsible for variability in brain concentrations of AEDs. 
However, at present, this does not provide us with an adequate explanation for why 
some people with epilepsy experience pharmacoresistant seizures. 
 
1 
 
 
 
 
 
 
Chapter 1 
 
 
 
General Introduction 
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1.1. Epilepsy epidemiology 
Epilepsy is the most common brain disorder in the world; currently the World Health 
Organisation estimates epilepsy to affect 50 million people worldwide with  people in 
developing countries accounting for 80% of this figure (WHO, 2012). In the UK, 
412,000 people are registered as having epilepsy, a prevalence of 6.2 per 1000 
individuals (Booth et al., 2010). Epilepsy refers not to a distinct disorder but to a 
collection of syndromes characterised by a predisposition to unprovoked seizures 
(Dreifuss et al., 1981) - ‘transient occurrences of signs and/or symptoms due to 
abnormal excessive or synchronous neuronal activity in the brain’ (Fisher et al., 2005). 
Epilepsy syndromes fall into two broad categories: generalised or partial epilepsies, 
which can be classified based on clinical seizure type, electroencephalography (EEG) 
findings and the presence/absence of neurological or developmental abnormalities 
(Dreifuss et al., 1981; Cundy et al., 2004). Classification can also be made based on the 
epilepsy aetiology, recently three distinct causative factors for developing epilepsy have 
been advised: ‘genetic’, where the epilepsy is the direct result of a genetic  defect, 
‘structural/metabolic’, where another distinct metabolic/ structural disease has been 
demonstrated to substantially increase the risk of developing epilepsy, and ‘unknown,’ 
where the underlying cause of the epilepsy is currently unknown (Enerson et al., 2003).   
 
Although thought to have affected people since humans’ early evolution, the first 
descriptive reports of epilepsy date to ancient Mesopotamia around 2000 B.C. 
(Anonymous, 2003). In 400 B.C. the ancient Greek physician Hippocrates was the first 
to characterise epilepsy as a disease that needed treatment with diet and drugs not as a 
divine ‘possession’ or ‘choosing,’ contrary to popular belief (Temkin, 1945). In the late 
17th century scientific understanding of epilepsy began to advance, culminating in the 
19th century with John Hughlings Jackson’s first attempts to characterise the 
pathophysiology of epilepsy, the first use of therapeutics in the treatment of epilepsy, 
and the birth of modern neurology (Wang et al., 2006; Morris et al., 2008).   
 
 
 
 
 
 
3 
 
1.2. Treatment of epilepsy 
The first reasonable therapeutic treatment of epilepsy began in the mid-1800s when Sir 
Charles Locock reported that he had been able to cure ‘hysterical epilepsy’ in women 
with potassium bromide (Markovich, 2008). Thereafter, potassium bromide was used 
regularly for catamenial as well as other types of epilepsy and by the early 1900s was 
the mainstay of epilepsy treatment. The discovery of potassium bromide brought about 
new understanding that epilepsy could be well controlled with drugs.  In 1912, Alfred 
Hauptmann serendipitously observed that the then marketed hypnotic, phenobarbital 
(PB) possessed antiepileptic properties (Hauptmann, 1912). The use of PB as an 
anticonvulsant was not rapidly taken up internationally and was only first used in the 
UK and United States in the early 1920s, but by the 1940s PB  had become the mainstay 
of treatment throughout the world and today is still the most commonly prescribed 
antiepileptic drug (AED) in the developing world  (Kwan et al., 2004; Shorvon, 2009a).  
 
The next milestone in the treatment of epilepsy was the development of sodium 
diphenylhydantoinate (phenytoin (PHT)) by  Merritt and Putnam in 1937 (Merritt et al., 
1938a; Merritt et al., 1938b).  Their aim was to develop a less sedative anticonvulsant 
than PB and by testing non-sedative phenyl compounds using a cat model of electrically 
induced seizures discovered PHT.  PHT was sufficiently non-toxic for routine 
administration and could elicit greater protection from electrically induced seizures than 
bromide or PB without causing sedation.  The cat electroshock model was the first 
attempt of screening AEDs in a model of epilepsy and the first to accurately predict 
efficacy in humans,  transforming the  future development of antiepileptic agents 
(Pedley, 2009).  The next significant development was that of carbamazepine (CBZ) in 
the 1960s. First developed as a drug for the treatment of depression and later licenced as 
an anticonvulsant, CBZ was the first AED to be licenced on a strong evidence base 
from both animal and clinical trial data. The advent of CBZ represented a shift in how 
AEDs were developed, moving away from academia with the rise and domination of the 
pharmaceutical industry. CBZ continues to be the most prescribed AED in Europe 
(Schindler et al., 1954; Blom, 1962). 
 
Around the same time period the serendipitous discovery of sodium valproate (VPA) 
was published by a group at the small pharmaceutical company, La Laboratoire 
(Meunier et al., 1963).  The group were testing a range of compounds for a 
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tranquillising action in a rat model using VPA as the chosen solvent. Surprisingly all 
compounds tested were observed to elicit antiepileptic effects and VPA was subjected 
to testing as an AED alone. VPA showed considerable efficacy in both animal models 
and human clinical trials and was ultimately licenced in 1967. Together with CBZ, VPA 
continues to be one of the two most commonly prescribed AEDs in the developed world 
(Meunier et al., 1963; Shorvon, 2009b). 
 
By the 1970s, the modern era of AED discovery had begun. Mainly owing to the 
establishment of the Anticonvulsant Drug Development program in the United States, 
huge efforts were put into high throughput target orientated design of compounds, 
largely based around the discovery of ɣ-aminobutyric acid (GABA) as the major 
inhibitory neurotransmitter in the central nervous system (CNS). An extensive list of 
AEDs was successfully developed as a result of the Anticonvulsant Drug Development 
program, which undoubtedly improved epilepsy treatment. Of note is the development 
of lamotrigine (LTG), gabapentin (GBP), topiramate (TPM) and levetiracetam (LEV), 
which along with CBZ and VPA comprise the most commonly prescribed AEDs at 
present (Lamb et al., 1985; UK Gabapentin Study Group, 1990; Shorvon, 2009b; 
Brodie, 2010). Today, antiepileptic agents form the mainstay of epilepsy therapy; 
however in certain individuals neurosurgery to resect epileptic foci can be 
advantageous. In addition, the ketogenic diet can be a powerful tool in some 
individuals, for example those who are known to have a mutation in the high affinity 
glucose transporter 1 (GLUT1) (Leen et al., 2010). 
   
1.3 Pharmacology of commonly prescribed AEDs 
1.3.1  Phenytoin 
Although PHT is one of the drugs of choice for the treatment of epilepsy in the 
developing world and is still commonly used in the United States, its use in Europe has 
declined due to an extensive adverse effects profile and non-linear pharmacokinetics 
(Elger et al., 2008). The antiepileptic activity of PHT is thought to occur through 
binding to voltage-gated sodium channels and prolonging their inactivation (figure 1.1).  
At higher concentrations PHT is also suggested to inhibit axonal and nerve terminal 
calcium channels (Macdonald, 1999).  Oral absorption rates of PHT differ according to 
the formulation used, with capsule formulations possessing  approximately 90% 
bioavailability (Neurvonen, 1979). In plasma, PHT is 90% protein bound and less than 
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5% is excreted in the urine unchanged.  Consequently, the majority of PHT is 
metabolised, largely in the liver by cytochrome P450 2C9 (CYP2C9) oxidation (90%) 
but also by CYP2C19 oxidation (10%).  CYP2C9 dependent metabolism of PHT is 
saturable, which largely explains its non-linear pharmacokinetics. PHT is an enzyme 
inducer and is known to induce metabolising enzymes including its own major 
metabolising enzyme CYP2C9 and CYP3A4, which mediates the metabolism of many 
drugs (Brodie et al., 1996a).  As a result of its variable absorption and the strong 
association between serum level and seizure control, therapeutic drug monitoring of 
PHT is advised (Kutt et al., 1964; Eadie, 2009).   
 
1.3.2 Carbamazepine 
CBZ is used clinically as a first line or adjunctive therapy for partial and generalised 
tonic-clonic seizures, exerting its effects through the inhibition of voltage gated sodium 
channels (figure 1.1) similarly to PHT (Kuo, 1998). CBZ is orally administrated and 
titrated over a period of a few weeks until a maintenance dose of around 600mg/day is 
reached, although this varies according to inter-individual variation in kinetics and 
whether other CYP450 inhibitors/inducers are prescribed (Brodie et al., 1996a). 
Absorption of orally administered CBZ is relatively slow and variable, reflected in a 
half life of around 15-35 hours depending on the degree of auto-induction and a 
bioavailability of 75-85%. CBZ is moderately protein bound (75-80%) and undergoes 
extensive, mainly CYP3A4 mediated oxidative metabolism in the liver to an epoxide 
metabolite (carbamazepine 10-11, epoxide). As a result, only negligible amounts of 
CBZ are excreted unchanged in the urine (Morselli, 1995; Sillanpää et al., 2009).  The 
main issues of CBZ use surround its ability to induce the metabolism of co-administered 
drugs, resulting in a large number of drug-drug interactions and adverse hypersensitivity 
reactions associated with CBZ in predisposed individuals (Tomson et al., 1989; Brodie, 
1992).   
 
1.3.3 Sodium valproate 
VPA is a broad spectrum AED with activity against different seizures types including 
almost all primary generalised seizures and remains a first line treatment in idiopathic 
generalised epilepsies (Anonymous, 1988).  Its mechanism of action is controversial 
and likely multi-faceted, however it is agreed that VPA acts upon voltage-gated sodium 
channels and increases GABA concentrations in the brain (figure 1.1), albeit through 
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mechanisms that are not fully understood (Löscher, 2002).  VPA is usually prescribed at 
a starting dose of 500mg once or twice daily and increased according to individual 
response (Brodie et al., 1996a).  VPA is rapidly absorbed within 0.5-8 hours depending 
on how it is formulated; is not subject to extensive first pass metabolism and 
consequently has almost complete bioavailability. VPA is substantially (up to 90%) 
protein bound, which at therapeutic concentrations can become saturated  and is 
eliminated almost entirely by hepatic metabolism (Franke et al., 1995).  
Biotransformation is mediated by several pathways including uridine 5'-diphospho-
glucuronosyltransferase (UGT) mediated glucuronidation (UGT1A3, UGT2B7) and 
CYP450 (CYP2C9, CYP2C19, CYP2B6) mediated oxidation (Anari et al., 2000). VPA 
clearance can be affected by enzyme inducers such as PHT and CBZ due to its 
extensive CYP450 mediated metabolism. It is also a potent metabolic inhibitor itself 
and so readily inhibits the metabolism of many drugs, including the glucuronidation of 
LTG, markedly reducing LTG elimination (Kanner et al., 2000; Patsalos, 2005).  
Although VPA is possibly the most efficacious of all AEDs, its use is restricted by its 
teratogenic effects with increased rates of neural tube defects reported in the offspring 
of women receiving VPA treatment during pregnancy (Samrén et al., 1997).   
 
1.3.4 Lamotrigine 
LTG is a 2nd generation AED used clinically as monotherapy or as adjunctive therapy in 
the treatment of partial seizures and in some generalized epilepsy syndromes (Brodie et 
al., 1996b). LTG exerts its antiepileptic action by the blockade of voltage activated 
sodium and possibly calcium channels (Leach et al., 1986; figure 1.1). LTG is more 
than 95% bioavailable following oral administration and is rapidly absorbed into the 
blood in 1-3 hours. LTG is moderately (55%) bound to plasma proteins and undergoes 
extensive metabolism in the liver via N-glucuronidation, predominantly by UGT1A4. 
Around 80-90% of a LTG dose is excreted as the glucuronide metabolite via the urine 
(Cohen et al., 1987; Matsuo et al., 2009).   
 
1.3.5 Gabapentin 
GBP is currently licensed as a second line drug for the treatment of partial seizures in 
both adults and children, usually as an add-on therapy (UK Gabapentin Study Group, 
1990; Anhut et al., 1994). Structurally GBP is very similar to GABA suggesting an 
agonistic mechanism of action to increase GABA transmission; however its 
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antiepileptic effect is largely mediated by the blockade of voltage gated calcium 
channels (figure 1.1), although this is not thoroughly understood (Sills, 2006). GBP is 
rapidly absorbed and reaches peak plasma concentrations 2-3 hours after administration. 
However, in contrast with other AEDs, GBP has a bioavailability of less than 65% 
which is further reduced with increased dose, suggesting a saturable absorption process 
from the gut (Cundy et al., 2004). In the plasma, GBP is found in its free drug form, 
shows no protein binding and is not subject to metabolism in the liver; GBP is excreted 
entirely unchanged in the urine with an elimination half-life of 5-9 hours (Brodie et al., 
1996b; Somerville et al., 2009).   
 
1.3.6 Topiramate 
The antiepileptic action of TPM is multi-faceted, involving several pathways including 
the inhibition of kainate evoked currents, enhancement of GABA signalling, blockade 
of voltage gated sodium and calcium channels (figure 1.1) and inhibition of carbonic 
anhydrase, although the latter is now thought to occur independently of TPM’s 
antiepileptic action (Brodie et al., 1996b).  Partly due to its multiple pharmacological 
actions and as a result of its relative success in the treatment of various seizure types, 
TPM is classified as a broad spectrum AED and is approved for use in the treatment of 
Lennox-Gastaut syndrome in addition to various generalised and partial seizures 
(Bourgeois, 2000). As with many AEDs, TPM is almost 100% bioavailable and is 
absorbed rapidly reaching peak plasma levels within 2-4 hours. TPM is mainly excreted 
unchanged in the urine (60-70%), however a small percentage is subject to oxidative 
metabolism by microsomal cytochrome P450 (CYP450) enzymes. CYP450 metabolism 
of TPM can be induced to the extent that it accounts for up to 40% of elimination when 
TPM is co-administered with enzyme inducing drugs such as PHT and CBZ (Cross et 
al., 2009).   
 
1.3.7 Levetiracetam 
LEV is a pyrrolidone compound related to the cognitive enhancer piracetam (Genton et 
al., 2000) and is unusual in the respect that it was developed using non-classical animal 
models of seizures. As a result, LEV has no activity in classical seizure models 
(Rogawski et al., 1990), though it has a broad and efficacious mechanism of action 
unlike any other AED.  Although LEV weakly reduces voltage activated calcium 
currents and potentiates GABA signalling, its major antiepileptic effects arise from a 
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unique mechanism involving inhibition of neurotransmitter release from nerve terminals 
via binding to the synaptic vesicle protein SVA2 (figure 1.1), which is involved in 
neurotransmitter exocytosis (Patsalos, 2005). LEV is a first line therapy in the treatment 
of partial seizures, however as a result of its unique mechanism of action, LEV is 
becoming known as a broad spectrum AED (Stephen et al., 2011). LEV is rapidly 
absorbed and almost 100% orally bioavailable, reaching peak plasma concentrations in 
0.5-2 hours. LEV plasma protein binding is minimal (less than 10%) and most is 
excreted unchanged in the urine (66%). The remainder is subject to metabolism, mostly 
by hydrolysis to a carboxylic acid metabolite (24%) but also by oxidation (Splinter, 
2005; French et al., 2009).   
 
1.4 AED resistance and the transporter hypothesis 
Although AED therapy successfully controls seizures in the majority of people with 
epilepsy, up to 30% of people with epilepsy are not adequately controlled with AEDs 
and are classified as pharmacoresistant, i.e. they experience seizures which are resistant 
to AED action.  Drug resistant epilepsy is defined as: ‘failure of adequate trials of two 
tolerated and appropriately chosen and used AED schedules (whether as monotherapies 
or in combination) to achieve sustained seizure freedom’ (Kwan et al., 2010). The 
majority of observed drug resistance occurs relatively soon after diagnosis in early 
treatment and any further attempt to control seizures with drug treatment is usually 
futile.  This suggests the mechanism by which individuals become resistant is de novo, 
does not develop over time, and is not associated with prolonged therapy (Kwan et al., 
2000).  Although the causative biological mechanism of drug resistance in epilepsy is 
likely to be multifactorial, a number of hypotheses have been postulated over the last 
decade aiming to elucidate plausible causes of resistance. 
 
1.4.1 The target hypothesis 
The target hypothesis proposes a pharmacodynamic explanation for drug resistant 
epilepsy - that functional alterations in the cellular targets of AEDs lead to a reduced 
sensitivity to treatment. The main evidence directly supporting this hypothesis is that 
alterations in common AED targets such as changes in expression of the subunits which 
comprise voltage-gated sodium/calcium channels and GABAA receptors are observed in 
both animal models and human temporal lobe epilepsy (TLE) (Remy et al., 2003). 
However, association between observed changes in AED targets and sensitivity to 
9 
 
AEDs has thus far not been observed in vivo.  The main argument against this 
hypothesis is that a complete understanding of the molecular action of most AEDs is 
lacking but is likely to result from concerted efficacy at multiple targets. Given that 
people with drug resistant epilepsy are, by definition, resistant to multiple AEDs, the 
target hypothesis would only be plausible if the sensitivity of all of those targets to 
modulation by AEDs was impaired equally (Margineanu et al., 2009). 
 
1.4.2 The transporter hypothesis 
The arguments against the target hypothesis point towards a pharmacokinetic 
explanation of resistance which takes into account the heterogeneous nature of drug 
resistant epilepsy. The transporter hypothesis postulates that over-expression of drug 
efflux transporters on cerebral microvascular endothelial cells which contribute to the 
integrity of  the blood-brain barrier may reduce AED accumulation in the brain, 
preventing therapeutically active concentrations of AEDs from reaching their targets in 
the brain. The evidence supporting this hypothesis focuses on one drug efflux 
transporter in particular: P-glycoprotein (P-gp). P-gp has been shown to be 
overexpressed in cerebral microvascular endothelial cells from epileptic brain tissue 
resected from people with pharmacoresistant epilepsy and in rodent seizure models, 
particularly in those animals with drug resistant seizures (Tishler et al.; Sisodiya et al., 
2002; Volk et al., 2005). Several AEDs, including PHT, CBZ, LTG and GBP, have also 
been suggested to be substrates for multidrug transporters, further supporting the 
transporter hypothesis (Sills et al., 2002; Löscher et al., 2005b; Luna-Toetos et al., 
2008).  However, not all AEDs are substrates for multidrug transporters and of the 
AEDs implicated as substrates for P-gp none have consistently been shown to be 
transported to a significant extent. Moreover, conflicting evidence exists which suggests 
P-gp mediates very weak transport of AEDs at best (Owen et al., 2001; Sills et al., 
2002; Dickens et al., 2013). 
 
 
 
 
 
 
10 
 
 
Figure 1.1: Common molecular targets of AEDs used in this project. Adapted from (Bialer et al., 2010).      
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1.4.3 Alternative hypotheses 
The target and transporter hypotheses of drug resistant epilepsy are both the longest 
standing and most researched hypotheses attempting to explain drug resistant epilepsy. 
However, more recently several alternative hypotheses have been postulated. One 
hypothesis that has recently been postulated is that seizures are a manifestation of 
impaired mitochondrial energy production in the epileptogenic zone.  There is a 
significant correlation between lower bienergetic state in the epileptogenic i.e. impaired 
mitochondrial function and thus energy production and higher extracellular glutamate.  
High extracellular glutamate is linked with increased hyperexcitability hence there is a 
close relationship between metabolic dysfunction and hyperexcitability (Waldbaum et 
al., 2010; Yuen et al., 2011). One line of evidence supporting this hypothesis is that in 
many individuals with drug resistant epilepsy, the ketogenic diet is effective in reducing 
seizures (Masino et al., 2012). Experimentally, the positive effects of the ketogenic diet 
have been associated with up-regulation of mitochondrial genes and increased 
mitochondrial biogenesis (DeVivo et al., 1978).  Therefore increased cerebral 
mitochondrial function and thus energy may result in increased neuronal stability and 
seizure control.  However, the proponents of this hypothesis acknowledge that it is the 
interplay of mitochondrial energy production along with the ictogenic potential of the 
epileptic focus and efficacy of AEDs that determine the likelihood of a seizure 
occurring (Yuen et al., 2011).  
 
Another hypothesis recently postulated is the epigenetic hypothesis which proposes that 
drug resistance may result from epilepsy associated epigenetic alterations (Kobow et al., 
2013). This is based on the observation that the expression of many of the genes 
involved in processes such as inflammation, synaptic plasticity and synaptic 
transmission, which share common regulatory mechanisms such as histone tail 
modifications and DNA methylation are altered long term following seizures.  
However, the mechanisms of epigenetic alterations are still poorly understood  (Kobow 
et al., 2013).  One final hypothesis that is beginning to receive attention is the intrinsic 
severity hypothesis (Rogawski, 2013). Rather than trying to explain resistance by 
dependent cellular mechanisms, the intrinsic severity hypothesis simply suggests that 
pharmacoresistance is an inherent property of the epilepsy and results from factors 
relating to the underlying aetiology of the disease – the more severe the epilepsy, the 
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more likely it is to be resistant (Rogawski, 2013).  It should be borne in mind that these 
hypotheses, whether target, transporter or more recent alternatives, are not mutually 
exclusive. They are all potentially involved in the phenomenon of drug resistant 
epilepsy and two or more may be at play at any given time in any given patient who 
does not respond to AED therapy.  
 
1.5 The blood-brain barrier 
For any neurotherapeutic agent to reach its molecular target in the brain and exert its 
pharmacological effects, it must first penetrate a specialised, protective barrier which 
lines almost all cerebral microvessels, otherwise known as the blood-brain barrier 
(BBB; figure 1.2). The blood-brain barrier compromises a monolayer of endothelial 
cells, specialised in their barrier function due to the presence of elaborate junctional 
complexes (zonulae occludentes) that eliminate gaps between neighbouring cells and 
prevent toxins and blood-borne substances from penetrating the brain via paracellular 
diffusion (Abbott et al., 1996; Abbott et al., 2010). These junctional complexes between 
endothelial cells include tight junctions and adherens junctions.  Adherens junctions 
consist of cadherin proteins spanning the intercellular cleft and are linked to the cell 
cytoplasm by scaffolding proteins such as catenin. These scaffolding proteins link to the 
actin cytoskeleton of neighbouring cells and tether endothelial cells together to give 
structural support (Abbott et al., 2010).  Adherens junctions are critical for the 
formation of tight junctions, tight junctions consist of occludins and claudins which also 
span the intercellular cleft and along with junctional adhesion molecules (JAMs) 
connect adjacent endothelial cells.  JAMs also link to a number of cytoplasmic 
scaffolding and regulatory proteins, such as zonula occludens and cingulin, which link 
the junctional complex to the actin cytoskeleton and initiate signalling between 
neighbouring cells (Abbott et al., 2010).    
 
However, the BBB is not simply a protective barrier. It also serves as a dynamic 
interface interacting with CNS cells such as pericytes, astrocytes and microglia to form 
the neurovascular unit (Cardoso et al., 2010). Within the neurovascular unit, the BBB is 
crucial for homeostasis of the CNS and contributes to the control of molecular traffic to 
preserve neuronal connectivity, the maintenance of ion concentrations for optimal 
signalling, and immune surveillance to minimise inflammation and cell damage 
(Redzic, 2011; Benarroch, 2012). 
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Transporter Alias 
Cellular location (if 
known) 
ABCB1 MDR1/P-glycoprotein Apical 
ABCG2 Breast cancer resistance protein (BCRP) Apical 
ABCC1 Multidrug resistance protein 1 (MRP1) Apical and basolateral 
ABCC2 Multidrug resistance protein 2 (MRP2)  
ABCC3 Multidrug resistance protein 3 (MRP3)  
ABCC4 Multidrug resistance protein 4 (MRP4) Apical 
ABCC5 Multidrug resistance protein 5 (MRP5) Apical 
ABCC6 Multidrug resistance protein 6 (MRP6)  
SLCO1A2 Organic anion transporting polypeptide 1A2 (OATP1A2) Apical 
SLCO1A4 Organic anion transporting polypeptide 1A4 (OATP1A4) Basolateral 
SLCO1C1 Organic anion transporting polypeptide 1C1 (OATP1C1)  
SLCO2B1 Organic anion transporting polypeptide 2B1 (OATP2B1) Apical 
SLC22A1 Organic cation transporter 1 (OCT1) Apical 
SLC22A2 Organic cation transporter 2 (OCT2) Apical 
SLC22A3 Organic cation transporter 3 (OCT3)  
SLC22A5 Organic carnitine transporter 2 (OCTN2) Apical 
SLC22A6 Organic anion transporter 1 (OAT1)  
SLC22A7 Organic anion transporter 2 (OAT2) Apical 
SLC22A8 Organic anion transporter 3 (OAT3)  
SLC47A1 Multidrug and toxin extrusion pump 1 (MATE1)  
SLC16A1 Monocarboxylic acid transporter 1 (MCT1) Apical and basolateral 
SLC16A7 Monocarboxylic acid transporter 2 (MCT2) Basolateral 
SLC16A3 Monocarboxylic acid transporter 4 (MCT4)  
SLC16A2 Monocarboxylic acid transporter 8 (MCT8) Apical and basolateral 
SLC28A1 Nucleoside transporter CNT1 Basolateral 
SLC28A2 Concentrative nucleoside transporter 2 (CNT2)  
SLC28A3 Concentrative nucleoside transporter 3 (CNT3)  
SLC29A1 Equilibrative nucleoside transporter 1 (ENT1) Apical 
SLC29A2 Equilibrative nucleoside transporter 2 (ENT2)  
SLC29A4 Equilibrative Nucleoside Transporter 4 (PMAT/ENT4) Basolateral 
SLC2A13 Facilitated glucose transporter 13 (GLUT13)  
SLC5A1 Sodium/glucose co-transporter 1 (SGLT1) Basolateral 
SLC5A3 Sodium myoinositol co-transporter (SMIT) Apical 
SlC7A1 Cationic L-amino acid transporter 1 (CAT1) Apical 
SlC7A3 Cationic L-amino acid transporter 2 (CAT2)  
SLC7A5 L type acid transporter 1 (LAT1) Apical and basolateral 
SLC7A6 Y+L type amino acid transporter 2 (LAT2) Apical and basolateral 
SLC38A2 System N amino acid transporter 2 (SNAT2) Basolateral 
SLC38A3 System N amino acid transporter 3 (SNAT3) Basolateral 
SLC28A5 System N amino acid transporter 5 (SNAT5)  
SLC1A3 Excitatory amino acid transporter 1 (EAAT1) Basolateral 
SLC1A2 Excitatory amino acid transporter 2 (EAAT2)  
SLC1A1 Excitatory amino acid transporter 3 (EAAT3)  
SLC1A4 Glutamate/neutral amino acid transporter 4 (ASCT1) Basolateral 
SLC1A5 Neutral amino acid transporter 5 (ASCT2)  
 High affinity aspartate/glutamate transporter 6 (EEAT4) Apical 
SLC6A9 Glycine/neurotransmitter transporter 9 (GLYT1) Apical 
SLC6A6 Neurotransmitter transporter 6 (TAUT) Apical and basolateral 
SLC44A1 Choline transporter 1 (CTL1) Apical 
 
Table 1.1: Transporters which have been shown to be functional at the blood-brain 
barrier, adapted from (Abbott et al., 2010; Stieger et al., 2015).  In addition a number of 
transporters not included have been shown to be expressed at gene and/or protein level 
in isolated brain microvessels (Shawahna et al., 2011; Geier et al., 2013).   
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One characteristic of the BBB that aids in its homeostasis role is the expression of 
transporter proteins. These proteins function to actively transport nutrients into the CNS 
and to restrict toxins from entering (Urquhart et al., 2009). The distribution of 
transporter proteins at the BBB is polarized and expression is usually either apical or 
basolateral, depending on the particular function of the transporter protein (table 1.1). 
Efflux transporters are largely expressed on the basolateral surface of the BBB due to 
their role in pumping toxins out of the brain into the blood,  thus preventing chemical 
insult (Abbott, 2013). Influx transporters mainly function to supply the brain with 
nutrients and macromolecules which otherwise could not penetrate the BBB (Pardridge, 
1986) and thus are largely expressed at the apical surface (Abbott, 2013). In addition to 
their homeostasis role, transporter proteins expressed at the BBB are known to transport 
a variety of chemically diverse drugs and have been shown to impact on CNS 
accumulation of substrate drugs (König et al., 2013). 
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Figure 1.2: The blood brain barrier, adapted from (Abbott et al., 2010).  
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1.6 The ABC superfamily of transporters 
The ATP-binding cassette (ABC) superfamily of transporter proteins includes 49 
membrane bound proteins divided into seven families, designated ABC A to G (table 
1.2). ABC transporters share a common mechanism, utilising energy by hydrolysing 
ATP to translocate a broad range of molecules including vitamins, ions, peptides and 
xenobiotics across the plasma membrane and are specifically identified by the presence 
of a highly conserved ATP-binding cassette of 200-250 amino acids (Dallas et al., 
2006). Generally, the structure of ABC transporters consists of two linked functional 
units, each containing an ATP binding cassette and a 12-transmembrane domain 
complex (Stanley et al., 2009).  
 
1.6.1 The ABCB subfamily 
The ABCB subfamily contains the most comprehensively researched ABC transporter 
protein, multidrug resistance protein 1 (MDR1), more commonly known as P-gp. 
Although P-gp is commonly reported as the gene product of the ABCB1 gene, it is also 
encoded by the ABCB4 gene (van der Bliek et al., 1988). P-gp is ubiquitously expressed 
at the apical membrane of epithelial and endothelial cells, including those at the BBB. 
The highest expression of P-gp is found in tissues with an excretory function, such as 
the liver, kidneys and gastrointestinal tract (Klaassen et al., 2010).  P-gp was the first 
drug transporter to be discovered after it was shown to be over- expressed in CHO cells 
resistant to colchicine and various cytotoxic chemotherapy drugs (Juliano et al., 1976).  
Since its discovery as a drug transporter, P-gp has been shown to efflux a range of 
chemically diverse amphipathic drugs. As a result, it impacts on the bioavailability and 
accumulation of substrate drugs at target organs and therefore has been associated with 
drug resistance (de Lange, 2004). 
 
The transport of AEDs by P-gp has been extensively investigated however such 
investigation has reported conflicting findings with in vitro studies returning largely 
negative data while in vivo investigations have returned largely positive or inconclusive 
data.  In rodent models of epilepsy P-gp has been shown to contribute to 
pharmacoresistance.  Increased cerebral endothelial cell expression of P-gp is observed 
at the seizure focus of  pharmacoresistant rats compared to pharmacosensitive rats  and 
increased P-gp expression is associated with decreased brain concentrations of AEDs 
that are P-gp substrates (Potschka et al., 2001; Potschka et al., 2002; Sills et al., 2002; 
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Volk et al., 2005; van Vliet et al., 2007).  Furthermore, seizures transiently increase P-
gp expression at the BBB (Bankstahl et al., 2008) and inhibition of P-gp has been 
shown to enhance efficacy of AEDs (Brandt et al., 2006).  Conversely investigation into 
AED transport by P-gp using in vitro models including models of the BBB and cell 
lines overexpressing P-gp has produced almost exclusively negative results (Crowe et 
al., 2006; Dickens et al., 2013).  In human epilepsy tissue, P-gp expression is increased 
at the BBB in people with pharmacoresistant epilepsy, both in epileptogenic tissues 
removed in resection surgery (Tishler et al., 1995; Sisodiya et al., 2002; Aronica et al., 
2003) and post mortem (Liu et al., 2012).  Recently new technology utilising in-vivo 
PET imaging with the P-gp substrate (R)-[¹¹C] verapamil has provided direct in vivo 
evidence that there is over-activity of P-gp at the epileptic focus of patients with 
pharmacoresistant TLE, as compared with seizure free patients with TLE.  Furthermore 
such over-activity is associated with increased seizure frequency (Feldmann et al., 
2013).  Other efflux transporters have received some attention but similarly have 
returned ambiguous findings (Potschka et al., 2001; Cerveny et al., 2006). 
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Table 1.2: Currently identified ATP-binding cassette (ABC) transporter genes, 
according to the HUGO gene nomenclature committee http://www.genenames.org/. 
 
 
 
ABC 
family 
Subfamily members Protein product 
ABCA ABCA1 
ABCA2 
ABCA3 
ABCA4 
ABCA5 
ABCA6 
ABCA7 
ABCA8 
ABCA9 
ABCA10 
ABCA11 
ABCA12 
ABCA13 
 
ABCB ABCB1 
ABCB2 
ABCB3 
ABCB4 
ABCB5 
ABCB6 
ABCB7 
ABCB8 
ABCB9 
ABCB10 
ABCB11 
Multidrug resistance protein 1(MDR1) 
Transporter associated with antigen processing 1 (TAP1) 
Transporter associated with antigen processing 2 (TAP2) 
Multidrug resistance protein 3 (MDR3) 
 
 
 
 
 
 
ABCC ABCC1 
ABCC2 
ABCC3 
ABCC4 
ABCC5 
ABCC6 
ABCC7 
ABCC8 
ABCC9 
ABCC10 
ABCC11 
ABCC12 
Multidrug resistance associated protein 1 (MRP1) 
Multidrug resistance associated protein 2 (MRP2) 
Multidrug resistance associated protein 3 (MRP3) 
Multidrug resistance associated protein 4 (MRP4) 
Multidrug resistance associated protein 5 (MRP5) 
Multidrug resistance associated protein 6 (MRP6) 
Cystic fibrosis transmembrane conductance regulator (CFTR) 
Sulfonylurea receptor 1 (SUR) 
Sulfonylurea receptor 2 (SUR2) 
Multidrug resistance associated protein 7 (MRP7) 
Multidrug resistance associated protein 8 (MRP8) 
ABCD ABCD1 
ABCD2 
ABCD3 
ABCD4 
 
ABCE ABCE1  
ABCF ABCF1 
ABCF2 
ABCF3 
 
ABCG ABCG1 
ABCG2 
ABCG4 
ABCG5 
ABCG8 
 
Breast cancer resistance protein (BCRP) 
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1.6.2 The ABCC subfamily  
The ABCC sub-family encodes the multidrug resistance associated proteins (MRPs). 
The MRPs function endogenously to transport organic anions and are described as 
multidrug resistance transporters due to their associated resistance to many 
chemotherapy agents. The human ABCC family has 12 members, including the cystic 
fibrosis transmembrane conductance regulator (CFTR) encoded by ABCC7, the 
sulfonylurea receptors (SURs) encoded by ABCC8 and ABCC9, and ten transporter 
proteins known as the MRPs, six of which have been fully characterised and shown to 
transport drugs (Toyoda et al., 2008). MRPs are known to mediate the active efflux of 
many anionic drugs such as methotrexate, although MRP1, MRP2 and MRP3 have also 
been shown to transport neutral organic compounds (Löscher et al., 2005a). Homology 
between MRP isoforms varies, with MRP1, MRP2, MRP3 and MRP6 sharing around 
50% homology and accordingly possessing very similar substrate specificities. In 
contrast, MRP4 and MRP5 share less than 40% amino acid sequence homology with 
other isoforms due to their smaller size and lack of one transmembrane and N-terminal 
domain (Borst et al., 2000). As with all major efflux transporters, expression of MRPs 
is largely limited to blood-tissue barriers and organs with excretory functions such as 
the liver and kidneys. However, MRP3 and MRP4 are also expressed in tissues such as 
the pancreas, bladder, reproductive organs and gut, while MRP1 and MRP5 are 
ubiquitously expressed (Szakács et al., 2008). 
 
1.6.3 The ABCG subfamily 
The most widely known product of the ABCG gene family is breast cancer resistance 
protein (BCRP), which is encoded by the ABCG2 gene. In addition to P-gp and the 
MRP series of ABC transporters, BCRP has been widely implicated in multiple drug 
resistance. BCRP is a 70kDa protein which, like P-gp and MRP1, was discovered in cell 
lines resistant to chemotherapy drugs (Qian et al., 2013). At present, BCRP is known to 
actively extrude a wide variety of therapeutics including antivirals, chemotherapeutic 
drugs and antibacterials (Estudante et al., 2013). However, its role in the transport of 
AEDs is unclear with previous research finding no evidence of BCRP-mediated 
extrusion of the AEDs, including Primidone (PRM), PB, PHT, CBZ, LTG, clonazepam 
(CZP), ethosuximide (ESM) and VPA, in a stably transfected MDCK cell line (Cerveny 
et al., 2006). 
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1.7 The solute carrier superfamily  
The solute carrier (SLC) superfamily of transporters move molecules at around 102 – 
104 s-1 and include symporters, antiporters and passive transporters. The human SLC 
superfamily consists of 55 gene families (table 1.3) which comprise at least 362 
putatively functional genes whose protein products are predominantly transmembrane 
transporters (He et al., 2009).  Each protein within a single SLC family is thought to 
share around 20-25% amino acid sequence identity. Several significant families exist, 
including the organic cation transporters (OCTs), organic cation/carnitine transporters 
(OCTNs), organic anion transporters (OATs), organic anion transporting polypeptides 
(OATPs) and nutrient transporters including monocarboxylate transporters (MCTs), 
high affinity glucose transporters (GLUTs) and a variety of amino acid transporters.  In 
addition multiple less well-characterised transporters such as peptide transporters, 
nucleoside transporters, neurotransmitter transporters and bicarbonate transporters are 
known (Klaassen et al., 2010). 
 
1.7.1 Organic anion transporting polypeptides  
OATPs are members of the SLCO gene family of SLC transporters, of which there are 
11 known transporter proteins. Members of the same family of OATP transporter have 
around 40% amino acid sequence identity, with a total of six families described e.g. 
OATP1, OATP2, OATP3, OATP4, OATP5 and OATP6 (table 1.4). Members of the 
same sub-family, e.g. OAPT1A, OATP1B, share 60% amino acid homology 
(Hagenbuch et al., 2004).  Structurally, OATPs consist of 12 transmembrane domains, 
with a large extracellular domain containing conserved cysteine residues between 
transmembrane segments 9 and 10 and N-glycosylation sites in extracellular loops two 
and five  (Hagenbuch et al., 2004).  OATP orthologues vary in length from 643 amino 
acids (OATP2A1) to 848 amino acids (OATP5A1) and mediate the sodium-independent 
transport of various amphipathic organic compounds, particularly those with high 
molecular weight and high albumin binding (Kullak-Ublick et al., 2001; Tirona et al., 
2001; Mikkaichi et al., 2004; Huber et al., 2007; Hagenbuch et al., 2008). These include 
bile salts, steroid conjugates, drugs and other xenobiotics that are transported on an 
anion exchange based mechanism, coupling the cellular uptake of organic compounds 
with the efflux of anions such as bicarbonate (Hagenbuch et al., 2003). Although a 
collection of OATP transporters are involved solely in hepatic clearance, most OATPs 
are ubiquitous and found in various tissues such as the BBB, choroid plexus, lung, 
heart, kidney, intestine, testis and placenta (Kalliokoski et al., 2009) (table 1.4). 
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Gene Family Endogenous transport function 
SLC1 Glutamate and amino acid transporters 
SLC2 Facilitated glucose/fructose transporters 
SLC3 Heavy chain amino acid transporters 
SLC4 Sodium bicarbonate/ anion exchangers 
SLC5 Sodium coupled sugar/vitamin/ monocarboxylate transporters 
SLC6 Neurotransmitter/ neutral amino acid transporters 
SLC7 Amino acid transporters 
SLC8 Sodium/calcium transporters 
SLC9 Proton linked cation antiporters 
SLC10 Sodium-bile co-transporters 
SLC11 Divalent metal ion transporters 
SLC12 Sodium/chloride/sulphate/ transporters 
SLC13 Sodium dependent dicarboxylate/citrate transporters 
SLC14 Urea transporters 
SLC15 Oligopeptide transporters 
SLC16 Monocarboxylate transporters 
SLC17 Vesicular glutamate/nucleotide transporters 
SLC18 Vesicular acetylcholine/ monoamine transporters 
SLC19 Folate/thiamine transporters 
SLC20 Phosphate transporters 
SLC22 Organic cation/anion transporters 
SLC23 Ascorbic acid transporters 
SLC24 Sodium/potassium/calcium exchangers 
SLC25 Mitochondrial carriers 
SLC26 Anion exchangers 
SLC27 Fatty acid transporters 
SLC28 Concentrative nucleoside transporters 
SLC29 Equililbrative nucleoside transporters 
SLC30 Zinc transporters 
SLC31 Copper transporters 
SLC32 Vesicular GABA transporters 
SLC33 Acetyl-CoA transporters 
SLC34 Sodium/phosphate transporters 
SLC36 Nucleotide/sugar transporters 
SLC37 Proton linked amino acid symporters 
SLC38 Unknown 
SLC39 Zinc transporters 
SLC40 Iron regulated transporters 
SLC41 Magnesium transporters 
SLC43 L-amino acid transporters 
SLC44 Choline transporters 
SLC45 Unknown 
SLC46 Folate transporters 
SLC47 Multidrug and toxin extrusion pumps 
SLC48 Heme transporters 
SLC50 Sugar efflux transporters 
SLC52 Riboflavin transporters 
SLCO Organic anion transporters 
 
Table 1.3: A comprehensive list of known SLC families approved by the HUGO gene 
nomenclature committee: http://www.genenames.org/. 
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Table 1.4: Classification of OATP family members on the basis of tissue distribution 
and substrate and inhibitor specificity.  Substrates and inhibitors included are for 
illustrative purposes only and do not reflect the full repertoire of known OATP 
substrates/inhibitors (Fujiwara et al., 2001; Hagenbuch et al., 2004; Lee et al., 2004; 
Kusuhara et al., 2005; Kalliokoski et al., 2009; Westholm et al., 2009; Giacomini et al., 
2010; Roth et al., 2012).  
 
 
 
 
 
 
 
 
Expression 
Endogenous 
substrates 
Substrate drugs Inhibitors 
OATP1A 
 
Ubiquitous  Estrone-3-sulphate/ 
bile salts/steroid 
conjugates 
prostaglandin E2/  
Beta-blockers/ 
celiprolol/fexofenadine/ 
levofloxacin/ 
methotrexate/ quinidine/ 
protease inhibitors/ 
erythromycin/ imatinib 
Naringin/ 
narringenin/ 
ritonavir/ 
lopinavir/ 
saquinavir/ 
rifampicin 
OATP1B 
 
Hepatocytes Estrone-3-sulphate/  
thyroxine (T4)/ 
triidothyronine (T3) 
Benzyl 
penicillin/statins/fluoresce
in/methotrexate/ 
olmesartan/saquinavir 
 
Ritonavir/ 
cyclosporine/ 
rifampicin/ 
lopinavir 
OATP1C BBB/choroid 
plexus/ ciliary 
body epithelium 
thyroxine (T4)/ 
triidothyronine (T3) 
Bromosulfophthalein Phenytoin/ 
fenamic acid/ 
diclofenac 
OATP2A Ubiquitous  Prostaglandin 
E1/E2/H2 other 
eicosanoids 
Unknown Unknown 
 
OATP2B Liver/placenta/ 
heart/ciliary body 
Estrone-3-sulphate/ 
prostaglandin E2/ 
thyroxine(T4) 
Statins/ benzyl penicillin/ 
bosentan/fenofenadine/ 
talinolol 
Rifampicin/ 
cyclosporine 
 
OATP3A Ubiquitous Prostaglandin E1/ 
prostaglandin 
E2/thyroxine 
OATP3A1_v1 only: 
estrone-3-sulphate 
OATP3A1_v2 
arachidonic acid 
Vasopressin 
OATP3A1_V1 only: 
benzyl penicillin 
deltorphin 
 
Unknown 
 
OATP4A Ubiquitous Triiodothyronine T3/ 
prostaglandin E2/ 
estrone-3-sulfate  
Benzyl penicillin p-aminohippuric 
acid   
OATP4C Kidney Thyroxine (T4)/ 
triiodothyronine (T3)/ 
estrone-3-sulphate/ 
cAMP 
Digoxin/methotrexate/ 
ouabain/ sitagliptin/ 
Unknown 
 
OATP5A Uncharacterised Unknown Unknown Unknown 
OATP6A Testis, spleen, 
brain, foetal brain, 
placenta 
Unknown Unknown Unknown 
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1.7.2 Organic anion transporters  
The OATs are a group of proteins belonging to a distinct and significant family of SLC 
transporters encoded by the SLC22A genes. OATs are membrane proteins, 542-553 
amino acids in length and are predicted to have 12 transmembrane domains arranged in 
two sets of six helices with two large loop structures expected between transmembrane 
domains 1 and 2 and 6 and 7 (Cha et al., 2000; Klaassen et al., 2010; Riedmaier et al., 
2012). OATs function via a sodium-independent dicarboxylic acid exchange, whereby 
organic anions are pumped into the cell  in exchange for dicarboxylate ions against a 
chemical and electrical gradient, thereby forcing anions into an already negative 
intracellular environment (Sekine et al., 2000; VanWert et al., 2010). The substrate 
specificity of OATs is incredibly diverse and includes important pharmacological 
agents, steroid hormones and their metabolites, biogenic amine metabolites, 
environmental contaminants, and toxins (VanWert et al., 2010).  Currently, 12 OAT 
isoforms have been identified of which 7 have human variants and 4 of which have been 
extensively investigated as drug transporters (Giacomini et al., 2010). Each of these is 
described briefly below. 
 
OAT1, encoded by the SLC22A6 gene, is predominantly expressed in the kidney 
proximal tubule and to a lesser extent in the placenta and brain (Giacomini et al., 2010; 
VanWert et al., 2010). OAT1 is known to mediate the high affinity transport of 
prostaglandins E2 and F2α, in addition to several acidic neurotransmitter metabolites 
and the second messenger cyclic guanosine monophosphate (cGMP) (Burckhardt et al., 
2011). Functional studies using expression systems such as Xenopus laevis oocytes, 
Chinese hamster ovary (CHO) cells, Drosophila melanogaster, and human embryonic 
kidney (HEK) cells have all been successful in characterising drug substrates and 
inhibitors of OAT1 (VanWert et al., 2010), as outlined in table 1.5.   
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Table 1.5: Substrates and inhibitors of the organic anion transporter 1 (OAT; adapted 
from (Burckhardt et al., 2011)).  + transported/inhibits, - not transported/inhibited, +/- 
transport/inhibition disputed.   
Drug Substrate Inhibitor  Drug Substrate Inhibitor 
Angiotensin II 
receptor blockers 
   Antibiotics   
Candesartan  +  Benzyl penicillin  +/- +/- 
Losartan  +  Cefaclor  + 
Olmesartan + +  Cefadroxil   + 
Pratosartan  +  Cefamandol   + 
Telmisartan  +  Cefazolin - + 
Valsartan  +  Cefdinir  + + 
Diuretics    Cefoperazone   + 
Bumetanide + +/-  Cefoselis - + 
Chlorothiazide   +  Cefotaxime   + 
Cyclothiazide  +  Cefotiam - + 
Ethacrynate   +  Ceftibuten  + + 
Furosemide + +  Ceftizoxime  + + 
Hydrochlorothiazide   +/-  Ceftriaxone   + 
Methazolamide   +  Cephalexin    
Torasemide   +  Cephaloridine  + + 
Trichlormethiaz  +  Cephalothin    
Statins/fibrates    Cephradine   + 
Atorvastatin  -  Cinoxacin  + 
Bezafibrate   +  Ciprofloxacin - - 
Fluvastatin   +  Doxycyclin  + 
Pravastatin - +/-  Erythromycin   
Rosuvastatin - -  Gentamycin   
Simvastatin  +  Grepofloxacin  - 
Antivirals    Levofloxacin - - 
Acyclovir  + +  Minocyclin   + 
Adefovir  + +  Nalidixate   + 
Cidofovir  + +  Oxytetracycline   + 
Ganciclovir  + +  Tetracycline + + 
Tenofovir  +   NSAIDs   
Zalcitabine  + +  Acetaminophen   + 
Zidovudine + +  Acetylsalicylate - + 
Antidiabetics    Antipyrine   + 
Metformin -   Diclofenac   + 
Sitagliptin - -  Diflusinal   + 
H2 antagonists/PPI’s    Etodolac   + 
Cimetidine  + +  Flufenamate   + 
Famotidine - -  Flurbiprofen   + 
Omeprazole   +  Ibuprofen  +/- + 
Ranitidine +   Indomethacin  + + 
Other    Ketoprofen  +/- + 
Valproate  +  Loxoprofen   + 
Allopurinol  +  Mefenamate   + 
Benzbromarone  +  Naproxen   + 
Probenecid  +  Phenacetin   + 
Fenofenadine -   Phenylbutazone   + 
ACE Inhibitors    Piroxicam   + 
Captopril + +  Salicylic acid + + 
Quinaprilat +   Sulindac  + 
Antineoplastics    Tolmetin  + 
Azathioprine  -  Immunosuppressant’s  + 
Imatinib -   Cyclosporin A  - 
6-Mercaptopurine     Mycophenolate - + 
Methotrexate +/- -  Tacrolimus  - 
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OAT2, encoded by the  SLC22A7 gene, is the only OAT transporter which has 
ubiquitous expression and is highly abundant in most tissues (Cropp et al., 2008). Like 
OAT1, OAT2 also mediates the transport of endogenous prostaglandins, transporting 
prostaglandin E2 at a higher affinity than OAT1 (Sekine et al., 2000). In addition, 
OAT2 is thought to transport endogenous nucleobases, nucleosides, and nucleotides, 
particularly guanine analogues and cyclic nucleotides, most prominently cGMP (Cropp 
et al., 2008). The drug substrate profile of OAT2 is somewhat similar in chemical 
diversity to OAT1, however at present the number of known substrates is significantly 
less (Cropp et al., 2008; VanWert et al., 2010; Burckhardt et al., 2011).   
 
OAT3, encoded by the SLC22A8 gene, possesses a very similar substrate-inhibitor 
profile to OAT1 (Giacomini et al., 2010; VanWert et al., 2010) but has much lower 
affinity for substrate drugs (Anzai et al., 2006).  However, OAT3 mediates the transport 
of endogenous prostaglandins at the highest affinity of all OAT transporters and 
additionally transports cGMP, cAMP, cortisol and bile salts (Burckhardt et al., 2011). 
OAT3 is expressed in the proximal tubule of the kidney and is thought to be expressed 
in the brain both at the choroid plexus and BBB (Rizwan et al., 2007; Giacomini et al., 
2010).   
 
OAT4 is the only OAT isoform specific to humans and has been reported to be 
expressed in the kidneys, adrenal gland and placenta only  (Rizwan et al., 2007). 
Endogenous transport functions include the high affinity transport of estrone and its 
derivatives, prostaglandins E2 and F2α and urate. OAT4 exhibits a similar but less 
extensive drug substrate profile to other OATs discussed (Anzai et al., 2006; VanWert 
et al., 2010; Burckhardt et al., 2011).   
 
1.7.3 Organic cation transporters  
Like OATs, OCTs belong to the SLC22A gene family. OCTs are responsible for the 
transport of both endogenous and exogenous cations, which are positively charged at 
physiological pH. Due to the heterogeneous nature of substrates transported by OCTs, 
they are classified as polyspecific and have been shown to transport cations 
electrogenically using a Na+ independent mechanism (Ciarimboli, 2008). Three human 
isoforms of OCT exist, OCT1, OCT2 and OCT3, ranging from 550 to 560 amino acids 
in length. These proteins share similar membrane topology, consisting of 12 
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transmembrane domains, intracellular C- and N-termini, a large glycosylated 
extracellular loop between transmembrane domains 1 and 2 and a large intracellular 
loop with phosphorylation sites between transmembrane domains 6 and 7 (Choi et al., 
2008). Despite structural similarities and overlapping substrate specificities, tissue 
expression of the different OCT isoforms is relatively distinct (Ciarimboli, 2008). 
 
OCT1, encoded by the SLC22A1 gene, is a protein of 553 amino acids in length that is 
largely expressed in hepatocytes and intestinal enterocytes but has also been detected in 
placenta, on the apical membrane of ciliated epithelial cells in the lung, and most 
recently on the apical membrane of brain microvascular endothelial cells (Ciarimboli, 
2008; Giacomini et al., 2010). OCT1 has been shown to transport substrates such as 
tetraethylammonium, N-methylpyridinium, oxaliplatin and metformin, and is inhibited 
by compounds such as quinine, quinidine and verapamil (Giacomini et al., 2010). Most 
significantly with regard to epilepsy, OCT1 has recently been shown to mediate the 
high affinity transport of LTG in an in vitro BBB model and in a stably transfected 
OCT1 cell line (Dickens et al., 2012).     
OCT2, encoded by the SLC22A2 gene, is two amino acids longer than OCT1, has 
broader tissue expression than its orthologue and has been shown to be expressed in 
proximal tubule cells of the kidney and has also been detected in the spleen, placenta, 
small intestine and brain (Ciarimboli, 2008; Giacomini et al., 2010). Substrates of 
OCT2 include dopamine, N-methylpyridinium, tetraethylammonium, metformin, 
pindolol, procainamide, ranitidine, amantadine, amiloride, oxaliplatin, varenicline, 
cisplatin and lamivudine. Transport of these substrates by OCT2 can be inhibited by 
cimetidine, quinidine, testosterone and pilsicainide (Giacomini et al., 2010). 
 
OCT3, encoded by the SLC22A3 gene, is a 556 amino acid protein that has a wide tissue 
distribution, including the brain, placenta, heart, skeletal muscle, blood vessels and liver 
(Choi et al., 2008).  Although OCT3 is the most widespread OCT protein, it has been 
shown to transport a smaller number of substrates than OCT1 and OCT2. These include 
atropine, dopamine, epinephrine and tetraethylammonium (Klaassen et al., 2010). 
OCT3 mediated transport of these substances is inhibited by several steroids, and most 
potently by β-estradiol (Wu et al., 1998). 
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OCTN1 and OCTN2, encoded by the genes SLC22A4 and SLC22A5 respectively, 
comprise a subfamily of organic carnitine/cation transporters with approximately 30% 
homology to classical OCT proteins. The OCTNs are so called because of their 
predominant endogenous function, which is to transport carnitine for use in fatty acid 
oxidation (Koepsell et al., 2007). OCTN1 and OCTN2 are 551 and 557 amino acids in 
length respectively and, like many other members of the SLC superfamily, are predicted 
to have 12 transmembrane domains. OCTN1 and OCTN2 are ubiquitously expressed, 
with strongest expression in the kidney (Dresser et al., 2000). OCTNs have a similar but 
less extensive substrate specificity to OCT1 and OCT2, but exhibit a much lower 
affinity for these substrates (Koepsell et al., 2007). 
 
In addition to the OCTs discussed above, there are two additional cation-specific 
transporters within the SLC transporter superfamily known as the multidrug and toxic 
compound extrusion (MATE) proteins. These proteins, MATE1 and MATE2, are 
encoded by the SLC47A1 and SLC47A2 genes respectively. The resulting proteins, 
which are 570 and 602 amino acids in length respectively, share around 50% sequence 
homology and consist of 13 transmembrane helices (Zhang et al.; Komatsu et al., 2011). 
MATE transporters are unusual in comparison to other SLC family members by the fact 
that they function physiologically as efflux rather than influx transporters. However, 
depending on cellular pH, MATEs can also function as influx transporters, with a more 
acidic pH increasing MATE mediated extrusion of substrate drugs and a more alkaline 
pH promoting MATE mediated uptake (Müller et al., 2013).  As their name suggests 
MATE transporters are involved in the elimination of toxins and xenobiotics from the 
body, thus they are primarily found in the excretory organs: liver and kidney where they 
work in concert with OCTs to provide an elimination pathway for organic cations 
(Ciarimboli, 2008). Nevertheless, expression has also been observed in the CNS 
(Koepsell et al., 2007).  MATEs are known to mediate the transport of over 40 
clinically relevant cationic drugs such as metformin, cisplatin and captopril in a cation-
proton antiport system, with the extrusion of cations enhanced by an opposing (influx) 
gradient of protons (Staud et al., 2013).  
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1.7.4 Monocarboxylic acid transporters  
The MCT family currently contains 14 identified member genes, 7 of which encode 
functional transporters and 7 of which encode orphan proteins with no known transport 
role (table 1.6).  All MCTs are predicted to have 12 conserved transmembrane domains, 
with intracellular C- and N-termini, and a large cytosolic loop between transmembrane 
segments 6 and 7 (Halestrap et al., 2004; Halestrap, 2013). MCT1 to MCT4, which are 
encoded by SLC16A1, SLC16A7, SLC16A8 and SLC16A4  respectively, have been well 
characterised experimentally and shown to transport important monocarboxylic fuels 
such as lactate, pyruvate and ketone bodies in a proton linked mechanism (Halestrap et 
al., 1990). More recently, MCT8 (encoded by SLC16A2) and MCT10 (encoded by 
SLC16A10) have been shown to mediate the high affinity transport of thyroid hormones 
and aromatic amino acids, respectively. Interestingly transport by these isoforms is 
thought to be facilitative rather than proton or sodium linked as with other family 
members (Friesema et al., 2003; Heuer et al., 2009).  
 
1.7.5 Other SLC families of significance 
The GLUT family is a group of 13 SLC transporter proteins that are responsible for the 
facilitated transport of hexoses into mammalian cells down an electrochemical gradient 
(Joost et al., 2001).  All members of the GLUT family share a common 12 
transmembrane helical structure, with both carboxyl and amino terminals located at the 
cytosolic face and a unique N-linked oligosaccharide side-chain present in either the 
first or forth extracellular loop (Joost et al., 2001). Of particular interest is GLUT1, 
which is encoded by the SLC2A1 gene.  GLUT1 is found in almost every tissue in the 
body reflecting its role as the predominant facilitator of glucose transport into cells. Cell 
and tissue specific expression of GLUT1 is thus related to the rate of cellular glucose 
metabolism.  For example, high expression is observed at the BBB due to the brain 
using glucose as its predominant energy source (Uldry et al., 2004). A genetic 
deficiency in cerebral GLUT1-mediated can result in an infantile epileptic 
encephalopathy, amongst other CNS complications. A less severe GLUT-1 deficient 
phenotype has been associated with sporadic epilepsies (Byrne et al., 2011; Mullen et 
al., 2011). 
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Alias Gene 
name 
Tissue distribution 
(high-low) 
Endogenous 
substrates 
 
Substrate 
drugs 
 
Inhibitory 
drugs 
MCT1 SLC16A1 Ubiquitous (except 
pancreatic β cells) 
Lactate 
Pyruvate 
Ketone bodies 
Salicylic 
acid 
XP13512 
Salicylic 
acid 
XP13512 
MCT2 SLC16A7 Testis, spleen, heart, 
kidney, pancreas, 
skeletal muscle, 
brain, leucocytes 
Pyruvate 
Lactate 
Ketone bodies 
 
GHB 
MCT3 SLC16A8 Retina, choroid 
plexus 
Lactate 
  
MCT4 SLC16A3 Skeletal muscle, 
chondrocytes, 
leucocytes, testis, 
lung, ovary, placenta, 
heart, brain 
Lactate  
Ketone bodies 
 
Fluvastatin 
Atorvastatin 
Lovastatin 
Simvastatin 
 
MCT5 SLC16A4 Brain, muscle, liver, 
kidney, lung, ovary, 
placenta, heart 
N/A  
(Orphan 
transporter) 
N/A N/A 
MCT6 SLC16A5 Kidney, muscle, 
brain, heart, pancreas, 
prostate, lung, 
placenta 
Unknown 
Bumetanide 
Probenecid 
Nateglinide 
Furosemide 
Azosemide 
MCT7 SLC16A6 Brain, pancreas, 
muscle, prostate 
N/A (Orphan 
transporter) 
N/A N/A 
MCT8 SLC16A2 Most tissues: liver, 
heart, brain, intestine, 
ovary, placenta, lung, 
kidney, skeletal 
muscle 
T2,  
T3/ rT3 
T4  
Imatinib 
Bosatinib 
Dasatinib 
Sunitinb 
MCT9 SLC16A9 Endometrium, testis, 
ovary, breast, brain, 
kidney, spleen, retina  
N/A (Orphan 
transporter) 
N/A N/A 
MCT10  
(TAT1) 
SLC16A10 Kidney, intestine, 
muscle, placenta, 
heart 
Phenylalanine 
L-tyrosine 
L-tryptophan 
T3/T4 
L-DOPA  
MCT11 SLC16A11 Skin, lung, ovary, 
breast, lung, 
pancreas, retina, 
choroid plexus 
N/A (Orphan 
transporter) 
N/A N/A 
MCT12 SLC16A12 Kidney, retina, lung, 
testis 
N/A (Orphan 
transporter) 
N/A N/A 
MCT13 SLC16A13 Breast, bone marrow N/A (Orphan 
transporter) 
N/A N/A 
MCT14 SLC16A14 Brain, heart, muscle, 
ovary, prostate, 
breast, lung, 
pancreas, liver, 
spleen, thymus 
N/A (Orphan 
transporter) 
N/A N/A 
 
Table 1.6: The monocarboxylic acid transporter (MCT) family, adapted from (Morris et 
al., 2008; Halestrap, 2013).  L-DOPA (Levodopa), T2 (3, 5-Diiodo-L-thyronine), rT3 
(reverse triiodothyronine), T3 (triidothyronine), T4 (thyroxine), TAT-1 (T-type amino 
acid transporter 1).  
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Members of the SLC7 family are expressed in most tissues of the body. They can be 
grouped into two main categories, each of which transports specific amino acids; the 
cationic amino acid transporters (CATs) and the L-type amino acid transporters (LATs) 
(Fotiadisa et al., 2013). CATs are N-glycosylated 14 transmembrane domain proteins 
and form the major route of entry for all cationic amino acids into cells via a sodium-
dependant facilitative mechanism.  Conversely, LAT proteins consist of 12 
transmembrane domains and mediate the high affinity transport of large neutral amino 
acids via an exchange mechanism (Verrey et al., 2003).  
 
1.8 Aims 
The aims of the experiments described in this thesis were to investigate SLC 
transporters known to be expressed at the BBB and to determine which (if any) 
mediated the active transport of AEDs at therapeutic concentrations. Throughout these 
experiments, seven commonly prescribed AEDs, namely PHT, CBZ, VPA, LTG, GBP, 
TPM and LEV, were consistently studied.   
 
Characterisation of AED transport was undertaken using widely reported model systems 
such as Xenopus laevis oocytes and the human cerebral microvascular endothelial cell 
line hCMEC/D3, together with novel stably transfected MDCK II cell lines. OATP1A2, 
the MCT family and the OAT family were specifically selected for investigation due to 
current knowledge of their substrate specificity, their abundant expression at the BBB, 
the availability of pharmacological inhibitors, and also because they had not previously 
been investigated for their potential to transport AEDs.   
 
In addition to investigation of AED transport by MCTs, OATs and OATP1A2, the 
induction/inhibition of expression of SLC transporters by AEDs was explored in the 
hCMEC/D3 cell line, in an attempt to understand how AEDs might influence the 
functionality of endogenous transport pathways.  A further study explored the 
fundamental physiochemical properties of AEDs, which is relevant to their penetration 
into the brain. 
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Chapter 2  
 
 
 
Transport of antiepileptic drugs by OATP1A2 
and MCT1 in a X. laevis transport model 
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2.1 Introduction 
The transporter hypothesis aims to explain resistance to AEDs as a result of changes in 
expression of transporters at the BBB, which may reduce AED accumulation in the 
brain. The majority of research surrounding this hypothesis has focused on the role of 
efflux transporters, in particular P-gp, whilst the role of influx transporters of the SLC 
family has been largely overlooked.  Transporters of the SLC family are critical for 
uptake and homeostasis of many essential nutrients (Pardridge et al., 1977; Pardridge, 
1986).  In addition it is becoming increasing clear that a number of drugs are subject to 
transport by the SLC family and that SLC transporters may influence the 
pharmacokinetics of substrate drugs (König et al., 2013).       
 
The organic anion transporting polypeptides (OATPs) are a well characterised family of 
SLC transporters encoded by the SLCO gene family and have been shown to mediate 
the sodium-independent transport of a range of chemically diverse drugs (Tamai et al., 
2000; Zhang et al., 2002). OATP1B1 and OATP1B3 are the best studied members of 
the OATP family due to their expression at the sinusoidal membrane of hepatocytes 
(Hagenbuch et al., 2003; Hagenbuch et al., 2004).  Here they mediate the rate limiting 
step in the hepatic clearance of many substrate drugs such as statins by transporting 
them across the sinusoidal membrane into hepatocytes where they are metabolically 
cleared by the CYP450 system (Hirano et al., 2004; Hirano et al., 2006).   
 
One isoform of this family, OATP1A2 is a 670 amino acid glycoprotein which shares 
66-77% homology with its rodent orthologs (Hagenbuch et al., 2003). OATP1A2 is 
predominantly expressed at the BBB and although the precise location of its membrane 
expression is debated, the majority of evidence suggests that OATP1A2 is expressed on 
the apical membrane of brain endothelial cells (Urquhart et al., 2009). OATP1A2 would 
thus likely act to pump drugs into brain endothelial cells that comprise the blood-brain 
barrier from the blood, therefore a reduction in the expression of OATP1A2 might 
reasonably explain the lack of accumulation of substrate drugs in the brain.  
 
OATP1A2 has been shown to transporter a number of therapeutic agents including 
imatinib (Eechoute et al., 2011a; Eechoute et al., 2011b), methotrexate (Badagnani et 
al., 2006), levofloxacin (Maeda et al., 2007) and antiretroviral protease inhibitors 
(Hartkoorn et al., 2010). 
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Monocarboxylic acid transporters (MCTs), encoded by the SLC16 gene family function 
endogenously to transport fuels and so are predominantly expressed in tissues with high 
energy demands (Halestrap, 2013).  One MCT isoform, MCT1 is known to be 
expressed at the basolateral and apical membranes of cerebral microvascular endothelial 
cells (Pierre et al., 2005). The MCT transporter system is critical for brain uptake of 
fuels such as lactate, pyruvate and in times of calorific restriction ketones and utilises a 
proton dependent transport mechanism (Pardridge et al., 1986).   
 
MCT1 was the first MCT isoform to be cloned from Chinese hamster ovary (CHO) 
cells in 1994 (Garcia et al., 1994).  MCT1 is a 494 amino acid protein, (Enerson et al., 
2003) and is ubiquitously expressed (Halestrap et al., 1999).  MCT1 transports lactate 
and pyruvate with high affinity and Km values of  3-5mM and 0.7mM respectively have 
been reported depending on the expression system employed (Halestrap et al., 2004). 
 
Both membrane expression and activity of MCT1 has been shown to be dependent on 
its association with an essential accessory protein basigin (Wilson et al., 2005). 
Although MCT1 preferentially associates with basigin, it can also associate with 
another accessory protein embigin in the absence of its primary partner (Poole et al., 
1997; Kirk et al., 2000).  Basigin and embigin are glycoproteins containing a single 
transmembrane span which acts as a chaperone, translocating MCT1 to the plasma 
membrane where the transporter and its accessory protein remain tightly bound. 
Furthermore dissociation from the accessory protein renders the transporter defunct 
(Manoharan et al., 2006).   
 
MCT1 has been implicated in the transport of a number of drugs including the drug of 
abuse γ-hydroxybutyrate (GHB) and the gabapentin pro-drug XP13512 (Cundy et al., 
2004; Wang et al., 2006; Morris et al., 2008).  More interestingly, MCT1 has been 
implicated in the transport of VPA (Utoguchi et al., 2000; Fischer et al., 2008) and 
recently a deficiency of MCT1 on cerebrovascular endothelial cells has been shown in 
both animal models of temporal lobe epilepsy (TLE) and human tissue resected in the 
surgical treatment of TLE (Lauritzen et al., 2011; Lauritzen et al., 2012).   
 
Many in vitro models have been used previously to investigate functional transport of 
drugs including surrogate transport cell lines such as Caco-2 cells, overexpressing cell 
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lines (where the transporter of interest is cloned and transfected into cell lines such as 
MDCK or HEK293), and Xenopus laevis oocytes.   
 
The X. laevis oocyte method of transporter expression is a proven, robust tool in the 
identification of drug transport.  cDNAs cloned from cells or other sources can, after in 
vitro transcription to cRNAs, be injected into individual X. laevis oocytes and 
transporter function determined after just 3 days using a radiotracer uptake assay. The 
main advantages of the X. laevis system over somatic cell expression systems are that 
genetic information can be transferred easily and rapidly, transfection rates are high and 
the oocytes express very few endogenous transporter proteins to interfere with results 
(Xia et al., 2007; Markovich, 2008).  
 
The aim of the study described in this chapter was to firstly develop X. laevis expression 
models for both OATP1A2 and MCT1 and to characterise their functional transport 
using well described control substrates, estrone-3-sulfate and L-lactic acid respectively. 
These models could then be used in radiotracer uptake assays to determine if OATP1A2 
and MCT1 actively transport commonly prescribed antiepileptic drugs at therapeutically 
relevant concentrations.  
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2.2 Materials and methods 
2.2.1 Materials 
Animals: Adult female X.laevis were purchased from Xenopus Express (France). 
Chemicals: [3H]-estrone-3-sulfate (specific activity 54.3 Ci/mmol), [14C]-L-lactic acid 
(specific activity 130.8mCi/mmol), [14C]-phenytoin (specific activity 53.1mCi/mmol) 
were purchased from Perkin Elmer (Massachusetts, USA). [3H]-lamotrigine (specific 
activity 5Ci/mmol), [3H]-levetiracetam (specific activity 5Ci/mmol), [3H]-topiramate 
(specific activity 8Ci/mmol), [14C]-valproic acid (specific activity 8Ci/mmol) were 
purchased from American Radiolabeled Chemicals Inc. (St. Louis, USA). [14C]-
carbamazepine (specific activity 49mCi/mmol) was kindly gifted by Professor Kevin 
Park (University of Liverpool). SLC16A1 cDNA I.M.A.G.E. clone was purchased from 
Source Bioscience Life Sciences (Nottingham, UK), who also carried out sequencing of 
positive pBluescriptII-KSM-MCT1 clones.  ClaI, SpeI, SacI restriction enzymes, 
restriction digest buffers 1, 3 and 4, bovine serum albumin (BSA), T4 ligase, Antarctic 
phosphatase and 5-alpha chemically competent E.coli were purchased from New 
England Biolabs (Hitchen, UK). T3 mMessage mMachine Transcription kit was 
purchased from Ambion Ltd (Warrington, UK). Fast Start High Fidelity PCR system 
reagents were purchased from Roche Diagnostics (Burgess Hill, UK).  Unless otherwise 
stated, all other materials were purchased from Sigma-Aldrich (Poole, UK).   
 
2.2.2 Extraction of human SLC16A1 I.M.A.G.E. cDNA clone plasmid DNA from 
E.coli glycerol stocks 
A 50ml culture of LB (Luria-Bertani) broth supplemented with 50µg/ml ampicillin was 
firstly inoculated with the SLC16A1 cDNA I.M.A.G.E. clone agar stock and the culture 
grown overnight at 370C with vigorous shaking (300rpm; ThermoScientific Thermo 
Max Q 4450).  The following day, overnight cultures were streaked onto LB agar plates 
(autoclaved, 1M agar supplemented with 50µg/ml ampicillin) at various serial dilutions 
(neat, 1 in 10, 1 in 100, 1 in 1000) and grown overnight at 370C.  Distinct, single 
colonies were selected the following day and grown firstly for 8 hours in a small (9ml) 
LB broth culture (supplemented with appropriate antibiotic) at 370C with vigorous 
shaking and secondly overnight in a 50ml culture at the same conditions.  The following 
day plasmid DNA was extracted using the GenElute plasmid maxiprep extraction kit 
according to manufacturer’s protocol as follows. 
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Overnight cultures were centrifuged at 3,000 x g for 15 minutes and the supernatant 
discarded.  The pellet was then resuspended in a total of 12ml resuspension fluid by 
pipetting up and down. Suspended cells were lysed with 12ml lysis buffer, inverted 6-8 
times to mix and left for 3-5 minutes. Lysis was then neutralised with 12ml 
neutralisation buffer, inverted 4-6 times, and 9ml of binding fluid added. The mixture 
was then inverted 1-2 times, poured into a filter syringe and incubated for 5 minutes at 
room temperature to form a white aggregate.  Binding columns were prepared by adding 
12ml of column preparation to a GenElute column inserted in a 50ml Falcon tube and 
centrifuging at 3000 x g for 2 minutes. Half of the lysed material was then filtered into 
the prepared column and centrifuged at 3000 x g for 2 minutes. The eluant was 
discarded, the remainder of the lysed material filtered into the column and the column 
centrifuged at 3000 x g for 2 minutes. The column containing the bound plasmid DNA 
was then washed in 12ml of wash solution 1 and centrifuged at 3000 x g for 2 minutes. 
The eluant was discarded and the column washed in 12ml of wash solution 2 and 
centrifuged at 3000 x g for 5 minutes. The column was then transferred to a new 50ml 
Falcon tube and 1.2ml of elution solution added, incubated for a few minutes and 
centrifuged at 3000 x g for 5 minutes to elute the bound plasmid DNA.  Plasmid DNA 
was then quantified using the Nanodrop spectrophotometer (see section 2.2.3 for 
protocol) and stored at 40C for immediate use or -200C for long term storage.   
 
2.2.3 Using the NanoDrop spectrophotometer 
DNA/RNA was quantified using the NanoDrop 8000 spectrophotometer (Thermo 
Scientific).  Briefly, the NanoDrop software was opened and the nucleic acid module 
selected.  The nucleic acid type (DNA/cDNA/RNA) for quantification was then selected 
and the spectrophotometer initialised by adding 1.5µl of milliQ water to each optical 
surface, lowering the arm and selecting initialise.  A blank measurement was then made 
by adding 1.5µl of the buffer in which samples are dissolved (for quantification of 
plasmid DNA this was elution solution provided in the GenElute plasmid maxiprep 
extraction kit) and selecting ‘blank’.  Samples (1.5µl) were then measured by loading 
onto the machine and selecting ‘measure’.  The concentration of the sample in ng/µl is 
then displayed on the screen.  The NanoDrop additionally provides purity readings of 
the samples (260/280 ratio).  The 260/280 ratio of a sample is the ratio of absorbance at 
260 and 280 nm.  DNA with a 260/280 absorption ratio of ~ 1.8 is accepted as adequate 
purity, while RNA with a 260/280 absorption ratio of ~ 2.0 is accepted as adequate 
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purity.  If the ratio is substantially lower it may indicate phenol or protein 
contamination.     
 
2.2.4 Linearisation of SLC16A1 cDNA clone plasmid DNA 
Extracted SLC16A1 cDNA clone plasmid DNA was linearised in a 2 hour restriction 
digest reaction in a thermal cycler (Applied Biosystems Verti 96 well thermal cycler) at 
370C with the SacI restriction endonuclease.  SacI produces a single cut in the 
supercoiled DNA after the SLC16A1 coding region. A 50µl reaction was prepared 
containing 2µg of plasmid DNA, 5µl of NewEngland Biolabs (NEB) buffer 1 (1 x final 
concentration), 0.5µl (1µg/ml final concentration) BSA and 0.5µl (10 units) of SacI 
made up to 50µl with water. Digested DNA was then visualised along with supercoiled 
DNA by agarose gel electrophoresis. A 1% agarose gel containing 1µg/ml ethidium 
bromide in 1 x Tris-borate EDTA (TBE) was cast and allowed to set before transfer to 
an electrophoresis tank containing 1 x TBE.  Both linear and supercoiled plasmid DNA 
was then prepared (5µl) with 2µl of 6x loading buffer and loaded onto the gel along 
with 5µl of a 10kb DNA ladder (NEB ladder: 2µl diluted with 2µl loading buffer and 
4µl water) as a reference. Gel electrophoresis was then allowed to run for 30 minutes at 
100V before visualisation under UV light. Successful linearisation produced a DNA 
band which migrates slower than the supercoiled form (figure 2.1).   
 
 
 
Figure 2.1: Visualisation of linear (1) and supercoiled (2) SLC16A1 cDNA I.M.A.G.E. 
clone DNA on a 1% agarose gel using NEB 10kb ladder. 
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2.2.5 Amplification of SLC16A1 template DNA 
The SLC16A1 coding sequence was amplified from linear plasmid DNA using Fast 
Start High Fidelity PCR system reagents (Roche Diagnostics, Burgess Hill, UK).  This 
hot start PCR kit utilises an enzyme blend containing hot start Taq polymerase with a 
proofreading enzyme to achieve high accuracy amplification of template DNA.  A 
single round of PCR was applied to amplify the full coding sequence of SLC16A1. Two 
primers (Sigma-Aldrich) were used to amplify the coding sequence of human SLC16A1 
from the I.M.A.G.E. clone plasmid DNA;  a sense primer 5’ 
CTTATCGATGCCACCATGCCACCAGCAG 3’ containing a ClaI restriction site and 
corresponding to the 5’ end of SLC16A1 and an antisense primer 5’ 
AAGACTAGTTCAGACTGGACTTTCCTCC 3’ containing a SpeI restriction site and 
corresponding to the 3’ end of SLC16A1.  Each PCR reaction contained the following: 
5µl of 10X reaction buffer with 18mM MgCl2, 1µl of PCR grade nucleotide mix 
(200nM final concentration of each dNTP), 0.5µl FastStart High Fidelity Enzyme Blend 
(mix of Taq polymerase (5U/µl) plus proof-reading enzyme), 27.5µl PCR grade water, 
5µl of both sense and anti-sense primers (400nM final concentration), 5µl template 
DNA (30ng/µl) and 1µl DMSO. Negative control reactions were also carried out in the 
absence of DNA to check for PCR reagent contamination.  Reactions were prepared in 
100µl low density plastic PCR tubes and thermal cycling performed on a 96 well block 
thermal cycler (Applied Biosystems Verti) using the following thermal profile: Initial 
denaturation (940C for 15 minutes), 45 cycles of denaturation (940C for 10 seconds), 
annealing (700C for 30 seconds) and elongation (720C for 2 minutes), before a final 
elongation (720C for 7 minutes). Amplification products were then visualised using 
agarose gel electrophoresis as described in section 2.2.4 to determine if the SLC16A1 
coding region (1.6Kb) had been successfully amplified (figure 2.2).    
 
Figure 2.2 Visualisation of amplified SLC16A1 template DNA (1) and (2) on a 1% 
agarose gel using NEB 10kb ladder. 
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2.2.6 Restriction digest of SLC16A1 template/pBluescriptII-KSM plasmid  
Successfully amplified SLC16A1 template DNA was purified using the GenElute PCR 
clean-up kit according to the manufacturer’s protocol as follows.  Miniprep binding 
columns were firstly prepared by adding 0.5ml of column preparation to a binding 
column inserted into a 1.5ml collection tube and centrifuging at 12,000 x g for 1 minute 
in a table top centrifuge. Purified DNA was then mixed with binding solution in a 5:1 
ratio (binding solution: DNA) to form complexes and transferred 500µl at a time to the 
binding column. Columns were then centrifuged at 12,000 x g for 1 minute, the eluant 
discarded and centrifugation repeated with any remaining DNA-binding solution. The 
column was then washed with 0.5ml of wash solution containing ethanol, centrifuged at 
12,000 x g for 1 minute and the eluant discarded. The column (without any wash 
solution) was then centrifuged again at 12,000 x g for 2 minutes to remove any residual 
wash solution and any eluant discarded.  The binding column was then transferred to a 
clean collecting tube and 25µl of elution solution added, allowed to incubate at room 
temperature for 1 minute and centrifuged at 12,000 x g for 1 minute to collect the now 
purified DNA. Concentration and purity was then quantified using the Nanodrop 
spectrophotometer (see section 2.2.3 for protocol) and DNA kept at 40C.   
 
The SLC16A1 template DNA and linear pBluescriptII-KSM DNA (linearised using SacI 
restriction digest as described in section 2.2.4) were then correspondingly digested in 
consecutive single restriction digest reactions with ClaI and SpeI restriction 
endoucleases respectively to produce complementary restriction sites for subsequent 
ligation. Restriction reaction conditions were as follows; SLC16A1 template DNA and 
pBluescriptII-KSM were digested firstly with ClaI at 370C for 2 hours 15 minutes with 
reactions assembled as follows: 2µg pBluescriptII-KSM/SLC16A1 template DNA, 5µl 
NEB buffer 3 (1 x final concentration), 1µl (10 units) of ClaI, 0.5µl BSA (1µg/ml final 
concentration), and water up to 50µl.  The ClaI digested DNA was then purified using 
the GenElute PCR clean-up kit as described previously and sequentially digested with 
SpeI at 370C for 2 hours and 30 minutes with reactions assembled as follows: 2µg 
pBluescriptII-KSM/SLC16A1 template DNA, 5µl of NEB buffer 4 (1 x final 
concentration), 1µl (10 units) of SpeI, 0.5µl BSA (1µg/ml final concentration) and water 
up to 50µl.  The double digested pBluescriptII-KSM and SLC16A1 template DNA was 
then purified using the using the GenElute PCR clean-up kit according to the 
manufacturer’s protocol as described previously and visualised by ethidium bromide 
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stained agarose gel electrophoresis as described in section 2.2.4 to confirm successful 
digestion (figure 2.3).   
 
Figure 2.3: Visualisation of ClaI and SpeI sequentially digested SLC16A1 template 
DNA (1) and (2) and pBluescriptII-KSM plasmid (3) and (4) on an agarose gel (1%) 
using NEB 10kb ladder. 
 
Purified double digested DNA was subsequently isolated from a crystal violet agarose 
gel and extracted using the GenElute gel extraction kit as follows. A 1% agarose gel 
containing 1mg/ml crystal violet was cast and transferred to an electrophoresis tank 
containing 1 X TBE (plus 1mg/ml crystal violet). 5µl of digested pBluescriptII-KSM 
DNA and SLC16A1 template DNA was mixed with 2µl crystal violet loading buffer 
(30% glycerol, 20mM EDTA and 100µl/ml crystal violet), loaded onto the gel and 
allowed to run at 100V until bands had fully migrated.  The corresponding 
pBluescriptII-KSM DNA and SLC16A1 template DNA bands were then excised from 
the gel using a sterile scalpel and weighed. The gel bands were then dissolved in 
solubilisation solution in a 1:3 ratio of weight (mg) to volume (µl) and incubated at 50-
600C for 10 minutes until completely solubilised. Binding columns were prepared by 
inserting GenElute G columns containing 500µl of column preparation into 1.5ml 
collecting tubes, centrifuging for 1 minute at 12,000 x g and discarding the eluant.  
Isopropanol was then added to the solubilised gel solutions in a 1:1 weight to volume 
ratio and the solution loaded into the prepared binding columns. Columns were 
centrifuged for 1 minute at 12,000 x g to bind DNA contained in the gel slice and the 
eluant discarded. The columns were washed with 700µl of wash solution, centrifuged at 
12,000 x g for 1 minute and the eluant discarded. The binding columns were then 
transferred to clean collecting tubes; 50µl of elution solution (at 650C) was added and 
incubated at room temperature for 1 minute.  DNA was recovered by centrifugation at 
12,000 x g for 1 minute and quantified using the Nanodrop spectrophotometer as 
described in section 2.2.3.  DNA was stored at -200C until downstream ligation.   
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2.2.7 Ligation of SLC16A1 template DNA into pBluescriptII-KSM  
To enable ligation with the SLC16A1 template DNA, pure pBluescriptII-KSM DNA 
was dephosphorylated in a 1 hour reaction at 370C, reaction reagents were as follows: 
1µl (5 units) antarctic phosphatase, 5µl antarctic phosphatase buffer (1 x final 
concentration), 1µg pBluescriptII-KSM DNA, and water up to a total volume of 50µl.  
The reaction was then terminated by heat inactivation at 650C for 10 minutes.  
Subsequent ligation was achieved using T4 DNA ligase in an overnight reaction at 40C.  
A total of 150µg of DNA was required for a 20µl ligation reaction in a 3:1 ratio of insert 
(SLC16A1 template DNA) to vector (pBluescriptII-KSM) set up as follows: 6µl of 
SLC16A1 template DNA (112.5µg), 2µl of phosphatase treated vector (37.5µg), 2µl (1x 
final concentration) T4 DNA ligase buffer (with 1mM ATP), 1µl (400 units) T4 DNA 
ligase and 9µl of water.  The following day ligated pBluescriptII-KSM-SLC16A1 and a 
negative control (pBluescriptII-KSM vector only) were transformed into NEB 5-alpha 
chemically competent E.coli using the NEB high efficiency transformation protocol.   
 
Briefly, 5-alpha competent E.coli were allowed to thaw on ice for 10 minutes before 
adding 3µl of pBluescriptII-KSM-SLC16A1 plasmid DNA/vector only negative control. 
The tubes were then carefully flicked 4-5 times to mix and incubated on ice for 30 
minutes. The E.coli mix was heat shocked for exactly 30 seconds at 420C and placed on 
ice for 5 minutes. A 950µl aliquot of super optimal broth with catabolite repression 
(SOC) medium was added and E.coli cultured for 60 minutes at 370C with vigorous 
shaking (250rpm). The transformed E.coli was then mixed by flicking and inverting and 
several 10-fold serial dilutions were prepared in SOC medium.  A 100µl volume of each 
dilution was spread using a bacterial loop to warmed agar selection plates (containing 
100µg/ml ampicillin) and incubated overnight at 370C. 
 
The following day, vector-only negative control culture plates were observed for any 
bacterial growth and clear, single E.coli clones transformed with the pBluescriptII-
KSM-SLC16A1 plasmid were selected and analysed for SLC16A1 expression using 
PCR (figure 2.4) according to the conditions described in section 2.2.5.  Any SLC16A1 
positive colonies were grown overnight in LB broth (plus 100µg/ml ampicillin) at 370C 
with vigorous shaking (250rpm). The following day, plasmid DNA was extracted from 
overnight cultures using the GenElute maxi-prep kit as described in section 2.2.2. 
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Figure 2.4: Agarose gel visualisation of positive pBluescriptII-KSM-SLC16A1 clones 
(1-10) and the vector-only transformation negative control (11) using NEB 10kb ladder 
after analysis by PCR. 
 
Five clones shown to express the ligated plasmid and therefore SLC16A1 template were 
sent to Source Bioscience Lifesciences (Cambridge, UK) for single tube sequencing.  
Linear plasmid DNA at a concentration of 100ng/µl was supplied and the plasmid DNA 
sequenced from the T3 promoter and T7 reverse sites within the pBluescriptII-KSM 
vector sequence; this enabled the full insertion site of the vector to be sequenced.  
Sequence results were then analysed to ensure the inserted SLC16A1 template was 
identical to the published protein coding sequence.  A single clone was then selected for 
subsequent transfection.    
 
2.2.8 Sub-cloning of SLCO1A2 into pBluescriptII-KSM 
Sequence verified pBluescriptII-KSM-SLCO1A2 plasmid transcript was available in the 
department and was kindly gifted for use in the project by Professor Andrew Owen.  
The SLCO1A2 gene insert was cloned from cDNA obtained from A549 and Huh-7D12 
cells, and sub-cloned into the pBluescriptII-KSM plasmid using the same techniques as 
described in sections 2.2.4 – 2.2.7. 
 
2.2.9 In-vitro transcription 
Confirmed full length pBluescriptII-KSM-SLCO1A2 and pBluescriptII-KSM-SLC16A1 
clones were firstly linearised using the SacI restriction endonuclease (figure 2.5) and 
visualised by agrose gel electrophoresis (according to conditions outlined in section 
2.2.4).  Complementary RNA (cRNA) was then prepared by in vitro transcription using 
the T3mMessage mMachine kit as per the manufacturer’s protocol. Briefly, reagents 
were vortexed until thawed (RNA polymerase kept on ice) and kept at room 
temperature (NTP/CAP (a neutralised buffer containing 15mM ATP, 15mM CTP, 
15mM UTP, 3mM GTP and 12mM cap analog) kept on ice).  A 20µl reaction was 
prepared with the following reagents made up to 20µl with nuclease free water: 10µl 
NTP/CAP, 1µg of linear pBluescriptII-KSM-SLCO1A2/ pBluescriptII-KSM-SLC16A1 
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template DNA, 2µl of reaction buffer (1x final concentration), 2µl of enzyme mix 
(RNase inhibitor plus RNA polymerase; concentration not specified).  The reaction mix 
was then incubated in a thermal cycler for 2 hours at 370C and immediately transferred 
to ice. A 30µl volume of nuclease free water and 30µl of 7.5M lithium chloride (LiCl) 
precipitation solution (with 50mM EDTA) was added to terminate the polymerase 
reaction and the reaction mixed thoroughly and incubated at -200C for 2 hours. The LiCl 
precipitate was then centrifuged at 16,000 x g for 15 minutes at 40C to pellet the RNA, 
the supernatant was carefully discarded and the pellet washed in 1ml of 70% ethanol. 
The pellet was centrifuged again at 16,000 x g for 15 minutes at 40C, the ethanol 
carefully discarded, and the pellet allowed to air dry for 5 minutes before re-suspension 
in 15µl of nuclease free water. The cRNA concentration and was determined using the 
Nanodrop spectrophotometer (as described in section 2.2.3) and cRNA diluted to 
1µg/ul. Aliquots (5µl) were prepared and stored at -800C for future transfection.   
 
 
Figure 2.5: Visualisation of supercoiled (1) and linear (2) pBluescript-KSM-SLCO1A2 
(a) and pBluescriptII-KSM-SLC16A1 (b) DNA on a 1% agarose gel using NEB 10kb 
ladder. 
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2.2.10 X. laevis husbandry 
Adult female X. laevis were kept in fresh water filtered tanks; water temperature was 
maintained at ~170C with heater systems. Tanks included light and dark areas and were 
cleaned fortnightly. Animals were fed specialised X. laevis pellets twice per week and 
handled in a net. Animals were sacrificed by submerging the animal in MS222 
anaesthetic solution (5g/L) for 45 minutes.   
 
2.2.11 X. laevis oocyte extraction and microinjection 
Oocytes were extracted from the frog abdomen by dissection, with ovary lobes isolated 
using forceps and collagenase treated in calcium negative Barth’s solution (88mM 
NaCl, 1mM KCl, 15mM HEPES, 1% penicillin streptomycin) containing 1mg/ml 
collagenase for ~1 hour (shaking).  Oocytes were then washed three times with calcium 
containing Barth’s solution (88mM NaCl 1mM KCl, 15mM HEPES, 0.3mM 
CaCNO3.6H2O, 41mM CaCl2_6H2O, 0.82mM MgSO4_7H2O, 1% penicillin 
streptomycin), and stored overnight at 180C. Healthy, mature oocytes with distinct 
hemispheres were selected for microinjection the following day. Needles were firstly 
prepared from thin wall glass capillaries (1mm diameter, 102mm length) using the 
PUL-1 machine (World Precision Instruments), loaded onto the micro-manipulator and 
trimmed using forceps. OATP1A2/ MCT1 cRNA (1ug/ul) or water (50nl) was then 
loaded into the needle by vacuum pump (DA7C, Charles Austen Pumps) where it was 
held by compressed air using the picopump PV830 (World Precision Instruments). The 
drop size was then calibrated to 4µm in diameter and injected into the yolk side of the 
oocyte. Around 200 oocytes were injected per condition (water injected control and 
SLC01A2/SLC16A1 transfected) and maintained in modified Barth’s solution (calcium 
positive) at 180C for three days. 
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2.2.12 Cellular uptake assay in X. laevis expression system  
Uptake experiments employed a radiolabelled concentration of 0.3µCi/ml supplemented 
with non-radiolabelled drug to give final concentrations of 2µM estrone-3-sulfate (E3S; 
OATP1A2 positive control substrate) and 5µM of L-lactic acid (LA; MCT1 positive 
control substrate) prepared in transport medium (HBSS supplemented with 25mM 
HEPES and 0.1% bovine serum albumen (BSA), at pH7.4).  A radiolabel concentration 
of 0.3µCi/ml afforded sufficient disintegrations per minute to give accurate readings of 
radioactive content without saturating the scintillation counter.   
 
On the day of the assay, control (water injected) and SLCO1A2/SLC16A1 transfected 
oocytes were selected, washed three times in transport buffer and eight oocytes (in 
250µl of transport buffer) added to a single well per condition (water injected or 
SLCO1A2/SLC16A1 transfected) for each drug. Transport medium (250µl) containing 
the radiolabelled drug (dosing solution) with either vehicle (0.1% DMSO), or inhibitor 
(100µM naringenin for OATP1A2,  100µM salicylic acid for MCT1 ) was added to 
control or SLCO1A2/SLC16A1 transfected oocytes and incubated at room temperature 
for 90 minutes (OATP1A2) or 60 minutes (MCT1).  In the meantime, samples (20µl) of 
transport buffer alone (blanks) and samples (20µl) of dosing solution (standards) were 
taken and added to scintillation vials for later determination of background radiation and 
radioactive content of a known concentration of each drug solution, respectfully.  After 
incubation, oocytes were washed three times in ice cold HBSS, transferred to 
scintillation vials and solubilised with 500µl of 10% sodium dodecyl sulphate (SDS). 
The solubilised solution was mixed with 4ml scintillation fluid (Goldstar Multipurpose 
liquid scintillation cocktail (Meridian, UK) and vials mixed by inverting several times 
before radioactive content was determined using a scintillation counter (1500 Tri Carb 
LS Counter; Packard).  Results in dpm were corrected for background counts, 
quantified in relation to standards of known concentration and expressed in 
pmol/oocyte.   
 
The above method was repeated with AEDs at final concentrations of 25µM PHT, 
20µM CBZ, 300µM VPA, 10µM LTG, 10µM TPM, 10µM GBP and 6µM LEV.   
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2.2.13 Statistical analysis 
All data are presented as mean ± standard error of the mean (SEM) from three (MCT1 
data) or four (OATP1A2 data) independent experiments where n=8 for each group, with 
the exception of data described in sections 2.3.1 and 2.3.4 which are presented as mean 
± standard deviation from one experiment where n=8.  In order to correct for differential 
uptake between drugs and to account for inter-batch variation in oocytes, data were 
expressed as percentage of the mean control value for each experimental day, where 
control equals 100% uptake. For data derived from uptake comparisons of control vs 
SLCO1A2/SLC16A1 transfected oocytes with or without inhibitor, normal distribution 
was assessed using the Shapiro-Wilk test and statistical differences determined using 
analysis of variance (ANOVA), with Tukey’s post hoc test to correct for multiple 
comparisons.  A p value of <0.05 was taken to indicate significance. 
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2.3 Results 
2.3.1 Kinetics of estrone-3-sulfate transport in SLCO1A2 transfected X. laevis 
oocytes 
A time course study of the known OATP1A2 substrate estrone-3-sulfate in control 
(water-injected) oocytes compared to SLCO1A2-transfected oocytes was undertaken to 
determine the optimum time point for further investigation with AEDs (figure 2.6).  
Optimum transport of 2µM estrone-3-sulfate was observed between 90 and 120 minutes 
before reaching a plateau and then falling away by 180 minutes. The 90 minute time 
point at the peak of the linear phase for estrone-3-sulfate transport was chosen for 
subsequent experiments with AEDs in SLCO1A2-transfected oocytes. 
 
Figure 2.6: A comparison of estrone-3-sulfate uptake over time in control (solid circles) 
and SLCO1A2-transfected (solid squares) oocytes.  Results are expressed as mean (± 
standard deviation) uptake in pmols per oocyte following exposure to 2µM estrone-3-
sulfate over a 3 hour period.  Each data point represents the mean of eight observations 
(n=8), obtained from a single experiment.   
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2.3.2 Estrone-3-sulfate uptake in X. laevis oocytes transfected with SLCO1A2  
To confirm SLCO1A2 transfection of X. laevis oocytes was successful and to validate 
the experimental model, uptake of 2µM estrone-3-sulfate was investigated in control 
(water-injected) oocytes compared to SLCO1A2-transfected oocytes with and without 
co-incubation with the OATP1A2 inhibitor naringenin (100µM; figure 2.7).  Mean 
uptake of estrone-3-sulfate was 1326 ± 171% of the control value (100 ±21%) in 
SLCO1A2-transfected oocytes (p≤0.001). Co-incubation with the OATP1A2 inhibitor 
naringenin reduced uptake in SLCO1A2-transfected oocytes to 378 ± 44% of the control 
value (p≤0.01). This finding suggests that SLCO1A2 transfection was successful and 
confirmed the validity of the experimental model. 
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Figure 2.7: Estrone-3-sulfate (E3S) uptake into SLCO1A2-transfected X. laevis oocytes 
compared to control water injected oocytes with and without the OATP1A2 inhibitor 
naringenin.   Cultures were exposed to 2μM radiolabelled E3S with or without 
naringenin at 100µM for 90 minutes at room temperature.  Results are expressed as the 
mean ± standard error of the mean (SEM) percentage of the mean control value of E3S 
uptake (in pmols/oocyte) on each experimental day.  The experiment was performed on 
four separate occasions with percentage of control data calculated on each occasion and 
with n=8 oocytes in each group each time. Statistical significance (* p ≤0.01, 
**p<0.001) was determined by one-way analysis of variance with Tukey’s correction 
for multiple testing. 
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2.3.3 Uptake of AEDs in SLCO1A2 transfected X. laevis oocytes 
Seven commonly prescribed AEDs were investigated to determine whether they were 
subject to OATP1A2-mediated transport at therapeutically relevant concentrations. 
These were phenytoin (25µM), carbamazepine (20µM), valproate (300µM), lamotrigine 
(10µM), gabapentin (10µM), topiramate (10µM) and levetiracetam (6µM).  Each drug 
was incubated with both control and SLCO1A2-transfected oocytes, with or without the 
OATP1A2 inhibitor naringenin (100µM).  No significant difference in uptake was seen 
for any of the seven AEDs in SLCO1A2-transfected oocytes compared to controls, with 
only minor changes in relative AED transport observed (table 2.1).  GBP uptake 
increased to 304 ± 47% of the control value in the presence of 100µM naringenin 
(p≤0.001).  No such effect was observed for any of the other AEDs tested (table 2.1). 
 
 
Table 2.1: Comparison of antiepileptic drug uptake in control and SLCO1A2-
transfected X. laevis oocytes and effects of the OATP1A2 inhibitor naringenin 
(100µM). Estrone-3-sulfate (2µM) was employed as a positive control compound. 
Results are expressed as mean ± standard error on the mean (SEM) percentage of mean 
control uptake following exposure to antiepileptic drugs for 90 minutes. The experiment 
was performed on four separate occasions with percentage of control data calculated on 
each occasion and with n=8 oocytes in each group each time. Statistical significance 
(*p<0.01, **p<0.001) was determined by one-way analysis of variance with Tukey’s 
correction for multiple testing. 
 
 
 
 
Antiepileptic drug 
Concentration 
(µM) 
Control 
SLCO1A2 
transfected 
SLCO1A2 
transfected plus 
inhibitor 
 
 
Mean ± SEM uptake (% of control) 
Estrone-3-sulfate  2 100 ± 21 1326 ± 171** 378 ± 44* 
Phenytoin  25 100 ± 2.3 98.1 ± 8.2 105 ± 8.8 
Carbamazepine  20 100 ± 3.5 91.3 ± 2.8 98.0 ± 3.2 
Sodium valproate  300 100 ± 9.0 111 ± 7.3 101 ± 6.1 
Lamotrigine  10 100 ± 6.1 128 ± 7.7 138 ± 8.8 
Gabapentin  10 100 ± 19 104 ± 17 304 ± 47** 
Topiramate  10 100 ± 4.5 111 ± 6.5 127 ± 8.8 
Levetiracetam  6 100 ± 7.3 94.5 ± 7.0 124 ± 12 
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2.3.4 Kinetics of L-lactic acid transport in SLC16A1 transfected X.laevis oocytes 
A time course study of the known MCT1 substrate L-lactic acid in control (water-
injected) oocytes compared to SLC16A1-transfected oocytes was undertaken to 
determine the optimum time point for further investigation with AEDs (figure 2.8). 
Optimum transport of 5µM L-lactic acid was observed between 60 and 90 minutes, with 
uptake falling away thereafter. The 60 minute time point at the peak of the linear phase 
for lactic acid transport was chosen for subsequent experiments with AEDs in 
SLC16A1-transfected oocytes.  
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Figure 2.8: A comparison of L-lactic acid uptake over time in control (solid circles) and 
SLC16A1-transfected (solid squares) X. laevis oocytes.  Results are expressed as mean 
(± standard deviation) uptake in pmols per oocyte following exposure to 5µM L-lactic 
acid over a 2 hour period.  Each data point represents the mean of eight observations 
(n=8), obtained from a single experiment.   
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2.3.5 L-lactic acid uptake in X. laevis oocytes transfected with SLC16A1  
To confirm successful SLC16A1 transfection of X. laevis oocytes and to validate the 
experimental model, uptake of L-lactic acid (LA; 5µM) was investigated in control 
(water injected) oocytes compared to MCT1 transfected oocytes with and without co-
incubation with the MCT1 inhibitor salicylic acid (100µM; figure 2.9).  Mean uptake of 
LA was 2607 ±240% of the control value (100 ±5.9%) in SLC16A1-transfected oocytes 
(p≤0.001). Co-incubation with the MCT1 inhibitor salicylic acid reduced uptake in 
SLC16A1-transfected oocytes to 1134 ± 110% of the control value (p≤0.01). This 
finding suggests that SLC16A1 transfection was successful and confirmed the validity of 
the experimental model. 
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Figure 2.9: L-lactic acid (LA) uptake into SLC16A1-transfected X. laevis oocytes 
compared to control water injected oocytes with and without the MCT1 inhibitor 
salicylic acid.  Cultures were exposed to 5μM radiolabelled LA with or without salicylic 
acid at 100µM for 60 minutes at room temperature.  Results are expressed as the mean ± 
standard error of the mean (SEM) percentage of the mean control value of LA uptake 
(in pmols/oocyte) on each experimental day.  The experiment was performed on four 
separate occasions with percentage of control data calculated on each occasion and with 
n=8 oocytes in each group each time. Statistical significance (* p ≤0.01, **p<0.001) 
was determined by one-way analysis of variance with Tukey’s correction for multiple 
testing.  
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2.3.6 Uptake of AEDs in SLC16A1 transfected X. laevis oocytes 
To determine which, if any of the seven commonly prescribed AEDs namely: phenytoin 
(25µM), carbamazepine (20µM), valproate (300µM), lamotrigine (10µM), gabapentin 
(10µM), topiramate (10µM) and levetiracetam (6µM) are transported by MCT1; each 
drug was incubated with control and SLC16A1-transfected oocytes with/without the 
MCT1 inhibitor salicylic acid (100µM).  Gabapentin uptake was increased to 164% 
±15% in SLC16A1-transfected oocytes compared to control (100 ±10%; p≤0.05), 
however this could not be inhibited significantly by salicylic acid (123% ±12%).  No 
significant difference in uptake was seen for the other AEDs tested (table 2.2).    
 
Table 2.2: Comparison of antiepileptic drug uptake in control and SLC16A1-transfected 
X. laevis oocytes and effects of the MCT1 inhibitor salicylic acid (100µM). L-lactic acid 
(5µM) was employed as a positive control compound. Results are expressed as mean ± 
standard error on the mean (SEM) percentage of mean control uptake following 
exposure to antiepileptic drugs for 60 minutes. The experiment was performed on three 
separate occasions with percentage of control data calculated on each occasion and with 
n=8 oocytes in each group each time. Statistical significance (*p<0.01, **p<0.001) was 
determined by one-way analysis of variance with Tukey’s correction for multiple 
testing. 
 
 
 
 
 
 
Antiepileptic drug 
Concentration 
(µM) 
Control 
SLC16A1 
transfected 
SLC16A1 transfected 
plus inhibitor 
  Mean ± SEM uptake (% of control) 
L-lactic acid 5 100 ±5.9 2607 ±240** 1134 ±110* 
Phenytoin  25 100 ±3.9 108 ±2.6 109 ±3.6 
Carbamazepine  20 100 ±1.8 110 ±4.1 113 ±2.6 
Sodium valproate  300 100 ±5.7 94.0 ±3.8 86.3±3.0 
Lamotrigine  10 100 ±4.1 77.6 ±5.7 78.0 ±4.0 
Gabapentin  10 100 ±10 164±15* 123 ±12 
Topiramate  10 100±3.2 110 ±3.0 122 ±4.5 
Levetiracetam  6 100 ±6.0 115 ±5.9 114 ±4.8 
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2.4 Discussion  
Despite their common use, the mechanisms by which AEDs penetrate into the brain 
remain largely unknown.  A lot of attention has centred on the role of efflux transporters 
in the brain disposition of AEDs in particular P-gp; however the role of the SLC 
transporter family has been largely overlooked.   
 
Due to its predominant expression at the BBB, OATP1A2 was selected as a potential 
candidate for the transport of AEDs. Although the precise location of its membrane 
expression is debated, the majority of evidence suggests that OATP1A2 is expressed on 
the apical membrane of brain endothelial cells (Urquhart et al., 2009). OATP1A2 would 
thus likely act to pump drugs into brain endothelial cells that comprise the BBB from 
the blood, therefore a reduction in the expression of OATP1A2 might reasonably 
explain the lack of accumulation of substrate drugs in the brain. 
 
OATP1A2 is known to be involved in the transport of various drugs including the folate 
antimetabolite methotrexate and the quinolone antibacterial agent levofloxacin 
(Badagnani et al., 2006; Maeda et al., 2007).  The X. laevis model was used to 
demonstrate transport in both cases. Interestingly, many of the side effects associated 
with levofloxacin are central nervous system related including seizures, toxic 
psychoses, increased intracranial pressure and central nervous system stimulation 
(Maeda et al., 2007; Urquhart et al., 2009).  Brain accumulation of levofloxacin as a 
result of OATP1A2-mediated transport may be at least partly accountable for its adverse 
central nervous system effects; this would also lend weight to the relative importance of 
OATP1A2-mediated transport at the BBB.  More recently it was shown again using X. 
laevis oocytes transfected with SLCO1A2 that OATP1A2 also transports the HIV 
protease inhibitors saquinavir and lopinavir (Hartkoorn et al., 2010). 
 
Such studies suggest that OATP1A2 transports diverse substrates from different 
chemical and pharmacological groups and can partly explain why certain drugs attain 
greater than expected central nervous system concentrations.  Therefore, OATP1A2 has 
the potential to transport antiepileptic drugs, a chemically diverse group of drugs, at the 
BBB. 
 
Following the MCT family of transporters were chosen as a rational target to investigate 
possible AED transport as several members of the family are thought to be expressed at 
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the BBB (Geier et al., 2013; Shawahna et al., 2011; Uchida et al., 2011).  Furthermore 
there is mounting research suggesting VPA entry into the brain may be MCT mediated. 
Firstly in a human intestinal epithelial (Caco-2) and rat brain endothelial (RBE4) cell 
line various monocarboxylic acids such as benzoate, salicylate, acetate, propionate, 
butyrate, hexanoate, diclofenac and ibuprofen were shown to be strong inhibitors of 
valproate uptake and that uptake was a proton dependent rather than sodium dependent 
process.  From this the authors concluded that due to lack of expression of any other 
MCT protein at the rat brain endothelium, MCT1 is the predominant VPA uptake 
system at the rat BBB (Fischer et al., 2008).  However this could not be said for VPA 
transport at the intestinal epithelium, where a specific proton dependent, DIDS –
insensitive mechanism not identical with MCT1 was identified as the probable 
mechanism of VPA transport (Fischer et al., 2008).  In concurrence with these findings, 
apical to basolateral transport of VPA was shown to be inhibited by monocarboxylic 
acids but not dicarboxylic acids or anion exchange inhibitors in a human trophoblast 
cell line (BeWo).  Furthermore, on analysis of Lineweaver-Burk plots of VPA uptake 
into BeWo cells, benzoic acid, a marker for MCT1, was found to compete with VPA for 
transport, thus suggesting an MCT sensitive system for VPA transport, presumed to be 
MCT1 mediated (Utoguchi et al., 2000). 
 
Corresponding to data suggesting a MCT mediated mechanism is likely to be 
responsible for VPA transport, MCT1 was shown to be severely deficient on the 
endothelium of microvessels at the epileptogenic focus from tissue surgically resected 
in the treatment of individuals with drug resistant TLE.  A similar deficiency was also 
observed on the endothelium of microvessels in three novel rat models of TLE 
(Lauritzen et al., 2011; Lauritzen et al., 2012).  These studies provide evidence to 
suggest that VPA penetration into the brain is mediated by an MCT transporter, 
presumably MCT1 and furthermore that a deficiency of MCT expressed in brain 
microvessels may explain why lower than expected concentrations of VPA are observed 
in the brain.   
 
In this chapter, the possibility that OATP1A2 and/or MCT1 transport commonly 
prescribed antiepileptic drugs, including PHT, CBZ, VPA, LTG, GBP, TPM and LEV 
was evaluated using a X. laevis oocyte model.  Positive control substrates estrone-3-
sulfate and L-lactic acid were shown to be transported by OATP1A2 and MCT1, 
respectively. A significant increase in uptake in SLCO1A2 and SLC16A1-transfected 
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oocytes compared to controls was observed and was substantially inhibited by the 
OATP1A2 and MCT1 inhibitors naringenin and salicylic acid respectively, confirming 
the validity of the model and the reliability of the data.  
 
Subsequent data generated using this model clearly showed that none of the seven 
antiepileptic drugs investigated in this study was a substrate for OATP1A2-mediated 
transport.  No significant increase in antiepileptic drug uptake was observed in 
SLCO1A2-transfected oocytes compared to control oocytes that had been injected with 
water alone. Furthermore no decrease in transport was observed in the presence of the 
OATP1A2 inhibitor naringenin. Thus it would appear that OATP1A2 is not responsible 
for the transport of any of the antiepileptic drugs tested.   
 
However, OAPT1A2 demonstrates strong pH dependence, showing increased transport 
at lower pH. Imatinib is a substrate of OATP1A2 where pH dependent transport has 
been well characterised (Eechoute et al., 2011a). Although antiepileptic drug transport 
at low pH is not applicable to penetration at the BBB, where it is expected to be close to 
the physiological value of 7.4, it may potentially be important in intestinal absorption of 
AEDs, which up to now has gone largely uncharacterised. 
 
Although no increase in the transport of AEDs tested were observed in SLCO1A2-
transfected oocytes compared to control, GBP transport was seen to significantly 
increase in SLCO1A2-transfected oocytes in the presence of the OATP1A2 inhibitor 
naringenin.  Flavonoid compounds such as naringenin have been demonstrated to effect 
the activity of mammalian enzyme systems including protein kinases, ATPase 
phospholipase and cyclooxygenases.  It is not known if these effects extend to non-
mammalian enzyme systems, however the increase in GBP observed in the presence of 
naringenin could possibly be accounted for by such metabolic changes in X. laevis 
oocytes (Middleton et al., 2000).  It would however be expected that these effects would 
be observed in the presence of naringenin irrespective of the expression of human 
SLCO1A2 and the AED being tested.  As the effect is only observed with GBP it is 
unlikely this effect is due to interference with enzyme systems in X. laevis oocytes but 
perhaps a result of a chemical interaction between naringenin and GBP, seemingly 
aiding GBP uptake.  Alternatively the increase in GBP uptake observed in the presence 
of naringenin in the SLCO1A2-transfected oocytes may due to upregulation of an 
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endogenous transport system caused either by narringenin effects on cellular metabolic 
pathways or by the transfection process, in which GBP is able to exploit.   
 
A significant increase in gabapentin uptake was observed in SLC16A1-transfected 
oocytes compared to water injected controls, suggesting MCT1 mediated transport of 
gabapentin.  The inclusion of the MCT1 inhibitor salicylic acid reduced the elevation in 
gabapentin transport observed, however failed to reach statistical significance.  It 
therefore remains unclear whether MCT1 transports gabapentin or not.  The lack of 
inhibition by salicylic acid may be due to a lack of specificity at the concentration 
tested. It is also possible that gabapentin transport by MCT1 is mediated through an 
alternative binding site to that which accommodates lactic acid. If so, the simple 
competitive inhibition observed would appear to be without effect.  
 
No significant difference in PHT, CBZ, VPA, LTG, TPM and LEV uptake was 
observed in SLC16A1-transfected oocytes compared to water injected controls.  
Although strongly suggested in two functional studies using rat brain endothelial cells 
and trophoblasts, human MCT1 does not appear to transport VPA in a X. laevis oocyte 
model.  These conflicting findings could suggest that the inhibition of VPA uptake by 
monocarboxylic acids, shown by other groups previously (Utoguchi et al., 2000; 
Fischer et al., 2008), may be due to competition at another monocarboxylic acid 
transporter other than MCT1.  In total, there are ten known MCTs, of which 6 are 
functionally characterised and 3 have been shown to be expressed at least at mRNA 
level in a human BBB model. MCT1, MCT4 and MCT8 (Price et al., 1998; Pellerin et 
al., 2005).  It is therefore possible that another MCT isoform is responsible for the 
transport of VPA observed in previous investigation (Utoguchi et al., 2000; Fischer et 
al., 2008). This will be investigated further in chapter 3.   
 
The X. laevis transport model was chosen to investigate the ability of OAPT1A2 and 
MCT1 to transport AEDs.  The model was selected based on its proven use in transport 
studies and its non-mammalian origin.  A non-mammalian model is useful over 
physiologically relevant human cell lines, as endogenous expression of other 
transporters, efflux transporters in particular, may impact on the results.  Furthermore as 
X. laevis oocytes have to grow in unfavourable conditions in their natural environment, 
they are resilient and intrinsically possess substrates needed for growth and translation 
of proteins.  As the oocytes do not rely on uptake of exogenous nutrients from the 
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environment they also express very low numbers of endogenous membrane transporters 
(Wagner et al., 2000).  X. laevis oocytes have also been shown to inherently express the 
accessory protein basigin (Kirk et al., 2000), essential for the function of MCT1, 
therefore X. laevis oocytes are suitable as a vehicle for successful MCT1 expression.   
 
The main limitations of this study were predominantly associated with the labour 
intensive and time consuming nature of the X.laevis oocyte model, meaning that high 
throughput screening of multiple compounds at different concentrations with and 
without a number of inhibitors at a range of concentrations is almost impossible to 
achieve.  Another limitation of the model is that as a frog is poikilothermic therefore 
experiments with oocytes had to be performed at room temperature rather than the 
preferred mammalian physiological temperature.  Active transport is a temperature 
sensitive process, therefore transporter kinetics determined for OATP1A2 and MCT1 in 
oocytes may not represent that observed at mammalian physiological temperatures.  In 
addition although the levels of endogenous transporters and ion channels expressed in 
X. laevis oocytes are low, exogenously expressed proteins have been described to 
interfere with endogenous proteins.  For example when LAT-1 is transfected into 
X.laevis oocytes along with 4F2hc, a glycoprotein essential for heterodimer formation 
and therefore LAT-1 function, the activity of several endogenous amino acid 
transporters was induced (Wagner et al., 2000).  It is therefore possible that the 
transfection process and presence of high levels of exogenous protein may have induced 
the expression of endogenous transporter systems.   
 
In conclusion OATP1A2 and MCT1 do not appear to transport the AEDs PHT, CBZ, 
VPA, LTG, TPM and LEV. Thus, it is reasonable to assume that these transporters do 
not influence the brain penetration of most AEDs and do not contribute to 
pharmacoresistance in general.  Although it should not be discounted completely, 
attempts to test additional AEDs are probably not worthwhile as any remaining agents 
not investigated in this study are not commonly used in the clinic.  There is, however, 
some evidence from this study of MCT1-mediated transport of GBP. This merits further 
investigation to determine whether this is a potentially relevant mechanism in the brain 
penetration of GBP and perhaps even in the systemic disposition of the drug.  
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Chapter 3 
 
 
 
AED transport in hCMEC/D3 cells and the 
effects of MCT inhibitors 
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3.1 Introduction 
In the previous chapter, the ability of two distinct isoforms of SLC transporter, 
OATP1A2 and MCT1, to transport AEDs was investigated in a X.laevis transport 
model.  In addition to MCT1, 13 human MCT transporters have been identified and 
their tissue distributions at cDNA level defined (Price et al., 1998).  Of these, 5 have 
been functionally characterised and are discussed in detail below (Halestrap et al., 
1999). 
MCT4 has striking similarities to MCT1 in terms of structure and substrate/inhibitor 
specificity however differs in respect to its substrate affinity and hypothesised 
endogenous role (Morris et al., 2008).  In contrast to the ubiquitous tissue distribution of 
MCT1, MCT4 is predominantly expressed in tissues with a high glycolytic requirement 
such as white muscle and white blood cells, reflecting its suggested role in the efflux of 
lactate (Wilson et al., 1998).  Similarly to MCT1, MCT4 is known to transport the 
endogenous fuels lactate and pyruvate, however their affinity for MCT4 is markedly 
lower with Km values of 28mM and 150mM observed respectively (Dimmer et al., 
2000).  MCT1 and MCT4 are also both sensitive to inhibition by organomercurial 
compounds such as p-chloromercuribenzene sulfonate (pCMBS).  Inhibition by such 
compounds has been shown to be through the disruption of the essential accessory 
protein basigin which is required for membrane expression and catalytic activity of both 
MCT1 and MCT4 (Wilson et al., 2005).  Basigin is a glycoprotein containing a single 
transmembrane span which acts as a chaperone, translocating MCT1/MCT4 to the 
plasma membrane where the transporter and basigin remain tightly bound. Dissociation 
of MCT1/MCT4 from basigin renders the transporter defunct (Manoharan et al., 2006).  
In addition to inhibition by organomercurials, MCT4 has been shown to be inhibited by 
HMG-CoA reductase inhibitors (i.e. statin drugs) which possess monocarboxylate 
structures.  In a stably co-transfected MCT4/CD147 pig kidney epithelial cell line, 
lipophilic statins such as fluvastatin, atorvastatin, lovastatin acid, simvastatin acid and 
cerivastatin were shown to significantly inhibit L-lactic acid transport, with IC50 values 
between 32µM and 96µM (Kobayashi et al., 2006).  Therapeutic agents known to 
inhibit MCT1 are described in the previous chapter.      
MCT2 shares around 60% sequence identity with MCT1 and is expressed in most of the 
same tissues.  Vital for membrane expression of MCT2 is its interaction with an 
accessory protein, embigin.  Embigin is a glycoprotein, homologous to the 
MCT1/MCT4 accessory protein basigin which similarly acts as a chaperone, 
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translocating MCT2 to the plasma membrane where the two proteins remain tightly 
associated (Wilson et al., 2005).  Although MCT1 and MCT4 preferentially associate 
with basigin and MCT2 with embigin, all three transporters can interact with either 
accessory protein in the absence of its primary partner (Poole et al., 1997; Kirk et al., 
2000; Wilson et al., 2002).  Due to its preferential association with embigin in 
mammalian cells, MCT2, unlike MCT1/MCT4, is insensitive to organomercurial 
inhibition (Wilson et al., 2005).  The ability to specifically inhibit MCT1 has recently 
been pursued by AstraZeneca who have developed a new class of specific and high 
affinity MCT1 inhibitors such as AR-C155858 as part of their immunosuppressive drug 
discovery programme (Murray et al., 2005; Guile et al., 2006).  AR-C155858 exhibits 
maximal inhibition of L-lactic acid transport by MCT1 at concentrations as low as 2nM, 
independent of its associated accessory protein.  Interestingly, MCT4 is insensitive to 
AR-C155858 inhibition, an observation attributed to differences in the structure of 
transmembrane domains 7-10 in MCT1 and MCT4.  Unlike with MCT1, AR-C155858 
inhibition of MCT2 was found to be dependent on its interaction with either basigin or 
embigin.  When associated with embigin, the binding affinity of AR-C155858 to MCT2 
is greatly reduced (Ovens et al., 2010a; Ovens et al., 2010b).  
MCT1 to MCT4 represent the lactate transporting members of the MCT family and 
share many structural and functional similarities.  A number of molecules have been 
shown to inhibit these transporters and can be divided into 3 chemical categories.  The 
most potent MCT inhibitors are diverse amphiphilic compounds such as bioflavonoids 
and anion transport inhibitors which exhibit Ki concentrations of 1-10µM.  MCT 
transport is also potently inhibited by bulky or aromatic monocarboxylates such as 
phenylpyruvate and derivatives of α-cyancinnamate which exhibit Ki values of 50-
500µM.  MCT2 is more sensitive to inhibition by derivatives of α-cyancinnamate than 
MCT1 whereas little inhibition of MCT4 is observed.  Finally, some stilbene-2, 
2’disulphonates such as 4, 4′-diisothiocyanatostilbene-2, 2′-disulfonic acid (DIDS) are 
known to inhibit MCT transport; MCT2 is more sensitive to stilbene-2, 2’disulphonate 
inhibition than MCT1 and only very little inhibition of MCT4 is observed.  MCT 
transport is also irreversibly inhibited by a range of thiol reagents, MCT1 and, to a 
lesser extent, MCT4 are sensitive to organomercurial inhibition, whereas MCT2 is 
insensitive as described previously (Halestrap et al., 2004; Halestrap, 2013).  Detailed 
inhibitor specificity for MCT3 is lacking and although very similar to MCT1, MCT2 
and MCT4 in terms of  structure and substrate specificity, MCT3 has  a very restricted 
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tissue distribution and is confined to the basal membrane of the retinal pigment 
epithelium and choroid plexus epithelia (Morris et al., 2008). 
MCT8 and MCT10 share around 30% sequence identity with MCT1 to MCT4 and the 
tissue distribution of both proteins is generally widespread.  In the brain, MCT8 
expression  was originally thought to be restricted to neurons, however a recent study 
reported additional expression in human cerebral microvessels (Roberts et al., 2008).  
Unlike MCT1 to MCT4, MCT8 and MCT10 do not transport fuels such as lactate and 
pyruvate and instead function via a proton- independent, Na+-dependent mechanism to 
transport thyroid hormones and aromatic amines respectively (Morris et al., 2008).  
Data summarising the sensitivity of MCT8 and MCT10 to generic MCT inhibitors is not 
available, however MCT8 has been suggested to be inhibited by tyrosine kinase 
inhibitors in a non-competitive manner.  In MCT8 transfected canine kidney epithelial 
cells, sunitinib, imatinib, bosutinib and dasatinib were all shown to inhibit MCT8-
mediated transport of both iodothyronine (T3) and thyroxine (T4) with IC50 values 
between 13µM and 38µM (Braun et al., 2011).   
The need for an in vitro BBB model that mimics the in vivo properties of the human 
BBB and that can be cultured easily and used in high throughput screening is essential 
for CNS compound development in industry and academic CNS research (Eigenmann et 
al., 2013). The immortalised human cerebral microvascular endothelial cell line 
(hCMEC/D3) represents such a model.  hCMEC/D3 cells were derived from human 
temporal lobe microvessels, isolated during resective surgery for the treatment of 
epilepsy.  The cells were sequentially immortalised by lentiviral vector transduction and 
the resulting clones characterised in terms of their biological properties (Weksler et al., 
2013).  hCMEC/D3 cells were found to phenotypically mimic the in vivo human BBB, 
constitutively expressing endothelial cell markers, tight junction proteins and 
transporter proteins at the appropriate subcellular location (Tai et al., 2009; Eigenmann 
et al., 2013; Weksler et al., 2013).  In addition to the initial characterisation of 
hCMEC/D3 cells, a recent array study described the expression of a variety of SLC 
transporters at mRNA level.  Relatively high expression of SLC16A1 (MCT1) and 
SLC16A3 (MCT4) was observed, while little to no expression of SLC16A2 (MCT8) was 
described.  Expression of other MCT transporters was not investigated in this analysis 
(Carl et al., 2010).  
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The hCMEC/D3 cell line has been successfully used in a number of drug transport 
studies aiming to characterise BBB uptake of drugs of interest.  A recent study used 
hCMEC/D3 cells to elucidate the reason for strikingly different rates of brain uptake 
between two very structurally similar anti-influenza drugs: adamantine and rimantadine.  
Uptake of the two drugs was inhibited by various cationic transporter inhibitors and was 
dependent on pH, membrane depolarisation and Na+/Cl- ions, indicating the 
involvement of a neutral and cationic amino acid transporter in the uptake of these drugs 
(Kooijmans et al., 2012).  The hCMEC/D3 cell line was also recently utilised with a 
panel of organic cation transporter inhibitors in a similar study to demonstrate the 
involvement of OCT1 in the uptake of LTG (Dickens et al., 2012).     
The studies described in this this chapter utilised the hCMEC/D3 cell line and a panel of 
MCT inhibitors (table 3.1) in an effort to identify whether any commonly used AEDs, 
including PHT, CBZ, VPA, LTG, GBP, TPM and LEV, are subject to MCT mediated 
transport and if so, to elucidate which particular MCT transporter may be responsible.   
 
 
 
 
 
 
 
 
 
 
 
 
 
65 
 
3.2 Materials and methods 
3.2.1 Experimental plan 
To fully characterise MCT mediated transport of seven commonly prescribed AEDs (as 
listed above), a panel of MCT transport inhibitors were selected.  Incubation 
concentrations of inhibitors were chosen based on previous findings from available 
literature, with the exception of simvastatin acid which concentration was reduced from 
100µM to 10µM after significant cell death was observed at the higher concentration in 
initial experiments.  A number of non-specific MCT transport inhibitors along with 
compounds thought to selectively inhibit specific MCT transporters were included and 
are listed in table 3.1.  These inhibitors were co-incubated with AEDs in the 
hCMEC/D3 BBB model.   
 
 
 
Table 3.1: Summary of monocarboxylic acid transporter (MCT) inhibitors used in this 
chapter.  NPPB (5-nitro-2-(3-phenylpropylamino) benzoic acid), DIDS (4, 4′-
diisothiocyanatostilbene-2, 2′-disulfonic acid), SITS (4-acetamido-4′-isothiocyanato-2, 
2′-stilbenedisulfonic acid), 4-MBA (4-(hydroxymercuri) benzoic acid).   
 
 
 
 
Inhibitor 
Concentration 
(µM) 
Chemical class 
Known MCT 
selectivity 
Phenyl-pyruvate 100 Aromatic monocarboxylate None 
Ethyl-
cyancinnomate 
100 α-cyancinnamate derivative 
Higher affinity for 
MCT2 
Methyl-
cyancinnomate 
100 α-cyancinnamate derivative 
Higher affinity for 
MCT2 
Phloretin 1000 
Bioflavanoid 
 
None 
Quercetin 1000 Bioflavanoid None 
Niflumic acid 100 Anion transport inhibitor None 
NPPB 100 Anion transport inhibitor None 
DIDS 1000 Stilbene-2,2’disulphonate 
Higher affinity for 
MCT2 
SITS 1000 Stilbene-2,2’disulphonate 
Higher affinity for 
MCT2 
4-MBA 100 Organomercurial MCT1 and MCT4 
Simvastatin acid 10 Statin Unknown 
Imatinib 100 Tyrosine kinase inhibitor MCT8 
L-lactic acid 1000 
Monocarboxylate 
 
Higher affinity for 
MCT2 
Salicylic acid 1000 Monocarboxylate None 
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3.2.2 Materials 
[14C]-L-lactic acid (specific activity, 130.8mCi/mmol) was purchased from Perkin 
Elmer (Massachusetts, USA).  [3H]-lamotrigine (specific activity, 5Ci/mmol), [3H]-
levetiracetam (specific activity, 5Ci/mmol), [3H]-topiramate (specific activity, 
8Ci/mmol) and [3H]-gabapentin (specific activity, 110Ci/mmol) were purchased from 
American Radiolabeled Chemicals Inc (St. Louis, USA).  [3H]-phenytoin (specific 
activity 1.1Ci/mmol), [3H]-carbamazepine (specific activity 10Ci/mmol) and [3H]-
valproic acid (specific activity 55Ci/mmol) were purchased from Moravek (Brea, 
California, USA).  Rat tail collagen type I and chemically defined lipid concentrate 
were purchased from Invitrogen (Paisley, UK).  Cell culture plasticware was purchased 
from Nunc Fisher Scientific (Loughborough, UK).  EBM-2 medium was purchased 
from Lonza (Slough, UK).  All other drugs and chemicals were purchased from Sigma-
Aldrich (Poole, Dorset, UK), unless otherwise stated.  The hCMEC/D3 cell line was 
provided courtesy of Dr Ignacio Romero (Department of Life Sciences, The Open 
University, Milton Keynes, UK) and Professor Pierre Couraud (Institut Cochin, 
Université Paris Descartes, Paris, France).   
 
3.2.3 Human cerebral microvascular  endothelial cell (hCMEC/D3) culture 
hCMEC/D3 cells were cultured in collagen type I (100ug/ml) coated T175 flasks, 
maintained in EBM-2 medium supplemented with 5% foetal calf serum (FCS), 1% 
penicillin-streptomycin, 0.5% chemically defined lipid concentrate, 10mM HEPES, 
1.4µM hydrocortisone, 5µg/ml ascorbic acid and 1ng/ml basic fibroblast growth factor 
(figure 3.1) and housed in an incubator at 370C, 5% CO2 (Thermo Scientific Function 
Line).  Cells were passaged every 2-3 days and seeded onto collagen type I coated six-
well plates at a concentration of 3x106cells/well as required. The passage/seeding 
procedure was as follows; media was removed from flasks using a serological pipette 
and flasks washed twice in 10ml of warm Hanks balanced salt solution (HBSS).  Cells 
were then cleaved from the flask surface with 10ml of 0.25% trypsin-EDTA and left to 
incubate at 370C for 5 minutes.  Thereafter, 20ml of EBM-2 media was added to 
neutralise the trypsin, and the cell suspension transferred to a 50ml Falcon tube and 
centrifuged at 250 x g for 5 minutes to pellet the cells (Thermo Scientific Heraus 
Megafuge IIR).  Cells were resuspended in 10ml of complete media and a cell count 
made (see section 3.2.4).  The cell suspension was diluted with complete media to 
1.5x106cells/ml and 2ml of the suspension added to each well, cells were then incubated 
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at 370C for 2 days.  The remainder of the suspension was returned to T175 flasks at a 
1:5 dilution to grow on. 
 
 
Figure 3.1: A light microscopy image of a confluent hCMEC/D3 monolayer.  
 
3.2.4 Cell Counting 
Before seeding the hCMEC/D3 cells, a cell count was made using the Countess 
automated cell counter (Invitrogen, Paisley, UK).  A 10µl volume of the resuspended 
cell pellet was added to a 1.5ml Eppendorf tube and mixed with 10µl of 0.4% trypan 
blue.  The mixture was then pipetted under the cover slip of a Countess cell counting 
chamber slide and inserted into the instrument.   
 
3.2.5 Cellular uptake of AEDs and effects of a panel of MCT inhibitors 
Uptake experiments employed a radiolabelled concentration of 0.3µCi/ml supplemented 
with non-radiolabelled drug to give final concentrations of 25µM PHT, 20µM CBZ, 
300µM VPA, 10µM LTG, 10µM TPM, 10µM GBP and 6µM LEV, all prepared in 
transport medium (HBSS supplemented with 25mM HEPES and 0.1% bovine serum 
albumen (BSA), at pH7.4).  A radiolabel concentration of 0.3µCi/ml afforded sufficient 
disintegrations per minute to give accurate readings of radioactive content without 
saturating the scintillation counter.  Final concentrations of monocarboxylate transporter 
(MCT) inhibitors employed are listed in table 3.1. 
 
On the day of the assay, media was aspirated from the cells and cells allowed to 
equilibrate in transport medium at 370C for 30 minutes.  A dosing solution was made 
for each AED using transport medium containing the respective radiolabelled/non-
radiolabelled drug (to a final concentration as stated previously) with either inhibitor or 
vehicle (DMSO; for control purposes). This solution was added to the cells, which were 
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then incubated at 370C for 60 minutes.  In the meantime, samples (20µl) of transport 
buffer alone (blanks) and samples (20µl) of dosing solution (standards) were taken and 
added to scintillation vials for later determination of background radiation and 
radioactive content of a known concentration of each drug solution, respectfully.  After 
incubation, cells were washed three-times in ice cold HBSS to terminate uptake and 
solubilised for 30 minutes at 370C with 400µl of 10% sodium dodecyl sulphate.  The 
resulting solution was then transferred to individual scintillation vials and 4ml of 
scintillation fluid (Goldstar Multipurpose Scintillation Cocktail (Meridian, UK) added 
to all vials.  Vials were mixed by inverting several times before radioactive content was 
determined using a scintillation counter (1500 Tri Carb LS Counter; Packard).  Results 
in dpm were corrected for background counts, quantified in relation to standards of 
known concentration and expressed (in pmol/100,000 cells) in relation to the number of 
cells per well. 
 
3.2.6 Statistical testing 
All data is presented as the mean (± standard error of the mean) percentage of mean 
control transport (AED without inhibitor) for each AED on each experimental day.  
Individual experiments were performed in triplicate and repeated on at least three 
occasions (n≥9).  Data was assessed for normality using the Shapiro-Wilk test and 
found to be normally distributed.  An analysis of variance (ANOVA) was performed on 
the data with Tukey’s post hoc test for multiple comparisons.  A value of p≤0.05 was 
taken to indicate statistical significance. 
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3.3  Results 
3.3.1 PHT uptake and effects of a panel of MCT inhibitors   
A significant decrease in PHT uptake was observed in the presence of the bioflavonoids 
phloretin and quercetin,  reducing PHT uptake to 14 ± 0.9% and 53 ± 2.4% of the 
control value (100 ± 2.0%), respectively (p≤0.001).  A significant decrease in PHT 
uptake was also observed in the presence of simvastatin, reducing uptake to 52 ± 6.4% 
of control (100 ± 1.1%; p≤0.001).  Conversely, a significant increase in PHT uptake 
was seen in the presence of lactic acid (126 ± 9.9%) in comparison to control (100 ± 
2.0%; p≤0.05).  Minor changes in PHT uptake were observed in the presence of ethyl-
cyancinnomate (116 ± 7.1%), methyl-cyancinnomate (117 ± 8.7%), DIDS (118 ± 7.2%) 
and SITS (82 ± 6.3%) compared to control; however none was statistically significant 
(figure 3.2; table 3.2).     
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Figure 3.2: Effects of a panel of MCT inhibitors on the uptake of phenytoin (PHT) into hCMEC/D3 cells. Cultures were exposed to 25μM 
radiolabelled PHT with or without inhibitors at the concentrations shown for one hour at 370C. Results are expressed as the mean ± standard error of 
the mean (SEM) percentage of the mean control value of PHT uptake (in pmols/100,000 cells) on each experimental day. Experiments were performed 
in triplicate on three separate occasions (n=9). Statistical significance (**p<0.001, *p<0.05) was determined by one-way analysis of variance with 
Tukey’s correction for multiple testing. (NPPB, 5-nitro-2-(3-phenylpropylamino) benzoic acid); DIDS, 4,4′-diisothiocyanatostilbene-2,2′-disulfonic 
acid; SITS, 4-acetamido-4′-isothiocyanato-2,2′-stilbenedisulfonic acid; 4-MBA, 4-(hydroxymercuri)benzoic acid.
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3.3.2 CBZ uptake and effects of a panel of MCT inhibitors   
The bioflavanoid quercetin significantly increased CBZ uptake to 408 ± 60% of the 
control value (100 ± 3.0%; p ≤0.001); none of the remaining MCT inhibitors 
demonstrated any significant effect on CBZ uptake (figure 3.3; table 3.2). 
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Figure 3.3: Effects of a panel of MCT inhibitors on the uptake of carbamazepine (CBZ) into hCMEC/D3 cells. Cultures were exposed to 20μM 
radiolabelled CBZ with or without inhibitors at the concentrations shown for one hour at 370C. Results are expressed as the mean ± standard error of 
the mean (SEM) percentage of the mean control value of CBZ uptake (in pmols/100,000 cells) on each experimental day. Experiments were performed 
in triplicate on three separate occasions (n=9). Statistical significance (*p<0.001) was determined by one-way analysis of variance with Tukey’s 
correction for multiple testing. (NPPB, 5-nitro-2-(3-phenylpropylamino) benzoic acid); DIDS, 4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid; SITS, 
4-acetamido-4′-isothiocyanato-2,2′-stilbenedisulfonic acid; 4-MBA, 4-(hydroxymercuri)benzoic acid).
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3.3.3 VPA uptake and effects of a panel of MCT inhibitors 
An increase in VPA uptake to 168 ± 10% of the control value (100 ± 8.0%) was 
observed in the presence of the bioflavanoid compound quercetin (p ≤0.001). VPA 
uptake also increased to 138 ± 6.5% of the control in the presence of 4-MBA, but this 
effect failed to reach statistical significance.  None of the remaining MCT inhibitors 
demonstrated any significant effect on VPA uptake (figure 3.4; table 3.2).    
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Figure 3.4: Effects of a panel of MCT inhibitors on the uptake of valproic acid (VPA) into hCMEC/D3 cells.  Cultures were exposed to 300μM 
radiolabelled VPA with or without inhibitors at the concentrations shown for one hour at 370C.  Results are expressed as the mean ± standard error of 
the mean (SEM) percentage of the mean control value of VPA uptake (in pmols/100,000 cells) on each experimental day.  Experiments were 
performed in triplicate on three separate occasions (n=9).  Statistical significance (*p<0.001) was determined by one-way analysis of variance with 
Tukey’s correction for multiple testing.  (NPPB, 5-nitro-2-(3-phenylpropylamino) benzoic acid); DIDS, 4,4′-diisothiocyanatostilbene-2,2′-disulfonic 
acid; SITS, 4-acetamido-4′-isothiocyanato-2,2′-stilbenedisulfonic acid; 4-MBA, 4-(hydroxymercuri)benzoic acid). 
75 
 
 
3.3.4 LTG uptake and effects of a panel of MCT inhibitors   
The bioflavanoid compound quercetin and the anion transport inhibitors niflumic acid 
and NPPB increased LTG uptake to 180 ± 8.4% (p ≤0.001), 132 ± 7.1% (p ≤0.01) and 
147 ± 11% (p ≤0.01) of the control value (100 ± 3.2%), respectively.   A decrease in 
LTG uptake was observed in the presence of phloretin and imatinib, reducing LTG 
uptake to 26 ± 2.0% and 33 ± 2.5% of control (both p ≤0.001), respectively.  Minor 
changes in LTG transport were observed in the presence of DIDS (120 ± 24%) and 
SITS (77 ± 3.0%), but these did not reach statistical significance (figure 3.5; table 3.2).   
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Figure 3.5: Effects of a panel of MCT inhibitors on the uptake of lamotrigine (LTG) into hCMEC/D3 cells. Cultures were exposed to 10μM 
radiolabelled LTG with or without inhibitors at the concentrations shown for one hour at 370C. Results are expressed as the mean ± standard error of 
the mean (SEM) percentage of the mean control value of LTG uptake (in pmols/100,000 cells) on each experimental day. Experiments were performed 
in triplicate on three separate occasions (n=9). Statistical significance (**p<0.001, *p<0.05) was determined by one-way analysis of variance with 
Tukey’s correction for multiple testing. (NPPB, 5-nitro-2-(3-phenylpropylamino) benzoic acid); DIDS, 4,4′-diisothiocyanatostilbene-2,2′-disulfonic 
acid; SITS, 4-acetamido-4′-isothiocyanato-2,2′-stilbenedisulfonic acid; 4-MBA, 4-(hydroxymercuri)benzoic acid).
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3.3.5 GBP uptake and effects of a panel of MCT inhibitors  
Increases in GBP uptake were observed in the presence of quercetin, NPPB, DIDS, 
SITS, simvastatin and salicylic acid, with GBP uptake increasing to 242 ± 20% (p 
≤0.001), 261 ± 22% (p ≤0.001), 159 ± 16% (p ≤0.001), 131 ± 5.1% (p ≤0.01), 129 ± 
3.3% (p ≤0.05) and 128 ± 2.6% (p ≤0.05) of the control value (100 ± 3.7%), 
respectively.  In contrast, a decrease in GBP uptake compared to control was observed 
in the presence of phloretin (5.3 ± 1.0%, p<0.001) and 4-MBA (3.0 ± 0.2%, p<0.001) 
(figure 3.6; table 3.2).  
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Figure 3.6: Effects of a panel of MCT inhibitors on the uptake of gabapentin (GBP) into hCMEC/D3 cells. Cultures were exposed to 10μM 
radiolabelled GBP with or without inhibitors at the concentrations shown for one hour at 370C. Results are expressed as the mean ± standard error of 
the mean (SEM) percentage of the mean control value of GBP uptake (in pmols/100,000 cells) on each experimental day. Experiments were performed 
in triplicate on three separate occasions (n=9). Statistical significance (***p<0.001, **p<0.01, *P<0.05) was determined by one-way analysis of 
variance with Tukey’s correction for multiple testing. (NPPB, 5-nitro-2-(3-phenylpropylamino) benzoic acid); DIDS, 4,4′-diisothiocyanatostilbene-
2,2′-disulfonic acid; SITS, 4-acetamido-4′-isothiocyanato-2,2′-stilbenedisulfonic acid; 4-MBA, 4-(hydroxymercuri)benzoic acid).
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3.3.6 TPM uptake and effects of a panel of MCT inhibitors   
The presence of phloretin and SITS decreased TPM uptake to 49 ± 3.9% (p≤0.001) and 
75 ± 3.4% (p≤0.001) of the control value (100 ± 2.3%), respectively.  Conversely, ethyl-
cyancinnamate, quercetin and niflumic acid increased TPM uptake to 115 ± 2.5% 
(p≤0.05), 168 ± 2.1% (p≤0.001) and 117 ± 1.6% (p≤0.01) of control, respectively 
(figure 3.7; table 3.2). 
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Figure 3.7: Effects of a panel of MCT inhibitors on the uptake of topiramate (TPM) into hCMEC/D3 cells. Cultures were exposed to 10μM 
radiolabelled TPM with or without inhibitors at the concentrations shown for one hour at 370C. Results are expressed as the mean ± standard error of 
the mean (SEM) percentage of the mean control value of TPM uptake (in pmols/100,000 cells) on each experimental day. Experiments were performed 
in triplicate on three separate occasions (n=9). Statistical significance (***p<0.001, **p<0.01, *p<0.05) was determined by one-way analysis of 
variance with Tukey’s correction for multiple testing. (NPPB, 5-nitro-2-(3-phenylpropylamino) benzoic acid); DIDS, 4,4′-diisothiocyanatostilbene-
2,2′-disulfonic acid; SITS, 4-acetamido-4′-isothiocyanato-2,2′-stilbenedisulfonic acid; 4-MBA, 4-(hydroxymercuri)benzoic acid). 
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3.3.7 LEV uptake and effects of a panel of MCT transporter inhibitors   
A decrease in LEV uptake was observed in the presence of the bioflavanoid phloretin, 
reducing LEV uptake to 20 ± 9.1% (p≤0.001) of the control value (100 ± 3.2%).  No 
changes in uptake were observed in the presence of any other MCT inhibitor (figure 
3.8; table 3.2).   
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Figure 3.8: Effects of a panel of MCT inhibitors on the uptake of levetiracetam (LEV) into hCMEC/D3 cells. Cultures were exposed to 6μM 
radiolabelled LEV with or without inhibitors at the concentrations shown for one hour at 370C. Results are expressed as the mean ± standard error of 
the mean (SEM) percentage of the mean control value of LEV uptake (in pmols/100,000 cells) on each experimental day. Experiments were performed 
in triplicate on three separate occasions (n=9). Statistical significance (*p<0.001) was determined by one-way analysis of variance with Tukey’s 
correction for multiple testing. (NPPB, 5-nitro-2-(3-phenylpropylamino) benzoic acid); DIDS, 4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid; SITS, 
4-acetamido-4′-isothiocyanato-2,2′-stilbenedisulfonic acid; 4-MBA, 4-(hydroxymercuri)benzoic acid). 
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Table 3.2: Effects of a panel of MCT inhibitors on the uptake of a panel of antiepileptic drugs into hCMEC/D3 cells. Cultures were exposed to 25µM radiolabelled 
phenytoin, 20µM radiolabelled carbamazepine, 300µM radiolabelled sodium valproate, 10µM radiolabelled lamotrigine, 10µM radiolabelled gabapentin, 10µM 
radiolabelled topiramate and 6µM radiolabelled levetiracetam with or without inhibitors at the concentrations shown for one hour at 370C. Results are expressed as 
the mean ± standard error of the mean (SEM) percentage of the mean control value of uptake (in pmols/100,000 cells) on each experimental day. Experiments were 
performed in triplicate on three separate occasions (n=9). Statistical significance (***p<0.001, **p<0.01, *p<0.05) was determined by one-way analysis of variance 
with Tukey’s correction for multiple testing. (NPPB, 5-nitro-2-(3-phenylpropylamino) benzoic acid); DIDS, 4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid; SITS, 
4-acetamido-4′-isothiocyanato-2,2′-stilbenedisulfonic acid; 4-MBA, 4-(hydroxymercuri)benzoic acid). 
 
Mean ± SEM uptake (% of control) 
Phenytoin Carbamazepine 
Sodium 
valproate 
Lamotrigine Gabapentin Topiramate Levetiracetam 
Control 100 ±1.9  100 ±3.0 100 ±8.0 100 ±3.2 104 ±3.7 100 ±2.3 100 ±3.2 
Phenylpyruvate 100µM 98.9 ±4.2    118 ±4.8 135 ±5.2 107 ±5.9 67.7 ±3.5 108 ±4.4 106 ±3.6 
Ethyl-cyancinnomate 100µM 116 ±10 133 ±22 123 ±7.0 110 ±7.8 106 ±3.9 115 ±2.4* 115 ±11 
Methyl-cyancinnomate 100µM 117 ±12 130 ±27 109 ±6.4  102 ±11 97.9 ±8.1 109 ±1.4 122 ±18 
Phloretin 1000µM 14.0 ±1.3*** 120 ±27 93.8 ±7.0 26.0 ±2.5*** 5.31 ±1.4*** 49.2 ±3.9*** 20.1 ±9.1*** 
Quercetin 1000µM 53.2 ±3.4*** 408 ±60*** 168 ±10*** 180 ±12*** 242 ±20*** 168 ±2.1*** 109 ±9.1 
Niflumic acid 100µM 107 ±7.1 127 ±16 86.2 ±8.2 147 ±11* 261 ±22 89.4 ±9.6** 105 ±5.3 
NPPB 100µM 85.7 ±4.2 104 ±6.1 132 ±10 132 ±9.2* 111 ±11*** 117 ±1.6 117 ±9.9 
DIDS 1000µM 118 ±7.2 78.7 ±5.9 105 ±11 120 ±24 159 ±16*** 86.2 ±5.9 100 ±4.6 
SITS 1000µM 81.9 ±6.3 85.4 ±6.9 99.1 ±11 77.4 ±3.0 131 ±5.1** 74.8 ±3.3** 98.4 ±5.9 
4-MBA 100µM 100 ±3.0 126 ±11 138 ±22 102 ±8.2 2.75 ±0.23*** 91.7 ±2.3 120 ±12 
Simvastatin 10µM 51.6 ±6.4*** 106 ±2.8 102 ±10 96.5 ±8.5 129 ±3.3* 107 ±4.9 98.4 ±3.0 
Imatinib 100µM 108 ±6.1 101 ±8.9 112 ±9.9 39.8 ±4.2*** 111 ±0.46 94.9 ±6.3 101 ±15 
L-lactic acid 1000µM 126 ±14* 126 ±14 130 ±10 95.5 ±7.5 92.8 ±6.0 103 ±1.1 123 ±15 
Salicylic acid 1000µM 81.1 ±5.2 91.8 ±6.5 102 ±5.1 101 ±4.9 128 ±2.6* 100 ±1.4 103 ±5.6 
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3.4 Discussion 
Members of the MCT family are known to be expressed at the BBB where they function 
to supply the brain with nutrients and to transport thyroid hormones (Pierre et al., 2005; 
Roberts et al., 2008).  In addition, a number of drugs have been suggested to be 
substrates and/or inhibitors of MCT-mediated transport  (Neuhoff et al., 2005; 
Kobayashi et al., 2006; Wang et al., 2006; Braun et al., 2011) including the AED VPA 
(Utoguchi et al., 2000; Fischer et al., 2008) and the GBP prodrug, gabapentin enacarbil 
(Cundy et al., 2004; Lal et al., 2010).   
 
In this chapter the transport of commonly prescribed AEDs was investigated in the 
hCMEC/D3 cell line, with the aim of characterising any MCT-mediated transport by the 
inclusion of various chemical inhibitors of MCTs.  The hCMEC/D3 cells were chosen 
as the investigative in vitro model of the BBB as they are phenotypically very similar to 
brain endothelial cells in vivo (Weksler et al., 2013).  In addition, hCMEC/D3 cells 
have been reported to express several  MCT transporters (Carl et al., 2010). To 
summarise the findings, the inclusion of various chemical MCT inhibitors had a 
significant impact on the transport of PHT, LTG, GBP and TPM and minor influences 
on the transport of CBZ, VPA and LEV.  
 
PHT uptake was seen to both increase and decrease with the inclusion of MCT 
inhibitors.  The bioflavonoids phloretin and quercetin and the HMG-CoA inhibitor 
simvastatin significantly decreased PHT uptake, whereas lactic acid significantly 
increased PHT uptake (figure 3.1; table 3.2).  HMG-CoA inhibitors have been 
demonstrated to inhibit MCT4 transport (Kobayashi et al., 2006) suggesting the 
decrease in PHT uptake in the presence simvastatin acid is due to inhibition of MCT4 
mediated transport.  However it is not known whether inhibition is specific to MCT4 or 
if activity extends to multiple MCT transporters.  Given the overlapping substrate 
specificity of MCT1 - 4 it is conceivable that simvastatin acid inhibits all four proteins 
albeit with varying potency.  Furthermore both phloretin and quercetin are non-specific 
MCT transport inhibitors therefore it cannot be confirmed which MCT transporter, if 
any, is responsible for the decreases in PHT uptake observed.  Alternatively, it is 
plausible that the inhibition of PHT uptake observed in the presence of these inhibitors 
is not MCT-mediated.  In addition to MCT4, HMG-CoA inhibitors such as simvastatin 
have been demonstrated to be both substrates and inhibitors of the organic anion 
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transporting polypeptides OATP1B1, OATP1B3 and OATP2B1 (Hirano et al., 2004; 
Chen et al., 2005; Kopplow et al., 2005; Hirano et al., 2006; Ho et al., 2006), the latter 
of which has been demonstrated to be expressed in hCMEC/D3 cells (Carl et al., 2010).  
Furthermore OATP2B1-mediated transport of estrone-3-sulphate in X.laevis oocytes  
has also been shown to be subject to inhibition by phloretin and quercetin (Shirasaka et 
al., 2012).  In addition inhibition of GLUT1-mediated transport of glucose in 
erythrocytes (Martin et al., 2003) and GLUT2/GLUT8-mediated transport of 
dihydroascorbic acid in SLC2A2/SLC2A8 transfected X.laevis oocytes (Corpe et al., 
2013) has also been demonstrated to be potently inhibited by both flavonoids.  Due to 
the demonstrated activity of simvastatin, phloretin and quercetin at other transporters, 
the changes in PHT uptake observed in hCMEC/D3 cells cannot be confidently 
attributed to inhibition of MCT-mediated transport and further work is necessary to 
identify the transporter implicit in the uptake of PHT into hMEC/D3 cells.   
 
The modest increase in PHT uptake observed in the presence of L-lactic acid could be 
explained by potential efflux of PHT by an MCT.  In white skeletal muscle fibres 
MCT4 has been demonstrated to be expressed in a muscle to blood orientation on the 
muscle fibre membrane, where it functions to efflux lactic acid into the blood (Manning 
Fox et al., 2000; Halestrap et al., 2004).  Expression of MCT4 in hCMEC/D3 cells has 
only been shown at mRNA level (Carl et al., 2010), therefore the membrane location of 
the protein product it is not known.  However if orientated in the brain to blood 
orientation at the apical membrane of cerebral endothelial cells, it may function to 
efflux lactic acid and other substrates.  If so, the increase in PHT uptake in the presence 
of lactic acid observed may be due to competition for MCT4, therefore less PHT is 
effluxed from the cell.   
 
LTG uptake was dramatically reduced in the presence of imatinib and phloretin (figure 
3.5; table 3.2).  Imatinib has recently been shown to inhibit MCT8-mediated transport in 
an MDCK cell line stably expressing MCT8 (Braun et al., 2011).  However, as with 
phloretin which has been shown to inhibit a number of SLC transporters as discussed 
previously, imatinib has also been implicated in the inhibition of other SLC transporters 
in addition to MCT8.   Recently, imatinib has been shown to be transported by both 
cationic and anionic transporters.  Imatinib was demonstrated to be subject to 
OATP1A2-mediated transport  in a HEK293 cell line stably expressing OATP1A2 (Hu 
et al., 2008). In addition,  LTG and imatinib have been shown to be substrates for 
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organic cation transporter 1 (OCT1) in a KCL22 cell line stably expressing OCT1 and a 
human T-lymphoblastoid (CCRF-CEM) cell line, respectively (Thomas et al., 2004; 
Dickens et al., 2012).  The inhibition of LTG uptake observed in the presence of 
imatinib could therefore be a result of competitive inhibition for OATP1A2 or OCT1 
transport.  However, in chapter 2 LTG was not observed to be transported by OATP1A2 
and furthermore OATP1A2 was shown not to be expressed in hCMEC/D3 cells, 
therefore LTG transport in hCMEC/D3 cells is unlikely to be mediated by OATP1A2.  
Interestingly, Braun et al, 2011 showed that inhibition of MCT8 by imatinib was non-
competitive whereas OCT1/OATP1A2 mediated inhibition has been demonstrated to be 
competitive.   
 
Conversely, an increase in LTG uptake was observed in the presence of the 
bioflavonoid quercetin and the anion transport inhibitors NPPB and niflumic acid, 
suggesting active efflux of LTG.  Although this cannot be attributed to MCT 
transporters due to the overlapping specificity of these chemical inhibitors with anion 
transporters (Halestrap et al., 2004).  Given the ability to effect LTG transport with 
chemical inhibition in this study and that LTG has previously been shown to be 
transported by OCT1 (Dickens et al., 2012), it is likely that LTG transport in and out of 
the brain occurs as a result of active transport.  This is potentially mediated by several 
transporters from various families including MCT transporters, however this hypothesis 
is speculative and cannot be proven without significant further investigation.   
 
TPM transport was also subject to inhibition, with increases in uptake observed in the 
presence of ethyl-cyancinnomate, quercetin and nuflumic acid and decreases seen with 
phloretin and SITS (figure 3.7; table 3.2).  All of the inhibitors observed to influence 
TPM uptake into hCMEC/D3 cells are non-specific MCT inhibitors.  Although these 
observations may potentially be attributed to MCT transporter, identification of the 
isoform/s involved cannot be achieved without further investigation.  Furthermore a 
number of the MCT inhibitors shown to significantly effect TPM uptake, namely 
nuflumic acid, phloretin, quercetin and SITS are also known to inhibit anionic transport 
(Forman et al., 1982; Halestrap et al., 2004).  Given that TPM is known to form an 
anion at physiological pH (Maryanoff et al., 1987), the changes in TPM transport 
observed in this study might equally be due to inhibition of an anion transporter 
expressed in hCMEC/D3 cells. 
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In addition, the bioflavonoids quercetin and phloretin have been shown to inhibit P-gp 
(Conseil et al., 1998; Zhang et al., 2003) and TPM has been demonstrated to be subject 
to active efflux by P-gp (Sills et al., 2002).  P-gp is known to be expressed at the apical 
membrane of the BBB in vivo where it actively effluxes substrate drugs from the brain 
(Klassen et al., 2010).  Furthermore P-gp has been shown to be relatively highly 
expressed in hCMEC/D3 cells (Carl et al., 2010).  Therefore the increases in TPM 
uptake observed in the presence of chemical inhibitors may be a result of inhibition of 
P-gp mediated efflux of TPM out of hCMEC/D3 cells, therefore more TPM is 
accumulating inside the cell.  
 
More than half of the inhibitors included in this investigation inhibited GBP transport 
into hCMEC/D3 cells (figure 3.6; table 3.2). Phloretin and 4-MBA both dramatically 
reduced GBP uptake; 4-MBA is known to exert its inhibitory effects by interacting with 
the MCT1/MCT4 accessory protein basigin (Wilson et al., 2005).  Moreover, MCT2 is 
insensitive to 4-MBA inhibition (as described previously) suggesting that GBP uptake 
in hCMEC/D3 cells is MCT1 or possibly MCT4 mediated, compounding the 
observation in chapter 2 of this thesis that GBP may be transported by MCT1.  
Interestingly, the presence of quercetin, NPPB, DIDS, SITS, simvastatin and salicylic 
acid significantly increased GBP uptake, suggesting efflux of GBP.  MCT1expression is 
known to be polarised in brain endothelial cells and there is support that MCT1 
mediates bidirectional transport of substrates and so may play a role in both influx and 
efflux of substrate drugs (Gerhart et al., 1997; Hertz et al., 2004).  Given that MCT4 has 
been demonstrated to be expressed apically in other organ tissues where it functions to 
efflux lactic acid (Manning Fox et al., 2000), it is possible the changes in GBP transport 
in the presence of the chemical inhibitors tested are attributed to inhibition of MCT 
mediated efflux and influx in hCMEC/D3 cells.  The influence MCT transport inhibitors 
were observed to have on the transport of GBP in hCMEC/D3 cells provides the 
strongest justification of all the AEDs tested for an MCT mediated transport 
mechanism. Although overlapping substrate specificity of many of the inhibitors 
observed to influence GBP transport means involvement of other transporters in the 
transport of GBP in hCMEC/D3 cells cannot be completely discounted.  These 
observations along with observations from chapter 2 of this thesis suggest that MCT 
transporters, most likely MCT1 could be involved (at least partly) in the transport of 
GBP at the BBB.   
 
88 
 
 
In the previous chapter, MCT1 was demonstrated not to transport VPA in a X.laevis 
model, an observation that disagreed with previous research reports in which several 
groups had suggested an MCT1 involvement in the cellular uptake of VPA (Utoguchi et 
al., 2000; Fischer et al., 2008). Data from hCMEC/D3 cells, however, is in agreement 
with findings in chapter 2 of this thesis; none of the MCT inhibitors (with the exception 
of a modest enhancing effect of phloretin) had any significant effect on VPA transport 
(figure 3.4; table 3.2).  This observation was unexpected and suggests that contrary to 
previous research and to the monocarboxylic acid structure of VPA, VPA is not 
transported by MCTs.  There are various explanations for the discrepancy between these 
and previous findings,  one possibility is that another transporter expressed in the cell 
lines used previously not belonging to the MCT family was responsible for the observed 
VPA transport. For example, a recent study used a Dictyostelium model to explore cell 
signalling pathways regulated by VPA and reported transport of VPA by a bicarbonate 
transporter (Terbach et al., 2011). There is sufficient sequence homology between 
Dictyostelium and human forms of this transporter to suggest that VPA might also be 
transported by the human form (encoded by SLC4A11) (Terbach et al., 2011). The 
disparity observed in MCT-mediated VPA uptake could also be explained by pH 
dependence.  The MCT-mediated transport of VPA demonstrated by Utoguchi et al, 
2000 was much more pronounced at pH 6 than pH 7.4. This might suggest that at low 
pH when VPA is not in its anionic form it is transported by an MCT transporter, 
whereas at higher pH VPA uptake is not mediated by MCTs (Utoguchi et al., 2000). 
Although transport at pH 6 is not of interest when investigating VPA permeation into 
the brain, it may be of importance in VPA absorption from the gut.   
 
No significant changes in CBZ and LEV uptake were observed in the presence of MCT 
inhibitors, except with quercetin and phloretin, respectively (figures 3.3 and 3.8; table 
3.2).  Interestingly, phloretin and quercetin showed at least modest influences on the 
transport of all AEDs included in this investigation (figures 3.2 to 3.8; table 3.2).  
Phloretin and quercetin are notoriously promiscuous transport inhibitors and are known 
to interact with many transporter families including influx and efflux transporters 
(Forman et al., 1982; Conseil et al., 1998; Leslie et al., 2001; Zhang et al., 2003; 
Halestrap et al., 2004; Zhang et al., 2004).  This might suggest that all of the AEDs 
tested are subject to active transport in hCMEC/D3 cells.  However flavonoid 
compounds such as phloretin and quercetin have been demonstrated to effect the 
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activity of mammalian enzyme systems including protein kinases, ATPase 
phospholipase and cyclooxygenases (Middleton et al., 2000).  It is therefore plausible 
that changes in AED transport observed in hCMEC/D3 cells may be a result of cellular 
metabolic changes rather than direct transporter protein inhibition.   
 
The hCMEC/D3 cell line has been proven to share phenotypic characteristics of the 
human BBB in vivo and provides a useful model with which to investigate drug 
transport at the BBB (Poller; et al., 2008).  Although the chemical inhibition technique 
employed in this investigation is a powerful screening tool in identifying whether a drug 
is subject to active transport at the BBB, its sensitivity in terms of identifying drug 
interactions with specific transporters responsible is limited by the  lack of availability 
of potent and selective inhibitors.  This proved a major limitation of this study and may 
explain the largely ambiguous data generated in which clear conclusions cannot be 
drawn.  Several potent MCT1-selective inhibitors have recently been developed by 
AstraZeneca (Murray et al., 2005; Guile et al., 2006; Ekberg et al., 2007) and would be 
valuable in further studies aimed at determining whether the chemical inhibition of 
PHT, LTG, GBP and TPM uptake was mediated via MCT1.  However, when 
approached, AstraZeneca was not in a position to allow the use of these inhibitors in 
this project. 
 
The experiments described in this chapter suggest that multiple AEDs may be subject to 
MCT-mediated transport at the BBB but that this cannot be reliably concluded or the 
individual transporter(s) identified because of the limitations of the available inhibitors 
in terms of selectivity and overlapping specificities. Of all AEDs tested, GBP appeared 
to be most susceptible to MCT-mediated transport, most probably by MCT1 but 
possibly by MCT4. 
 
This study has highlighted the limitations of the use of chemical inhibitors to identify 
specific transporter proteins responsible for the uptake of AEDs into hCMEC/D3 cells. 
An alternative experimental approach is the use of small interfering RNA (siRNA) to 
target specific transporters.  Using this approach the expression of functional MCT 
transporter proteins and combinations of MCT transporter proteins can be significantly 
reduced by interference and ultimate breakdown of target gene mRNA, therefore 
preventing protein translation.  Uptake of AEDs in siRNA treated and non-treated 
hCMEC/D3 cells can then be compared and any differences analysed.  The use of such 
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techniques could be utilised to follow up the observations made in this study and 
identify which, if any MCT transporter is involved in the transport of PHT, LTG, TPM 
and GBP in hCMEC/D3 cells.   
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Chapter 4 
 
 
 
Antiepileptic drug transport by OAT 
transporters 
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4.1 Introduction 
Organic anion transporters (OATs) are a subset of major facilitator transporters and 
belong to the SLC transporter superfamily.  OATs have become a major area of 
transporter research due to their role in the elimination of a number of therapeutically 
relevant drugs (Riedmaier et al., 2012).  OATs transport chemically diverse, mainly 
hydrophilic anions up to 400-500Da in size but are also known to transport amphiphilic 
anions, uncharged molecules and even cationic molecules.  Transport of such 
molecules, although energy dependent, does not directly utilize ATP hydrolysis 
(Rizwan et al., 2007).  OATs instead function via a specialised secondary active 
transport mechanism, often termed ‘tertiary’ active transport (VanWert et al., 2010).  
This involves the exchange of intracellular anions such as α-ketoglutarate (the 
intracellular dicarboxylate preferred by OAT1 and OAT3) for extracellular anions.  The 
intracellular anion concentration is kept above that of the extracellular environment by 
sodium coupled anion transporters, which are co-expressed with OAT transporters to 
fulfil this function (Rizwan et al., 2007; Burckhardt, 2012).  OAT transporters are found 
in the brain and most organs with excretory or barrier functions, including liver and 
placenta, however by far the highest and most diverse expression of OAT transporters is 
in the kidney.  Here OAT transporters, including OAT1, OAT2 and OAT3, expressed 
on the interstitial (basolateral) membrane of proximal tubule cells are believed to 
represent the rate limiting step in the in vivo renal clearance of anionic drugs, 
metabolites and toxins due to their role in the uptake of such molecules from the blood 
into proximal tubule cells (Sekine et al., 2000; Gallegos et al., 2012).  OATs expressed 
at the luminal membrane of the proximal tubule, including OAT4, OAT10 and the urate 
anion exchanger 1 (URAT1), are also believed to play a pivotal role in the secretion of 
anionic drugs from proximal tubule cells into the filtrate to be excreted in the urine 
(Burckhardt, 2012; Volk, 2014).  
 
In 1998, OAT1 was first cloned in humans from kidney mRNA (Reid et al., 1998) and 
has since been detected at lower levels in the brain, placenta and skeletal muscle (Anzai 
et al., 2006). The prototypic control substrate of OAT1 is p-aminohippuric acid (PAH), 
an amide derivative of glycine first used in the functional characterisation of human 
OAT1 in X.laevis oocytes (Race et al., 1999).  PAH is transported by OAT1 with high 
affinity and Km values of 3.1µM-112.7µM have been reported depending on the 
expression system employed (Riedmaier et al., 2012).  PAH is almost completely 
cleared from the blood by OAT transporters expressed at the proximal tubule cells in a 
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single pass through the kidney.  As a result PAH is used clinically to estimate renal 
plasma flow (Sekine et al., 2000). Rapid transport of PAH into the brain suggests that 
OAT1 is also likely to be expressed at the BBB (Kusuhara et al., 1999), and there is 
evidence that OAT1 is expressed in both rat and human brain (Sekine et al., 1997; 
Cihlar et al., 1999; Eraly et al., 2003; Bleasby et al., 2006).   
 
Human OAT3 was first cloned from human kidney and fully characterised in 1999 in 
X.laevis oocytes (Race et al., 1999).  Of the OAT transporters, OAT3 is thought to have 
the highest expression in human brain and has been shown to be expressed at the 
basolateral membrane of rat brain endothelial cells (Ohtsuki et al., 2002; Kikuchi et al., 
2003; Mori et al., 2003).  Interestingly the OAT3 gene, SLC22A8, is found paired with 
the OAT1 gene SLC22A6 on chromosome 11q12.3.  Such pairing is thought to reflect a 
potential partnership in both tissue distribution and transport function (Eraly et al., 
2003).  In contrast to OAT1, PAH is not widely employed as a prototypic test substrate 
for OAT3, due to its much lower affinity for OAT3 (Km ~87µM) (Cha et al., 2001).  
Instead estrone-3-sulphate (E3S) is commonly used, which has a high affinity for 
OAT3, with Km values between 2.2µM and 21.2µM reported (Burckhardt, 2012).  The 
ability of OAT3 to transport E3S at high affinity also distinguishes OAT3 mediated 
transport from OAT1, which mediates only very low affinity transport of E3S, if any 
(Burckhardt et al., 2011).    
 
OAT2 was first identified in rat liver in 1994 (Simonson et al., 1994) and in 2001 the 
human homologue was cloned from human liver and functionally characterised (Sun et 
al., 2001).   OAT2 has received less interest than OAT1 and OAT3 as its expression in 
the kidneys is much lower than its homologues.  As a consequence, its contribution to 
the renal clearance of anionic therapeutic agents is thought to be minimal.  Although it 
is predominantly expressed in the liver and to a lesser extent in the kidneys, OAT2 has 
also been detected in pancreas, small intestine, testis, lung, brain, spinal cord and heart 
(in order of descending expression) (Cropp et al., 2008).  In contrast to OAT1 and 
OAT3, which preferentially exchange intracellular α-ketoglutarate (a 5-carbon 
dicarboxylate) for extracellular anions, OAT2 was found to favour intracellular 
succinate or fumarate, suggesting that OAT2 preferentially exchanges 4-carbon 
dicarboxylates  (Kobayashi et al., 2005; Burckhardt et al., 2011).  The prototypic test 
substrate used in the study of OAT2 transport is also more ambiguous than OAT1 and 
OAT3.  Both PAH and E3S have been employed previously, in addition to salicylate 
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and prostaglandin F2α (Enomoto et al., 2002; Kobayashi et al., 2005; Burckhardt et al., 
2011).   
 
A number of routinely prescribed therapeutic agents have been shown to be substrates 
and/or inhibitors of both OAT1 and OAT3 and in some cases OAT2 also.  These 
include antihypertensives, antibiotics, antiviral agents, non-steroidal anti-inflammatory 
drugs (NSAIDS) and HMG CoA reductase inhibitors (Burckhardt, 2012).  As a result of 
their overlapping substrate specificity, many studies have investigated both OAT1 and 
OAT3 in the transport of anionic drugs.  For example, in HEK293 cells stably 
expressing OAT1 and OAT3, the angiotensin II receptor blocker olmersartan was 
shown to be transported by both OAT1 and OAT3 with respective Km values of 0.07µM 
and 0.12µM (Yamada et al., 2007).  Furthermore, in Flp293 cells stably transfected with 
OAT1 and OAT3, candesartan, valsartan, olmesartan, losartan, pratosartan and 
telmisartan all inhibited OAT1 transport and, with greater potency, OAT3 transport of 
uric acid (IC50 values obtained ranged from 0.28µM to 17µM for OAT1 and 0.027µM 
to 1.6µM for OAT3).  Telmisartan was found to be the exception in this class of drugs, 
which elicited greater inhibition of OAT1 (IC50 0.46µM) than OAT3 (IC50 1.6µM) (Sato 
et al., 2008). 
 
For some years, the AED VPA has also been suggested to be transported by an anion 
transporter.  Despite VPA being more than 99% ionised at physiological pH and 
reasonably hydrophilic, it is known to readily penetrate the BBB (Loscher et al., 1984).  
It was therefore hypothesised that VPA must enter the brain via a facilitated process.  
Adkinson and colleagues investigated this in an in situ rat brain perfusion model and 
found that not only was VPA uptake into the brain a saturable process but uptake could 
be inhibited in the presence of anion transport substrates/inhibitors, such as octanoate, 
PAH and probenecid (Adkinson et al., 1996).  The same investigators had previously 
investigated VPA transport in isolated rat brain endothelial cells and observed similar 
results, although interestingly PAH did not significantly inhibit VPA uptake (Naora et 
al., 1995).   
 
OAT1 and OAT3 have been shown to be critical in the renal clearance of a number of 
therapeutic agents due to their role in anion uptake from the blood into the kidney 
proximal tubule cells.  This presents potential for drug-drug interactions (DDIs) to occur 
between drugs which are heavily dependent on OAT1 and OAT3 uptake for efficient 
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renal clearance.  For example the loop diuretic furosemide was shown to inhibit uptake 
of the thiazide diuretic chlorothiazide in CHO and HEK293 cells stably transfected with 
OAT1 or OAT3 respectively (Juhász et al., 2013).  Furthermore the renal clearance of 
furosemide has been observed to be dependent on OAT1 and OAT3 transport in vivo.  
In a clinical study investigating the effects of co-administration of the uricosuric drug 
(and prototypic OAT inhibitor) probenecid with furosemide, renal clearance of 
furosemide decreased by 75% when co-administered with probenecid (Chennavasin et 
al., 1979).  Similarly the NSAIDs indomethacin and ketoprofen have been shown to 
significantly impair renal clearance of the immunosuppressant methotrexate, which is 
up to 90% cleared by the kidneys (Maiche, 1986; Thyss et al., 1986; Elmorsi et al., 
2013).  Such DDIs can cause nephrotoxic precipitation of methotrexate and its 
metabolites in the tubular lumen, which can ultimately lead to severe and potentially 
fatal renal impairment (Widemann et al., 2006; Hagos et al., 2010).   
 
Although the hCMEC/D3 cell line represents a physiologically relevant model of the 
BBB, it has been shown to lack the expression of OATs, even though these are thought 
to be expressed at the BBB in vivo (Abbott et al., 2010; Carl et al., 2010; Weksler et al., 
2013).  Various epithelial cells stably expressing transporter proteins of interest have 
been used extensively to investigate transport of therapeutic agents.  The main 
advantage of using such a model is that the transporter of interest can be selectively 
expressed at high levels, diminishing the contribution of endogenous transporters to the 
net transport of the investigated compound.  On the other hand it is unknown what 
effect the transfection process has on cellular morphology and behaviour.  A variety of 
cell lines have been used to stably transfect OAT transporter proteins including 
HEK293, MDCK and CHO cells (Aslamkhan et al., 2003; Chu et al., 2007; Hagos et 
al., 2007; Shin et al., 2010; Xue et al., 2011).  HEK293 cells are widely used as they are 
easy to culture and transfect, achieving high transfection rates and protein expression.  
MDCK II cells are an alternative cell line of choice, again due to their ease of culture 
and their ability to form polarised monolayers, reflecting the protein and lipid 
composition of epithelia in vivo (Ander et al., 1984).  
 
The work described in this chapter aimed to initially generate and characterise three 
novel MDCK II cell lines stably transfected with SLC22A6, SLC22A7 and SLC22A8, 
over-expressing OAT1, OAT2 and OAT3 respectively.  The novel cell lines were 
characterised on the basis of gene expression, protein expression and functional 
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transport of a test substrate.  PAH was employed as the test substrate for 
SLC22A6_MDCK II cell analysis and E3S employed as the test substrate for both 
SLC22A7_MDCK II and SLC22A8_MDCK II cell analysis.  PAH/E3S transport in 
SLC22A6, SLC22A7 and SLC22A8 transfected MDCK II cells was also assessed in the 
presence of the prototypic OAT transport inhibitor probenecid and compared to 
transport in control ‘mock transfected’ cells stably transfected with vector only 
(pcDNA_MDCK II cells).  The fully characterised cell lines were then used to 
investigate potential OAT1, OAT2 and OAT3 mediated transport of commonly 
prescribed AEDs, including PHT, CBZ, VPA, LTG, GBP, TPM and LEV.  AED 
transport in SLC22A6, SLC22A7 and SLC22A8 transfected MDCK II cells with and 
without probenecid (200µM) was compared to that of control pcDNA_MDCK II cells.   
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4.2 Materials and Methods 
4.2.1 Materials 
SLC22A6, SLC22A7 and SLC22A8 I.M.A.G.E. consortium cDNA clones were 
purchased from Source Bioscience Lifesciences (Nottingham, UK) who also carried out 
sequencing of SLC22A6_pcDNA3.1/V5-His TOPO and SLC22A8_pcDNA3.1/ V5-His 
TOPO clones.  EcoRV, AleI and XbaI restriction enzymes and buffers were purchased 
from New England Biolabs (Hitchin, UK).  pcDNA3.1/V5-His TOPO expression kit, 
One Shot TOP10 chemically competent E.coli, Lipofectamine transfection reagent, 
FBS, OPTI –MEM/DMEM media, Taqman gene expression assays (canine β-actin/ 
human SLC22A6/canine SLC22A6/human SLC22A7/human SLC22A8), gene expression 
mastermix and all NuPAGE western blotting reagents and pre cut nitrocellulose 
membrane/filter paper sandwiches were purchased from Life Technologies (Paisley, 
UK).  Prism protein ladder (10-175kDa), mouse monoclonal anti-SLC22A6 antibody, 
mouse monoclonal anti-GAPDH [6C5] antibody, rabbit polyclonal anti-SLC22A8 
antibody and goat polyclonal secondary antibody to mouse IgG (HRP conjugated) were 
purchased from Abcam (Cambridge, UK).  Goat secondary antibody to rabbit IgG (HRP 
conjugated) was purchased from Santa Cruz Biotechnology (Dallas, Texas, USA). [3H]-
estrone-3-sulfate (specific activity, 54.3 Ci/mmol) and [3H]-p-aminohippuric acid 
(specific activity, 130.8mCi/mmol) were purchased from Perkin Elmer (Massachusetts, 
USA).  [3H]-lamotrigine (specific activity, 5Ci/mmol), [3H]-levetiracetam (specific 
activity, 5Ci/mmol), [3H]-topiramate (specific activity, 8Ci/mmol) and [3H]-gabapentin 
(specific activity, 110Ci/mmol) were purchased from American Radiolabeled 
Chemicals Inc (St. Louis, USA).  [3H]-phenytoin (specific activity 1.1Ci/mmol), [3H]-
carbamazepine (specific activity 10Ci/mmol) and [3H]-valproic acid (specific activity 
55Ci/mmol) were purchased from Moravek (Brea, CA, USA).  Fast Start High Fidelity 
PCR system reagents were purchased from Roche Diagnostics (Burgess Hill, UK).  All 
other materials unless otherwise stated were purchased from Sigma-Aldrich (Poole, 
UK). 
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4.2.2 Extraction of human SLC22A6, SLC22A7 and SLC22A8 I.M.A.G.E.  cDNA 
clone plasmid DNA from E.coli glycerol stocks 
Purchased agar stocks of SLC22A6, SLC22A7 and SLC22A8 cDNA clones were firstly 
prepared in a 50ml culture of LB broth supplemented with either 50µg/ml ampicillin 
(SLC22A6 cDNA clone) or 20µg/ml chloramphenicol (SLC22A7/SLC22A8 cDNA 
clones) depending on which antibiotic resistance gene each cDNA clone carried.   The 
culture was then grown overnight at 370C with vigorous shaking (300rpm; 
ThermoScientific Thermo Max Q 4450).  The following day, overnight cultures were 
streaked onto LB agar plates (autoclaved, 1M agar supplemented with appropriate 
antibiotic as described previously) at various serial dilutions (neat, 1 in 10, 1 in 100, 1 in 
1000) and grown overnight at 370C.  Distinct, single colonies were selected the 
following day and grown firstly for 8 hours in a small (9ml) LB broth culture 
(supplemented with appropriate antibiotic) at 370C with vigorous shaking and secondly 
overnight in a 50ml culture at the same conditions.  The following day, plasmid DNA of 
each culture was extracted using the GenElute plasmid DNA midi prep kit (Sigma 
Aldrich).  The GenElute plasmid DNA midi prep protocol is described in chapter 2 
(section 2.2.2.), however the volumes of reagents differ slightly and were as follows: 
4ml re-suspension solution, lysis buffer, neutralisation solution, 3ml binding solution, 
4ml wash solution 1 and 2, 1ml elution solution.  The extracted DNA was then 
quantified using the Nanodrop spectrophotometer (see section 2.2.3 for details).    
 
4.2.3 Linearisation of  SLC22A6, SLC22A7 and SLC22A8 cDNA clone plasmid 
DNA 
Extracted plasmid DNA was linearised in a 2 hour restriction digest reaction in a 
thermal cycler (Applied Biosystems Verti 96 well thermal cycler) at 370C for use in 
downstream amplification.  A 50µl reaction volume was prepared for each cDNA clone 
as follows.  SLC22A6: 32.2µl (2µg) of SLC22A6 cDNA clone DNA, 0.1µl (10 units) 
EcoRV, 5µl of NEB buffer 3 (1x final concentration), 0.5µl (1µg/ml final 
concentration) of BSA and 12.2µl water.  SLC22A7: 8.64µl (2µg) of SLC22A7 cDNA 
clone DNA, 0.1µl (10 units) XbaI, 5µl of NEB buffer 4 (1 x final concentration), 0.5µl 
(1µg/ml final concentration) of BSA, 35.76µl water.  SLC22A8: 9.02µl (2µg) of 
SLC22A8 cDNA clone DNA, 0.1µl (10 units) XbaI, 5µl of NEB buffer 4 (1x final 
concentration), 0.5µl (1µg/ml final concentration) BSA, 35.38µl water.  The resulting 
DNA was then analysed by gel electrophoresis (see section 2.2.4 for protocol) to 
confirm DNA was successfully linearised (linearised DNA migrates less far than the 
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supercoiled form on an agarose gel).  SLC22A7 and SLC22A8 cDNA clone plasmid 
DNA was successfully linearised by restriction with XbaI, however EcoRV failed to 
linearise the SLC22A6 cDNA clone DNA (figure 4.1).  Linearisation of the SLC22A6 
cDNA clone DNA was achieved following a second attempt with XbaI instead of 
EcoRV (32.2µl (2µg) of SLC22A6 cDNA clone DNA, 0.1µl (10 units) XbaI restriction 
endonuclease, 5µl of NEB buffer 4 (1x final concentration), 0.5µl (1µg/ml final 
concentration) BSA, 12.2µl water; figure 4.1).  Restriction digest reactions were then 
repeated in a total volume of 150µl (3 x 50µl reaction volumes) to achieve enough DNA 
for amplification and purified using the GenElute PCR clean up kit (Sigma Aldrich; see 
section 2.2.6 for details of manufacturer’s protocol).  
 
Figure 4.1: Visualisation of linearised SLC22A6, SLC22A7 and SLC22A8 cDNA clones 
pre and post restriction digest with XbaI and EcoRV on a 1% agarose gel using NEB 
10kb DNA ladder as a reference (A).  From left to right: 1kb DNA ladder (1), 
supercoiled SLC22A6 DNA (2), SLC22A6 DNA post restriction digest (3), supercoiled 
SLC22A7 DNA (4), SLC22A7 DNA post restriction digest (5), supercoiled SLC22A8 
DNA (6), SLC22A8 DNA post restriction digest (7).  SLC22A7 and SLC22A8 were 
successfully linearised by restriction digest.  Linearisation of the SLC22A6 cDNA clone 
was unsuccessful and restriction digest subsequently repeated successfully with XbaI 
and visualised on a 1% agrose gel using NEB 10kb DNA ladder as reference (B).  From 
left to right: 1kb DNA ladder (1), supercoiled SLC22A6 DNA (2), SLC22A6 DNA post 
restriction digest (3).   
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4.2.4 Amplification of SLC22A6, SLC22A7 and SLC22A8 templates  from plasmid 
DNA 
Purified, linear SLC22A6, SLC22A7 and SLC22A8 cDNA clone plasmid DNA was 
amplified by PCR using Fast Start High Fidelity PCR system reagents (Roche 
Diagnostics, Burgess Hill, UK) as described in section 2.2.5 (see table 4.1 for primer 
sequences) using the following thermal profile: an initial denaturing step for two 
minutes at 950C, followed by 40 cycles of denaturation at 950C for 30 seconds, 
annealing at 670C (SLC22A6) or 690C (SLC22A7) or 720C (SLC22A8) for 30 seconds, 
and elongation at 720C for two minutes. This was followed by a terminal elongation 
step at 720C for seven minutes.  The annealing temperature for each template was 
determined based on primer melting temperatures (Tmo).     
 
Template 
Reverse (upstream) primer sequence 
(5’-3’) 
Forward (downstream) primer 
sequence (5’-3’) 
SLC22A6 CTTCTCACAGTCCTCAGAGTCC CCCAATGGCCTTTAATGACCTC 
SLC22A7 TTAGTTCTGGACCTGCTTCATGGG GCCACCAGCATGGGCTTT 
SLC22A8 CGTTGTCCTCAGCTGGAG GCCACCGTGCCATGACCTTCT 
 
Table 4.1 Full sequence of each primer pair used in SLC22A6, SCL22A7 and SLC22A8 
template DNA amplification.   
 
Templates were analysed by gel electrophoresis (figure 4.2) to ensure successful 
amplification of the correct size template (gel electrophoresis protocol is described in 
section 2.2.4).  Template DNA was then purified using the GenElute PCR clean up kit 
(see section 2.2.6 for details of manufacturer’s protocol). At this point due to the 
inability to amplify the SLC22A7 template from its respective I.M.A.G.E cDNA clone, 
SLC22A7 cloning was abandoned.  Following further troubleshooting it was discovered 
that the SLC22A7 I.M.A.G.E. cDNA clone contained a truncated SLC22A7 sequence; 
no alternative full sequence cDNA clones with the correct SLC22A7 template were 
available.   
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Figure 4.2: Amplified SLC22A6 (A) and SLC22A8 (B) and SLC22A7 (C) templates 
visualised on a 1% agarose gel using NEB 10kb ladder as reference.  From left to right: 
1kb DNA ladder (1), cDNA clone (2), amplified template (3).  SLC22A6 and SLC22A8 
template DNA containing its respective protein coding sequence (1.6kb) was 
successfully amplified from its respective cDNA clone.  The SLC22A7 template could 
not be amplified from its respective cDNA clone.   
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4.2.5 Ligation of SLC22A6 and SLC22A8 templates into a mammalian expression 
vector 
SLC22A6 and SLC22A8 template DNA was ligated into a mammalian expression vector 
(pcDNA 3.1/V5-His-TOPO®) and transformed into chemically competent E. coli (One 
Shot® TOP10).  The pcDNA 3.1/V5-His TOPO® TA Expression kit provides a high 
efficiency one step cloning strategy for direct insertion of Taq polymerase amplified 
PCR products into a plasmid vector.  Topoisomerase I from Vaccinia cleaves the duplex 
plasmid DNA and binds to phosphate residues at the 5’ and 3’ ends of a cloning site 
within the plasmid, holding it in an ‘open’ conformation.  The additional 
deoxyadenosine base added to the DNA templates by Taq amplification binds to the 3’ 
deoxythymidine residue overhang of the plasmid, releasing the Topoisomerase and 
ligating the PCR template into the plasmid vector.   
 
Firstly, agar plates (autoclaved, 1M agar supplemented with 50µg/ml ampicillin) were 
prepared and incubated at 370C for later transformation.  The ligation reaction was 
prepared in a 1.5ml Eppendorf tube according to manufacturer’s protocol and contained 
the following: 3µl fresh PCR product (SLC22A6/SLC22A8 template), 1µl salt solution, 
1µl sterile water, 1µl Topo vector.  A control ligation reaction was also prepared for 
each ligation reaction containing:  1µl salt solution, 4µl sterile water, 1µl Topo vector.   
3 ligation reactions were prepared in total (SLC22A6/SLC22A8 ligation and a vector 
only reaction).  The vector only reaction acts as a control to detect non-plasmid 
expressing bacterial growth; no growth should be observed in the control, only bacteria 
expressing the pcDNA 3.1/V5-His TOPO® TA plasmid (expressing ampicillin 
resistance gene) should grow.  Each ligation reaction was mixed by flicking the 
Eppendorf tube 3-4 times and incubated at room temperature for 30 minutes.  
Thereafter, each ligation reaction was placed on ice and 2µl of each reaction added to 
thawed chemically competent E.coli bacteria that had previously been stored at -800C.  
The bacterial solutions were then incubated with the ligation reaction on ice for 15 
minutes before being heat-shocked at 420C for 30 seconds.  After heat-shock, the 
bacterial solution was immediately returned to ice for a further 5 minutes to complete 
transformation of the ligated plasmid into the E.coli host.  A 250µL volume of SOC 
medium was then added to the E.coli and the bacteria allowed to multiply for 1 hour at 
370C with vigorous shaking (200rpm; ThermoScientific Thermo Max Q 4450).  A 
200µl aliquot of the transformed bacterial cultures was then streaked onto agar plates 
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using a sterile loop at various serial dilutions (neat, 1 in 10, 1 in 100, and 1 in 1000) and 
allowed to incubate overnight at 370C.  
 
4.2.6 Analysis of resultant bacterial colonies 
After overnight incubation, distinct single colonies were selected for analysis by PCR to 
determine if the ligation had been successful.  PCR was carried out at the conditions 
described in section 2.2.5.  Each 20µl reaction contained the following:  transformed 
bacterial clone DNA (achieved by inoculating the PCR tube with a pipette tip 
containing each bacterial colony), 2µl of 10x FastStart High Fidelity reaction buffer 
with 18mM MgCl2, 0.4µl PCR grade nucleotide mix (200nM final concentration of 
each dNTP), 0.4µl DMSO, 13µL PCR grade water, 0.2µL FastStart High Fidelity 
Enzyme Blend (5U/µl), 2µl of both sense and anti-sense primers (400nM final 
concentration; see table 4.1 for primer sequences).  Ten colonies were selected for each 
ligation reaction (SLC22A6 and SLC22A8).  Negative control reactions were also 
carried out in the absence of bacterial DNA to check for PCR reagent contamination.  
At the same time, aliquots of 3ml LB broth (supplemented with 50µg/ml ampicillin) 
were inoculated with each of the 10 colonies selected from each ligation reaction.  Any 
colonies in which the SLC22A6 or SLC22A8 template could be amplified by PCR were 
subsequently grown for 8 hours in the culture to allow the transformed bacteria to reach 
exponential growth rate.  The 8 hour cultures were then transferred to a larger culture 
(15ml LB broth supplemented with 50µg/ml ampicillin) and grown overnight at 370C 
with vigorous shaking (300rpm; ThermoScientific Thermo Max Q 4450).   
 
The following day, SLC22A6 and SLC22A8 template positive bacterial colonies grown 
overnight were further analysed by restriction digest.  The plasmid DNA of 8 colonies 
from which SLC22A6 and SLC22A8 had been successfully amplified (figure 4.3) was 
first extracted as described in section 4.2.2 before a 2 hour restriction digest reaction.  
The AleI and EcoRV restriction endonucleases were used as both the SLC22A6 and 
SLC22A8 plasmid DNA contains one AleI and one EcoRV restriction site in the insert 
and vector section of the sequence respectively.  The 50µl reactions were set up in 
200µl low density plastic PCR tubes and incubated at 370C in a 96 well block thermo 
cycler for 2 hours.  Reaction mixtures contained the following components, made up to 
50µl with water: 2µg plasmid DNA, 10 units (AleI; 1µl, EcoRV; 0.1µL) of restriction 
endonuclease, 5µl (1 x final concentration) of appropriate buffer (NEB buffer 4 for AleI 
reactions, NEB buffer 3 for EcoRV reactions), 0.5µl (1µg/ml final concentration) BSA 
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(EcoRV reactions only).   Resulting DNA was visualised by gel electrophoresis (see 
section 2.2.4).  Plasmid DNA containing the successfully ligated vector, positive for the 
SLC22A6 or SLC22A8 template, was linearised by digestion with both AleI and EcoRV, 
with successfully linearised DNA traveling less far on an agarose gel than its respective 
supercoiled form (figures 4.4-4.5). 
 
Three of the clones shown to express the ligated plasmid and therefore SLC22A6 or 
SLC22A8 template were sent to Source Bioscience Lifesciences (Cambridge, UK) for 
single tube sequencing.  Linear plasmid DNA at a concentration of 100ng/µl was 
supplied and the plasmid DNA sequenced from the T7 promoter and BGH reverse 
priming sites within the pcdna3.1/V5-His TOPO vector sequence; this enabled the full 
insertion site of the vector to be sequenced.  Sequence results were then analysed to 
ensure the inserted SLC22A6 or SLC22A8 template was identical to the published 
protein coding sequence for each gene.  A single clone for SLC22A6 and SLC22A8 was 
then selected for subsequent transfection.    
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Figure 4.3: Visualisation of successfully amplified SLC22A6 (A) and SLC22A8 (B) 
template DNA from plasmid DNA of transformed E.coli cultures.  Samples were run on 
a 1% agarose gel using NEB 10kb ladder as a reference.  From left to right: 1kb DNA 
ladder (1), positive control (template amplified from cDNA clone; (2)), SLC22A6 (A) or 
SLC22A8 (B) template DNA amplified from plasmid DNA (3-10), negative control 
reaction containing no DNA (11).  SLC22A6 template DNA was successfully amplified 
from plasmid DNA in all 8 colonies of transformed E.coli (part A, lanes 3-10).  
SLC22A8 template DNA was successfully amplified from plasmid DNA in 6 of the 8 
colonies of transformed E.coli included (part B, lanes 5-10).    
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Figure 4.4: Restriction digest of SLC22A6 positive plasmid DNA from transformed 
E.coli cultures with AleI (A) and EcoRV (B).  Samples were run on a 1% agarose gel 
using NEB 10kb ladder as reference.  From left to right: 1kb DNA ladder (1), 
supercoiled SLC22A6 cDNA clone as a positive control (2), supercoiled SLC22A6 
positive plasmid DNA (lanes 3-10), digested SLC22A6 CDNA clone (11),  AleI (A) or 
EcoRV (B) digested SLC22A6 positive plasmid DNA (lanes 12-19).  Restriction digests 
with AleI (A) and EcoRV (B) successfully linearised plasmid DNA from 7 of the 8 
transformed E.coli colonies included.  Colony 5 (lane 16) produced an unexplained 
band ~3kb.   
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Figure 4.5: Restriction digest of SLC22A8 positive plasmid DNA from transformed 
E.coli cultures with AleI (A) and EcoRV (B).  Samples were run on a 1% agarose gel 
using NEB 10kb ladder as reference.  From left to right: 1kb DNA ladder (1), 
supercoiled SLC22A8 cDNA clone (2), digested SLC22A8 cDNA clone as a positive 
control (3),  supercoiled SLC22A8 positive plasmid DNA (lanes 4,6,8,10,12,14),  AleI 
(A) or EcoRV (B) digested SLC22A8 positive plasmid DNA (lanes 5,7,9,11,13,15).  
Restriction digests with AleI (A) and EcoRV (B) successfully linearised plasmid DNA 
from 5 of the 6 transformed E.coli colonies included.  Colony 5 (lanes 12-13) produced 
a double band when digested with AleI (A) and EcoRV (B) suggesting incomplete 
ligation of the full SLC22A8 template or insertion at the incorrect ligation site.   
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4.2.7 MDCK II cell culture 
WT MDCK II cells and MDCK II cells stably transfected with SLC22A6 and SLC22A8 
were maintained in complete media consisting of DMEM supplemented with 10% FBS 
and 1% penicillin streptomycin (for stably transfected cells complete media was also 
supplemented with 0.8µg/ml gentamycin) and kept in an incubator (Thermo Scientific 
Function Line) at 370C with 5% CO2.  All cell culture was performed in a class II 
microbiological safety cabinet.  Cells were grown in three T175 flasks at any one time 
and passaged and seeded to further flasks and/or 12-well plates every 3-4 days, as 
follows.  Briefly, media was removed from each flask using a 25ml serological pipette 
and each flask washed twice with warm HBSS.  A 10ml volume of 0.25% trypsin-
EDTA was then added to each flask and flasks were returned to the incubator for 10-15 
minutes.   Once all cells were detached from the flask, trypsin was neutralised with 
20ml of complete media and flask contents transferred to a 50ml Falcon tube before 
centrifugation at 250 x g for 5 minutes (Thermo Scientific Heraeus Megafuge IIR).  The 
supernatant was removed and the resulting pellet resuspended in 1ml of complete 
media.  Pellet suspensions were combined (three in total) and made up to a total volume 
of 10ml.  If seeding to flasks only 2ml of the resuspended cells were added to 3x T175 
flasks to give a 1:5 dilution and allowed to grow on.  When seeding to plates, a cell 
count was first made (as described in section 3.2.4) to give the number of cells per ml 
and the cell solution subsequently diluted with complete media to a density of 1.5x105 
cells per ml.  A 1ml aliquot was then added to each well of a 12-well plate.   
 
 
4.2.8 Generation of SLC22A6_MDCK II and SLC22A8_MDCK II cell lines 
Fresh cultures of sequence verified SLC22A6, SLC22A8 and pcDNA plasmid DNA 
were transfected into low passage number MDCK II cells using Lipofectamine 
transfection reagent according to manufacturer’s protocol.  Briefly, MDCK II cells were 
seeded into 24-well plates at a density of 6x104 cells per well in DMEM media 
supplemented with 10% FBS only.  Cells were transfected the following day or when 
cells were 60-80% confluent.  Firstly, the transfection was optimised, with various 
concentration combinations of plasmid DNA and Lipofectamine reagent trialled (9 
combinations in total; see figure 4.6).   
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Figure 4.6: Plate layout used for optimisation of transfection conditions.  Low passage 
MDCK II cells were seeded at a density of 6x104 cells per ml into a 24 well plate and 
various combinations of plasmid DNA and Lipofectamine reagent trialled to determine 
the optimal conditions for high yield transfection.  No lipofectamine and/or no plasmid 
DNA was added to 7 wells as negative controls.   
 
The transfection process was carried out as follows; pcDNA plasmid DNA was diluted 
in 50µl of OPTI MEM (reduced serum Eagle's minimum essential medium) to give 
0.8µg, 1.5µg and 2.5µg concentrations of DNA. 3µl, 4µl and 5µl volumes of 
Lipofectamine reagent were then diluted in 50µl of OPTI MEM and allowed to incubate 
at room temperature for 5 minutes.  The OPTI MEM plasmid DNA solution was then 
added to the diluted Lipofectamine reagent (100µl total volume) and incubated at room 
temperature for 20 minutes to allow complexes to form.  Thereafter, 100µl of the DNA-
Lipofectamine complex solution was added to the appropriate well.  A 100µl volume of 
OPTI MEM containing various concentrations (as stated previously) of plasmid DNA 
without Lipofectamine was also added to appropriate wells as negative controls (see 
figure 4.6 for plate layout).  Cells were allowed to recover for 24 hours before the 
existing media was replaced with one supplemented with 0.8mg/ml gentamycin (G418) 
to select for successfully transfected cells containing the vector (the pcDNA 3.1/V5-His 
TOPO vector expresses gentamycin resistance gene).   After 7 days selection, the well 
with the optimum growth was used for single cell clone selection.  A total of 0.8µg of 
plasmid DNA and 3µl of Lipofectamine reagent was determined as the optimum 
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combination for transfection and was utilised for subsequent SLC22A6 and SLC22A8 
transfection.  To select single clones, the transfected cells were first passaged as 
follows.  Briefly, media was aspirated from the well using a vacuum and cells were 
washed twice with 0.5ml warm HBSS, 0.5ml of 0.25% trypsin-EDTA was then added 
and the plate returned to the incubator for 10-15 minutes or until cells were fully 
detached.  Trypsin was then neutralised in 2ml of complete media supplemented with 
0.8mg/ml gentamycin (selection media). The resulting cell suspension was then 
centrifuged at 250 x g for 5 minutes to collect a cell pellet and resuspended in 1ml of 
selection media.  A cell count was then made and cells seeded at various serial dilutions 
in 96-well plates to obtain single cell clones.  Cells were fed every 3 days with fresh 
selection media and after two weeks of selection, 12 wells were selected based on 
growth rate and passaged into 24 well and ultimately 6 well plates.  The 12 single cell 
clones were then crudely analysed for SLC22A6 and SLC22A8 expression by PCR 
(section 4.2.10) before quantitative RT-PCR analysis to determine which clones 
possessed the highest expression of SLC22A6 or SLC22A8 (section 4.2.13).  To 
determine functional transport differences between the 12 clones, each clone was 
incubated with a well characterised positive hOAT1/hOAT3 substrate (section 4.2.18).   
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4.2.9 DNA extraction of MDCK II clones stably transfected with SLC22A6 and 
SLC22A8 
On the day of extraction the media was aspirated from each well of selected clones from 
section 4.2.8 and each washed twice with warm HBSS.  A 1ml volume of 0.25% 
trypsin-EDTA was then added and plates were then returned to an incubator for around 
5 minutes, or until cells were fully detached.  A 2ml volume of complete media was 
added to neutralise the trypsin and the contents of each well transferred to a 1.5ml 
Eppendorf tube and centrifuged at 250 x g for 5 minutes to obtain a cell pellet.  The 
supernatant was then discarded and cell pellets kept at room temperature for subsequent 
DNA extraction.  DNA was then extracted using the GenElute mammalian DNA 
extraction kit reagents according to manufacturer’s protocol (Sigma Aldrich).  Briefly a 
heat block was first set to 700C and the supplied Proteinase K solution prepared in water 
to give a final concentration of 20mg/ml.  Each cell pellet was firstly resuspended in 
200µl of resuspension solution and a 20µl aliquot of RNase A solution was then added 
and each sample incubated at room temperature for 2 minutes to obtain RNA free-
genomic DNA.  Cells were then lysed by the addition of 20µl of 20mg/ml proteinase K 
solution and 200µl of lysis solution and vortexed briefly before incubation at 700C for 
10 minutes.  In the meantime, centrifuge columns for each sample were prepared in 
collecting tubes, labelled and 500µl of column preparation added to the column and 
centrifuged at 12,000 x g for 1 minute to maximise subsequent DNA binding.  Once the 
sample incubation had elapsed, 200µl of 95% ethanol was added to each sample and 
mixed thoroughly to obtain a homogeneous solution by vortexing for 5-10 seconds.  
The sample lysate was then transferred to the binding column and centrifuged at 6,500 x 
g for 1 minute.  Binding columns were then transferred to clean collecting tubes, the 
flow-through discarded and 500µl of wash solution added to the column.  The columns 
were then centrifuged at 6,500 x g for 1 minute, the flow through discarded and the 
binding column transferred to a new collecting tube.  The wash step was then repeated 
and columns centrifuged at 12,000 x g for 3 minutes to dry the column.  The binding 
columns were then transferred to clean collecting tubes and 200µl of elution solution 
added and incubated for 5 minutes before a final centrifugation at 6,500 x g for 1 minute 
to elute the bound DNA.  The concentration and purity of resulting DNA was then 
analysed on the Nanodrop spectrophotometer (see section 2.2.3 for protocol details) and 
the samples used for subsequent PCR analysis.   
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4.2.10 Amplification of SLC22A6 and SLC22A8 template DNA from MDCK II 
clones stably transfected with SLC22A6 and SLC22A8 
Genomic DNA extracted in section 4.2.9 was used in subsequent PCR, carried out as 
described in section 4.2.4.  PCR products for each MDCK II clone stably transfected 
with SLC22A6 and SLC22A8 were then visualised by gel electrophoresis (see section 
2.2.4 for protocol details), with MDCK II clones positive for the human SLC22A6 gene 
displaying an amplified fragment at 1.6Kb (figure 4.8(B); figure 4.9(B).    
 
4.2.11 RNA extraction of MDCK II clones stably transfected with SLC22A6 and 
SLC22A8   
The RNA of 12 MDCK II clones transfected with SLC22A6 and SLC22A8 along with 
three MDCK II clones that were ‘mock’ transfected with empty pcDNA3.1 vector alone 
was extracted using Trizol reagent according to manufacturer’s protocol (Sigma 
Aldrich,UK), as follows.  On the day of extraction, the media was aspirated from each 
well and 1ml of Trizol reagent added directly to the cells.  Cells were lysed and 
homogenised in the well by pipetting up and down several times and each clone was 
subsequently removed to individual RNAse and DNAse free 1.5ml Eppendorf tubes.  
Homogenised samples were incubated at room temperature for 5 minutes to permit 
dissociation of the nucleoprotein complex.  After 5 minutes had elapsed, 200µl of 
chloroform (Sigma Aldrich, UK) was added to each sample, the caps were secured and 
each tube was vigorously shaken by hand for 15 seconds.  Samples were then incubated 
at room temperature for 2-3 minutes before centrifugation at 12,000 x g for 15 minutes 
at 40C to separate the sample into a lower phenol-chloroform phase, an interphase and a 
colourless upper aqueous phase.  The aqueous upper phase of each sample (containing 
the RNA) was transferred to a clean RNAse and DNAse free Eppendorf and 500µl of 
100% isopropanol added.  Samples were then allowed to incubate for 10 minutes at 
room temperature before a second centrifugation step at 12,000 x g for 10 minutes at 
40C.  After centrifugation, a small, clear RNA pellet was visible.  The supernatant was 
then removed from the tube to leave only the pellet and the pellet washed in 1ml of 75% 
ethanol.  Samples were vortexed briefly before a final centrifugation step at 7500 x g for 
5 minutes at 40C.  The supernatant was then discarded, the resulting RNA pellet allowed 
to air dry at room temperature for 5-10 minutes (care was taken not to allow the pellet to 
dry out completely) and the pellet resuspended in 30µl of RNAse free water.  The 
concentration and purity of each sample was then analysed on the Nanodrop 
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spectrophotometer (see section 2.2.3 for details) and the samples used for later reverse 
transcription.    
 
4.2.12 Reverse transcription 
Extracted RNA was reverse transcribed to cDNA for use in quantitative RT-PCR using 
High capacity cDNA reverse transcription reagents (Life Technologies) according to 
manufacturer’s protocol, as follows.  Reagents were thawed on ice and vortexed briefly 
before use.  A 2 x reverse transcription mastermix was made up with the following 
constituents: 2µl of reverse transcription buffer (10 x initial concentration), 0.8µl of 
dNTPs mix (100mM), 2µl of reverse transcription random primers (10 x final 
concentration), 1µl of multiscribe reverse transcription enzyme (50U/µl) and 4.2µl of 
nuclease free water (quantities given are for one reaction (20µl total), quantities of each 
constituent were factored up according to the number of samples).   The mastermix was 
inverted to mix and 10µl added to labelled PCR tubes and kept on ice. A 10µl aliquot 
(2µg) of RNA was then added to the relevant tube and flicked to mix.  Tubes were 
centrifuged briefly and kept on ice.  Each PCR tube was then transferred to the heat 
block of a 96 well thermal cycler and the following incubation steps followed: 10 
minutes at 250C, 370C for 2 hours, 850C for 5 minutes before cooling and holding at 
40C.  Following reverse transcription, the cDNA concentration and purity was 
determined using the Nanodrop spectrophotometer (see section 2.2.3 for details).     
 
4.2.13 Analysis of MDCK II clones stably transfected with SLC22A6 and SLC22A8 
by quantitative RT-PCR 
Quantitative real time PCR (qRT-PCR) was carried out using Taqman technology 
according to manufacturer’s protocol.  Each Taqman assay contains forward and reverse 
primers specific to the gene transcript (SLC22A6, canine SLC22A6, SLC22A8, canine β-
actin) and a third oligonucleotide labelled with a fluorescent reporter molecule and 
quencher molecule covalently attached.  This third oligonucleotide binds to the 
transcript between the binding sites of the two target-specific primers and when 
permanently separated from the quencher (i.e. during Taq amplification of the target 
sequence) the reporter generates a fluorescent signal which is directly proportional to 
template amplification.  The endogenous control assay chosen (canine β-actin) contains 
a different reporter dye (VIC labelled) than the SLC22A6 and SLC22A8 assays (FAM 
labelled), therefore a duplex reaction could be achieved in which both the target 
transcript (SLC22A6 or SLC22A8) and the endogenous control transcript could be 
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quantified in the same reaction.  A reaction mix was made up in a 1.5ml DNAse and 
RNAse free Eppendorf containing 5µl of the target assay (SLC22A6 or SLC22A8), 5µl 
of the endogenous control assay (canine β-actin), 50µl of Taqman mastermix 
(containing reaction buffer and Taq polymerase), 20µl of RNAse free water and 20µl of 
cDNA template (20ng/µl).  This volume allowed 4 replicate reactions to be included.  
The reaction mix was flicked several times to mix and for each clone, 4 aliquots of 20µl 
were transferred to 4 separate wells of a 384 well plate.  Once reactions for all samples 
had been loaded, the plate was sealed with an optical seal, centrifuged briefly (Thermo 
Scientific Heraeus Megafuge 16) and transferred to the heat block of a 7900HT Fast 
Start Real Time PCR System (Applied Biosystems).  The following PCR conditions 
were used according to manufacturer’s protocol:  initial 2 minute step at 500C and 10 
minute step at 950C, followed by 40 cycles of 950C for 15 seconds and 600C for 1 
minute.  SDS 2.3 software was used to quantify amplification plots and Rq manager 
was used to generate Ct values for each sample.  
 
4.2.14 Quantitative RT-PCR data analysis 
Relative SLC22A6 and SLC22A8 gene expression in stably transfected MDCK II cell 
clones was calculated using the comparative Ct method.  Rq manager was used to 
generate Ct values (i.e. the PCR cycle at which the reporter signal crosses an arbitrary 
threshold) from amplification plots.  The comparative Ct method uses the following 
equation to calculate the fold change expression (2-∆∆Cᵗ) of two samples where each 
sample is related to an internal control (canine β-actin).  
 
          2-∆∆CT =    [(Ct gene of interest – Ct internal control) sample A  
   - (Ct gene of interest – Ct internal control) sample B] 
 
 
Internal control (β actin) Ct values obtained in each duplex reaction were subtracted 
from target (SLC22A6/SLC22A8) Ct values for each sample (or clone).  An average 
(∆Ct) was then calculated from the 4 replicates included for each sample. Sample ∆Ct 
values were then compared to the ∆Ct value of a comparable sample, for the purposes of 
determining relative expression.  For SLC22A6, the comparative sample employed was 
the canine homologue of SLC22A6.  SLC22A8 does not have a canine homologue; 
therefore the clone which generated the highest Ct value was used as a comparative 
sample in this case.  The ∆Ct of the comparative sample was subtracted from the target 
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∆Ct (comparative sample was subtracted from itself to give 0) to give the ∆∆Ct for each 
sample.  The fold change in expression (2-∆∆Cᵗ) of each clone in relation to the 
comparative sample could then be calculated.  
 
4.2.15 Generation of protein lysates and western blotting 
Protein lysates from SLC22A6, SLC22A8 and mock pcDNA3.1 transfected MDCK II 
cells were generated for use in western blot analysis.  Briefly, frozen aliquots of 2x106 
cells were defrosted from -800C storage, transferred to a 1.5ml Eppendorf tube and 
centrifuged at 250 x g for 5 minutes to retrieve the cell pellet.  The supernatant was 
removed and the cell pellet resuspended in 100µl of ice cold RIPA buffer (Thermo 
Scientific, Loughborough, UK), supplemented with 10µl/ml protease cocktail (Sigma 
Aldrich, UK).  The samples were incubated on ice for 30 minutes and centrifuged 
(Thermo Scientific Heraeus Fresco 21) at 12,000 x g for 15 minutes at 40C.  The lysate 
containing the cellular proteins was then transferred to a clean 1.5ml Eppendorf tube 
and then sonicated (VWR Ultrasonic cleaner) for 30 seconds followed by 20 seconds 
incubation on ice, three times.  Protein concentration in each sample was then 
determined using the Bio-rad detergent compatible assay reagents (Bio-rad, Hemel 
Hempstead, UK) according to the manufacturer’s instructions, as follows.  First, 
standards of known concentrations (0.2, 0.4, 0.6, 0.8, 1.0, 1.5, 2.0, 2.5mg/ml) of BSA 
were prepared in RIPA buffer.  Then, 5µl aliquots of standards and samples were 
transferred to a clean, clear, 96-well flat bottom Grenier plate in triplicate and 25µl of 
Reagent A (supplemented with 20µl/ml Reagent S) added.  Thereafter, 200µl of 
Reagent B was added and the plate briefly shaken and incubated at room temperature.  
After 15 minutes, the absorbance of the standards and samples was read at 650nm on a 
DTX 880 Multimode detector (Beckman Coulter, UK).  A standard curve was generated 
from the absorbance of known standard concentrations of protein (BSA) and each 
sample concentration determined from this.     
 
4.2.16 Denaturing gel electrophoresis 
Protein lysates prepared as described in section 4.2.15 were eluted by denaturing gel 
electrophoresis according to the NuPAGE manufacturer’s protocol for use in 
subsequent western blotting.  Samples were first prepared in 10µl aliquots containing 
2.5µl NuPAGE loading buffer, 1µl NuPAGE reducing agent, xµl sample lysate (where 
x is the quantity required to give 20µg of protein), and yµl water (where y is the 
quantity required to make the reaction volume up to 10µl).  Samples were briefly 
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vortexed, heated at 700C for 5 minutes in a heat block and incubated on ice until cool.  
Meanwhile, a 1.0mm 4-12% bis-tris pre cast NuPAGE gel was  secured in an Xcell Sure 
lock electrophoresis chamber (Invitrogen, UK) and the outer and inner chambers filled 
with 1x running buffer (50ml 20x NuPAGE MOPS SDS running buffer in 950ml water) 
and 1x running buffer supplemented with NuPAGE antioxidant  (500µl in 200ml 1x 
running buffer) respectively. The cooled samples and a reference protein ladder (10-
175kDa Prism Protein Ladder) were then loaded onto the gel and the chamber topped 
up with 1 x running buffer to cover the loaded samples.  Samples were then allowed to 
elute at an initial voltage of 70V for 10 minutes followed by 45 minutes at 170V.  
 
4.2.17 Western blotting 
Protein analysis by western blotting aimed to confirm OAT1 and OAT3 expression in 
MDCK II cells stably transfected with SLC22A6 and SLC22A8 respectively.  OAT1 and 
OAT3 expression was also analysed in both mock transfected MDCK II cells and 
hCMEC/D3 cells.  The expression of an endogenous control protein (GAPDH) was also 
analysed as an experimental control.   First, the gel containing the eluted proteins as 
described in section 4.2.16 was transferred to a nitrocellulose membrane according to 
the NuPAGE manufacturer’s protocol: 1x transfer buffer was prepared (50ml of 20x 
NuPAGE transfer buffer, 100ml methanol, and 850ml water), with blotting pads and a 
nitrocellulose sandwich soaked in the transfer buffer.  The transfer chamber (Bio-Rad 
mini Trans-Blot cell) was then constructed and a gel sandwich prepared as follows: the 
gel cassette was broken open and the foot of the gel removed, a filter paper soaked in 
transfer buffer was then laid on a clean surface and the gel turned out onto the filter 
paper, the nitrocellulose membrane was then laid on top followed by a 2nd filter paper 
(all pre-cut to size).   A 10ml serological pipette was then rolled over the gel sandwich 
to remove any bubbles and ensure a tight seal, before placing the sandwich between two 
blotting pads soaked in transfer buffer in a cassette and securing the cassette.  The 
cassette was then transferred to the transfer chamber, ensuring the nitrocellulose 
membrane side of the sandwich was positioned away from the cathode core of the 
chamber.   An ice pack was then inserted behind the transfer cassette adjacent to the 
cathode core, a magnetic flea placed in the chamber and the chamber filled with transfer 
buffer.  The lid of the transfer chamber was then applied, the chamber positioned on a 
magnetic stirrer and connected to a power pac (Bio-Rad power-pac 300) at 110V for 
1.25 hours.        
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Following transfer, the cassette containing the gel sandwich was opened and the 
membrane removed and washed in 0.2% ponceau red dye to visualise the protein bands 
that had been transferred.  The membrane was then washed three times in 1x tris 
buffered saline plus tween (TBS/T), which constitiuted:100ml of 10 x TBS (80g NaCl, 
2g KCl, 30.3g Trizma base, 800ml water adjusted to pH7.4 with pure HCl and made up 
to 1L with water), 1ml of tween and 899mlof water) to remove the dye.  The membrane 
was blocked in 5% milk solution (5g skimmed milk powder in 100ml 1xTBS/T) for 2 
hours at room temperature to minimise non-specific binding of the primary antibody 
before 10ml of the primary mouse monoclonal SLC22A6 (2.5µg/ml in 5% milk 
solution) or rabbit polyclonal SLC22A8 antibody (1µg/ml in 5% milk solution) was 
added to the membrane and incubated at room temperature for 1 hour with gentle 
rocking (Stuart Scientific gyro-rocker SSL3).  The membrane was then washed three 
times for 5 minutes each in 1x TBS/T and incubated with 0.2µl/ml goat anti-mouse or 
goat anti-rabbit (0.2µl/ml) horseradish peroxidase (HRP) conjugated secondary 
antibody respectively, for 1 hour at room temperature.  The membrane was again 
washed three times for 5 minutes each in 1 x TBS/T and then exposed to 
chemoluminescence substrate for detection of HRP conjugates.  
 
Chemoluminescence substrate was prepared according to manufacturer’s instructions 
(Sigma Aldrich, UK), 500µl of reagent A was added to 500µl reagent B and 
immediately added to the membrane.  The membrane was placed on a sheet of acrylic 
and the chemoluminescence substrate added evenly across the membrane.  The 
chemoluminescence was exposed to light for one minute, the excess blotted from the 
membrane with a tissue and a sheet of acrylic placed on top.  Any bubbles were 
removed and the membrane secured in a photography cassette between the sheets of 
acrylic.  An x-ray film (Carestream, Kodak, Biomax light film (Sigma Aldrich, UK)) 
was then exposed to the membrane for 5 minutes in a dark room.  After exposure the x-
ray film was placed in a tray containing developer (Carestream, Kodak, auto 
radiography GBX developer/replenisher (Signma Aldrich, UK)) and rocked back and 
forth until bands appeared.  Once bands appeared the film was quickly removed to 
minimise background development, washed in water and allowed to incubate for a few 
minutes in fixative (Carestream, Kodak, auto radiography GBX fixer/replenisher 
(Signma Aldrich, UK)).  The x-ray film was then washed again in water and allowed to 
dry overnight.  Samples containing the target protein (OAT1 or OAT3) produced a band 
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in the corresponding lane at the correct protein size, with the intensity of the band 
representing the level of expression (figure 4.8(C); figure 4.9(C)).   
 
After analysis of the target protein, the antibody was stripped from the membrane.  This 
was achieved by incubating the membrane in stripping buffer (20ml 10% SDS, 12.5ml 
Tris HCl buffer at pH6.8, 66.8ml H2O, and 700µl of β-mercaptoethanol) at 600C with 
moderate shaking for 30 minutes.  The membrane was then blocked a second time with 
5% milk solution for 1 hour at room temperature and incubated with the mouse 
monoclonal GAPDH primary antibody (0.2µl/ml in 5% milk solution) overnight at 40C 
with gentle rocking.  The next day the membrane was washed three times for 5 minutes 
each in 1% TBS/T and incubated with goat anti-mouse HRP conjugated secondary 
antibody (0.2µl/ml in milk solution) for 1 hour.  The membrane was then washed again 
in 1% TBS/T and the membrane exposed to chemoluminescence and an x-ray film 
developed as described previously.  Following incubation with GAPDH antibody, bands 
are expected for all samples (figure 4.8(C); figure 4.9(C)).   
 
4.2.18 Functional transport comparison of MDCK II cell clones stably transfected 
with SLC22A6 and SLC22A8  
Transport function of all 12 selected SLC22A6 and SLC22A8 clones was analysed 
utilising a well-characterised radiolabelled positive control substrate for each of 
SLC22A6 and SLC22A8.  [3H]-PAH was used to explore SLC22A6 mediated transport at 
an isotope concentration of 0.3µCi/ml and a final drug concentration on 2µM.  [3H]-E3S 
was used to explore SLC22A8-mediated transport also at an isotope concentration of 
0.3µCi/ml and a final drug concentration of 8.8µM. Both radiolabelled drugs were 
prepared in transport medium (HBSS supplemented with 25mM HEPES and 0.1% 
BSA, at pH7.4).  An isotope concentration of 0.3µCi/ml afforded sufficient 
disintegrations per minute to give accurate readings of radioactive content without 
saturating the scintillation counter.   
 
MDCK II cell clones stably transfected with SLC22A6 and SLC22A8 were seeded into 
12-well plates at a density of 1.5x106 cells per ml. On the day of the assay (three days 
thereafter), media was aspirated from the cells and cells allowed to equilibrate in 
transport medium at 370C for 30 minutes.  A dosing solution of PAH/E3S was prepared 
using transport medium containing the respective radiolabelled/non-radiolabelled drug 
(to the final concentrations reported above). The dosing solution was added to the cells, 
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which were then incubated at 370C for 60 minutes.  In the meantime, 20µl samples of 
transport buffer alone (blanks) and dosing solution (standards) were taken and added to 
scintillation vials for later determination of background radiation and radioactive 
content of a known concentration of each drug solution, respectively.  After incubation, 
cells were washed three-times in ice cold HBSS to terminate uptake and solubilised for 
30 minutes at 370C with 400µl of 10% SDS.  The resulting solution was then transferred 
to individual scintillation vials and 4ml scintillation fluid (Goldstar Multipurpose 
Scintillation Cocktail, Meridian, UK) added to all vials.  Vials were mixed by inverting 
several times before radioactive content was determined using a scintillation counter 
(1500 Tri Carb LS Counter; Packard).  Results in dpm were corrected for background 
counts, quantified in relation to standards of known concentration and expressed (in 
pmol/100,000 cells) in relation to the number of cells per well.   
 
 
4.2.19 Kinetic analysis of SLC22A6_MDCK II and SLC22A8_MDCK II cells with a 
positive control substrate 
For this and all subsequent uptake assays, the SLC22A6 and SLC22A8 transfected 
MDCK II cell clones which observed the greatest uptake of probe substrate and the 
most robust mRNA and protein expression were used.  SLC22A6_MDCK II and 
SLC22A8_MDCK II cells were again incubated with radiolabelled PAH and E3S at 
final concentrations of 2µM and 8.8µM, respectively (isotope concentration = 
0.3µCi/ml in both cases). Uptake assays were carried out as described in section 4.2.18 
but with cells incubated with positive control drug for a range of times (5, 10, 20, 40, 60 
and 120 minutes) to determine a time point to be used in subsequent experiments.   
 
4.2.20 IC50 determination 
IC50 values to determine the potency of OAT inhibitors on the uptake of OAT1 or 
OAT3 substrates were generated using the uptake assay method described in section 
4.2.18. A dosing solution was made for each substrate drug (PAH and E3S) using 
transport medium containing the respective radiolabelled/non-radiolabelled drug (to the 
final concentration reported previously) with various concentrations of inhibitor (0-
300µM).   
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4.2.21 Uptake of AEDs 
Uptake experiments with AEDs (all at an isotope concentration of 0.3µCi/ml) were 
performed at final concentrations of 25µM PHT, 20µM CBZ, 300µM VPA, 10µM 
LTG, 10µM TPM, 10µM GBP and 6µM LEV, all prepared in transport medium.  
Uptake assays were carried out as described in section 4.2.18. Dosing solutions 
consisted of transport medium containing the respective radiolabelled AED (to the final 
concentrations shown above) with either inhibitor or vehicle (0.1% DMSO). 
 
4.2.22 Statistical analysis 
All data is presented as the mean (± standard error of the mean) percentage of mean 
control transport (pcDNA_MDCK II cells) for each AED on each experimental day.  
Individual experiments were performed in triplicate and repeated on at least three 
occasions (n≥9).  Data was assessed for normality using the Shapiro-Wilk test and 
found to be normally distributed in all cases.  An analysis of variance (ANOVA) was 
performed on the data with Tukey’s post hoc test for multiple comparisons.  A value of 
p≤0.05 was taken to indicate statistical significance. 
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4.3 Results 
4.3.1 Abundance of OAT mRNA in brain endothelial cells 
mRNA abundance (ΔCt; mean ± SEM; log10 scale) of human SLC22A6 (OAT1), 
SLC22A7 (OAT2) and SLC22A8 (OAT3), relative to the endogenous control (human 
GAPDH), was analysed in hCMEC/D3 cells using quantitative RT-PCR.  OAT1 
abundance was detected at a very low level (4.4x10-5), relative to GAPDH abundance 
(1.00).  OAT2 and OAT3 were undetectable (figure 4.7). 
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Figure 4.7: mRNA abundance (ΔCt; mean ± SEM; log10 scale) of human SLC22A6 
(OAT1), SLC22A7 (OAT2) and SLC22A8 (OAT3) in a human cerebral microvascular 
endothelial cell line (hCMEC/D3).  Results are expressed as mean abundance relative to 
that of GAPDH, which was used as an endogenous control gene.   OAT2 and OAT3 
were undetectable in these cells. 
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4.3.2 SLC22A6_MDCK II  clone analysis 
To be confident that the newly-generated, stably transfected cells were expressing 
functional OAT1 protein, SLC22A6 expression was first analysed at DNA and mRNA 
level.  PCR analysis confirmed that all of the 11 clones analysed contained the 
SLC22A6 gene sequence (figure 4.8(B)).  SLC22A6 gene expression was subsequently 
quantified using qRT-PCR, confirming SLC22A6 expression in all 11 clones selected. 
Of these, clone 10 had the highest relative expression, with a 7173 fold higher relative 
expression than that of the canine SLC22A6 gene in mock pcDNA control MDCK cells 
(figure 4.8(A)).  OAT1 expression in clone 4 (moderate SLC22A6 mRNA expression) 
and clone 10 (high SLC22A6 mRNA expression) was also analysed at protein level and 
confirmed in both clones (figure 4.8(C)).  The functional capacity of OAT1 to transport 
the positive control substrate (PAH) in the 11 clones selected was also assessed.  Clone 
10 showed the greatest uptake of PAH (18948 ± 797%) after 5 minutes incubation 
compared to uptake in control pcDNA_MDCK II cells (100 ± 4.3%; figure 4.8(D))and 
was subsequently selected for transfection. 
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Figure 4.8: Analysis of SLC22A6_MDCK II clones.  a) Agarose gel (1%) 
visualisation of SLC22A6 DNA in a positive control (1), negative control (2), control 
pcDNA MDCK II cells (3) and 11 OAT1 single cell clones (lanes 4-14).  All clones 
were positive for SLC22A6 template DNA following amplification of MDCK 
II_SLC22A6 clones by PCR.  b) qRT-PCR analysis of 11 single cell clones, of which 
clone 10 showed the highest mRNA expression.  Total RNA was extracted from 
SLC22A6_MDCK II clones and reverse-transcribed into cDNA.  The cDNA used 
was then used to quantify relative expression for each gene and the mean Ct values 
obtained from test gene amplification plots were normalised to the mean Ct of the 
housekeeping gene canine β actin.  Data are presented as the relative test gene 
expression (∆∆Ct), according to the comparative Ct method.  c) Analysis of OAT1 
protein expression by western blotting.  Sample lysates from left to right: 
hCMEC/D3 (1), clone 4 (2), clone 6 (3), clone 10 (4) and control pcDNA (5). d) 
Functional uptake of [3H]-p-aminohippuric acid (PAH; OAT1 substrate) in 11 
MDCK II_SLC22A6 clones compared to control (MDCK II_pcDNA). Cultures were 
exposed to 2μM radiolabelled PAH for 5 minutes at 370C. Results are expressed as 
the mean ± the standard error of the mean (SEM) percentage of the mean control 
value of PAH uptake (in pmols/100,000 cells) for one experiment where n=3. 
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4.3.3 SLC22A8_MDCK II clone analysis 
SLC22A8 clones were first analysed at the DNA and mRNA level.  PCR analysis 
confirmed that all of the 12 clones analysed contained the SLC22A8 DNA sequence 
(figure 4.9(B)).  SLC22A8 gene expression was subsequently quantified using qRT-
PCR, confirming SLC22A8 expression in all 12 clones selected. Of these, clone 2 had 
the highest relative expression, with a 258 fold higher relative expression than that of 
the lowest expressing clone (clone 5): given the arbitrary value 1; figure 4.9(A)).  A 
canine homologue of SLC22A8 does not exist; therefore expression in mock pcDNA 
control MDCK cells was not determined.  OAT3 protein expression in clone 7 and 8 
(moderate SLC22A8 mRNA expression) and clone 2 and 12 (high SLC22A8 mRNA 
expression) was also analysed by western blotting and confirmed in all four clones 
(figure 4.9(C)).  The functional capacity of OAT3 to transport the control substrate 
E3S (8.8µM) in the 12 clones selected was also assessed.  Clone 2 showed the 
greatest uptake of E3S (239 ± 18.3%) after 5 minutes incubation compared to uptake 
in control pcDNA_MDCK II cells (100 ± 9.27; figure 4.9(D)) and was subsequently 
selected for transfection. 
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Figure 4.9: Analysis of SLC22A8_MDCK II clones. a) Agarose gel (1%) visualisation 
of SLC22A8 DNA in a negative control (1), positive control (2), control (pcDNA) 
MDCK II cells (3) and 12 SLC22A8 single cell clones (lanes 4-15).  All clones were 
positive for SLC22A8 template DNA following amplification by PCR of MDCK 
II_SLC22A8 clones. b) qRT-PCR analysis of 12 single cell clones, of which clone 2 
showed the highest mRNA expression.  Total RNA was extracted from 
SLC22A8_MDCK II clones and reverse-transcribed into cDNA and the cDNA used to 
quantify relative expression for each gene.  Mean Ct values obtained from test gene 
amplification plots were normalised to the mean Ct of the clone with lowest expression 
(clone 5) and are presented as the relative test gene expression (∆∆Ct), according to the 
comparative Ct method.  c) Analysis of OAT3 protein expression by western blotting.  
Sample lysates from left to right: clone 2 cell lysate (1), clone 12 cell lysate (2), clone 
11 cell lysate (3), clone 8 cell lysate (4) control pcDNA_MDCK II cell lysates (5) and 
hCMEC/D3 cell lysates (6). d) Functional uptake of [3H]-Estrone-3-sulfate (E3S; OAT3 
substrate) in 12 MDCK II_SLC22A8 clones compared to control (MDCK II_pcDNA). 
Cultures were exposed to 8.8μM radiolabelled E3S for 5 minutes at 370C. Results are 
expressed as the mean ± the standard error of the mean (SEM) percentage of the mean 
control value of E3S uptake (in pmols/100,000 cells) for one experiment where n=3.   
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4.3.4 Kinetics of the OAT1 substrate p-aminohippuric acid in a SLC22A6 stably-
transfected MDCK II cell line 
A time course study of the OAT1 substrate PAH in SLC22A6_MDCK II cells compared 
to control (pcDNA transfected) MDCK II cells was undertaken to determine the 
optimum time point for further investigation with AEDs (figure 4.10).  Optimum 
transport of 2µM PAH was observed between 40 and 60 minutes (104±16 pmol/1x106 
cells) before uptake saturated. The 40 minute time point in the linear phase of PAH 
transport was therefore chosen for subsequent experiments with AEDs. PAH was 
subsequently incubated for 40 minutes with and without the OAT1 inhibitor probenecid. 
Uptake of PAH in SLC22A6_MDCK II cells was 3943±311% (p≤0.001) of the 
corresponding control value (100±5.1%) in pcDNA transfected cells. In the presence of 
200µM probenecid, the increase in PAH transport in SLC22A6_MDCK cells relative to 
transport in control cells was attenuated to 247±14% of control (p≤0.001; figure 4.11).  
PAH uptake in SLC22A6_MDCK II cells was also investigated in the presence of 
various concentrations (0.1, 1.0, 3.0, 10, 30, 100 and 300µM) of probenecid to generate 
a concentration-response curve. Uptake of PAH at each concentration of probenecid in 
control (pcDNA-transfected) cells was deducted from uptake in SLC22A6_MDCK II 
cells and an IC50 value of 3.4µM determined (figure 4.12) 
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Figure 4.10: p-aminohippuric acid (PAH) uptake in SLC22A6_MDCK II cells (OAT1) 
compared to control pcDNA-transfected MDCK II cells over time. Cultures were 
exposed to 2μM radiolabelled PAH for 5, 10, 20, 40, 60 and 120 minutes at 370C. 
Results are expressed as mean PAH uptake ± standard error of the mean (SEM) (in 
pmols/100,000 cells) on each experimental day. Experiments were performed in 
triplicate on three separate occasions (n=9). 
 
 
 
0 2 0 4 0 6 0 8 0 1 0 0 1 2 0 1 4 0
0
5 0
1 0 0
1 5 0
T im e  (m in u te s )
M
e
a
n
 ±
S
E
M
 P
A
H
 u
p
ta
k
e
 (
p
m
o
l/
1
x
1
0
6
c
e
l
l
s
)
p c D N A
O A T 1
128 
 
p
cD
N
A
O
A
T
1
O
A
T
1
 +
 2
0
0
µ
M
 p
ro
b
e n
e c
id
0
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
5 0 0 0
M
e
a
n
 ±
S
E
M
 P
A
H
 u
p
ta
k
e
 (
%
 o
f 
c
o
n
tr
o
l) **
 
Figure 4.11: p-aminohippuric acid (PAH) uptake into SLC22A6_MDCK II cells 
(OAT1) compared to control pcDNA-transfected MDCK II cells with and without the 
OAT1 inhibitor probenecid.  Cultures were exposed to 2μM radiolabelled PAH with or 
without probenecid at 200µM for 40 minutes at 370C. Results are expressed as the mean 
± standard error of the mean (SEM) percentage of the mean control value of PAH 
uptake (in pmols/100,000 cells) on each experimental day. Experiments were performed 
in triplicate on three separate occasions (n=9). Statistical significance (*p<0.001) was 
determined by one-way analysis of variance with Tukey’s correction for multiple 
testing. 
129 
 
 
Figure 4.12: p-aminohippuric acid (PAH) uptake into SLC22A6_MDCK II cells in the 
presence of various concentrations of probenecid to determine inhibitory potency.  
Cultures were exposed to 2µM radiolabelled PAH with and without probenecid for 40 
minutes at 370C to generate a concentration response.  The concentration response 
included the following concentrations of probenecid: 0µM vehicle only (0.1% DMSO), 
1µM, 3µM, 10µM, 30µM, 100µM and 300µM.  Response in mock transfected cells at 
the corresponding concentrations was subtracted from that in SLC22A6_MDCK II cells 
to account for passive transport and to allow determination of inhibitory effects on 
OAT1 mediated transport only.  Results are expressed as the mean ± standard error of 
the mean (SEM) PAH uptake in pmol/1,000,000 cells on each experimental day.  
Experiments were performed in triplicate on three occasions (n=9).   
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4.3.5 Kinetics of the OAT3 substrates estrone-3-sulphate and p-aminohippuric acid 
in a stably transfected SLC22A8_MDCK II cell line 
A time course study employing the OAT3 substrate E3S in SLC22A6_MDCK cells was 
undertaken to determine the optimum time point for further investigation with AEDs 
(figure 4.13).  Optimum transport of 8.8µM E3S (69.1±12 pmol/1x106 cells) was 
observed following 40 minutes incubation, with uptake saturating thereafter. The 40 
minute time point was therefore chosen for subsequent experiments with AEDs in 
SLC22A8_MDCK II cells.  Transport of E3S was then investigated with and without the 
OAT3 inhibitor probenecid. Uptake of E3S in SLC22A8_MDCK II cells was 256±24% 
(p≤0.001) of the corresponding control value (100±5.95%) in pcDNA transfected cells. 
In the presence of 200µM probenecid, the increase in E3S transport in 
SLC22A8_MDCK cells relative to transport in control cells was attenuated to 
156±22.5% of control (p≤0.001; figure 4.14).   SLC22A8 transport of PAH in 
SLC22A8_MDCK II cells was also investigated with and without the OAT3 inhibitor 
probenecid.  Uptake of PAH was 303±49% (p≤0.001) of the corresponding control 
value (100±5%) in pcDNA transfected cells. In the presence of 200µM probenecid, the 
increase in PAH transport relative to transport in control cells was attenuated to 
200±17% of control (p≤0.001; figure 4.15).  SLC22A8 PAH uptake in 
SLC22A8_MDCK II cells was also investigated in the presence of various 
concentrations of probenecid (0.1, 1.0, 3.0, 10, 30, 100 and 300µM) to obtain a 
concentration response curve.  Uptake of PAH at each concentration of probenecid in 
control (pcDNA-transfected) cells was deducted from uptake in SLC22A8_MDCK II 
cells and an IC50 value of 8.7µM determined (figure 4.16).   
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Figure 4.13: Estrone-3-sulfate (E3S) uptake in SLC22A8_MDCK II cells (OAT3) 
compared to control pcDNA-transfected MDCK II cells over time. Cultures were 
exposed to 8.8μM radiolabelled E3S for 5, 10, 20, 40, 60 and 120 minutes at 370C. 
Results are expressed as mean ± standard error of the mean (SEM) E3S uptake (in 
pmols/100,000 cells) on each experimental day. Experiments were performed in 
triplicate on three separate occasions (n=9). 
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Figure 4.14: Estrone-3-sulfate (E3S) uptake into SLC22A8_MDCK II cells (OAT3) 
compared to control pcDNA-transfected MDCK II cells with and without the OAT3 
inhibitor probenecid.  Cultures were exposed to 8.8μM radiolabelled E3S with or 
without probenecid at 200µM for 40 minutes at 370C. Results are expressed as the mean 
± standard error of the mean (SEM) percentage of the mean control E3S uptake (in 
pmols/100,000 cells) on each experimental day. Experiments were performed in 
triplicate on three separate occasions (n=9). Statistical significance (*p<0.01, 
**p<0.001) was determined by one-way analysis of variance with Tukey’s correction 
for multiple testing. 
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Figure 4.15: p-aminohippuric acid (PAH) uptake into SLC22A8_MDCK II (OAT3) 
cells compared to control pcDNA-transfected MDCK II cells with and without the 
OAT3 inhibitor probenecid.  Cultures were exposed to 2μM radiolabelled PAH with or 
without probenecid at 200µM for 40 minutes at 370C. Results are expressed as the mean 
± standard error of the mean (SEM) percentage of the mean control value of PAH 
uptake (in pmols/1,000,000 cells) on each experimental day. Experiments were 
performed in triplicate on three separate occasions (n=9). Statistical significance 
(*p<0.05, **p<0.001) was determined by one-way analysis of variance with Tukey’s 
correction for multiple testing. 
 
134 
 
-2 -1 0 1 2 3
1 .0
1 .2
1 .4
1 .6
1 .8
2 .0
2 .2
lo g  p r o b e n e c id  c o n c e n tr a t io n   ( µ M )
M
e
a
n
 ±
S
E
M
 P
A
H
 u
p
ta
k
e
 (
p
m
o
l/
1
x
1
0
6
c
e
ll
s
)
 
Figure 4.16: p-aminohippuric acid (PAH) uptake into SLC22A8_MDCK II cells in the 
presence of various concentrations of probenecid to determine inhibitory potency.  
Cultures were exposed to 2µM radiolabelled PAH with and without probeneid for 40 
minutes at 370C to generate a concentration response.  The concentration response 
included the following concentrations of probenecid: 0µM vehicle only (0.1% DMSO), 
1µM, 3µM, 10µM, 30µM, 100µM and 300µM.  Response in mock transfected cells at 
the corresponding concentrations was subtracted from that in SLC22A8_MDCK II cells 
to account for passive transport and to allow determination of inhibitory effects on 
OAT3 mediated transport only.  Results are expressed as the mean ± standard error of 
the mean (SEM) PAH uptake in pmol/1,000,000 cells on each experimental day.  
Experiments were performed in triplicate on three occasions (n=9).  
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4.3.6 Antiepileptic drug transport in a stably transfected SLC22A6 MDCK II cell 
line 
AEDs were incubated with control (mock pcDNA transfected) and SLC22A6-
transfected MDCK II cells with and without the OAT1 inhibitor probenecid (200µM) 
for 40 minutes at 370C.  VPA uptake was 139±15% (p≤0.01) in SLC22A6_MDCK II 
cells compared to control (100±3.1%), but was not significantly inhibited in the 
presence of probenecid (124±6.3%; figure 4.17; table 4.2).  Likewise, LTG uptake was 
147±4.4% (p≤0.01) in SLC22A6_MDCK II cells compared to the control (100±0.93%) 
and although a decrease was observed in the presence of probenecid (131±4.3%), this 
did not reach statistical significance (figure 4.17; table 4.2).  To elucidate if LTG 
transport observed may be due to a compensatory increase in endogenous canine cation 
transporters, LTG uptake in the presence of the cation transport inhibitor verapamil was 
investigated.  Interestingly, when co-incubated with the organic cation transporter 
(OCT) inhibitor verapamil (100µM), the uptake of LTG in both control (24.3±1.5%; 
p≤0.001) and SLC22A6_MDCK II cells (22.4±1.4%; p≤0.001) was dramatically 
reduced (figure 4.19) in comparison to that of LTG alone in control cells.  LTG was 
also seen to act as an inhibitor of the uptake of the prototypic OAT1 substrate PAH in 
SLC22A6_MDCK II cells, with an IC50 value of 32.9µM obtained (figure 4.20). No 
significant differences in uptake were observed for the other AEDs tested (figures 4.17 
and 4.18).  
 
Antiepileptic drug 
Mean ± SEM uptake (% of control) 
control pcDNA OAT1 OAT1 + 200µM probenecid 
Phenytoin 100 ±2.7 69.8 ±1.9 70.3 ±2.3 
Carbamazepine 100 ±1.3 143 ±7.7 125 ±7.7 
Sodium valproate 101 ±6.2 155 ±0.84* 158 ±4.4 
Lamotrigine 100 ±0.93 138 ±5.0** 123 ±4.9 
Gabapentin 100 ±1.7 133 ±22 138 ±18 
Topiramate 100 ±1.7 91.0 ±3.5 81.2 ±2.9 
Levetiracetam 100 ±4.6 108 ±8.9 102 ±5.7 
Table 4.2: Antiepileptic drug uptake into SLC22A6_MDCK II cells (OAT1) compared to 
control pcDNA-transfected MDCK II cells with and without the OAT1 inhibitor probenecid.  
Cultures were exposed to 25µM radiolabelled phenytoin, 20µM radiolabelled carbamazepine, 
300µM radiolabelled sodium valproate, 10µM lamotrigine, 10µM radiolabelled gabapentin, 
10µM topiramate or 6µM levetiracetam with or without probenecid at 200µM for 40 minutes at 
370C. Results are expressed as the mean ± standard error of the mean (SEM) percentage of the 
mean control value of uptake (in pmols/100,000 cells) on each experimental day. Experiments 
were performed in triplicate on three separate occasions (n=9). Statistical significance (*p<0.01, 
**p<0.001,) was determined by one-way analysis of variance with Tukey’s correction for 
multiple testing. 
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Figure 4.17 Phenytoin (PHT) (A), carbamazepine (CBZ) (B), valproic acid (VPA) (C) 
and lamotrigine (LTG) uptake (D) into SLC22A6_MDCK II cells compared to control 
pcDNA-transfected MDCK II cells with and without the OAT1 inhibitor probenecid.  
Cultures were exposed to 25µM radiolabelled PHT, 20µM radiolabelled CBZ, 300µM 
radiolabelled VPA or 10µM radiolabelled LTG respectively with or without probenecid 
at 200µM for 40 minutes at 370C. Results are expressed as the mean ± standard error of 
the mean (SEM) percentage of the mean control value of uptake (in pmols/100,000 
cells) on each experimental day. Experiments were performed in triplicate on three 
separate occasions (n=9). Statistical significance (*p<0.01, **p<0.001,) was determined 
by one-way analysis of variance with Tukey’s correction for multiple testing. 
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Figure 4.18: Gabapentin (GBP) (A), topiramate (TPM) (B) and levetiracetam (LEV) 
uptake (C) into SLC22A6_MDCK II cells compared to control pcDNA-transfected 
MDCK II cells with and without the OAT1 inhibitor probenecid.  Cultures were 
exposed to 10µM radiolabelled GBP, 10µM radiolabelled TPM or 6µM radiolabelled 
LEV respectively with or without probenecid at 200µM for 40 minutes at 370C. Results 
are expressed as the mean ± standard error of the mean (SEM) percentage of the mean 
control value of uptake (in pmols/100,000 cells) on each experimental day. Experiments 
were performed in triplicate on three separate occasions (n=9). 
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Figure 4.19: Lamotrigine (LTG) uptake into SLC22A6_MDCK II cells compared to 
control pcDNA-transfected MDCK II cells with and without the OCT inhibitor 
verapamil.  Cultures were exposed to 10µM radiolabelled LTG with or without 
verapamil at 100µM for 40 minutes at 370C. Results are expressed as the mean ± 
standard error of the mean (SEM) percentage of the mean control value of LTG uptake 
(in pmols/100,000 cells) on each experimental day. Experiments were performed in 
triplicate on three separate occasions (n=9). Statistical significance (*p<0.001) was 
determined by one-way analysis of variance with Tukey’s correction for multiple 
testing. 
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Figure 4.20: p-aminohippuric acid (PAH) uptake into SLC22A6_MDCK II cells in the 
presence of various concentrations of lamotrigine (LTG) to determine inhibitory 
potency.  Cultures were exposed to 2µM radiolabelled PAH with and without LTG for 
40 minutes at 370C to generate a concentration response.  The concentration response 
included the following concentrations of LTG: 0µM vehicle only (0.1% DMSO), 1µM, 
3µM, 10µM, 30µM, 100µM and 300µM.  Response in mock transfected cells at the 
corresponding concentrations was subtracted from that in SLC22A6_MDCK II cells to 
account for passive transport and to allow determination of inhibitory effects against 
OAT1 mediated transport only.  Results are expressed as the mean ± standard error of 
the mean (SEM) PAH uptake in pmol/1,000,000 cells on each experimental day.  
Experiments were performed in triplicate on three occasions (n=9).   
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4.3.7 Antiepileptic drug transport in a stably transfected SLC22A8 MDCK II cell 
line 
AEDs were incubated with control (mock pcDNA transfected) and SLC22A8_MDCK II 
cells with and without the OAT3 inhibitor probenecid (200µM) for 40 minutes at 370C. 
LTG uptake was higher in SLC22A8_MDCK II cells (121±5.1% of control) compared 
to control (100±2.2%; p<0.01). This effect was reversed in the presence of probenecid, 
with LTG uptake into SLC22A8_MDCK II cells returning to 103±9.5% of control 
(p<0.05; figure 4.21; table 4.3).  TPM uptake was also higher in SLC22A8_MDCK II 
cells (151±3.1% of control) than in the corresponding controls (100±1.7%; p≤0.001) but 
this observation was not influenced by the presence of probenecid, with TPM uptake 
remaining at 145±2.3% of control (figure 4.22; table 4.3).  VPA uptake was lower in 
SLC22A8_MDCK II cells (62.7 ±7.2% of control) than in the corresponding control 
cells (100±3.4%; p<0.05), an effect that was not influenced by the presence of 
probenecid, with VPA uptake remaining at 54.9±6.9% of control (figure 4.21; table 
4.3).   
 
Antiepileptic drug 
Mean ± SEM uptake (% of control) 
control pcDNA OAT3 
OAT3 + 200µM 
probenecid 
Phenytoin 100 ±2.2 98.5 ±8.5 87.2 ±7.8 
Carbamazepine 100 ±2.1 95.4 ±6.8 101 ±12 
Sodium valproate 100 ±3.4 62.7 ±7.2* 54.9 ±6.9 
Lamotrigine 100 ±1.5 121 ±5.1** 103 ±5.6* 
Gabapentin 100 ±1.7 95.4 ±6.8 101 ±12 
Topiramate 100 ±1.7 151 ±3.4*** 145±2.3 
Levetiracetam 100 ±4.6 125 ±7.0 121 ±2.5 
 
Table 4.3: Antiepileptic drug uptake into SLC22A8 MDCK II cells (OAT3) compared to 
control pcDNA-transfected MDCK II cells with and without the OAT3 inhibitor probenecid.  
Cultures were exposed to 25µM radiolabelled phenytoin, 20µM radiolabelled carbamazepine, 
300µM radiolabelled sodium valproate, 10µM lamotrigine, 10µM radiolabelled gabapentin, 
10µM topiramate or 6µM levetiracetam with or without probenecid at 200µM for 40 minutes at 
370C. Results are expressed as the mean ± standard error of the mean (SEM) percentage of the 
mean control value of uptake (in pmols/100,000 cells) on each experimental day. Experiments 
were performed in triplicate on three separate occasions (n=9). Statistical significance (*p<0.05, 
**p<0.01, *** p<0.001) was determined by one-way analysis of variance with Tukey’s 
correction for multiple testing. 
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To determine if the increases observed in VPA and TPM uptake in SLC22A8_MDCK II 
cells could be successfully reversed with alternative OAT inhibitors other than 
probenecid, TPM was co-incubated with a series of additional OAT3 inhibitors.  Uptake 
of TPM in SLC22A8_MDCK II cells (151±3.1%) was reversed in the presence of 
benzyl penicillin (100µM) to 116±5.5% of control (p ≤0.01). In contrast, incubation 
with indomethacin (100µM) observed an increase in TPM uptake in SLC22A8_MDCK 
II cells to 182±11% of control values (p<0.01). No significant change in TPM uptake 
was observed in the presence of diclofenac (100µM; figure 4.23).  A small increase in 
VPA uptake was seen in the presence of indomethacin (85±20%) compared to uptake in 
SLC22A8_MDCK II cells without indomethacin (65.9±2.7%), but this did not reach 
statistical significance.  Neither benzyl penicillin nor diclofenac had any significant 
effect on VPA uptake in SLC22A8_MDCK II cells (figure 4.24) and no significant 
differences in uptake were observed for other AEDs tested (figures 4.21 and 4.22).  
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Figure 4.21: Phenytoin (PHT) (A), carbamazepine (CBZ) (B), valproic acid (VPA) (C) 
and lamotrigine (LTG) uptake (D) into SLC22A8_MDCK II cells compared to control 
pcDNA-transfected MDCK II cells with and without the OAT3 inhibitor probenecid.  
Cultures were exposed to 25µM radiolabelled PHT, 20µM radiolabelled CBZ, 300µM 
radiolabelled VPA or 10µM radiolabelled LTG respectively with or without probenecid 
at 200µM for 40 minutes at 370C.  Results are expressed as the mean ± standard error of 
the mean (SEM) percentage of the mean control value of uptake (in pmols/100,000 
cells) on each experimental day. Experiments were performed in triplicate on three 
separate occasions (n=9).  Statistical significance (*p<0.05, **p<0.01,) was determined 
by one-way analysis of variance with Tukey’s correction for multiple testing. 
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Figure 4.22: Gabapentin (GBP) (A), topiramate (TPM) (B) and levetiracetam uptake 
(C) into SLC22A8_MDCK II cells compared to control pcDNA-transfected MDCK II 
cells with and without the OAT3 inhibitor probenecid.  Cultures were exposed to 10µM 
radiolabelled GBP, 10µM radiolabelled TPM or 6µM radiolabelled LEV respectively 
with or without probenecid at 200µM for 40 minutes at 370C.  Results are expressed as 
the mean ± standard error of the mean (SEM) percentage of the mean control value of 
uptake (in pmols/100,000 cells) on each experimental day. Experiments were performed 
in triplicate on three separate occasions (n=9). Statistical significance (*p<0.001) was 
determined by one-way analysis of variance with Tukey’s correction for multiple 
testing. 
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Figure 4.23: Topiramate (TPM) uptake into SLC22A8_MDCK II cells compared to 
control pcDNA-transfected MDCK II cells with and without the OAT3 inhibitors 
probenecid, benzyl penicillin, diclofenac and indomethacin.  Cultures were exposed to 
10µM radiolabelled TPM with or without probenecid at 200µM, benzyl penicillin at 
100µM, diclofenac at 100µM and indomethacin at 100µM for 40 minutes at 370C. 
Results are expressed as the mean ± standard error of the mean (SEM) percentage of the 
mean control value of TPM uptake (in pmols/100,000 cells) on each experimental day. 
Experiments were performed in triplicate on three separate occasions (n=9). Statistical 
significance (*p<0.01, **p<0.001,) was determined by one-way analysis of variance 
with Tukey’s correction for multiple testing. 
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Figure 4.24: Valproic acid (VPA) uptake into SLC22A8_MDCK II cells compared to 
control pcDNA-transfected MDCK II cells with and without the OAT3 inhibitors 
probenecid, benzyl penicillin, diclofenac and indomethacin.  Cultures were exposed to 
300µM radiolabelled VPA with or without probenecid at 200µM, benzyl penicillin at 
100µM, diclofenac at 100µM and indomethacin at 100µM for 40 minutes at 370C. 
Results are expressed as the mean ± standard error of the mean (SEM) percentage of the 
mean control value of VPA uptake (in pmols/100,000 cells) on each experimental day. 
Experiments were performed in triplicate on three separate occasions (n=9).  
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4.4 Discussion 
OAT transporters are a well-researched family of SLC transporters implicated in the 
disposition of a number of therapeutic agents.  The majority of research into OAT 
transporters has focused on their function at kidney proximal tubule cells, where they 
are known to mediate the rate limiting step in the renal clearance of a number of drugs.  
Recently, OAT1 and OAT3 have been suggested to be expressed at the BBB, where 
they could potentially impact on substrate drug penetration into the brain (Kusuhara et 
al., 1999; Ohtsuki et al., 2002; Kikuchi et al., 2003; Mori et al., 2003). 
 
In this study, commercially available SLC22A6, SLC22A7 and SLC22A8 cDNA clones 
were purchased, sub-cloned and transfected into MDCK II cells to generate stably 
transfected SLC22A6_MDCK II, SLC22A7_MDCK II and SLC22A8_MDCK II cell 
lines. Unfortunately, numerous attempts to amplify the SLC22A7 template from the 
I.M.A.G.E. cDNA clone were unsuccessful (figure 4.2). Upon further investigation and 
troubleshooting, the SLC22A7 template present in the I.M.A.G.E. cDNA clone was 
found to be truncated.  An alternative cDNA clone was offered by the suppliers; 
however, upon examination, this contained a single missing base pair.  The impact of 
the deletion upon the amino acid translated was investigated to determine if the coding 
sequence with the missing base would produce functional OAT2 protein, however the 
deletion was found to be crucial in the translation of functional OAT2.  With no further 
SLC22A7 I.M.A.G.E. clones available, the decision was made to abandon SLC22A7 
cloning attempts and continue with SLC22A6 and SLC22A8 only. 
 
SLC22A6 and SLC22A8 genes were successfully amplified and cloned into 
pcDNA3.1/V5-His TOPO.  Resulting plasmid DNA was transfected into MDCK II cells 
and clones selected and analysed at gene and protein level to confirm SLC22A6 and 
SLC22A8 expression (figures 4.8 and 4.9).  In addition, protein function in the selected 
clones was analysed by uptake studies using a radiolabelled substrate (figure 4.8 and 
4.9).  The SLC22A6_MDCK II and SLC22A8_MDCK II clones with the most 
pronounced SLC22A6 and SLC22A8 expression and protein function were then selected 
and their transport kinetics characterised using a probe substrate to determine assay 
conditions for further investigation with AEDs.  
 
SLC22A6_MDCK II cells exhibited a significantly enhanced ability to transport the 
respective probe substrate PAH in comparison to the mock transfected control cells 
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(figure 4.11).  SLC22A8_MDCK II cells also showed an increase in the transport of the 
respective probe substrate E3S compared to control cells, albeit with a much less 
impressive elevation than that seen with SLC22A6 (figure 4.14). This was at least partly 
explained by the lower relative gene expression in SLC22A8_MDCK II cells compared 
to SLC22A6_MDCK II cell clones, suggesting that SLC22A8 transfection may not have 
been as efficient as that of SLC22A6 or that MDCK II cells may not have translated the 
OAT3 protein as efficiently as OAT1.  
 
Transport of VPA was significantly higher in SLC22A6_MDCK II and significantly 
lower in SLC22A8_MDCK II cells than in control mock transfected MDCK II cells 
(figure 4.17 ad 4.21).  This finding is in agreement with previous literature suggesting 
that VPA is transported by an anion transporter (Adkinson et al., 1996), and perhaps 
suggests that VPA transport is mediated by the combined action of OAT1 and OAT3. 
Although speculative, there is some pharmacological precedence for this conclusion. In 
in vitro studies using HEK293 cells stably transfected with SLC22A6 and SLC22A8 and 
also in vivo studies in rats, the transport of the fibrate compound gemcabene and also 
that of the angiotensin-converting enzyme inhibitor quinapril was shown to be 
dependent on both OAT1 and OAT3 (Yuan et al., 2009).  It has been suggested that 
OAT1 and OAT3 work in synergy at the kidney to transport anionic drugs from the 
blood into the kidney proximal tubule (Chennavasin et al., 1979).  It is possible that 
OAT1 and OAT3 may work in a similar manner to transport anionic drugs across the 
BBB.  However VPA uptake was observed to decrease in SLC22A8_MDCK II cells, 
suggesting VPA is effluxed from the cell.  VPA was the only AED tested in which an 
unexpected decrease in uptake was observed in SLC22A8_MDCK II cells.  Although it 
is possible that the human OAT3 protein may be orientated in MDCK II cells to 
function as an efflux rather than influx transporter, this effect would certainly extend 
across all AEDs tested?  As both LTG and TPM uptake increased in SLC22A8_MDCK 
II cells it is, although not impossible, unlikely that OAT3 could function to influx some 
substrates and efflux others in SLC22A8_MDCK II cells.  OAT transporters function to 
transport extracellular anions in a tertiary active transport mechanism which involves 
the exchange of intracellular anions (Van Wert et al., 2010).  The intracellular anion 
preferred by OAT1 and OAT3 is the dicarboxylate α-ketoglutarate (Rizwan et al., 2007; 
Burckhardt, 2012).  However under stress such as that cells are exposed to during the 
transfection process, the metabolic rate of the cells may decrease and therefore the 
synthesis of α-ketoglutarate may decrease, forcing the transporters to utilise alternative 
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sources of intracellular anions. VPA also has a dicarboxylate structure.  Therefore the 
observed decrease in VPA uptake in SLC22A8_MDCK II cells could alternatively be 
explained by intracellular VPA being utilised as the exchange anion in its own uptake 
and therefore actively pumped out of the cell at a higher rate than its uptake to maintain 
a higher extracellular anion concentration.     
 
The decrease in VPA uptake in SLC22A8_MDCK II cells compared to mock-
transfected controls was not reversed in the presence of OAT inhibitor probenecid, nor 
was it significantly attenuated by additional OAT inhibitors, including benzyl penicillin, 
indomethacin and diclofenac (figure 4.24).  This suggests that at the concentrations used 
these OAT inhibitors do not inhibit VPA transport.    
 
LTG transport also increased in both SLC22A6_MDCK II cells and SLC22A8_MDCK 
II cells when expressed as a percentage of transport in control cells.  This effect was 
attenuated in the presence of the OAT inhibitor probenecid; although the reversal only 
reached statistical significance in SLC22A8_MDCK II cells (figures 4.17 and 4.21).  
Recently, LTG has been shown to be subject to OCT1 mediated transport (Dickens et 
al., 2012).  LTG transport in both mock transfected MDCK II cells and 
SLC22A6_MDCK II cells was significantly inhibited in the presence of the OCT 
inhibitor verapamil (figure 4.19).  As MDCK II cells are derived from canine kidney it 
is likely that there is endogenous expression of canine cation transporters, if these 
canine transporters are homologous to human OCT1 it is possible that LTG is being 
actively transported into MDCK II cells, which would explain the indiscriminate 
inhibitory effect of verapamil.  Furthermore, the selection process, irrespective of 
whether it introduced a functional gene or not, may have induced a compensatory 
increase in the expression of endogenous transporter proteins in SLC22A6_MDCK II 
cells therefore the 47% increase in uptake of LTG in SLC22A6_MDCK II cells may be 
attributed to increased expression of an endogenous canine OCT transporters in these 
cells.  However, LTG was also shown to inhibit PAH uptake in the SLC22A6_MDCK II 
cells with an IC50 of 32.9µM (figure 4.20), suggesting that it acts as a weak inhibitor of 
OAT1 at concentrations just above the therapeutic range. Recently, it has been shown 
that the mouse homologues of OAT1 and OAT3 mediate the transport of a number of 
organic cations including verapamil (Ahn et al., 2009). Assuming this is also the case 
for human OATs, this may offer an alternative explanation for the increase in LTG 
transport observed in both SLC22A6_MDCK II cells and SLC22A8_MDCK II cells.  
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Thus LTG transport into SLC22A6_MDCK II and SLC22A8_MDCK II cells could be 
attributed to combined activity of an endogenous OCT transporter and human OAT1 or 
OAT3 respectively.  Providing the endogenous OCT transporter could be identified, this 
hypothesis could be tested by using siRNA to ‘knock down’ the canine OCT transporter 
in MDCK II cells (both mock transfected controls and OAT transfected) and comparing 
any differences in LTG uptake.   
 
Uptake of TPM in SLC22A8_MDCK II cells (but not SLC22A6_MDCK II cells) was 
also significantly increased compared to uptake in the corresponding mock transfected 
cells (figure 4.22).  Although this effect was not diminished in the presence of 
probenecid, it was attenuated in the presence of the OAT inhibitor benzyl penicillin and 
conversely enhanced in the presence of indomethacin (figure 4.23). Without more 
detailed understanding of the relative contributions of individual OATs to cellular 
transport and of the selectivity of individual inhibitory compounds, it is difficult to 
arrive at a plausible explanation for the effects seen with TPM.  The effects observed 
with benzylbpenicllin may suggest inhibition of OAT3 mediated uptake of TPM which 
could not be achieved with probenecid, potentially due to differences in inhibitory 
potency of the two compounds.  Conversely the effects observed with indomethacin 
may be due to activity of an endogenous efflux transporter.  In addition to OATs 
indomethacin is known to inhibit efflux transporters known as multidrug resistance 
proteins (MRPs) (Draper et al., 1997).  MRP transporters are known to be expressed in 
the human kidney where they contribute to the transport of renally cleared substrate 
drugs (Inui et al., 2000).  Therefore assuming the transporter expression profile is 
similar in canine kidney and providing TPM is a substrate for a canine MRP transporter, 
the increases in TPM uptake observed in the presence of indomethacin may be 
attributed to inhibition of MRP mediated efflux of TPM.  Although plausible, without 
analysing the effects of indomethacin on TPM transport in mock transfected MDCK II 
cells this hypothesis is speculative.   
 
A number of experimental systems can be used to investigate functionality of 
transporter proteins in vitro, including the X.laevis oocyte model employed to 
investigate AED transport by MCT1 and OATP1A2 in chapter 2 and 
epithelial/endothelial cell lines transiently or stably transfected with the transporter of 
interest.  The use of transfected epithelial cell lines overexpressing a transporter protein 
represents a robust method to identify and characterise the individual proteins 
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responsible for the transport of therapeutic agents.  Stable transfection was chosen over 
transient transfection for this investigation as the planned studies required the long term 
cell culture of transfected cell lines for use in an extended series of drug transport assay. 
Transient transfection would have risked potential loss of expression of the protein of 
interest over prolonged culture and a significant impact on results (Kim et al., 2010). 
However, it is unknown what impact the stable transfection and subsequent clone 
selection process had on the expression profile of the native cell line. Introducing a 
large sequence of foreign DNA into the host genome may have caused changes in 
expression of endogenous genes, including transporters.  Furthermore clonal selection 
involves and may in part explain the differences in transport data observed with LTG in 
SLC22A6_MDCK II cells.   
 
Observations made in this chapter suggest that OAT1 and/or OAT3 may be, at least 
partly responsible for the transport of several AEDs in stably transfected SLC22A6 and 
SLC22A8 MDCK II cells.  Although significant increases/decreases in the uptake of 
these AEDs was observed, the conclusions are constrained by the inability to reliably 
inhibit this transport with the prototypic OAT inhibitor probenecid.  Further attempts to 
inhibit transport with additional OAT inhibitors gave conflicting results.   
It is difficult to speculate why observed changes in AED transport could not be 
inhibited to a similar degree as observed with the inhibition of the positive control 
substrates PAH and E3S (figures 4.11 and 4.14; table 4.2 and 4.3).  One explanation is 
that there is interference of endogenous transporters, either constitutively expressed or 
induced by the pressures of the transfection and selection process.  Therefore there may 
be a number of active processes occurring in the cells contributing to both influx and 
efflux of AEDs therefore producing ambiguous results in terms of inhibitor selectivity.  
The impact of the selection process on endogenous transporter expression could be 
analysed by qRT-PCR to determine any increases/decreases in transporter expression, 
however this would rely on identifying the canine transporters endogenously expressed 
in MDCK II cells.  Alternatively the results obtained using stably transfected 
SLC22A6_MDCK II and SLC22A8_MDCK II cells which underwent clonal selection 
could be compared to data generated in transiently transfected SLC22A6 and SLC22A8 
MDCK cells and the impact of the selection process determined.    
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Chapter 5 
 
 
 
Changes in transporter expression at the BBB 
following antiepileptic drug treatment 
 
 
 
 
 
 
 
152 
 
 
5.1 Introduction 
Over the past 15 years, knowledge of transporters has grown rapidly and a number of 
well-characterised transporters have now been detected at the blood-brain barrier (BBB) 
and have been shown to affect accumulation of therapeutic agents in the brain. 
 
Several studies have aimed to determine the expression profile of transporters at the 
BBB (Dauchy et al., 2009; Carl et al., 2010; Uchida et al., 2011; Geier et al., 2013).  
One approach evaluated the BBB expression of a panel of transporters from the SLC 
and ABC families using qRT-PCR arrays in human cerebral microvascular endothelial 
cells (hCMEC/D3), which have been proposed as a useful in vitro model of the BBB  
Expression of 70 out of 84 transporters included were observed  in this analysis, which 
also showed a high relative expression of several transporters known to efflux a number 
of therapeutic agents including: ABCB1 (P-gp), ABCC1 (MRP1), ABCC4 (MRP4) and 
ABCC5 (MRP5).  Of the SLC transporters evaluated, significant expression of the 
monocarboxylic acid transporters SLC16A1 and SLC16A3 and the equilibrative 
nucleoside transporters (SLC29 family) was observed.  However very few transporters, 
known to be clinically relevant in drug disposition such as the transporters belonging to 
the SLCO and SLC22 families were detected (Carl et al., 2010).  More recently, the 
expression of SLC and ABC transporters was investigated in enriched human brain 
microvessels (BMVs) and showed that the BBB is rich and diverse in expression of 
both ABC and SLC transporters.  Expression of 244 out of 344 SLC transporters 
included and 42 out of 49 ABC transporters included was detected in BMVs, a number 
of which had not previously been shown to be expressed at the BBB.  These included 
the multifunctional anion exchangers of the SLC26 family, the thiamine transporter 
SLC19A3, the GABA neurotransmitter transporter SLC6A13 and the multidrug and 
toxin extrusion (MATE2) transporter SLC47A2 (Geier et al., 2013).  In addition 
quantitative protein expression utilising a proteomics approach investigated transporter 
expression in human BMVs and reported highest expression of ABCG2 (BCRP), while 
expression of ABCB1 (P-gp) was less abundant in humans than previously reported in 
mice (Kamiie et al., 2008).  Interestingly, members of the multidrug resistance-
associated proteins (MRPs), organic anion transporters (OATs) and organic anion 
transporting polypeptides (OATPs) were below quantification limits in this analysis, 
with the exception of MRP4 (Uchida et al., 2011). 
153 
 
 
The transporter hypothesis aims to explain resistance to AEDs as a result of changes in 
expression of transporters at the BBB.  Research surrounding the transporter hypothesis 
has focused on the role of transporters in brain penetration of substrate AEDs; however 
the role of transporter regulation and its implications in multidrug resistance has also 
received attention and has produced conflicting results.   
 
There is existing evidence which supports changes in brain transporter expression in 
people with epilepsy (Lauritzen et al., 2011; Leroy et al., 2011; Aronica et al., 2012).  
Different mechanisms have been postulated and investigated to explain these 
differences in expression; however what is not clear, and which remains disputed, is 
whether the difference in transporter expression is intrinsic or acquired. That is to say, 
are the changes in BBB transporter expression due to the underlying pathology, the 
consequence of uncontrolled seizures, the result of chronic AED treatment or a 
combination of all of these factors (Aronica et al., 2012)?  Supporters of an intrinsic 
mechanism argue that increased expression of transporters such as P-gp is present 
before the onset of seizures and the institution of AED treatment and therefore is a 
result of disease pathophysiology.  Malformations of cortical development (MCDs) are 
known to be a common cause of refractory epilepsy, with most people who have MCDs 
going on to develop the disease. As such, people with MCDs could be considered to be 
‘pre-epileptic’.  The expression of P-gp was investigated in brain tissue from AED 
naive people and found an overexpression of P-gp in 10 out of 16 MCD samples 
analysed compared to 2 out of 16 controls, supporting an intrinsic difference in 
transporter expression in those individuals (Sisodiya et al., 1999).   
 
The arguments for an intrinsic mechanism are opposed by the ability of various AEDs 
to induce the expression of a number of transporters.  A recent study investigating P-gp 
expression in the rat brain, demonstrated that changes in P-gp activity could be 
monitored in vivo by measuring the brain to plasma ratio of the P-gp substrate 
rhodamine 123.  A decrease in the brain concentration of rhodamine 123 was observed, 
suggesting increased P-gp activity, following chronic (21 day) treatment with PHT, 
phenobarbital (PB) and CBZ.  In addition, immunohistochemistry showed that P-gp was 
localised mainly to brain endothelial cells in both cortex and hippocampus (Wen et al., 
2008).  Furthermore, P-gp expression has been investigated in mouse brain utilising a 
radiolabelled P-gp substrate, 11C-desmethylloperamide.  The authors’ analysed 
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concentrations of this ligand in control mouse brain in vivo compared to mice pre-
treated with therapeutic and supra-therapeutic doses of LEV, TPM, PHT and VPA.  A 
decrease in cerebral 11C-desmethylloperamide concentration was observed in mice pre-
treated with therapeutic doses of LEV, TPM and PHT but not VPA, suggesting 
induction of P-gp with selected AEDs.  However, at supra-therapeutic doses, there was 
no difference in the brain concentration of 11C-desmethylloperamide between pre-
treated and control mice, suggesting that induction of P-gp by AEDs is dose-dependent 
(Moermana et al., 2011).   
 
Investigation into changes in the brain expression of P-gp in epilepsy has received more 
attention to date than studies of other transporters. Nevertheless, several studies have 
investigated changes in the expression of influx transporters of the SLC family in both 
animal models of epilepsy and human epilepsy tissue.  As discussed in chapter 3 MCT1 
was found to be deficient on cerebral microvessels in  surgically resected brain tissue 
from people with AED resistant temporal lobe epilepsy (Lauritzen et al., 2011).  
Conversely, up- regulation of the BBB glucose transporters GLUT1 (SLC2A1) and 
GLUT3 (SLC2A3) and the monocarboxylic acid transporters MCT1 (SLC16A1) and 
MCT2 (SLC16A2) was observed in a lithium-pilocarpine induced rat model of temporal 
lobe epilepsy (Leroy et al., 2011).   
 
Investigations described in this chapter employed the hCMEC/D3 cell line and a 
commercially available human transporter qRT-PCR array to investigate the expression 
profile of a panel of human transporters in an in vitro model of the BBB.  The effects of 
AED treatment on transporter expression were determined following a 48 hour exposure 
with seven commonly prescribed AEDs employed throughout this thesis.   
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5.2 Methods 
5.2.1 Materials 
Taqman Human Transporter Gene Array Plates, Taqman Gene Expression Master Mix, 
High Capacity cDNA Reverse Transcription Kit, rat tail collagen type I, chemically 
defined lipid concentrate and foetal bovine serum (FBS) were purchased from Life 
Technologies (Paisley, UK).  Cell culture plasticware was purchased from Nunc Fisher 
Scientific (Loughborough, UK).  EBM-2 medium was purchased from Lonza (Slough, 
UK).  PHT, CBZ, VPA, LTG, GBP, TPM, LEV and all other chemicals not described 
were purchased from Sigma-Aldrich (Poole, Dorset, UK).  The hCMEC/D3 cell line 
was provided courtesy of Dr Ignacio Romero (Department of Life Sciences, The Open 
University, Milton Keynes, UK) and Professor Pierre Couraud (Institut Cochin, 
Université Paris Descartes, Paris, France).   
 
5.2.2 Cell culture 
hCMEC/D3 cells were cultured in rat tail collagen type I (100ug/ml) coated T175 flasks 
and maintained in EBM-2 medium supplemented with 5% FBS, 1% penicillin-
streptomycin, 0.5% chemically defined lipid concentrate, 10mM HEPES, 1.4µM 
hydrocortisone, 5µg/ml ascorbic acid and 1ng/ml basic fibroblast growth factor 
(referred to as complete media from here on).  Cells were passaged every 2-3 days and 
seeded onto collagen type I coated six-well plates at a density of 3x106cells/well, as 
required. The passage/seeding procedure was as follows; media was removed from the 
T175 flasks using a serological pipette and cells washed twice in 10ml of warm Hanks 
balanced salt solution (HBSS).  Cells were then removed from the flask surface with 
10ml of 0.25% trypsin-EDTA and left to incubate at 370C for 5 minutes.  Thereafter, 
20ml of complete media was added to neutralise the trypsin, and the cell suspension 
transferred to a 50ml Falcon tube and centrifuged at 250 x g for 5 minutes to pellet the 
cells.  Pellets were re-suspended in 10ml of complete media and a cell count made (see 
section 3.2.4 for protocol).  The cell suspension was diluted with complete media to 
give a density of 1.5x106cells/ml and 2ml of the suspension added to each well.  The 
remainder of the suspension was returned to three T175 flasks at a 1 in 5 dilution and 
allowed to grow on. 
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5.2.3 MTT Assays 
An MTT reduction assay was used to determine if therapeutic concentrations of PHT, 
CBZ, VPA, LTG, GBP, TPM and LEV elicit any cytotoxicity.  Each AED included in 
the study was assessed for 24, 48 and 72 hours in triplicate at the following 
concentrations: 1µM, 3µM, 10µM, 30µM and 100µM, with the exception of VPA, 
which was assessed at the following concentrations: 10µM, 30µM, 100µM, 300µM and 
1000µM.   
 
Firstly, hCMEC/D3 cells were passaged as described in section 5.2.2, counted (see 
section 3.2.4 for cell count protocol) and diluted to give a density of 0.5 x 106 cells/ml.  
A 50µl aliquot of the cell solution was then transferred to each well of a 96 well flat 
bottom plate and allowed to incubate for 30 minutes at 370C.  Each AED solution (AED 
stock solutions were made up at 1000x final concentration in DMSO) and DMSO 
controls were then diluted in complete media at double the desired final concentrations 
and 50µl was added to the appropriate wells.  Media plus 0.1% DMSO was added to 
three wells per time point to act as blanks.  Plates were then incubated at 370C for 24, 
48 and 72 hours.  After 24, 48 or 72 hours incubation 20µl of 5M 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (5mg of MTT 
in 1ml HBSS) was added to each well and incubated at 370C for 2 hours.  A 200µl 
aliquot of lysis buffer (20g sodium dodecyl sulphate in 50:50 
dimethylformamide:water) was then added to each well and incubated for a minimum of 
4 hours in darkness.  Fluorescence was then measured on a microplate reader at 570nm.   
 
5.2.4 AED treatment of hCMEC/D3 cells 
hCMEC/D3 cells were seeded onto 6 well plates as described previously in section 5.2.2 
and incubated with AEDs at concentrations similar to those observed clinically in 
patient serum (PHT 25µM, CBZ 20µM, VPA 300µM, LTG 10µM, GBP 60µM, TPM 
10µM and LEV 90µM) for 48 hours.  Control, non AED treated cells were incubated 
with vehicle (DMSO; 0.1%) only.   
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5.2.5 RNA extraction 
After 48 hours incubation, RNA from AED treated and control hCMEC/D3 cells was 
extracted using Trizol reagent according to the manufacturer’s protocol, as described in 
section 4.2.11.  The resulting RNA was quantified on a Nanodrop spectrophotometer 
(see section 2.2.3 for protocol) and diluted to a concentration of 200ng/µl with PCR 
grade water for subsequent reverse transcription.   
 
5.2.6 Reverse transcription to cDNA 
RNA extracted from AED treated and control hCMEC/D3 cells was reverse transcribed 
to its corresponding cDNA using High Capacity cDNA Reverse Transcription reagents 
(Life technologies) according to the manufacturer’s protocol, as described in section 
4.2.12.   
 
5.2.7 qRT-PCR  
qRT-PCR was performed using human transporter TaqMan Array 96-well plates and 
Taqman Gene Expression Mastermix according to the manufacturer’s protocol.  Briefly, 
cDNA and gene expression mastermix were added to RNase and DNase free, 1.5ml 
Eppendorf tubes to give a volume sufficient for 96 x 20µl reactions.  Each tube was then 
gently vortexed to mix the solution, centrifuged briefly and kept on ice.  In parallel, 
Taqman array plates were centrifuged briefly and the plate seal removed.  A 20µl 
aliquot of the cDNA plus master mix solution was then added to each well of the 96 
well of an array plate.  8 array plates in total were prepared for each condition (control 
(DMSO; 0.1%) and seven AEDs at concentrations described previously).  Plates were 
then covered with an optical adhesive seal, briefly centrifuged and kept at 40C before 
loading into the instrument.  Thermal cycling conditions were as follows: 500C for 2 
minutes, 950C for 10 minutes followed by 40 PCR cycles of 950C for 15 seconds and 
600C for 1 minute.   
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5.2.8 qRT-PCR Analysis 
Ct values calculated from the amplification curve generated by Amplicon 3 software 
were normalised to the mean Ct of 3 housekeeping genes (GAPDH (glyceraldehyde 3-
phosphate dehydrogenase), HPRT1 (hypoxanthine phosphoribosyltransferase) and 
GUSB (beta-glucuronidase) and the relative abundance or expression presented 
according to the comparative Ct method of calculation: 
 
          2-∆CT =   [(CT gene of interest – CT internal control) 
 
          2-∆∆CT =   [(CT gene of interest – CT internal control) sample A  
   - (CT gene of interest – CT internal control) sample B] 
     
 
5.2.9 Statistical analysis 
MTT assay data was assessed for normality using the Shapiro-Wilk test and found to be 
normally distributed in all cases.  A one-way analysis of variance (ANOVA) was 
performed on the data with Tukey’s post hoc test for multiple comparisons.  A value of 
p≤0.05 was taken to indicate statistical significance.  Gene expression data from 
quantitative RT-PCR analysis was generated at n=1 therefore statistical analysis could 
not be applied.  Instead any changes in expression that were observed and that 
represented a more than two fold difference from control were taken to be of potential 
importance.    
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5.3 Results 
5.3.1 Effects of increasing AED concentration on hCMEC/D3 cell viability 
To evaluate possible cytotoxic effects of the AEDs investigated, an MTT reduction 
assay was performed.  Cytotoxicity was observed following 48 hours and 72 hours 
treatment with 100µM PHT, with hCMEC/D3 cell viability reduced to 73.4 ±4.1%  (p 
≤0.05) and 70.0 ±9.8% of control values (100 ±5.5% and 100 ±7.2 ), respectively 
(figure 5.1).  Cytotoxicity was also observed following 48 hours and 72 hours treatment 
with 100µM CBZ, with hCMEC/D3 cell viability reduced to 75.2 ±1.65% and 77.5 
±5.16% respectively, however only the 48 hour treatment time reached statistical 
significance (figure 5.1). No significant cytotoxicity was observed with lower 
concentrations of PHT or CBZ at any of the time points investigated (figure 5.1).  Cell 
viability in hCMEC/D3 cells also decreased following 72 hours treatment with 100µM 
LTG (71.4 ±6.2%) compared to control (100 ±7.2%), however did not reach statistical 
significance (figure 5.2).  No significant cytotoxicity was observed within the test 
concentration range for other AEDs following incubation of up to 72 hours (figures 5.2-
5.4).   
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Figure 5.1: Effects of (A) phenytoin (PHT) and (B) carbamazepine (CBZ) on 
hCMEC/D3 cell viability.  Cultures were exposed to 1µM, 3µM, 10µM, 30µM and 
100µM PHT or CBZ for 24, 48 and 72 hours at 370C and cell viability determined by 
MTT reduction assay.  Results are expressed as the mean percentage ± standard error of 
the mean (SEM) of mean control viability, as determined in hCMEC/D3 cells incubated 
with 0.1% DMSO only.  Experiments were performed in triplicate for each time point, 
with statistical differences from control explored using one-way analysis of variance 
with Tukey’s correction for multiple testing (*p<0.05 for 100uM PHT and CBZ at 48h 
incubation and 100 uM PHT at 72h incubation).    
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Figure 5.2: Effects of (A) valproate (VPA) and (B) lamotrigine (LTG) on hCMEC/D3 
cell viability.  Cultures were exposed to 10µM, 30µM, 100µM, 300µM and 1000µM 
VPA or 1µM, 3µM, 10µM, 30µM and 100µM LTG for 24, 48 and 72 hours at 370C and 
cell viability determined by MTT reduction assay.  Results are expressed as the mean 
percentage ± standard error of the mean (SEM) of mean control viability, as determined 
in hCMEC/D3 cells incubated with 0.1% DMSO only.  Experiments were performed in 
triplicate for each time point, with statistical differences from control explored using 
one-way analysis of variance with Tukey’s correction for multiple testing.    
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Figure 5.3: Effects of (A) gabapentin (GBP) and (B) topiramate (TPM) on hCMEC/D3 
cell viability.  Cultures were exposed to 1µM, 3µM, 10µM, 30µM and 100µM GBP or 
TPM for 24, 48 and 72 hours at 370C and cell viability determined by MTT reduction 
assay.  Results are expressed as the mean percentage ± standard error of the mean 
(SEM) of mean control viability, as determined in hCMEC/D3 cells incubated with 
0.1% DMSO only.  Experiments were performed in triplicate for each time point, with 
statistical differences from control explored using one-way analysis of variance with 
Tukey’s correction for multiple testing.    
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Figure 5.4: Effects of levetiracetam (LEV) on hCMEC/D3 cell viability.  Cultures were 
exposed to 1µM, 3µM, 10µM, 30µM and 100µM LEV for 24, 48 and 72 hours at 370C 
and cell viability determined by MTT reduction assay.  Results are expressed as the 
mean percentage ± standard error of the mean (SEM) of mean control viability, as 
determined in hCMEC/D3 cells incubated with 0.1% DMSO only.  Experiments were 
performed in triplicate for each time point, with statistical differences from control 
explored using one-way analysis of variance with Tukey’s correction for multiple 
testing.   
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5.3.2 Expression of human transporter protein genes in hCMEC/D3 cells 
Of the 84 transporters included in this analysis, 57 were found to be expressed in 
hCMEC/D3 cells (table 5.1, 5.2 and 5.3).  The transporters with the highest relative 
abundance (defined as higher abundance than the mean abundance of three 
housekeeping genes (1)) were largely nutrient transporters including: SLC16A3 
(monocarboxylate transporter 4: 1.385), SLC2A1 (facilitative glucose transporter 1; 
1.157) and SLC7A5 (large neutral amino acid transporter; 1.753) (table 5.2). High 
relative expression of ATP6 (lysosomal ATPase transporter; 7.890), MVP (major vault 
protein; 1.165) and VDAC1 (voltage dependant anion channel 1; 1.815) was also 
detected (table 5.3).  No expression was detected in control hCMEC/D3 cells for 27 of 
the test genes included (tables 5.1, 5.2 and 5.3).   
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Transporter gene Description   Relative abundance  
ABCA1 ATP-Binding Cassette Sub-Family A Member 1 (cholesterol efflux regulatory protein) 0.059 
ABCA12 ATP-Binding Cassette Sub-Family A Member 12 (lipid transporter) 0.002 
ABCA13 ATP-Binding Cassette Sub-Family A Member 13 0.001 
ABCA2 ATP-Binding Cassette Sub-Family A Member 2 0.066 
ABCA3 ATP-Binding Cassette Sub-Family A Member 3 (lipid transporter) 0.232 
ABCA4 ATP-Binding Cassette Sub-Family A Member 4 (retinal specific: transports retinoid substrates 0.003 
ABCA9 ATP-Binding Cassette Sub-Family A Member 9 (lipid transporter) No Ct 
ABCB1 ATP-Binding Cassette Sub-Family B Member 1 (multidrug resistance protein 1 (P-gp)) 0.796 
ABCB11 ATP-Binding Cassette Sub-Family B Member 11 (bile salt efflux (hepatic))  No Ct 
ABCB4 ATP-Binding Cassette Sub-Family B Member 4 (multidrug resistance protein 3) No Ct 
ABCB5 ATP-Binding Cassette Sub-Family B Member 5 (multidrug resistance protein 5) No Ct 
ABCB6 ATP-Binding Cassette Sub-Family B Member 6 (mitochondrial transporter) 0.047 
ABCC1 ATP-Binding Cassette Sub-Family C Member 1 (multidrug resistance-associated protein 1) 0.123 
ABCC10 ATP-Binding Cassette Sub-Family C Member 10 (multidrug resistance-associated protein 7) 0.058 
ABCC11 ATP-Binding Cassette Sub-Family C Member 11 (multidrug resistance-associated protein 8) No Ct 
ABCC12 ATP-Binding Cassette Sub-Family C Member 12 (multidrug resistance-associated protein 9) No Ct 
ABCC2 ATP-Binding Cassette Sub-Family C Member 2 (multidrug resistance-associated protein 2) 0.002 
ABCC3 ATP-Binding Cassette Sub-Family C Member 3 (multidrug resistance-associated protein 3) 0.050 
ABCC4 ATP-Binding Cassette Sub-Family C Member 4 (multidrug resistance-associated protein 4) 0.064 
ABCC5 ATP-Binding Cassette Sub-Family C Member 5 (multidrug resistance-associated protein 5) 0.332 
ABCC6 ATP-Binding Cassette Sub-Family C Member 6 (multidrug resistance-associated protein 6) 0.006 
ABCD1 ATP-Binding Cassette Sub-Family D Member 1 (adrenoleukodystrophy protein) 0.022 
ABCD3 ATP-Binding Cassette Sub-Family D Member 3  0.398 
ABCD4 ATP-Binding Cassette Sub-Family D Member 4 0.032 
ABCF1 ATP-Binding Cassette Sub-Family F Member 1 (protein translation / ribosome biogenesis) 0.199 
ABCG2 ATP-Binding Cassette Sub-Family G Member 2 (breast cancer resistance protein) 0.006 
ABCG8 ATP-binding cassette sub-family G member 8 (enterocyte transport of dietary cholesterol) No Ct 
Table 5.1: Abundance of a panel of ABC transporters in hCMEC/D3 cells.  Cultures of hCMEC/D3 cells were treated with 0.1% DMSO and incubated for 48 hours 
at 370C. Total RNA was then extracted, reverse-transcribed into cDNA, and the cDNA used to quantify relative expression for each ABC transporter.  Mean Ct 
values obtained from test gene amplification plots were normalised to the mean Ct of three housekeeping genes (GAPDH, HPRT1 and GUSB) and are presented as 
the relative test gene abundance in hCMEC/D3 cells, according to the comparative Ct method.   
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Transporter 
gene 
Description  
 Relative 
abundance  
SLC10A1 Solute carrier family 10 member 1 (sodium/bile acid co-transporter) No Ct 
SLC10A2 Solute carrier family 10 member 2 (sodium/bile acid co-transporter) No Ct 
SLC15A1 Solute carrier family 15 member 1 (oligopeptide transporter) No Ct 
SLC15A2 Solute carrier family 15 member 2 (oligopeptide transporter (kidney) 0.004 
SLC16A1 Solute carrier family 16 member 1 (monocarboxylic acid transporter 1) 0.401 
SLC16A2 Solute carrier family 16 member 2 (monocarboxylic acid transporter 8) 0.013 
SLC16A3 Solute carrier family 16 member 3 (monocarboxylic acid transporter 4 ) 1.385 
SLC19A1 Solute carrier family 19 member 1 (folate transporter) 0.321 
SLC19A2 Solute carrier family 19 member 2 (high affinity thiamine transporter) 0.064 
SLC19A3 Solute carrier family 19 member 3 (high affinity thiamine transporter) 0.018 
SLC22A1 Solute carrier family 22 member 1 (organic cation transporter 1) 0.002 
SLC22A2 Solute carrier family 22 member 2 (organic cation transporter 2) No Ct 
SLC22A3 Solute carrier family 22 member 3 (organic cation transporter 3) No Ct 
SLC22A6 Solute carrier family 22 member 6 (organic anion transporter 1) No Ct 
SLC22A7 Solute carrier family 22 member 7 (organic anion transporter 2) No Ct 
SLC22A8 Solute carrier family 22 member 8 (organic anion transporter 3) No Ct 
SLC22A9 Solute carrier family 22 member 9 (organic anion transporter 4) No Ct 
SLC25A13 Solute carrier family 25 member 13 (aspartate/glutamate carrier) 0.173 
SLC28A1 Solute carrier family 28 member 1 (concentrative nucleoside transporter 1) No Ct 
SLC28A2 Solute carrier family 28 member 2 (concentrative nucleoside transporter 2) No Ct 
SLC28A3 Solute carrier family 28 member 3 (concentrative nucleoside transporter 3) 0.002 
SLC29A1 Solute carrier family 29 member 1 (equilibrative nucleoside transporter 1) 0.235 
SLC29A2 Solute carrier family 29 member 2 (equilibrative nucleoside transporter 2) 0.013 
SLC2A1 Solute carrier family 2 member 1 (facilitated glucose transporter 1) 1.157 
SLC2A2 Solute carrier family 2 member 2 (facilitated glucose transporter 2) No Ct 
SLC2A3 Solute carrier family 2 member 3 (facilitated glucose transporter 3) 0.137 
SLC31A1 Solute carrier family 31 member 1 (high affinity copper transporter) 0.420 
SLC38A2 Solute carrier family 38 member 2 (system N amino acid transporter 2) 0.908 
SLC38A5 Solute carrier family 38 member 5 (system N amino acid transporter 5) 0.853 
SLC3A1 Solute carrier family 3 member 1 (neutral/dibasic amino acid transporter) No Ct 
SLC3A2 Solute carrier family 38 member 2 (large neutral amino acid transporter 2) 0.859 
SLC5A1 Solute carrier family 5 member 1 (sodium/glucose cotransporter 1) No Ct 
SLC5A4 Solute carrier family 5 member 4 (sodium/glucose cotransporter 3) 0.008 
SLC7A11 Solute carrier family 7 member 11 (anionic amino acid transporter 11) 0.117 
SLC7A5 Solute carrier family 7 member 5 (L type amino acid transporter 1) 1.753 
SLC7A6 Solute carrier family 7 member 6 (Y+L type amino acid transporter 2) 0.153 
SLC7A7 Solute carrier family 7 member 7 (Y+L type amino acid transporter 1) 0.003 
SLC7A8 Solute carrier family 7 member 8 (L type amino acid transporter 2) 0.130 
SLC7A9 Solute carrier family 7 member 9 (B type amino acid transporter 1) No Ct 
SLCO1A2 Solute Carrier organic anion transporter family member 1A2  No Ct 
SLCO1B1 Solute Carrier organic anion transporter family member 1B1 No Ct 
SLCO1B3 Solute Carrier organic anion transporter family member 1B3  No Ct 
SLCO2A1 Solute Carrier organic anion transporter family member 2A1 0.005 
SLCO2B1 Solute Carrier organic anion transporter family member 2B1 No Ct 
SLCO3A1 Solute Carrier organic anion transporter family member 3A1  0.013 
SLCO4A1 Solute Carrier organic anion transporter family member 4A1  0.097 
 
Table 5.2: Abundance of a panel of SLC transporters in hCMEC/D3 cells.  Cultures of 
hCMEC/D3 cells were treated with 0.1% DMSO and incubated for 48 hours at 370C. 
Total RNA was then extracted, reverse-transcribed into cDNA, and the cDNA used to 
quantify relative expression for each SLC transporter.  Mean Ct values obtained from 
test gene amplification plots were normalised to the mean Ct of three housekeeping 
genes (GAPDH, HPRT1 and GUSB) and are presented as the relative test gene 
abundance in hCMEC/D3 cells, according to the comparative Ct method.   
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Transporter gene Description / function (if known) 
 Relative 
abundance  
AQP1 Aquaporin 1 0.001 
AQP7 Aquaporin 7 No Ct 
AQP9 Aquaporin 9 No Ct 
ATP6V0C 
Lysosomal ATPase, H+ transporter 16kDa, V0 Subunit (acidification of a variety of intracellular 
compartments) 
7.890 
ATP7A;LOC644732 ATPase, copper transporter alpha polypeptide (copper homeostasis) 0.064 
ATP7B ATPase, copper transporter beta polypeptide (copper homeostasis) 0.054 
MVP Major vault protein  1.165 
TAP1 ATP-binding cassette sub-family B member 1 (peptide transporter involved in antigen processing 1) 0.392 
TAP2 ATP-binding cassette sub-family B member 2 (peptide transporter involved in antigen processing 2) 0.145 
VDAC1 Voltage-dependent anion channel 1 1.815 
VDAC2 Voltage-dependent anion channel 2 0.025 
 
Table 5.3: Abundance of miscellaneous transporters and transport-related genes in hCMEC/D3 cells.  Cultures of hCMEC/D3 cells were treated with 
0.1% DMSO and incubated for 48 hours at 370C. Total RNA was then extracted, reverse-transcribed into cDNA, and the cDNA used to quantify 
relative expression for each gene.  Mean Ct values obtained from test gene amplification plots were normalised to the mean Ct of three housekeeping 
genes (GAPDH, HPRT1 and GUSB) and are presented as the relative test gene abundance in hCMEC/D3 cells, according to the comparative Ct 
method.   
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5.3.3 Effects of AED treatment on ABC transporter expression in hCMEC/D3 cells 
Of the 27 ABC transporters analysed in this study, 15 appeared to have their expression 
induced or suppressed following treatment of hCMEC/D3 cells with AEDs.  Any 
change in expression following AED treatment which differed more than 2 fold from 
control expression (no treatment = 1) was considered important.  Treatment of 
hCMEC/D3 cells with PHT and CBZ increased ABCA1 expression in hCMEC/D3 cells 
5 fold (4.96) and 4 fold (3.71) respectively. Conversely, the modest expression of 
ABCA13 observed in control hCMEC/D3 cells was lost when cells were treated with 
PHT, however expression increased when cells were treated with CBZ (13.0) and VPA 
(3.44) (figure 5.5; table 5.4).  Expression of ABCC1 (5.75), ABCC10 (3.14), ABCC6 
(3.21), ABCD1 (3.21), ABCD4 (2.89), ABCF1 (5.75) and ABCG2 (3.28) increased from 
between 2 to 6 fold following treatment with CBZ when compared to expression in 
hCMEC/D3 cells untreated (figures 5.5, 5.7 and 5.8; table 5.4).  A decrease in 
expression of ABCB1 was observed following exposure of hCMEC/D3 cells to VPA 
(0.522), LTG (0.203), GBP (0.181) and TPM (0.274), but no change was observed 
following PHT (0.650), CBZ (0.808) and LEV (0.630) treatment (figure 5.6; table 5.4). 
Expression of ABCB6 also decreased in hCMEC/D3 cells treated with PHT (0.314), 
LTG (0.330), GBP (0.183) and LEV (0.427), however no significant effect was 
observed following treatment with CBZ (0.765), VPA (1.29) and TPM (0.808; figure 
5.6; table 5.4).  TPM treatment was also observed to decrease the expression of ABCD3 
(0.436) in hCMEC/D3 cells (figure 5.8; table 5.4).  Expression of ABCA4 (2.89), 
ABCC2 (2.74), ABCC4 (2.89), ABCC6 (2.29), ABCD3 (2.78), ABCD4 (4.87) and 
ABCG2 (3.30) increased following exposure to VPA (figures 5.7 and 5.8; table 5.4).  As 
did expression of ABCD4 following treatment with GBP (3.08), TPM (2.59) and LEV 
(2.72; figure 5.8; table 5.4).  Increases in the expression of ABCC1 and ABCF1 were 
also observed in hCMEC/D3 cells following treatment with PHT (2.22) and TPM (3.23) 
respectively (figures 5.7 and 5.8; table 5.4).   
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Transporter gene Untreated 
PHT 
treated 
CBZ 
treated 
VPA 
treated 
LTG 
treated 
GBP 
treated 
TPM 
treated 
LEV 
treated 
ABCA1 1.00 4.96 3.71 0.929 1.61 1.01 1.41 1.67 
ABCA12 1.00 0.829 1.65 1.251 0.779 0.903 0.694 0.781 
ABCA13 1.00 0.000 13.0 3.442 1.33 1.69 1.32 1.10 
ABCA2 1.00 1.00 1.55 0.781 0.841 0.922 0.843 0.831 
ABCA3 1.00 0.595 1.03 0.613 0.476 0.407 0.340 0.634 
ABCA4 1.00 1.30 1.48 2.895 1.38 1.04 1.07 1.45 
ABCB1 1.00 0.651 0.809 0.522 0.203 0.181 0.274 0.630 
ABCB6 1.00 0.314 0.765 1.295 0.330 0.183 0.808 0.427 
ABCC1 1.00 2.22 5.75 1.295 1.88 1.10 1.71 1.62 
ABCC10 1.00 1.23 3.15 1.120 0.895 0.714 1.50 1.11 
ABCC2 1.00 1.27 1.32 2.738 0.582 0.897 1.06 0.526 
ABCC3 1.00 0.660 1.26 0.675 0.603 0.694 1.04 0.584 
ABCC4 1.00 1.03 1.51 2.895 0.835 0.786 1.30 1.67 
ABCC5 1.00 0.732 0.935 1.260 0.563 0.464 0.552 0.592 
ABCC6 1.00 1.43 3.21 2.287 0.737 0.843 1.19 0.885 
ABCD1 1.00 1.39 3.21 1.845 1.14 1.04 1.30 1.01 
ABCD3 1.00 1.17 2.00 2.777 0.697 0.541 0.436 0.608 
ABCD4 1.00 1.45 2.89 4.868 0.763 3.08 2.59 2.72 
ABCF1 1.00 0.818 5.75 1.757 1.09 0.849 3.23 0.719 
ABCG2 1.00 1.33 3.28 3.302 0.940 1.28 0.891 1.28 
AQP1 1.00 0.418 2.42 2.119 0.387 0.552 0.464 0.634 
ATP6V0C 1.00 0.172 0.056 0.071 0.050 0.045 0.049 0.056 
ATP7A 1.00 0.344 0.464 0.792 0.274 0.274 0.245 0.245 
ATP7B 1.00 0.747 0.837 1.009 0.392 0.580 0.452 0.572 
MVP 1.00 0.889 1.35 0.744 0.824 0.292 0.471 0.704 
TAP1 1.00 0.847 767 4.64 0.395 0.430 3.44 0.617 
TAP2 1.00 1.13 16.4 1.10 16.0 1.58 0.568 2.93 
VDAC1 1.00 0.473 0.474 1.92 1.49 0.254 0.382 0.487 
VDAC2 1.00 1.54 1.10 2.18 0.785 0.754 0.770 1.84 
 
Table 5.4: Effects of AED treatment on the expression of selected transporter genes in 
hCMEC/D3 cells.  Cultures were treated with either 25µM phenytoin (PHT), 20µM 
carbamazepine (CBZ), 300µM valproate (VPA), 10µM lamotrigine (LTG), 60µM 
gabapentin (GBP), 10µM topiramate (TPM) or 90µM levetiracetam (LEV) for 48 hours 
at 370C. A further batch of cells (untreated) received vehicle (0.1% DMSO) only. Total 
RNA was then extracted, reverse-transcribed into cDNA, and the cDNA used to 
quantify relative expression for each gene.  Mean Ct values obtained from test gene 
amplification plots were normalised to the mean Ct of three housekeeping genes 
(GAPDH, HPRT1 and GUSB) and are presented as the relative test gene expression 
compared to expression in untreated hCMEC/D3 cells (relative expression = 1), 
according to the comparative Ct method.   
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Figure 5.5: Effect of AED treatment on expression of ABCA transporter genes in hCMEC/D3 cells.  Cultures were treated with either 25µM phenytoin 
(PHT), 20µM carbamazepine (CBZ), 300µM valproate (VPA), 10µM lamotrigine (LTG), 60µM gabapentin (GBP), 10µM topiramate (TPM) or 90µM 
levetiracetam (LEV) for 48 hours at 370C. A further batch of cells (control) received vehicle (0.1% DMSO) only. Total RNA was then extracted, 
reverse-transcribed into cDNA, and the cDNA used to quantify relative expression for each gene. Mean Ct values obtained from test gene 
amplification plots were normalised to the mean Ct of three housekeeping genes (GAPDH, HPRT1 and GUSB) and are presented as the relative test 
gene expression compared to expression in untreated hCMEC/D3 cells (relative expression = 1), according to the comparative Ct method.   
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Figure 5.6: Effect of AED treatment on expression of ABCB transporter genes in hCMEC/D3 cells.  Cultures were treated with either 25µM phenytoin 
(PHT), 20µM carbamazepine (CBZ), 300µM valproate (VPA), 10µM lamotrigine (LTG), 60µM gabapentin (GBP), 10µM topiramate (TPM) or 90µM 
levetiracetam (LEV) for 48 hours at 370C. A further batch of cells (control) received vehicle (0.1% DMSO) only. Total RNA was then extracted, 
reverse-transcribed into cDNA, and the cDNA used to quantify relative expression for each gene.  Mean Ct values obtained from test gene 
amplification plots were normalised to the mean Ct of three housekeeping genes (GAPDH, HPRT1 and GUSB) and are presented as the relative test 
gene expression compared to expression in untreated hCMEC/D3 cells (relative expression =1), according to the comparative Ct method.   
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Figure 5.7: Effect of AED treatment on expression of ABCC transporter genes in hCMEC/D3 cells.  Cultures were treated with either 25µM phenytoin 
(PHT), 20µM carbamazepine (CBZ), 300µM valproate (VPA), 10µM lamotrigine (LTG), 60µM gabapentin (GBP), 10µM topiramate (TPM) or 90µM 
levetiracetam (LEV) for 48 hours at 370C. A further batch of cells (control) received vehicle (0.1% DMSO) only. Total RNA was then extracted, 
reverse-transcribed into cDNA, and the cDNA used to quantify relative expression for each gene.  Mean Ct values obtained from test gene 
amplification plots were normalised to the mean Ct of three housekeeping genes (GAPDH, HPRT1 and GUSB) and are presented as the relative test 
gene expression compared to expression in untreated hCMEC/D3 cells (relative expression =1), according to the comparative Ct method.   
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Figure 5.8: Effect of AED treatment on expression of other ABC transporter genes in hCMEC/D3 cells.  Cultures were treated with either 25µM 
phenytoin (PHT), 20µM carbamazepine (CBZ), 300µM valproate (VPA), 10µM lamotrigine (LTG), 60µM gabapentin (GBP), 10µM topiramate 
(TPM) or 90µM levetiracetam (LEV) for 48 hours at 370C. A further batch of cells (control) received vehicle (0.1% DMSO) only. Total RNA was then 
extracted, reverse-transcribed into cDNA, and the cDNA used to quantify relative expression for each gene.  Mean Ct values obtained from test gene 
amplification plots were normalised to the mean Ct of three housekeeping genes (GAPDH, HPRT1 and GUSB) and are presented as the relative test 
gene expression compared to expression in untreated hCMEC/D3 cells (relative expression =1), according to the comparative Ct method.
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5.3.4 Effects of AED treatment on SLC transporter expression in hCMEC/D3 cells 
Of the 46 SLC transporters analysed in this study, 19 appeared to have their expression 
induced or suppressed following treatment of hCMEC/D3 cells with AEDs. Again, any 
change in expression following AED treatment which differed more than 2 fold from 
control expression (no treatment = 1) was considered important.  Expression of 
SLC16A2 increased following both CBZ (3.69) and VPA (7.48) treatment in 
hCMEC/D3 cells (figure 5.9; table 5.5).  Conversely, expression of SLC16A3 decreased 
following exposure to VPA (0.385), LTG (0.473), GBP (0.455), TPM (0.252) and LEV 
(0.421; figure 5.9; table 5.5).  Expression of SLC38A5 decreased following treatment 
with all AEDs tested (PHT 0.447; CBZ 0.280; LTG 0.202; GBP 0.284; TPM 0.328; 
LEV 0.326), with the exception of VPA with which an increase in SLC38A5 expression 
was observed (2.50; figure 5.11; table 5.5).  Expression of SLC5A4 decreased following 
treatment with LTG (0.325), GBP (0.251), TPM (0.416) and LEV (0.354; figure 5.11; 
table 5.5). Expression of the genes encoding L-type amino acid transporters (LATs) was 
also affected by AED exposure; expression of SLC7A5 (LAT1) was reduced by CBZ 
(0.345), VPA (0.335), LTG (0.351), GBP (0.484), TPM (0.328) and LEV (0.445; figure 
5.12; table 5.5).  SLC7A8 (LAT2) expression was reduced following exposure to all 
AEDs tested (PHT 0.045; CBZ 0.032; VPA 0.115; LTG 0.049; GBP 0.021; TPM 0.022 
and LEV 0.026; figure 5.12; table 5.5).  Increases in expression of SLC22A1 (4.80) and 
SLC29A2 (4.27) were observed following CBZ treatment (figure 5.10; table 5.5), as 
were increases in the expression of SLC15A2 (2.37), SLC31A1 (2.87), SLCO3A1 (76.8) 
and SLCO4A1 (control 4.83) following VPA exposure (figures 5.9, 5.11 and 5.13; table 
5.5).  An increase in the expression of SLC2A3 was also observed in hCMEC/D3 cells 
treated with TPM (4.60; figure 5.11; table 5.5).  Changes in the expression of SLCO2A1 
and SLCO3A1 were also observed following treatment with LEV (SLCO2A1 18.5; 
SLCO3A1 577) and TPM (SLCO2A1 3.32; SLCO3A1 0.393; figure 5.13; table 5.5).   
In addition decreases in the expression of SLC19A1 (0.466), SLC19A3 (0.0483) were 
observed in hCMEC/D3 cells treated with LTG (figure 5.9), as were decreases in the 
expression of SLC28A3 (0.439), SLC2A1 (0.433) and SLC7A7 (0.477) following 
treatment with GBP and SLC19A1 (0.471) following TPM treatment (figures 5.9-5.12).  
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Figure 5.9: Effect of AED treatment on expression of selected SLC15, SLC16 and SLC19 transporter genes in hCMEC/D3 cells.  Cultures were treated 
with either 25µM phenytoin (PHT), 20µM carbamazepine (CBZ), 300µM valproate (VPA), 10µM lamotrigine (LTG), 60µM gabapentin (GBP), 10µM 
topiramate (TPM) or 90µM levetiracetam (LEV) for 48 hours at 370C. A further batch of cells (control) received vehicle (0.1% DMSO) only. Total 
RNA was then extracted, reverse-transcribed into cDNA, and the cDNA used to quantify relative expression for each gene.  Mean Ct values obtained 
from test gene amplification plots were normalised to the mean Ct of three housekeeping genes (GAPDH, HPRT1 and GUSB) and are presented as the 
relative test gene expression compared to expression in untreated hCMEC/D3 cells (relative expression =1), according to the comparative Ct method.   
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Figure 5.10: Effect of AED treatment on expression of selected SLC22, SLC25, SLC28 and SLC29 transporter genes in hCMEC/D3 cells.  Cultures 
were treated with either 25µM phenytoin (PHT), 20µM carbamazepine (CBZ), 300µM valproate (VPA), 10µM lamotrigine (LTG), 60µM gabapentin 
(GBP), 10µM topiramate (TPM) or 90µM levetiracetam (LEV) for 48 hours at 370C. A further batch of cells (control) received vehicle (0.1% DMSO) 
only. Total RNA was then extracted, reverse-transcribed into cDNA, and the cDNA used to quantify relative expression for each gene.  Mean Ct values 
obtained from test gene amplification plots were normalised to the mean Ct of three housekeeping genes (GAPDH, HPRT1 and GUSB) and are 
presented as the relative test gene expression compared to expression in untreated hCMEC/D3 cells (relative expression =1), according to the 
comparative Ct method.   
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Figure 5.11: Effect of AED treatment on expression of selected SLC2, SLC3, SLC5, SLC31 and SLC38 transporter genes in hCMEC/D3 cells.  
Cultures were treated with either 25µM phenytoin (PHT), 20µM carbamazepine (CBZ), 300µM valproate (VPA), 10µM lamotrigine (LTG), 60µM 
gabapentin (GBP), 10µM topiramate (TPM) or 90µM levetiracetam (LEV) for 48 hours at 370C. A further batch of cells (control) received vehicle 
(0.1% DMSO) only. Total RNA was then extracted, reverse-transcribed into cDNA, and the cDNA used to quantify relative expression for each gene.  
Mean Ct values obtained from test gene amplification plots were normalised to the mean Ct of three housekeeping genes (GAPDH, HPRT1 and GUSB) 
and are presented as the relative test gene expression compared to expression in untreated hCMEC/D3 cells (relative expression =1), according to the 
comparative Ct method.   
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Figure 5.12: Effect of AED treatment on expression of selected SLC7 transporter genes in hCMEC/D3 cells.  Cultures were treated with either 25µM 
phenytoin (PHT), 20µM carbamazepine (CBZ), 300µM valproate (VPA), 10µM lamotrigine (LTG), 60µM gabapentin (GBP), 10µM topiramate 
(TPM) or 90µM levetiracetam (LEV) for 48 hours at 370C. A further batch of cells (control) received vehicle (0.1% DMSO) only. Total RNA was then 
extracted, reverse-transcribed into cDNA, and the cDNA used to quantify relative expression for each gene.  Mean Ct values obtained from test gene 
amplification plots were normalised to the mean Ct of three housekeeping genes (GAPDH, HPRT1 and GUSB) and are presented as the relative test 
gene expression compared to expression in untreated hCMEC/D3 cells (relative expression =1), according to the comparative Ct method.   
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Figure 5.13: Effect of AED treatment on expression of selected SLCO transporter genes in hCMEC/D3 cells.  Cultures were treated with either 25µM 
phenytoin (PHT), 20µM carbamazepine (CBZ), 300µM valproate (VPA), 10µM lamotrigine (LTG), 60µM gabapentin (GBP), 10µM topiramate 
(TPM) or 90µM levetiracetam (LEV) for 48 hours at 370C. A further batch of cells (control) received vehicle (0.1% DMSO) only. Total RNA was then 
extracted, reverse-transcribed into cDNA, and the cDNA used to quantify relative expression for each gene.  Mean Ct values obtained from test gene 
amplification plots were normalised to the mean Ct of three housekeeping genes (GAPDH, HPRT1 and GUSB) and are presented as the relative test 
gene expression compared to expression in untreated hCMEC/D3 cells (relative expression =1), according to the comparative Ct method.  
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5.3.5 Effects of AED treatment on miscellaneous transporter gene expression in 
hCMEC/D3 cells 
A number of miscellaneous membrane transporters and genes associated with transport 
were analysed in this study, some of which appeared to be subject to induction or 
suppression by AEDs.  A decrease in expression of ATP6 was observed following 
treatment with all AEDs included in the study (PHT 0.172; CBZ 0.056: VPA 0.072: 
LTG 0.050: GBP 0.045; TPM 0.049; LEV 0.056).  As was a decrease in expression of 
ATP7A after exposure to all AEDs (PHT 0.344; CBZ 0.464; LTG 0.274; GBP 0.274; 
TPM 0.245; LEV 0.245) other than VPA (0.792; figure 5.14; table 5.4) and ATP7B 
following exposure to LTG (0.392) and TPM (0.452; figure 5.14; table 5.4).  Changes in 
the expression of AQP1 were observed in hCMEC/D3 cells following treatment with 
PHT (0.417), CBZ (2.42), VPA (2.12), LTG (0.387) and TPM (0.464; figure 5.14; table 
5.4).  Expression of TAP1 was increased following treatment with CBZ (767), VPA 
(4.64) and TPM (3.44) and decreased following treatment with LTG (0.395) and GBP 
(0.430; figure 5.15; table 5.4).  The expression of TAP2 also increased after exposure to 
CBZ (16.4), LTG (16.0) and LEV (2.93; figure 5.15; table 5.4).  Conversely, decreases 
in the expression of VDAC1 were observed following treatment with PHT (0.473), CBZ 
(0.474), GBP 0.254), TPM (0.382) and LEV (0.487; figure 5.15; table 5.4).  A decrease 
in the expression of MVP was also observed in hCMEC/D3 cells treated with TPM 
(0.471; figure 5.14; table 5.4), while an increase in the expression of VDAC2 was 
observed following VPA treatment (2.18) in hCMEC/D3 cells (figure 5.15; table 5.4).   
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Transporter gene Untreated 
PHT 
treated 
CBZ 
treated 
VPA 
treated 
LTG 
treated 
GBP 
treated 
TPM 
treated  
LEV 
treated 
SLC16A1 1.00 1.05 1.47 1.628 0.959 0.873 1.02 0.935 
SLC16A2 1.00 1.27 3.69 7.482 1.04 1.98 1.90 1.51 
SLC16A3 1.00 0.521 1.29 0.385 0.473 0.455 0.252 0.421 
SLC19A1 1.00 1.21 0.792 0.522 0.467 0.719 0.471 0.530 
SLC19A2 1.00 1.17 1.47 0.961 0.651 0.671 0.626 0.808 
SLC19A3 1.00 0.611 1.35 2.005 0.483 0.714 0.576 0.548 
SLC22A1 1.00 1.37 4.80 1.551 1.40 1.39 1.06 0.675 
SLC25A13 1.00 1.06 1.19 0.694 0.693 0.724 0.867 1.33 
SLC28A3 1.00 0.674 0.903 0.617 0.521 0.439 0.588 1.08 
SLC29A1 1.00 1.64 1.28 1.437 0.883 0.831 1.10 1.12 
SLC29A2 1.00 0.829 4.27 1.991 1.15 1.32 1.54 1.73 
SLC2A1 1.00 0.889 0.754 0.792 0.547 0.433 0.617 0.519 
SLC2A3 1.00 1.27 1.83 1.417 1.13 0.545 4.61 0.825 
SLC31A1 1.00 0.796 0.975 2.875 0.595 0.556 0.608 0.519 
SLC38A2 1.00 0.768 0.995 1.269 1.01 0.652 0.820 1.53 
SLC38A5 1.00 0.448 0.280 2.502 0.202 0.284 0.328 0.326 
SLC3A2 1.00 0.785 1.29 0.680 0.555 0.634 0.661 0.588 
SLC5A4 1.00 0.717 0.803 1.686 0.325 0.251 0.416 0.354 
SLC7A11 1.00 0.796 1.01 1.304 0.607 0.680 0.648 0.689 
SLC7A5 1.00 0.578 0.345 0.335 0.351 0.484 0.328 0.445 
SLC7A6 1.00 1.48 1.25 0.891 1.01 0.533 0.630 0.975 
SLC7A7 1.00 1.04 1.22 1.75 1.09 0.477 0.626 0.797 
SLC7A8 1.00 0.045 0.032 0.115 0.049 0.021 0.022 0.026 
SLCO2A1 1.00 1.52 1.79 1.089 0.920 0.643 3.32 18.5 
SLCO3A1 1.00 0.877 1.45 76.8 0.590 0.617 0.393 577 
SLCO4A1 1.00 0.768 1.38 4.83 0.574 0.526 0.545 0.714 
 
Table 5.5: Effects of AED treatment on the expression of selected SLC transporter 
genes in hCMEC/D3 cells.  Cultures were treated with either 25µM phenytoin (PHT), 
20µM carbamazepine (CBZ), 300µM valproate (VPA), 10µM lamotrigine (LTG), 
60µM gabapentin (GBP), 10µM topiramate (TPM) or 90µM levetiracetam (LEV) for 48 
hours at 370C. A further batch of cells (untreated) received vehicle (0.1% DMSO) only. 
Total RNA was then extracted, reverse-transcribed into cDNA, and the cDNA used to 
quantify relative expression for each gene.  Mean Ct values obtained from test gene 
amplification plots were normalised to the mean Ct of three housekeeping genes 
(GAPDH, HPRT1 and GUSB) and are presented as the relative test gene expression 
compared to expression in untreated hCMEC/D3 cells (relative expression = 1.00), 
according to the comparative Ct method.    
 
 
 
 
 
182 
 
 
A
Q
P 1
A
T
P 6
V
0C
A
T
P 7
A
;L
O
C
6 4
4 7
3 2


A
T
P 7
B
M
V
P
0
1
2
3
m
R
N
A
 e
x
p
re
ss
io
n
 r
el
at
iv
e 
to
 c
o
n
tr
o
l 
ex
p
re
ss
io
n
 (


C
t)
C o n t ro l
P H T  2 5 µ M
C B Z  2 0 µ M
V P A  3 0 0 µ M
L T G  1 0 µ M
G B P  6 0 µ M
T P M  1 0 µ M
L E V  9 0 µ M
 
Figure 5.14: Effect of AED treatment on expression of various transporter related genes in hCMEC/D3 cells.  Cultures were treated with either 25µM 
phenytoin (PHT), 20µM carbamazepine (CBZ), 300µM valproate (VPA), 10µM lamotrigine (LTG), 60µM gabapentin (GBP), 10µM topiramate 
(TPM) or 90µM levetiracetam (LEV) for 48 hours at 370C. A further batch of cells (control) received vehicle (0.1% DMSO) only. Total RNA was then 
extracted, reverse-transcribed into cDNA, and the cDNA used to quantify relative expression for each gene.  Mean Ct values obtained from test gene 
amplification plots were normalised to the mean Ct of three housekeeping genes (GAPDH, HPRT1 and GUSB) and are presented as the relative test 
gene expression compared to expression in untreated hCMEC/D3 cells (relative expression =1), according to the comparative Ct method.   
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Figure 5.15: Effect of AED treatment on expression of various transporter-related genes in hCMEC/D3 cells.  Cultures were treated with either 25µM 
phenytoin (PHT), 20µM carbamazepine (CBZ), 300µM valproate (VPA), 10µM lamotrigine (LTG), 60µM gabapentin (GBP), 10µM topiramate 
(TPM) or 90µM levetiracetam (LEV) for 48 hours at 370C. A further batch of cells (control) received vehicle (0.1% DMSO) only. Total RNA was then 
extracted, reverse-transcribed into cDNA, and the cDNA used to quantify relative expression for each gene.  Mean Ct values obtained from test gene 
amplification plots were normalised to the mean Ct of three housekeeping genes (GAPDH, HPRT1 and GUSB) and are presented as the relative test 
gene expression compared to expression in untreated hCMEC/D3 cells (relative expression =1), according to the comparative Ct method.   
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5.4 Discussion 
Transporter proteins are known to be critical for BBB protection and supply of essential 
nutrients (Urquhart et al., 2009).  In addition, they are also known to play a role in the 
brain accumulation of substrate drugs (Giacomini et al., 2010).  Evidence exists that 
people with epilepsy have altered brain transporter expression (Tishler et al., 1995; 
Lauritzen et al., 2011; Aronica et al., 2012).  However, what is not clear is whether the 
changes in brain transporter expression observed in epilepsy are a result of the 
pathophysiology of the disease or a result of chronic AED treatment. 
 
This chapter aimed to characterise expression of both ABC and SLC transporters in an 
in vitro model of the BBB and to explore changes in transporter expression following 
treatment with commonly prescribed AEDs at concentrations similar to those seen 
clinically in the serum of people with epilepsy. 
 
Of the 84 transporter genes included in this analysis, 57 were expressed in control 
hCMEC/D3 cells.  The expression profile of ABC transporters is summarised in table 1. 
Relatively high expression of ABCB1 (which encodes P-gp) was observed in 
hCMEC/D3 cells, in line with a large body of evidence which suggests P-gp is the 
major efflux transporter expressed at the BBB (Tsuji et al., 1992; Abbott et al., 2010).  
Very low or no expression was found for all other multidrug resistance proteins (MDRs) 
and multidrug resistance-associated proteins (MRPs) analysed in this study.  Of the SLC 
transporters that were investigated, those involved in nutrient transport unsurprisingly 
had the highest expression.  In particular, the facilitative glucose transporter SLC2A1, 
the monocarboxylate transporters SLC16A1 and SLC16A3, and the neutral amino acid 
transporters SLC38A2 and SLC38A5 showed the most significant expression. Generally, 
the transporter expression profile observed in this study was in agreement with that 
published previously in the hCMEC/D3 model (Carl et al., 2010).  However, of note, is 
that the sensitivity of the methods employed in this study appears to be reduced, with 
significantly lower relative Ct values than were previously reported.  Interestingly, and 
in keeping with Carl and colleagues (2010), no expression of organic anion transporters 
(encoded by SLC22A6, SLC22A7 and SLC22A8) was detected. Conversely, Geier and 
colleagues (2013) have observed expression of organic anion transporters in fresh 
human brain microvessels, suggesting a possible discrepancy between immortalised cell 
models and their respective primary cells.        
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The expression of a number of transporters was altered following exposure to AEDs; 
this data is summarised in figures 5.5 to 5.15, with observations of note discussed here.  
Expression of ABCB1 (which encodes P-gp) decreased following treatment with VPA, 
LTG, GBP and TPM.  It has been shown and widely accepted for many years that P-gp 
is overexpressed in drug resistant epilepsy (Tishler et al., 1995; Zhang et al., 1999; 
Dombrowski et al., 2001; Volk et al., 2005).  Therefore, the observation that treatment 
with several AEDs decreases P-gp expression is unexpected and suggests that 
overexpression of P-gp in drug resistant epilepsy may be a result of disease pathology 
or recurrent seizure activity rather than chronic drug treatment.  Interestingly, the 
expression of ATP synthase (ATP6) also decreased following treatment with all AEDs 
used in the study; reduced ATP synthase and ultimately reduced ATP availability to the 
cells may explain, at least in part, the reduced expression of P-gp.  
 
The expression of ABCA1, a transporter involved in brain cholesterol homeostasis, was 
seen to increase following treatment with PHT and CBZ suggesting that ABCA1 is 
induced by PHT and CBZ.  This may be elicited through direct induction of the gene or 
by activation of the transcription factor responsible for regulation of ABCA1, the liver X 
receptor (LXR).  Interestingly, in addition to its predominant role in cholesterol 
homeostasis, LXR and its ligands have been suggested to promote neurogenesis in the 
developing brain and to prevent neurodegeneration and protect from neuroinflammation 
in the adult brain (Wang, 2002; Karasinska et al., 2013; Theofilopoulos et al., 2013).  
Treatment of hCMEC/D3 cells with CBZ also appeared to induce ABCC1 expression; 
strong evidence suggests that ABCC1 and ABCA1, amongst other ABC transporters 
including ABCB1, are involved in a ‘phase III’ detoxification process by which they are 
critically involved in the efflux of xenobiotics and steroids (Ishikawa, 1992; Adachi et 
al., 2007).  Accumulating evidence also exists that inducers of phase I and/or phase II 
metabolising enzymes such as PHT and CBZ can alter the expression of transporters 
implicated in this postulated phase III detoxification process (Nakata et al., 2006).  This 
suggests that CBZ and possibly PHT may induce transcription factors involved in these 
detoxification processes and providing they are substrates for ABCA1 and/or ABCC1 
may induce their own efflux from the brain.     
Expression of SLC16A3 (which encodes MCT4) decreased following treatment with all 
AEDs investigated other than CBZ, whereas expression of the closely related SLC16A2 
186 
 
was seen to increase following VPA treatment alone.  Lauritzen and colleagues (2011) 
showed in surgically resected brain tissue from people with drug resistant temporal lobe 
epilepsy, that a deficiency of SLC16A1 (monocarboxylic acid transporter 1) is present 
on cerebral microvessels.  The observation that monocarboxylate transporters (MCTs) 
can be induced and/or suppressed following AED treatment suggests that AEDs are able 
to modulate MCT expression at the BBB and may explain, at least partly, any 
differential expression reported in studies of resected human tissue.  
 
Treatment with AEDs also had significant effects on various amino acid transporters 
expressed at the BBB.  Expression of the genes encoding L-type amino acid transporters 
(SLC7A5 and SLC7A8) and the neutral amino acid transporter (SLC38A5) decreased 
following treatment with the majority of AEDs; VPA in contrast appeared to induce 
expression of SLC38A5. However, expression of the cationic amino acid transporter 
SLC7A9 increased following treatment with all AEDs.  The brain is a large consumer of 
amino acids; this observation suggests that in response to AEDs there is a shift in the 
pattern of amino acid transporter expression.  SLC38A5 is known to supply the brain 
with essential molecules including glycine and glutamine which underpin the major 
route for biosynthesis of the neurotransmitter glutamic acid (Bröer, 2014).  Glycine and 
glutamic acid are also the predominant inhibitory neurotransmitters in the CNS and it 
could be postulated that induction of SLC38A5 following VPA treatment may in part 
contribute to the therapeutic action of VPA, by increasing availability of inhibitory 
neurotransmitters in the brain.   
 
Expression of SLC31A1, the gene encoding an influx transporter involved in copper 
regulation, increased by three fold following VPA treatment. Although there is no 
current evidence to link SLC31A1 to epilepsy or to the transport of VPA, it is known to 
be critical for normal cell function and has received interest in the field of oncology due 
to its ability to transport platinum containing chemotherapy agents, such as cisplatin and 
its potential to modulate cell signalling pathways involved in development and 
progression of certain cancers (Katano et al., 2002; Wee et al., 2013).  
 
Expression of genes encoding several members of the OATP family was also observed 
to increase following AED treatment.  Moderate expression of SLCO2B1 was observed 
following treatment with TPM despite SLCO2B1 being undetectable in control 
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hCMEC/D3 cells and the expression of SLCO3A1 and SLCO4A1 was increased almost 
10- and 7-fold respectively following VPA exposure.  SLCO2B1, SLCO3A1 and 
SLCO4A1 have  been implicated in the transport of drugs such as benzyl penicillin 
(Roth et al., 2012).  Interestingly, TPM and VPA form anions at physiological pH and 
although no transport by SLCO1A2 was observed for either AED in the study described 
in chapter 2 of this thesis (table 2.1), the observation that both AEDs can induce 
expression of OATP transporters at the BBB may suggest that TPM and VPA are 
subject to transport by SLCO2B1 and SLC03A1 and/or SLCO4A1, respectively.   
 
Another interesting observation, although not directly relevant to brain penetration of 
AEDs in drug resistant epilepsy, was the 300-fold increase in expression of TAP1, a 
transporter involved in transporting antigens from the cytoplasm to the endoplasmic 
reticulum for association with MHC class I molecules, following treatment with CBZ. 
CBZ is known to cause hypersensitivity reactions in 5-10% of patients and in rare cases 
can cause Stevens-Johnson syndrome and toxic epidermal necrolysis (Vittorio et al., 
1995).  The observation that CBZ can dramatically induce expression of a transporter 
involved in antigen processing suggests this association may be implicated in the 
mechanism by which a hypersensitivity reaction to CBZ is initiated.   
 
Due to the cost of the Taqman transporter gene arrays used in this study it was only 
possible to generate a single set of data for each AED at a single concentration.  This 
lack of replicate data limits the study and the conclusions that can be drawn. At least 
one duplicate study would have been necessary to demonstrate that the observations are 
reproducible.  Despite these limitations, data generated in this study suggests that AED 
treatment causes changes in the expression profile of multiple transporter genes in an in 
vitro BBB model.  It is likely that these changes are elicited by a multifaceted 
regulatory system in response to treatment with AEDs, however further work is needed 
to reproduce the study employed in this chapter and furthermore elucidate if chronic 
AED treatment is responsible for changes in brain transporter expression observed in 
people with epilepsy.   
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Chapter 6 
 
 
 
Determination of physicochemical properties 
that influence BBB permeation of AEDs 
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6.1 Introduction 
For any neurotherapeutic agent to reach its molecular target in the brain and exert its 
pharmacological effects, it must first penetrate a specialised, protective barrier which 
lines almost all cerebral microvessels, otherwise known as the blood-brain barrier 
(BBB). It is assumed that small molecules can pass through this barrier by simple 
diffusion (both transcellular and paracellular), however it has been estimated that 100% 
of large molecules and  more than 98% of small molecule drugs cannot cross the BBB 
in this manner (Pardridge, 2005). The BBB compromises a monolayer of endothelial 
cells, specialised in their barrier function due to the presence of elaborate junctional 
complexes that eliminate gaps between neighbouring cells and effectively prevent the 
passage of polar hydrophilic drugs, toxins and blood-borne substances from penetrating 
the brain via paracellular diffusion (Abbott, 2013).   
 
The restricted paracellular transport at the BBB necessitates that to passively diffuse 
across the BBB; CNS active agents must use the transcellular pathway which is largely 
governed by a compound’s lipophilicity.  It has been accepted for a number of years that 
the octanol/water coefficients (distribution coefficient log D and partition coefficient log 
P) of a drug directly correlate with its ability to cross a lipid membrane via the 
transcellular route.  However, a number of other physicochemical properties have also 
been shown to influence permeability across a lipid bilayer.   
 
Lipinski’s rule of 5 has been widely adopted to predict if a molecule has sufficiently 
favourable physicochemical properties to be well absorbed orally.  Lipinski 
demonstrated that for a compound to be well absorbed it must have a molecular weight 
< 500, a log P < 5 and restricted hydrogen bonding (less than 5 hydrogen bond donors 
and/or less than 10 hydrogen bond acceptors) (Lipinski et al., 1997).  In addition to the 
properties outlined in Lipinski’s rule of 5, complementary research  has demonstrated a 
role of the polar surface area of a drug and its influence on passive permeation, 
suggesting that for a compound to be well absorbed orally it must also have a polar 
surface area no larger than 100 Å2 and a total surface area no larger than 350 Å2 (Palm 
et al., 1997).    
 
Recently, it has been suggested that predictors of good oral absorption (i.e. permeation 
across the gastrointestinal tract epithelium) do not accurately predict a molecule’s 
190 
 
ability to cross the BBB and that physicochemical factors governing BBB permeation 
are more stringent (Pajouhesh et al., 2005). It has been  estimated that for a molecule to 
pass through the BBB passively it must have a molecular weight under 450, a polar 
surface area of below 90Å2, no more than 5 hydrogen donors and/or 10 hydrogen 
acceptors, and a log D value greater than 0 but less than 3 (Waterbeemd et al., 1998).  
Furthermore BBB permeation has been shown to be optimal when Log P values are 
between 1.5 and 2.7 and although a compound with up to 5 hydrogen bond donors 
and/or 10 hydrogen bond acceptors will penetrate the BBB, currently marketed CNS 
active drugs have on average only 1.5 hydrogen bond donors and 2.12 hydrogen bond 
acceptors (Hansch et al., 1979; Leeson et al., 2004)       
 
Many CNS active agents do not meet these criteria and yet still achieve adequate brain 
penetration.  It is known that specific transport systems are expressed at the BBB to 
supply essential molecules such as glucose and amino acids to the brain (Pardridge et 
al., 1977; Pardridge, 1986).  It is therefore reasonable that drugs that achieve adequate 
brain uptake despite unfavourable physicochemical properties may also enter the brain 
via a similar transport system.  For example, the muscle relaxant baclofen is known to 
cross the BBB despite being highly hydrophilic and is thought to gain entry to the brain 
via the L-amino acid transporter system (van Bree et al., 1988; van Bree et al., 1991).  
In addition, the AED gabapentin displays good brain uptake despite its hydrophilic 
nature and has also been suggested to enter the brain by the L-amino acid transporter 
system (Welty et al., 1993).      
 
The work described in this chapter first aimed to determine in silico, the 
physicochemical properties known to influence BBB permeation of seven commonly 
prescribed AEDs, utilising the integrated chemical database SciFinder® 
(https://scifinder.cas.org/scifinder/login).  Experimentally determined log D values for 
each AED, obtained from liquid scintillation counting of radiolabelled drug and LC-
MS/MS analysis of unlabelled drug, were then compared with predicted log D values 
from SciFinder®. The collective physicochemical properties were then analysed in an 
attempt to determine if the AEDs included in earlier studies of this thesis possess 
physicochemical properties likely to favour passive entry into the brain or if they are 
likely to require a transporter system. Observed physicochemical data was also analysed 
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by multivariate linear regression to determine which, if any, properties predict AED 
accumulation in hCMEC/D3 cells, as reported in chapter 3.      
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6.2  Materials and methods 
6.2.1 Materials 
[3H]-lamotrigine (specific activity 5Ci/mmol), [3H]-levetiracetam (specific activity  
5Ci/mmol), [3H]-topiramate (specific activity  8Ci/mmol) and [3H]-gabapentin (specific 
activity  110Ci/mmol) were purchased from American Radiolabeled Chemicals Inc. (St. 
Louis, USA).  [3H]-phenytoin (specific activity 1.1Ci/mmol), [3H]-carbamazepine 
(specific activity 10Ci/mmol) and [3H]-valproic acid (specific activity 55Ci/mmol) were 
purchased from Moravek (Brea, California, USA).  Hanks balanced salt solution 
(HBSS) was purchased from Life Technologies (Paisley, UK).  Phenytoin-d10, 
carbamazepine-d10, valproic acid-d4, gabapentin-d4, topiramate-d12 and levetiracetam-d6 
were purchased from C/D/N isotopes (Quebec, Canada), lamotrigine-13C3was purchased 
from Medical Isotopes (Pelham, New Hampshire, USA).  All other reagents, unless 
otherwise stated, were purchased from Sigma Aldrich (Poole, UK).   
 
6.2.2 Computational determination of physicochemical properties 
In silico determination of physicochemical properties for the seven AEDs included in 
this study was carried out using the SciFinder® integrated chemical database 
(https://scifinder.cas.org/scifinder/login).  Registration to access the database is 
available through the University of Liverpool electronic library.  A search for each AED 
was carried out using the ‘substance identifier’ tool.  This returned all known 
information including chemical name, structure, regulatory information and 
experimental properties for each drug.  Any physicochemical information relevant to 
BBB permeation was then collated and compared with experimentally determined 
physicochemical properties.        
 
6.2.3 Log D analysis with radiolabelled AEDs 
Octanol/water distribution experiments employed a radiolabel concentration of 
0.4µCi/ml supplemented with non-radiolabelled drug to give final concentrations of 
50µM PHT, 40µM CBZ, 600µM VPA, 20µM LTG, 20µM TPM, 20µM GBP and 
90µM LEV, all prepared in transport medium (HBSS supplemented with 25mM HEPES 
and 0.1% bovine serum albumin (BSA), pH7.4).  A radiolabel concentration of 
0.4µCi/ml (0.2 µCi/ml final concentration) afforded sufficient disintegrations per 
minute to give accurate readings of radioactive content without saturating the 
scintillation counter. A 1ml aliquot of transport buffer containing AED was added to 
1ml of octanol in a 15ml Falcon tube to give final concentrations of 25µM PHT, 20µM 
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CBZ, 300µM VPA, 10µM LTG, 10µM TPM, 10µM GBP and 90µM LEV.  Each 
buffer/octanol solution was vigorously shaken by hand for 15 minutes and then 
centrifuged at 800 x g for 10 minutes to separate the aqueous and organic fractions.  
Samples (500µl) of both aqueous and octanol fractions were added to individual 
scintillation vials. This was repeated 4 times for each AED to give 4 replicates for each 
experiment. Samples (500µl) of transport buffer alone (blanks) were also taken and 
added to individual scintillation vials to allow estimation of background radiation. A 
4ml volume of scintillation fluid was then added to all scintillation vials and each vial 
was mixed by inverting several times before the radioactive content was determined 
using a scintillation counter (1500 Tri Carb LS Counter; Packard).  Results in dpm were 
corrected for background counts, and a mean of 4 replicate octanol and aqueous samples 
calculated for each AED.  The dpm in the octanol phase was then divided by the dpm in 
the aqueous phase and log transformed to give a partition coefficient (log D) value for 
each AED at pH 7.4.  The mean log D value for each AED was finally calculated from 3 
independent experiments, each comprising 4 replicates.   
 
6.2.4 Log D analysis using LC-MS/MS 
AEDs were prepared in transport medium (HBSS supplemented with 25mM HEPES 
and 0.1% BSA, pH7.4). A 1ml aliquot of transport buffer containing AED was added to 
1ml of octanol in a 15ml Falcon tube, giving final concentrations of 25µM PHT, 20µM 
CBZ, 300µM VPA, 10µM LTG, 10µM TPM, 10µM GBP and 90µM LEV.  Each 
buffer/octanol solution was vigorously shaken by hand for 15 minutes and then 
centrifuged at 800 x g for 10 minutes to separate the aqueous and organic fractions.  
Samples (500µl) of both aqueous and octanol fractions were added to individual 
Eppendorf tubes.  This was repeated 4 times for each AED to give 4 replicate 
experiments. Samples were dried down overnight using a vacuum evaporator and 
reconstituted in 100% LC-MS grade methanol.  Samples were then stored at -200C 
overnight and transported to the Buxton Laboratories at the Walton Centre NHS 
foundation Trust the following morning for LC-MS/MS analysis.  Samples were 
analysed on the Waters liquid chromatography tandem mass spectrometry (LC-MS/MS) 
system according to local standard operating procedures for analysis of samples for 
AED content, under the direction of Katherine Birch (clinical biochemist).   
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As PHT, CBZ, VPA and LTG are amongst the most widely used AEDs, an assay had 
previously been optimised at the Buxton laboratories in which samples for PHT, CBZ, 
VPA , LTG, carbamazepine epoxide and phenobarbital could all be analysed 
simultaneously in the same run.  Only single assays were available for GBP, TPM and 
LEV, therefore samples for these AEDs were analysed in separate LC-MS/MS runs.  
Firstly, previously prepared standards of known concentration and quality controls 
(QCs) for each AED were allowed to thaw at room temperature.  Standards were 
prepared in phosphate buffered saline with 0.1% BSA at the concentrations listed in 
table 6.1.  For PHT, CBZ, VPA and LTG, individual standards (1, 2, 3, 4 and 5) were 
mixed to enable simultaneous detection.  Two MassCheck Antiepileptic Drug Plasma 
Controls (low (16.5mg/L) and high (64.9mg/L) concentration, respectively) were used 
as internal QCs; controls were provided as lyophilised human plasma samples and were 
reconstituted in water according to the manufacturer’s protocol (Chromsystems, 
Gräfelfing, Germany).  Deuterated forms of each AED were used as internal assay 
standards to compensate for variation in extraction and ionisation on the LC-MS/MS 
system.  The combined internal standard for PHT, CBZ, VPA and LTG consisted of 
4mg/L phenytoin-d10, 1.2mg/L carbamazepine-d10, 5 mg/L carbamazepine epoxide-d10, 
8 mg/L valproic acid-d4, 550 µg/L lamotrigine-
13C3 and 5mg/L phenobarbital-d5 in LC-
MS grade methanol.  Individual internal standards were prepared in methanol for GBP 
(1mg/L gabapentin-d4), TPM (10mg/L topiramate-d12) and LEV (10mg/L levetiracetam-
d6).  A 20µl aliquot of each sample/standard/QC was transferred to a 96-well deep well 
plate and 80µl of the appropriate internal standard added to each well.  The plate was 
then heat-sealed, vortexed for 5 minutes, and centrifuged at 3000 x g for 5 minutes.  The 
seal was then removed and 80µl of LC-MS grade water added to each well.  The plate 
was again heat-sealed, vortexed for 5 minutes, and centrifuged at 3000 x g for 5 
minutes.  Plates were then placed in the autosampler of the LC-MS/MS instrument. 
After ensuring that sufficient volume of mobile phase solvents and wash were present, 
the LC-MS run was then initiated.  The mobile phases were first primed, before 
switching the MS into operate mode and turning both API and collision gases on. The 
mobile phase gradient was run to prepare the column, and the samples were then 
injected onto the LC column.  Resulting chromatograms were analysed to ensure the 
correct peak was integrated and AED concentrations were calculated from a calibration 
curve generated by Masslynx software (Waters, UK).  Concentrations calculated for 
each sample were used to determine the log D value for each AED as described in 
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section 6.2.3.  Data was expressed as mean ± standard error of the mean (SEM) log D, 
calculated for each AED from three separate experiments each comprising 4 replicates.   
 
  Blank 
Standard  
1 
Standard 
2 
Standard  
3 
Standard  
4 
Standard  
5 
Phenytoin 0 mg/L 3.1 mg/L 6.3 mg/L 12.5 mg/L 25 mg/L 50 mg/L 
Carbamazepine 0 mg/L 1.9 mg/L 3.8 mg/L 7.5 mg/L 15 mg/L 30 mg/L 
Valproic acid 0 mg/L 12.5 mg/L 25 mg/L 50 mg/L 100 mg/L 200 mg/L 
Lamotrigine 0 mg/L 1.6 mg/L 3.1 mg/L 6.3 mg/L 12.5 mg/L 25 mg/L 
Gabapentin 0mg/L 5mg/L 15mg/L 40mg/L 50mg/L  
Topiramate 0mg/L 5mg/L 15mg/L 25mg/L 40mg/L 50mg/L 
Levetiracetam 0mg/L 10mg/L 20mg/L 40mg/L 80mg/L  
 
Table 6.1: Final concentrations of phenytoin, carbamazepine, valproic acid, 
lamotrigine, gabapentin, topiramate and levetiracetam employed as calibration standards 
in LC-MS/MS analysis.   
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6.2.5 Multivariate  linear regression  
Raw data (table 6.2) generated from cellular uptake experiments with radiolabelled 
PHT, CBZ, VPA, LTG, GBP, TPM and LEV, as described in chapter 3 (see section 
3.2.5 for methodology), was used to generate a multivariate linear regression model.   
Cellular uptake data for all drugs and all physicochemical properties determined in the 
work described in this chapter, both computationally and experimentally, were analysed 
using the SPSS statistical package, with cellular accumulation employed as the 
dependent variable.  All other variables were selected as independent variables and a 
stepwise regression model was used. 
 
 
Radiolabelled AED Concentration (µM) 
Cellular accumulation 
(pmol/100000 cells)) 
[3H]-phenytoin 
20µM 138 ±11.2 
[3H]-carbamazepine 25µM 17.5  ± 1.00 
[3H]-valproic acid 300µM 47.0± 4.93 
[3H]-lamotrigine 10µM 55.3 ± 2.71 
[3H]-gabapentin 10µM 865± 30.8 
[3H]-topiramate 10µM 21.2± 3.86 
[3H]-levetiracetam 6µM 9.07± 1.12 
   
Table 6.2: Cellular uptake of antiepileptic drugs (AEDs) in a human cerebral 
microvascular endothelial cell line (hCMEC/D3).  Cultures were exposed to 
radiolabelled AEDs (25μM phenytoin, 20µM carbamazepine, 300µM valproic acid, 
10µM lamotrigine, 10µM gabapentin, 10µM topiramate, 6µM levetiracetam) for one 
hour at 370C. Results are expressed as the mean ± standard error of the mean (SEM) 
disintegrations per minute (DPM) for 5 independent experiments, where n=3 per 
experiment. Further details are reported in Chapter 3.   
 
 
 
 
 
197 
 
6.3  Results 
6.3.1 Determination of physicochemical properties using computational methods 
The molecular weight of all AEDs included in this study was found to be below the 
suggested limit of 450 for adequate BBB permeation (table 6.3). In addition, none of the 
AEDs were found to have 5 or more hydrogen bond donors and/or 10 hydrogen bond 
acceptors (table 6.3).  However, both LTG and TPM had polar surface areas above the 
suggested 90Å2 limit for adequate BBB permeation (90.7Å2 and 124Å2, respectively) 
(table 6.3).  The predicted log D value for all AEDs was also within the suggested limits 
(0 to 3) for adequate BBB penetration, with the exception of GBP (-1.42) and LEV (-
0.88) (table 6.4).  Furthermore, the log P values predicted for PHT (1.42), LTG (1.24), 
GBP (1.08) and LEV (-0.88) were outside of the suggested limits for adequate BBB 
permeation (1.5 to 2.7) (table 6.3).  
 
Drug 
Molecular 
weight 
Polar 
surface 
area (Ao2) 
H bond 
donors 
H bond 
acceptors 
Log P 
(250C) 
Phenytoin 252 58.2 
2 4 1.42 
Carbamazepine 236 46.3 
2 3 1.90 
Valproic acid 144 37.3 
1 2 2.58 
Lamotrigine 256 90.7 
4 5 1.24 
Gabapentin 171 63.3 
3 3 1.08 
Topiramate 339 124 
2 9 2.16 
Levetiracetam 170 63.4 
2 4 -0.88 
 
Table 6.3: Molecular weight, polar surface area, hydrogen bonding and partition 
coefficients (log P) of seven commonly prescribed antiepileptic drugs determined using 
the integrated chemical database SciFinder® (https://scifinder.cas.org/scifinder/login).   
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 log D values at varying  pH 
AED pH 1 pH 2 pH 3 pH 4 pH 5 pH 6 pH 7 pH 8 pH 9 pH 10 
Phenytoin 1.42 1.42 1.42 1.42 1.42 1.42 1.41 1.29 0.78 -0.01 
Carbamazepine 1.88 1.89 1.89 1.89 1.89 1.89 1.89 1.89 1.89 1.89 
Valproic acid 2.58 2.58 2.57 2.52 2.18 1.37 0.40 -0.50 -1.09 -1.16 
Lamotrigine -1.25 -1.20 -0.90 -0.13 0.71 1.15 1.23 1.24 1.24 1.24 
Gabapentin -2.02 -2.02 -1.99 -1.85 -1.55 -1.43 -1.42 -1.42 -1.44 -1.59 
Topiramate 2.16 2.16 2.16 2.16 2.16 2.16 2.15 2.13 1.96 1.34 
Levetiracetam -0.89 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 -0.88 
 
Table 6.4: Distribution coefficients (log D) of seven commonly prescribed antiepileptic 
drugs at pH 1-10, determined using the integrated chemical database SciFinder® 
(https://scifinder.cas.org/scifinder/login).   
 
6.3.2 Comparison of log D values obtained experimentally and in silico at pH 7.4 
The log D values for VPA and LEV determined by liquid scintillation counting (0.22 ± 
0.01 and -0.68 ± 0.01, respectively) were similar to the predicted log D values generated 
in silico (0.04 and -0.88, respectively).  However, the log D values for VPA and LEV 
determined using LC-MS/MS (1.25 ± 0.01 and -0.09 ± 0.02) were significantly different 
from those obtained by liquid scintillation counting.  Conversely, the log D for LTG 
determined by LC-MS/MS (1.05 ± 0.11) was similar to that predicted computationally 
(1.23), but higher than that determined by liquid scintillation counting (-0.03 ± 0.02).  
Interestingly, for GBP and TPM conflicting values were obtained; log D for GBP by 
liquid scintillation counting was -0.64 ± 0.04, by LC-MS/MS was 0.28 ± 0.03, and 
predicted computationally was -1.42, log D for TPM by liquid scintillation counting 
was -1.08 ± 0.01, by LC-MS/MS was -0.56±0.04, and predicted computationally was 
2.14.  Log D values for PHT and CBZ were comparable for all three methods employed 
(PHT - liquid scintillation counting 1.75 ± 0.20, LC-MS/MS 1.36 ± 0.03, 
computationally 1.36; CBZ - liquid scintillation counting 1.17 ± 0.03, LC-MS/MS 1.46 
± 0.03, computationally 1.89). All log D data is reported in table 6.5 for comparative 
purposes.            
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Table 6.5: A comparison of log D values for seven commonly prescribed antiepileptic 
drugs (AEDs) at pH7.4, determined in silico and experimentally.  Predicted log D 
values from in silico analysis were obtained using the integrated chemical database 
SciFinder® (https://scifinder.cas.org/scifinder/login).  Experimentally determined log D 
values were obtained using radiolabelled compounds (measured by liquid scintillation 
counting) and unlabelled compounds (measured by liquid chromatography tandem mass 
spectrometry (LC-MS/MS)) following partition into 50:50 (v/v) octanol: aqueous buffer 
solution.  AED concentrations in experimental studies were as follows; phenytoin (PHT, 
25µM), carbamazepine (CBZ, 20µM), valproic acid (VPA, 300µM), lamotrigine (LTG, 
10µM), gabapentin (GBP, 10µM), topiramate (TPM, 10µM) and levetiracetam (LEV, 
90µM). Results are expressed as mean ± standard error of the mean (SEM) log D from 
three independent experiments, each comprising 4 replicates.     
 
 
 
 
 
 
 
 
AED 
Computationally 
determined log D 
Experimentally determined log D 
  
Liquid scintillation 
counting 
LC-MS/MS 
Phenytoin 1.36 1.36 ± 0.03 1.75 ± 0.20 
Carbamazepine 1.89 1.17 ± 0.03 1.46 ± 0.03 
Valproic acid 0.04 0.22 ± 0.01 1.25 ± 0.01 
Lamotrigine 1.23 -0.03 ± 0.02 1.05 ± 0.11 
Gabapentin -1.42 -0.64 ± 0.04 0.28 ± 0.03 
Topiramate 2.14 -1.08 ± 0.01 -0.56 ± 0.04 
Levetiracetam -0.88 -0.68 ± 0.01 -0.09 ± 0.02 
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6.3.3 Multivariate linear regression analysis 
Multivariate linear regression analysis failed to identify any association between the 
various physicochemical parameters observed in this study (log D, log P, molecular 
weight, hydrogen bonding and polar surface area) and the extent of cellular uptake of 
the respective AED in hCMEC/D3 cells (table 6.6).   
 
 
 
 
Table 6.6: Descriptive statistics output from multivariate linear regression analysis.  
None of the physicochemical properties included in the regression model was found 
to be associated with the extent of cellular accumulation of AEDs in hCMEC/D3 
cells. Predictors marked with an asterisk (*) were determined in silico using the 
integrated chemical database SciFinder® (https://scifinder.cas.org/scifinder/login).  
 
 
 
 
 
 
 
 
 
 
 
Predictor Significance 
Molecular weight* 0.234 
Hydrogen bond donors* 0.232 
Hydrogen bond acceptors* 0.281 
Log D computational* 0.155 
Log D liquid scintillation 
counting 
0.318 
Log D LC-MS/MS 0.314 
Polar surface area* 0.407 
Log P* 0.430 
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6.4 Discussion 
It has been accepted for a number of years that the octanol/water coefficients (log D and 
log P) of a drug directly correlate with its ability to cross a lipid membrane via the 
transcellular route.  However, a number of other physicochemical properties have been 
shown to additionally influence permeability across a lipid membrane.  Lipinski’s rule 
of 5 has been widely adopted to predict if a molecule or drug has sufficiently favourable 
physicochemical properties to be well absorbed orally (Lipinski et al., 1997).  However, 
recently it has been suggested that predictors of good oral absorption do not accurately 
predict a molecule’s ability to cross the BBB and that physicochemical factors 
governing BBB permeation are more stringent (Pajouhesh et al., 2005). 
 
In this chapter, the physicochemical properties known to influence BBB penetration 
were investigated for seven commonly prescribed AEDs using the integrated chemical 
database SciFinder®.  The distribution coefficient (log D) for each AED was also 
determined using two experimental approaches; liquid scintillation counting and LC-
MS/MS respectively, in an attempt to compare values determined experimentally to 
those that had been predicted.  All of the resulting physicochemical parameters, 
irrespective of whether they had been determined in silico or experimentally, were then 
employed in a regression model to determine if any could reliably predict the cellular 
uptake of AEDs in hCMEC/D3 cells. 
 
When comparing log D values obtained by the two experimental methods employed, 
conflicting values were obtained for a number of AEDs.  The log D value for VPA 
obtained by liquid scintillation counting matched that predicted by SciFinder, but was 
lower than that determined by LC-MS/MS.  At physiological pH, VPA is almost 
completely ionised to its corresponding sodium salt. It is therefore possible that the 
greater log D value observed with LC-MS/MS may have been due to a larger percentage 
of the ionised, more lipophilic form being present in the sample.  Similarly, the log D 
value determined by liquid scintillation counting for LTG and GBP, both of which are 
also highly ionised at physiological pH, was significantly lower than that determined by 
LC-MS/MS. The distribution coefficient (log D) takes into account both un-ionised and 
ionised forms of the test molecule therefore must be calculated at a known pH (Smith et 
al., 2012).  Inconsistencies in experimental determination of log D values for highly 
ionised AEDs may therefore be due to variable sensitivity in the analysis of ionised 
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forms in experimental samples, therefore overall concentrations of LTG and GBP in the 
samples.  Furthermore GBP is known to have limited stability in solution, therefore over 
time the radiolabelled compound may have degraded and may have affected 
measurement of log D by liquid scintillation counting when compared to LC-MS/MS 
which utilised freshly prepared solutions.   
 
Experimentally determined log D values were consistent with predicted log D values for 
PHT and CBZ, neither of which is highly ionised at physiological pH. In addition, PHT 
and CBZ were the only AEDs in this study that were found to possess optimal 
physicochemical properties for passive brain uptake, which was reflected in their 
marked accumulations in hCMEC/D3 cells.         
  
Interestingly, for TPM, the log D values determined by both experimental methods were 
in agreement but were significantly lower than that predicted by in silico analysis (i.e. 
TPM is predicted to be much more lipophilic than it appears).  In addition, TPM was 
also found to have several physicochemical properties which might restrict its brain 
uptake, including a large polar surface area and high number of hydrogen bond 
acceptors.  Passive BBB permeation is typically restricted to those molecules that 
possess a molecular weight no greater than 400, a polar surface area no larger than 
90A2, no more than 10 hydrogen bond acceptors and/or 5 hydrogen bond donors, and a 
log D between 0 and 3 (Waterbeemd et al., 1998; Pajouhesh et al., 2005).  Despite not 
meeting these criteria, TPM still displays substantial uptake in hCMEC/D3 cells. TPM 
contains a sulphonamide group in its structure similar to the antipsychotic drugs 
sulpiride and amisulpride, which also achieve adequate brain uptake despite a polar 
surface area over the limit suggested for passive diffusion across the BBB.  Sulpiride 
transport has been demonstrated to be subject to inhibition by a number of PEPT1 
(peptide transporter 1), OCTN1 (organic cation/carnitine transporter 1) and OCTN2 
(organic cation/carnitine transporter 2) substrates and/or inhibitors in a caco-2 cell line.  
In addition sulpiride has also been demonstrated to be transported by OCT1 and OCT2 
in both hCMEC/D3 cells and HEK293 cells overexpressing OCT1 and OCT2 (Pereira 
et al., 2014).  Furthermore amisulpride was observed to be transported by OCT1, 
OCT2, OCT3, OCTN1 and OCTN2 in HEK293 cells overexpressing each transporter 
respectfully (Pereira et al., 2014).  Therefore it is plausible that one or more of these 
transporters may transport sulpiride across the intestinal epithelium (Watanabe et al., 
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2002).  PEPT1 and OCT1 are expressed in hCMEC/D3 cells (Carl et al., 2010) and 
OCTN2 has been suggested to be expressed at the BBB in vivo (Kusuhara et al., 2005), 
therefore the substantial TPM uptake observed in hCMEC/D3 cells may be due to 
carrier mediated uptake of TPM by one or more of these transporters.  In addition in 
mdr1 knockout mice, brain concentrations of TPM were greater than that observed in 
wild-type mice, strongly suggesting TPM is a substrate for efflux transport by P-gp 
(Sills et al., 2002).       
 
Like TPM, LTG and GBP showed physicochemical properties that might be suggestive 
of limited passive brain uptake.  The polar surface area of LTG was found to be over the 
suggested limit for adequate BBB penetration and the log D values for GBP, derived 
from both in silico and experimental studies were less than or close to 0, and thereby 
below the suggested limit for passive diffusion across the BBB.  Interestingly, these 
AEDs have previously been suggested to be subject to carrier-mediated uptake by 
OCT1 and LAT1 respectively (Welty et al., 1993; Dickens et al., 2012).   
 
Linear regression analysis failed to find an association between the various 
physicochemical properties of these seven AEDs and the extent of their accumulation in 
hCMEC/D3 cells.  This would suggest that, in the in vitro environment at least, cellular 
uptake of AEDs is essentially independent of their physicochemical properties and may 
therefore be mediated by active (i.e. transporter-dependent) processes.   
 
In conclusion, the experiments described in this chapter suggest firstly, that log D 
values determined for highly ionised molecules are subject to experimental variation 
and that in silico predictions may not be accurate in these cases.  Secondly, despite 
displaying marked cellular uptake in a human BBB model, several AEDs, including 
LTG, GBP and TPM, possess one or more unfavourable physicochemical properties 
that may limit their ability to passively enter the brain.  Finally, multivariate linear 
regression analysis failed to find an association between physicochemical properties and 
AED uptake in hCMEC/D3 cells.  These observations suggest that several AEDs 
namely LTG, GBP and TPM are unlikely to have accumulated in hCMEC/D3 cells by 
passive diffusion and that a carrier mediated transport system is likely to play a role in 
the uptake of these AEDs into hCMEC/D3 cells and conceivably the BBB in vivo.  
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Providing uptake of AEDs into hCMEC/D3 cells correlates with uptake in cerebral 
endothelial cells in vivo.    
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Chapter 7 
 
 
 
General Discussion 
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Despite the availability of a growing number of AEDs, up to 30% of people with 
epilepsy are not adequately controlled with AED therapy and are classified as 
pharmacoresistant.  The majority of observed drug resistance occurs relatively soon 
after diagnosis in early treatment and any further attempt to control seizures with drug 
treatment is usually futile.  This suggests that the mechanism by which individuals 
become resistant is de novo, does not develop over time, and is not associated with 
prolonged therapy (Kwan et al., 2000).  The causative biological mechanism of drug 
resistance in epilepsy is poorly understood but is likely to be multifactorial; an 
important observation of drug resistant epilepsy is that resistance is to multiple AEDs 
with different mechanisms of action, suggesting a general pharmacokinetic mechanism 
of pharmacoresistance.  
 
The transporter hypothesis accounts for this observation and postulates that over-
expression of drug efflux transporters on cerebral microvascular endothelial cells which 
contribute to the integrity of the BBB may reduce AED accumulation in the brain, 
preventing therapeutically active concentrations of AEDs from reaching their targets.  
However, this hypothesis relies on the fundamental assumption that multiple AEDs are 
substrates for one or more transporter systems at the BBB.  Research supporting this 
hypothesis has up to now focused almost exclusively on the investigation of AED 
transport by P-gp.  Such investigation has reported conflicting findings (see table 1.1) 
with in vitro studies returning largely negative data while in vivo investigations have 
returned largely positive or inconclusive data (Owen et al., 2001; Potschka et al., 2001; 
Potschka et al., 2002; Sills et al., 2002; Crowe et al., 2006; Dickens et al., 
2013)(Feldmann et al., 2013).  Other efflux transporters have received some attention 
but similarly have returned ambiguous findings (Potschka et al., 2001; Cerveny et al., 
2006).  Although research to date surrounding the transporter hypothesis of drug 
resistant epilepsy is yet to yield conclusive evidence in its support, much can be learned 
concerning the significance of the investigative system used to assess transporter 
systems and the danger of relying on a single experimental model to characterise a 
complex pharmacological relationship. 
   
In addition to the expression of efflux transporters such as P-gp, the BBB is known to 
possess a rich and diverse expression of influx transporters belonging to the SLC 
superfamily.  Despite over a decade of research surrounding the drug transporter 
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hypothesis, the role SLC transporters might play in this theory remains largely 
unaddressed.  Hence the major focus of this thesis was to investigate and identify 
transporter systems of interest that are expressed at the BBB and determine which, if 
any AEDs are substrates for such transporter systems.  Seven of the most commonly 
prescribed AEDs (PHT, CBZ, VPA, LTG, GBP, TPM and LEV) were investigated in 
this thesis and of these, VPA and GBP showed the greatest evidence for SLC-mediated 
transport, while other compounds were largely unremarkable in this respect. 
 
The findings of this thesis are summarised as follows (figure 7.1); in chapter 2 
OATP1A2 was shown not to transport any of the AEDs tested in SLCO1A2 transfected 
X. laevis oocytes.  Furthermore GBP was shown to be transported by MCT1 in 
SLC16A1 transfected X. laevis oocytes, however transport could not be reliably 
inhibited with the MCT1 inhibitor employed.  In chapter 3 several AEDs tested namely 
PHT, LTG, TPM and GBP, were sensitive to MCT transport inhibitors.  Overlapping 
substrate specificity of the inhibitors employed prevented clear conclusions being made 
in terms of crediting the observed effects as inhibition of MCT transporters specifically.  
However data generated strongly suggested GBP is transported by MCT1 and or MCT4 
in hCMEC/D3 cells.  In chapter 4 VPA, LTG and TPM transport increased in 
SLC22A6_MDCK II cells however these increases could not be attenuated by inclusion 
of the OAT1 inhibitor probenecid. LTG and TPM transport increased in 
SLC22A8_MDCK II cells, while VPA transport decreased.  LTG transport could be 
significantly inhibited with the inclusion of the OAT3 inhibitor probenecid, however the 
changes in transport observed for VPA and TPM could not be attenuated by inclusion of 
probeneicd.  Further attempts to inhibit the changes in AED transport observed in both 
SLC22A6_MDCK II and SLC22A8_MDCK II cells were unsuccessful.  In chapter 5 all 
of the AEDs tested were observed to supress and/or inhibit the expression of a number 
of transporter genes in hCMEC/D3 cells including P-gp, MRP transporters, MCT 
transporters, organic anion transporting polypeptides and amino acid transporters.  
Finally in chapter 6 analysis of the physicochemical properties of the AEDs included in 
this thesis revealed that a number of AEDs, namely LTG, TPM and GBP possess 
unfavourable characteristics to enter the brain passively and so it is plausible they enter 
via active uptake by transporters.   
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SLC transporters are known to be expressed at the BBB where they play a critical role 
in brain delivery of nutrients, which are otherwise restricted from entering the brain 
(Pardridge et al., 1977; Pardridge, 1986).  It is therefore plausible that AEDs may utilize 
influx transport systems expressed at the BBB and that changes in expression of these 
transporters may impact on AED brain penetration and therefore prevent therapeutic 
concentrations of AEDs reaching brain targets.  
 
Endothelial cells constituting the BBB are unique in the fact that they possess 
specialised tight junctions which almost completely restrict paracellular transport 
(Pardridge, 2005; Abbott, 2013). It is therefore a challenge to experimentally model the 
human BBB in vivo.  Surrogate BBB models such as Caco-2 and MDCK-MDR1 cells 
may provide a simple and inexpensive alternative for high throughput screening in 
industry; however these models do not accurately reflect the morphology of the BBB 
and lack expression of tight junction proteins expressed on cerebral endothelial cells 
(Hellinger et al., 2012).  To address this, a number of immortalised human in vitro 
models of the BBB have been established and characterised, including the hCMEC/D3 
cell line (Poller et al., 2008; Mkrtchyan et al., 2009; Eigenmann et al., 2013; Weksler et 
al., 2013).  The main advantage of the hCMEC/D3 cell line as a BBB model is that it 
maintains a stable phenotype which mimics the in vivo BBB phenotype and is easy to 
culture.  The hCMEC/D3 cell line is also well adapted to studying transport at the BBB.  
The expression of an array of human transporters in hCMEC/D3 cells was investigated 
in chapter 5 and found a similar expression profile to that previously reported (Carl et 
al., 2010), although a generally lower level of expression was observed for almost all 
transporters in my study in comparison to expression levels previously reported.  This 
may be due to differences in passage of cells used in the analysis and sensitivity of  
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Figure 7.1: Antiepileptic drug transport at the blood-brain barrier by the solute carrier family. A summary of the findings generated in this thesis 
and current knowledge from literature.  
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analytical methods employed, however it must be considered that the lack of replicate 
date generated in chapter 5 limits the study and the conclusions that can be drawn.  
Although data from this chapter gives thought-provoking insight into future 
investigation, any conclusions are speculative and findings would need to be reproduced 
to prove any observations of interest.  Of all SLC transporters, highest expression in 
hCMEC/D3cells was seen with nutrient transporter systems (chapter 5 and (Carl et al., 
2010), which is not surprising given the high metabolic demands of the brain.    
 
Research into the role of SLC transporters in the transport of AEDs is limited but MCT 
transporters have received specific attention and MCT1 in particular.  MCT1 was shown 
to be severely deficient on the endothelium of microvessels at the epileptogenic focus 
from tissue surgically resected in the treatment of individuals with drug resistant TLE 
(Lauritzen et al., 2011).  A similar deficiency was also observed on the endothelium of 
microvessels in three novel rat models of the TLE. These authors also observed a 
corresponding increase in astrocyte MCT1 expression (Lauritzen et al., 2012).  It is 
difficult to speculate why MCT1 might be deficient on the endothelium of microvessels 
in drug resistant TLE but one can reasonably suggest that a deficiency of MCT1 may 
contribute to drug resistance (Fischer et al., 2008). Monocarboxylates such as lactate, 
pyruvate and ketones are critical for normal brain function and rely on the MCT 
transport system to gain entry into the brain (Halestrap et al., 1999).  Although glucose 
is the brain’s main energy source, ketone bodies are important in energy storage in 
times of glycolytic restriction and may have direct anticonvulsant effects by enhancing 
GABAergic neurotransmission (Masino et al., 2012).  Furthermore, MCT1 has been 
implicated in the transport of VPA at the BBB (Utoguchi et al., 2000; Fischer et al., 
2008); therefore suggesting that VPA resistance in patients with TLE may be attributed 
to a loss of MCT1 in the epileptogenic focus. Despite VPA being more than 99% 
ionised at physiological pH and reasonably hydrophilic, it is known to readily penetrate 
the BBB (Löscher, 2002). It is therefore reasonable that VPA may enter the brain via a 
carrier mediated process.   
 
In chapter 2, I investigated transport of VPA in MCT1 transfected X. laevis oocytes, 
however no increase in VPA uptake was observed when compared to control.  Previous 
work suggesting VPA may be subject to MCT-mediated transport utilised cell models 
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which have inherent expression of other transport proteins (Utoguchi et al., 2000; 
Fischer et al., 2008) and it is therefore possible that another MCT is responsible for 
changes in VPA transport observed in these studies.  However, further investigation 
exposing hCMEC/D3 cells to VPA with and without a panel of MCT transport 
inhibitors (chapter 3) added additional weight to the conviction that VPA is not subject 
to transport by an MCT.   
 
This study is the first to investigate VPA transport by MCT1 in both a physiologically 
relevant in vitro model and an in vitro model in which MCT1 is exclusively 
overexpressed.  While the discrepancies in findings in studies that have investigated 
MCT transport of VPA are perplexing, it is important to note that many of those 
proposing transport of VPA by an MCT system were achieved using rodent cell models.  
We have learnt from the P-gp story the misconceptions of extrapolating between species 
and that transport of a drug by a rodent transporter does not necessarily mean the human 
orthologue will also transport the same drug.  All investigations to date carried out in 
human cell models has involved application of VPA, with and without MCT transport 
inhibitors, to cell lines such as Caco-2 cells (Fischer et al., 2008), BeWo cells (Utoguchi 
et al., 2000) and hCMEC/D3 cells (chapter 3), which express endogenous levels of 
MCT transporters but also inherently express other transporters.  The major limitation 
of such an investigational approach to the study of drug transport is that available 
inhibitors have overlapping specificities and lack selectivity.  Chemical transport 
inhibitors are notoriously promiscuous and typically inhibit transporters from several 
families, albeit with varying potency.  Therefore, although this kind of investigation can 
shed light on possible transporter systems involved in the penetration of a drug across 
biological membranes, it cannot categorically determine which transporter system is 
involved. 
 
Almost 15 years before the investigation of VPA transport by an MCT transporter 
system, VPA uptake was investigated in an in situ rat brain perfusion model, which 
showed that uptake could be inhibited in the presence of anion transport 
substrates/inhibitors (Adkinson et al., 1996).  The same investigators had previously 
investigated VPA transport in isolated rat brain endothelial cells and observed similar 
results (Naora et al., 1995). They went on to suggest that the observed inhibition may be 
due to uptake of VPA by rodent OAT3.  A number of prototypic monocarboxylate 
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inhibitors used in the investigation of VPA transport by the MCT system are also 
known to inhibit anion transport (Halestrap et al., 2004).  It is therefore possible to 
speculate that inhibition of VPA uptake observed in these studies may be due to 
inhibition of an anion transporter system.   
 
A number of OATs are thought to be expressed at the BBB and have been investigated 
in the pursuit of a transporter system for VPA (Sekine et al., 1997; Cihlar et al., 1999; 
Kusuhara et al., 1999; Ohtsuki et al., 2002; Eraly et al., 2003; Kikuchi et al., 2003; Mori 
et al., 2003; Bleasby et al., 2006; Terbach et al., 2011; Roth et al., 2012).  OAT1 and 
OAT3 are known to be involved in the disposition of a number of drugs and are thought 
to be expressed at the BBB in vivo (Sekine et al., 1997; Cihlar et al., 1999; Ohtsuki et 
al., 2002; Eraly et al., 2003; Kikuchi et al., 2003; Mori et al., 2003; Bleasby et al., 
2006).   As previously described (Carl et al., 2010) and replicated in chapter 5, the 
OATs of the SLC22 family are not expressed in hCMEC/D3 cells.  In an attempt to 
specifically determine if VPA transport is mediated by OAT1 and/or OAT3, stably 
transfected MDCK II cells overexpressing the OAT1 and OAT3 genes were generated 
(chapter 4).  Curiously, VPA uptake increased in MDCK II cells transfected with OAT1 
but decreased in MDCK II cells transfected with OAT3, suggesting a bidirectional 
transport of VPA that is mediated by the OAT transport system.  OAT1 and OAT3 
functionality in the kidney has received the most research interest to date, owing to the 
role of these transporters in the renal elimination of anions.  There is evidence to 
suggest that OAT1 and OAT3 function in synergy in the kidney (Chennavasin et al., 
1979), therefore it is plausible that this is also the case at the BBB.  Additionally, the 
gene encoding OAT1 (i.e.SLC22A6), is found paired with the gene encoding OAT3 
(i.e. SLC22A8) on chromosome 11q12.3, and such pairing may further indicate a 
potential partnership in both tissue distribution and transport function (Eraly et al., 
2003). In addition to showing here that VPA may be transported by OAT1 and OAT3, 
another transporter family has been implicated in the transport of VPA.  Cellular uptake 
of VPA was investigated in the Dictyostelium discoideum model and proposed to be 
carrier mediated and dependent on pH and a proton gradient (Terbach et al, 2011). VPA 
was also seen to compete with bicarbonate for uptake suggesting that a bicarbonate 
transporter may be involved.  Furthermore, the authors went on to identify a gene in 
Dictyostelium which is homologous to mammalian bicarbonate transporters of the 
SLC4 family and which they speculated to be SLC4A11 on the basis of sequence 
213 
 
identity (Terbach et al., 2011).  The ability of VPA to accumulate adequately in the 
brain despite its variable pharmacokinetics and moderately low log D (chapter 6) has 
prompted research groups to investigate and identify the carrier system involved; 
however despite much research, the mechanism by which VPA enters the brain still 
eludes us.  It is likely that transport at the BBB is to some extent mediated by the anion 
transporters OAT1 and OAT3 and possibly members of the SLC4 family. However, the 
relationship is likely to be more complex than can be explained by interaction with a 
single transporter.  VPA is known to show variable organ concentrations in vivo, which 
suggests that the mechanism by which VPA is transported across a particular membrane 
is organ-specific and that several transport systems may be implicated depending on the 
site of transport.   
 
It has been known for some time that GBP uptake into the brain is likely to involve the 
L-type amino acid transporter LAT-1 (Welty et al., 1993).  GBP is highly lipophilic at 
physiological pH but possesses several structural properties which limit its ability to 
passively permeate cellular membranes (chapter 6).  Uptake via the LAT-1 transporter 
is therefore believed to account for GBP reaching adequate concentrations in brain 
following a therapeutic dose.  Despite this and perhaps because of a lack of expression 
of LAT-1 in the gut (Prasad et al., 1999), GBP shows variable and dose dependent 
bioavailability thought to be the result of saturation of a low capacity transporter system 
(Gidal et al., 1998).  To combat this, XP13512, a novel gabapentin pro-drug was 
recently developed; it was designed to be absorbed through the gut by high capacity 
nutrient transporters, later confirmed to be MCT1 and the sodium dependent 
multivitamin transporter (SMAT) (Cundy et al., 2004). This drug has yet to reach the 
clinic and it is arguable whether it ever will, not least because investigation of AED 
transport in MCT1 transfected X. laevis oocytes (chapter 2) and hCMEC/D3 cells 
(chapter 3) would suggest that GBP is also subject to MCT1 mediated transport, 
potentially dispelling any benefit of XP13512. 
 
In addition to the substantial research efforts aimed at investigating P-gp transport of 
AEDs, research has also attempted to understand the role of transporter regulation, and 
that of P-gp in particular, and its implications in multidrug resistance in epilepsy.   
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There is existing evidence which supports changes in brain transporter expression in 
epilepsy (Sisodiya et al., 1999; Sisodiya et al., 2002; Aronica et al., 2003; Wen et al., 
2008; Ambroziak et al., 2010; Moermana et al., 2011).  However what is not clear and 
which remains disputed, is whether the difference in transporter expression is intrinsic 
or acquired.  That is to say, are the changes in BBB transporter expression due to the 
underlying pathology, the consequence of uncontrolled seizures, the result of chronic 
AED treatment, or a combination of all of these factors (Aronica et al., 2012)? 
Supporters of an intrinsic mechanism argue that increased expression of transporters 
such as P-gp is present before the onset of seizures and the initiation of AED treatment 
and is therefore a result of disease pathophysiology.  The arguments for an intrinsic 
mechanism are opposed by the ability of various AEDs to induce the expression of a 
number of transporters (Wen et al., 2008; Leroy et al., 2011; Moermana et al., 2011).   
   
P-gp has been shown to be induced in several in vitro investigations.  Firstly, chronic 
treatment with PHT, PB and CBZ was shown to decrease levels of the P-gp substrate 
rhodamine 123 in rat brain suggesting induced function and/or expression of P-gp 
following treatment with the respective AEDs (Wen et al., 2008).  Treatment with 
AEDs, in this case PHT, TPM and LEV, has also been shown to decrease brain 
concentrations of the P-gp substrate desmethyl-loperamide in the mouse, again 
suggesting induced expression of P-gp (Moermana et al., 2011).  Interestingly, in the 
latter of these investigations, induction of P-gp was seen to be concentration dependent, 
whereby therapeutic concentrations of PHT, TPM and LEV were reported to induce P-
gp, while supra-therapeutic concentrations did not.  In contrast, my investigation in 
hCMEC/D3 cells showed a decrease in expression of P-gp following treatment with 
VPA, LTG, GBP and TPM for 48 hours. In vitro studies, including findings from 
chapter 5, have largely reported that treatment with AEDs does not alter expression of 
P-gp (Aronica et al., 2012). However, there are several discrepancies between in vitro 
and in vivo findings (Wen et al., 2008; Moermana et al., 2011) that could account for 
the conflicting findings reported.  In vivo investigations have typically involved treated 
animals with AEDs for much longer time periods than those employed in in vitro 
studies, which could reasonably explain differences in the extent of induction observed. 
However, it is unlikely that this can fully explain why induction is observed in vivo but 
not in vitro.  In addition to the capacity to induce the expression of P-gp, it has been 
shown that some drugs can also activate P-gp; i.e. induce the transport of a substrate 
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without induction at the gene level (Sterz et al., 2009).  As the majority of in vivo 
investigations have drawn conclusions from the observation that P-gp substrate 
concentrations are decreased in the brain following AED treatment, it is possible that 
the decreased substrate concentration observed in these studies is the result of activation 
of P-gp by AEDs rather than induction of its expression.   
 
Several studies have investigated changes in the expression of influx transporters of the 
SLC family in both animal models of epilepsy and human epilepsy tissue.  As discussed 
previously, MCT1 has been shown to be deficient on the endothelium of microvessels at 
the epileptogenic focus in tissue resected in the treatment of drug resistant TLE 
(Lauritzen et al., 2011). The same authors reported a similar deficiency in MCT1 on the 
endothelium of microvessels in 3 novel rat models of TLE.  Recently, and in contrast to 
the reduced expression of MCT1 observed by Lauritzen and colleagues (2011), MCT1 
has been shown to be upregulated in the lithium-pilocarpine model of TLE (Leroy et al., 
2011).  Conflicting findings observed in these studies may be the result of differing 
methodologies, with one report investigating whole brain expression and the other 
studying microvessel expression only.  Interestingly, in addition to microvessel 
expression analysis, Lauritzen and colleagues (2012) also analysed astrocyte expression 
of MCT1 in rat models of TLE and reported an increase (Lauritzen et al., 2012).  Thus, 
the increase in overall expression of MCT1 observed by Leroy and colleagues (2011) 
may represent the cumulative change in expression of MCT1 in TLE, assuming that 
changes in astrocytic expression outweigh those observed at brain microvessels.  
Furthermore, as described in chapter 5, MCT1 expression in hCMEC/D3 cells was 
induced following treatment with CBZ and VPA, while VPA also increased MCT2 
expression (chapter 5).  These findings are intriguing and imply that changes in brain 
expression of MCT transport systems in people with epilepsy may be due to a 
combination of underlying disease pathology, uncontrolled seizures and chronic AED 
treatment. 
 
The ability of a drug to passively cross the BBB or to require carrier mediated brain 
uptake has been shown to be largely dependent on the octanol/water coefficient, i.e. its 
lipophilicity in addition to a number of physiochemical properties (Waterbeemd et al., 
1998; Pajouhesh et al., 2005).  The properties of AEDs that are known to influence their 
BBB permeability were investigated in chapter 6. A number of AEDs, including LTG, 
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GBP and TPM, possessed unfavourable properties and are thus unlikely to passively 
cross the BBB.  Despite this, LTG, GBP and TPM reach adequate brain concentrations 
and may therefore exploit a carrier mediated uptake system.  Indeed, LTG has been 
shown to be transported OCT1 (Dickens et al., 2012), in addition to weak transport by 
OAT1 and OAT3 (chapter 4). GBP is known to be transported by LAT-1 (Welty et al., 
1993; Dickens et al., 2012) and MCT1 (chapters 2 and 3), while TPM has been shown 
to be transported by P-gp (Sills et al., 2002) and is suggested to utilize PEPT1, OCTN1 
or OCTN2 or a combination of all three systems at the level of absorption from the gut 
(Watanabe et al., 2002).      
 
A number of AEDs achieve adequate brain accumulation despite unfavourable 
physiochemical properties and may thus be substrates for SLC transporters.  It is 
increasingly unlikely that changes in expression of transporters at the BBB prevent 
AEDs from reaching their intended targets in the brain and thereby causing drug 
resistance.  The scientific plausibility of the drug transporter hypothesis relies on the 
fundamental premise that multiple AEDs are substrates for one or more transporter 
systems at the BBB.  Despite almost two decades of research, it still remains largely 
unclear whether AEDs are transported by P-gp, far less any other ABC or SLC 
transporter. Individual differences in transporter expression at the BBB may be 
responsible for variability in brain concentrations of AEDs that rely on carrier mediated 
systems but this is unlikely to be clinically significant.  
 
Future work investigating the transporter hypothesis is unlikely to be of value, however 
the potential implication of transporter science in AED design to improve 
pharmacokinetics of current and future AEDs merits further attention.  
 
To overcome candidate drug attrition due to poor oral bioavailability the pharmaceutical 
industry have employed strategies to develop prodrugs which have been structurally 
designed to be recognised by high capacity uptake transporters expressed at the 
gastrointestinal epithelium (Majumdar et al., 2004).  Once across the gastrointestinal 
barrier the prodrugs are transformed chemically or enzymatically to the active drug.  
There has been some success using this strategy, for example in the design of prodrugs 
which are recognised by peptide (Balimane et al., 1998) or monocarboxylic acid 
transporters (Cundy et al., 2004) expressed at the gastrointestinal tract.  More recently 
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exploitation of transporters for tissue-specific delivery of drugs has emerged as a 
promising strategy for overcoming efficacy and toxicity issues (Zhou et al., 2015).  For 
example activators of glucokinase represent promising targets in the treatment of type 2 
diabetes (Leighton et al., 2005).  However their use is limited by concerns that systemic 
distribution will result in over activation of glucokinase expressed in the pancreas, 
eliciting risk of hypoglycaemia and increased stress on β-cells (Bebernitz et al., 2009).  
To overcome this, hepato-selective glucokinase activators have been designed to be 
recognised by the liver OATP transporters OATP1B1, OATP1B3 and OATP2B1, 
which are not expressed in pancreas, therefore enhancing liver uptake and minimising 
pancreatic exposure (Pfefferkorn et al., 2012). 
 
To date transporter targeted delivery across the BBB has not been actively pursued, 
potentially due to the lack of detailed characterisation of BBB transporters when 
compared to organs such as the intestine, kidney and liver.  However it is plausible that 
a similar strategy could be employed in the future to target delivery of CNS acting drugs 
such as AEDs to the brain.  Therefore improving brain accumulation and limiting 
exposure to other tissues, albeit providing the targeted transporter is not ubiquitously 
expressed.   
 
Recently an orphan transporter of the major facilitator family with unknown function; 
MFSD2A, has been shown to be specifically and constitutively expressed at the BBB 
(Ben-Zvi et al., 2014; Nguyen et al., 2014).  Interestingly MFSD2A has been 
demonstrated to maintain two functions at the BBB. To provide the major transport 
route of the essential omega-3 fatty acid docosahexaenoic into the brain (Nguyen et al., 
2014) and to regulate transcytosis in cerebral endothelial cells (Ben-Zvi et al., 2014).  
The later of the two functions has been demonstrated to be critical in the maintenance of 
the BBB.  Knock-out mice lacking the MFSD2A gene develop a ‘leaky’ BBB, 
permeable to large molecules, attributed to increased transcytosis opposed to tight-
junction disruption (Ben-Zvi et al., 2014).  In addition to its constitutive expression at 
the functional BBB, MFSD2A has been demonstrated to be expressed at various stages 
in mouse embryogenesis suggesting MFSD2A plays a role in the formation of the BBB 
(Ben-Zvi et al., 2014).   
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The identification of MFSD2A at the BBB represents an exciting opportunity for both 
BBB restoration and targeted CNS delivery.  This is the first transporter selectively 
expressed at the BBB and therefore could be exploited to specifically target delivery of 
new antiepileptic drugs (or indeed existing AEDs) to the brain.  Although extensive 
further work would be necessary to fully understand the physiological role of this 
membrane transporter and characterise the essential structural features for substrate 
binding, AEDs could be developed to be recognised by MFSD2A and actively 
transported across the BBB, therefore selectively enhancing exposure to the brain.  
Alternatively MFSD2A could be pharmacologically suppressed to enhance transcytosis-
mediated drug delivery to the brain, although this strategy is likely to be met with 
adverse effects.    
 
Transporter science may not have provided us with an adequate explanation for why 
some individuals with epilepsy experience pharmacoresistant seizures but it is 
nonetheless important to understand the role of carrier mediated systems in the 
disposition of AEDs and the potential of transporter-targeted delivery as a strategy to 
improve future AED development. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
219 
 
8. Bibliography 
 
Abbott JN (2013). Blood-brain barrier structure and function and the challenges for 
CNS drug delivery. Journal of Inherited Metabolism Disease 36(3): 437-449. 
 
Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ (2010). Structure 
and function of the blood-brain barrier. Neurobiology of Disease 37(1): 13-25. 
 
Abbott NJ, Romero IA (1996). Transporting theraputics across the blood-brain barrier. 
In: Molecular Medicine Today, pp 106-113: Elsevier Science LTD. 
 
Adachi T, Nakagawa H, Chung I, Hagiya Y, Kazuyuki Hoshijima1, Noguchi N, et al. 
(2007). Nrf2-dependent and -independent induction of ABC transporters ABCC1, 
ABCC2, and ABCG2 in HepG2 cells under oxidative stress. Journal of experimental 
Theraputics and Oncology 6: 335-348. 
 
Adkinson KDK, Shen DD (1996). Uptake of Valproic Acid into Rat Brain Is Mediated 
by a Medium-Chain Fatty Acid Transporter. Pharmacology and Experimental 
Theraputics 276: 1189-1200. 
 
Ahn S-Y, Eraly SA, Tsigelny I, Nigam SK (2009). Interaction of Organic Cations with 
Organic Anion Transporters. Journal of Biological Chemistry 284(45): 31422-31430. 
 
Anari MR, Burton RW, Gopaul S (2000). Metabolic profiling of valproic acid by 
cDNA-expressed human cytochrome P450 enzymes using negative-ion chemical 
ionisation gas chromatography-mass spectrometry. Journal of Chromatography B: 
Biomedical Sciences and Applications 742: 217-227. 
 
Ander JB-S, Pfeiffer SE, Fuller SD, Simons K (1984). Development of cell surface 
polarity in the epithelial Madin-Darby canine kidney (MDCK) cell line. The EMBO 
Journal 3(11): 2687-2694. 
 
Anhut H, Ashman P, Feuerstein TJ, Sauermann W, Saunders M, Schmidt B (1994). 
Gabapentin (Neurontin) as add on therapy in patients with partial seizures: a double-
blind, placebo-controlled study. Epilepsia 35: 795-801. 
 
Anonymous (1988). Sodium valproate. Lancet 2(8622): 1229-1231. 
 
Anonymous (2003). The History and Stigma of Epilepsy. Epilepsia 44(6): 12-14. 
 
Anzai N, Kanai Y, Endou H (2006). Organic anion transporter family: Current 
knowledge. Journal of Pharmacological Sciences 100(5): 411-426. 
 
Aronica E, Gorter JA, Jansen GH, van Veelen CWM, van Rijen PC, Leenstra S, et al. 
(2003). Expression and cellular distribution of multidrug transporter proteins in two 
major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal 
tumors. Neuroscience 118: 417-429. 
 
Aronica E, Sisodiya SM, Gorter JA (2012). Cerebral expression of drug transporters in 
epilepsy. Advanced Drug Delivery Reviews 64: 919-929. 
220 
 
 
Aslamkhan AG, Han Y-H, Yang X-P, Zalups RK, Pritchard JB (2003). Human Renal 
Organic Anion Transporter 1-Dependent Uptake and Toxicity of Mercuric-Thiol 
Conjugates in Madin-Darby Canine Kidney Cells. Molecular Pharmacology 63(2): 
590–596. 
 
Badagnani I, Castro RA, Taylor TR, Brett CM, Huang CC, Stryke D, et al. (2006). 
Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its 
genetic variants. Journal of Pharmacology and Experimental Therapeutics 318(2): 521-
529. 
 
Balimane PV, Tamai I, Guo A, Nakanishi T, Kitada H, et al. (1998). Direct evidence for 
Peptide Transporter (PepT1)-mediated Uptake of a Nonpeptide Prodrug, Valacyclovir. 
Biochemical and Biophysical Research Communications 250: 246-251.  
 
Bankstahl J, Loescher W (2008). Resistance to antiepileptic drugs and expression of P-
glycoprotein in two rat models of status epilepticus. Epilepsy Research 82: 70-85. 
 
Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, et al. (2009). Investigation 
of Functionally Liver Selective Glucokinase Activators for the Treatment of Type 2 
Diabetes. Journal of Medicinal Chemistry 52 (19): 6142–6152. 
 
Benarroch EE (2012). Blood-brain barrier: Recent developments and clinical 
correlations. Neurology 78: 1268-1276. 
 
Ben-Zvi A, Lacoste B, Kur E, Andreone BJ, Mayshar Y (2014). MFSD2A is critical for 
the formation and function of the blood-brain barrier. Nature 509: 507-511.   
 
Bialer M, White HS (2010). Proposed mechanisms of action of currently available 
AEDs at excitatory and inhibitory synapses. Nature Reviews Drug Discovery 9: 68-82. 
 
Bleasby K, Castle JC, Roberts CJ, Cheng C, Bailey WJ, Sina JF, et al. (2006). 
Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical 
species: A resource for investigations into drug disposition. Xenobiotica 36(10-11): 
963–988. 
 
Blom S (1962). Trigeminal neuralgia: its treatment with a new anticonvulsant drug (G-
32883). Lancet 1: 829-840. 
 
Booth L, Thompson G (2010). Epilepsy statistics, Statistics SaG (ed): House of 
Commons Library. 
 
Borst P, Evers R, Kool M, Wijnholds J (2000). A Family of Drug Transporters: the 
Multidrug Resistance-Associated Proteins. Journal of the National Cancer Institute 
92(16): 1295-1302. 
 
Bourgeois BFD (2000). Pharmacokinetics and Pharmacodynamics of Topiramate. 
Journal of Child Neurology 15(supplement 1): 27-30. 
 
221 
 
Brandt C, Bethmann K, Gastens AM, Löscher W (2006). The multidrug transporter 
hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal 
lobe epilepsy. Neurobiology of Disease 24(1): 202-211. 
 
Braun D, Kim TD, Coutre PL, Köhrle J, Hershman JM, Schweizer U (2011). Tyrosine 
kinase inhibitors noncompetitively inhibit MCT8 mediated Iodothyronine transport The 
Journal of Clinical Endocrinology and Metabolism 97(1-6). 
 
Brodie MJ (1992). Drug interactions in epilepsy. Epilepsia 33(Supplement 1): 13-22. 
 
Brodie MJ (2010). Antiepileptic drug therapy the story so far. Seizure 19: 650-655. 
 
Brodie MJ, Dichter MA (1996a). Antiepileptic Drugs. New England Journal of 
Medicine 334(7). 
 
Brodie MJ, Dichter MA (1996b). New Antiepileptic drugs. New England Journal of 
Medicine 334(24): 1583-1590. 
 
Bröer S (2014). The SLC38 family of sodium–amino acid co-transporters. European 
Journal of Physiology 466(1): 155-172  
 
Burckhardt G (2012). Drug transport by Organic Anion Transporters (OATs). 
Pharmacology and Therapeutics 136: 106-130. 
 
Burckhardt G, Burckhardt BC (2011). In Vitro and In Vivo Evidence of the Importance 
of Organic Anion Transporters (OATs) in Drug Therapy. In: Fromm MF, Kim RB 
(eds). Handbook of Experimental Pharmacology, edn, Vol. 201. Berlin: Springer-
Verlag. p^pp 29-104. 
 
Byrne S, Kearns J, Carolan R, McMenamin J, Klepper J, Webb D (2011). Refractory 
absence epilepsy associated with GLUT-1 deficiency syndrome. Epilepsia 52(5): 1021-
1024. 
 
Cardoso FL, Brites D, Brito MA (2010). Looking at the blood-brain barrier: Molecular 
anatomy and possible investigation approaches. Brain Research Reviews 64: 328-363. 
 
Carl SM, Lindley DJ, Couraud PO, Weksler BB, Romero I, Mowery SA, et al. (2010). 
ABC and SLC transporter expression and pot substrate chracterization across the human 
hCMEC/D3 blood-brain barrier cell line. Molecular Pharmaceutics 7(4): 1057–1068. 
 
Cerveny L, Pavek P, Malakova J, Staud F, Fendric Z (2006). Lack of Interactions 
between Breast Cancer Resistance Protein (BCRP/ABCG2) and Selected Antiepileptic 
Agents. Epilepsia 47(3): 461-468. 
 
Cha SH, Sekine T, Fukushima J-I, Kanai Y, Kobayashi Y, Goya T, et al. (2001). 
Identification and Characterization of Human Organic Anion Transporter 3 Expressing 
Predominantly in the Kidney. Molecular Pharmacology 59: 1277–1286. 
 
Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, et al. (2000). Molecular 
cloning and characterization of multispecific organic anion transporter 4 expressed in 
the placenta. Journal of Biological Chemistry 275(6): 4507-4512. 
222 
 
Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ et al (2005). Differential 
interaction of 3-hydroxy-3-methylglutaryl-coA reductase inhibitors with ABCB1, 
ABCC2, and OATP1B1. The American Society for Pharmacology and Experimental 
Therapeutics 33(4): 537-546.    
 
Chennavasin P, Seiwell R, Brater DC, Liang WMM (1979). Pharmacodynamic analysis 
of the furosemide-probenecid interaction in man. Kidney International 16: 187-195. 
 
Choi MK, Song IS (2008). Organic cation transporters and their pharmacokinetic and 
pharmacodynamic consequences. Drug Metabolism and Pharmacokinetics 23(4): 243-
253. 
 
Chu X-Y, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, et al. (2007). Transport of 
the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion Transporter 3, 
Organic Anion Transporting Polypeptide 4C1, and Multidrug Resistance P-
glycoprotein. Pharmacology and Experimental Theraputics 321(2): 673–683. 
 
Ciarimboli G (2008). Organic cation transporters. Xenobiotica 38(7-8): 936-971. 
 
Cihlar T, Lin DC, Pritchard JB, Fuller MD, Mendel DB, Sweet DH (1999). The 
Antiviral Nucleotide Analogs Cidofovir and Adefovir Are Novel Substrates for Human 
and Rat Renal Organic Anion Transporter 1. Molecular Pharmacology 56: 570-580. 
 
Cohen AF, Land GS, Breimer DD (1987). Lamotrigine, a new anticonvulsant: 
pharmacokinetics in normal humans. Clinical Pharmacology and Therapeutics 42: 535-
541. 
 
Conseil G, Baudichon-Cortay H, Dayan G, Jault JM, Barron D, Di Pietro A (1998). 
Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP and 
steroid binding sites on mouse P-glycoprotein. PNAS 95: 9831-9836.   
 
Corpe CP, Eck P, Wang J, Al-Hasani H, Levine M (2013). Intestinal Dehydroascorbic 
Acid (DHA) Transport Mediated by the Facilitative Sugar Transporters, GLUT2 and 
GLUT8. The Journal of Biological Chemistry 288(13): 9092–9101. 
 
Cropp CD, Komori T, Shima JE, Urban TJ, Sook WY, More SS, et al. (2008). Organic 
anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Molecular 
Pharmacology 73(4): 1151-1158. 
 
Cross JH, Riney CJ (2009). Topiramate. In: The Treatment of Epilepsy, Shorvon S, 
Perucca E, Engel J (eds), 3 edn, pp 673-683: Blackwell Publishing LTD. 
 
Crowe A, Teoh Y-K (2006). Limited P-glycoprotein mediated efflux for anti-epileptic 
drugs. Journal of Drug Targetting 14(5): 291-300. 
 
Cundy KC, Branch R, Chernov-Rogan T, Dias T, Estrada T, Hold K, et al. (2004). 
XP13512, A Novel Gabapentin Prodrug: I. Design, Synthesis, Enzymatic Conversion to 
Gabapentin, and Transport by Intestinal Solute Transporters. The Journal of 
Pharmacology and Experimental Theraputics 311(1): 315-323. 
 
223 
 
Dallas S, Miller DS, Bendayan R (2006). Multidrug resistance-associated proteins: 
Expression and function in the central nervous system. Pharmacological Reviews 58(2): 
140-161. 
 
Dauchy S, Miller F, Couraud P-O, Weaver RJ, Weksler B, Romero I-A, et al. (2009). 
Expression and transcriptional regulation of ABC transporters and cytochromes P450 in 
hCMEC/D3 human cerebral microvascular endothelial cells. Biochemical 
Pharmacology 77: 897-909. 
 
de Lange ECM (2004). Potential role of ABC transporters as a detoxification system at 
the blood-CSF barrier. Advanced Drug Delivery Reviews 56: 1793-1809. 
 
Dickens D, Owen A, Alfirevica A, Giannoudis A, Davies A, Weksler B, et al. (2012). 
Lamotrigine is a substrate for OCT1 in brain endothelial cells. Biochemical 
Pharmacology 83(6): 805-814. 
 
Dickens D, Yusof SR, Abbott NJ, Weksler B, Romero IA, Couraud P-O, et al. (2013). 
A Multi-System Approach Assessing the Interaction of Anticonvulsants with P-gp. 
PLOS One 8(5): 1-10. 
 
Dimmer K-S, Friedrich B, Lang F, Deitmer JW, Bröer S (2000). The low-affinity 
monocarboxylate transporter MCT4 is adapted to the export of lactate in highly 
glycolytic cells. Biochemical Journal 350: 219-227. 
 
Dombrowski SM, Desai SY, Marroni M, Cucullo L, Goodrich K, Bingaman W, et al. 
(2001). Overexpression of multiple drug resistance genes in endothelial cells from 
patients with refractory epilepsy. Epilepsia 42: 1501-1506. 
 
Draper MP, Martell RL, Levy SB (1997). Indomethacin-mediated reversal of multidrug 
resistance and drug efflux in human and murine cell lines overexpressing MRP, but not 
P-glycoprotein. British Joural of Cancer 75(6): 810–815.  
 
Dreifuss FE, Bancaud J, Henriksen O (1981). Proposal for revised clinical and 
electroencephalographic classification of epileptic seizures. Epilepsia 22(4): 489-501. 
 
Dresser MJ, Leabman MK, Giacomini KM (2000). Transporters Involved in the 
Elimination of Drugs in the Kidney: Organic Anion Transporters and Organic Cation 
Transporters. Journal of Pharmaceutical Sciences 90(4): 397-421. 
 
Eadie MJ (2009). Phenytoin. In: Shorvon S, Perucca E, Engel J (eds). The Treatment of 
Epilepsy, edn: Blackwell Publishing LTD. p^pp 605-618. 
 
Eechoute K, Franke RM, Loos WJ, Scherkenbach LA, Boere I, Verweij J, et al. 
(2011a). Environmental and genetic factors affecting transport of imatinib by 
OATP1A2. Clinical Pharmacology and Therapeutics 89(6): 816-820. 
 
Eechoute K, Sparreboom A, Burger H, Franke RM, Schiavon G, Verweij J, et al. 
(2011b). Drug transporters and imatinib treatment: Implications for clinical practice. 
Clinical Cancer Research 17(3): 406-415. 
 
224 
 
Eigenmann DE, Xue G, Kim KS, Moses AV, Hamburger M, Oufir M (2013). 
Comparative study of 4 immortalized human brain capillary endothelial cell lines, 
HCMEC/D3, HBMEC, TY10 and BB19, and optimization of culture conditions, for an 
in vitro blood-brain barrier model for drug permeability studies. Fluids and Barriers of 
the CNS 10(33). 
 
Ekberg H, Qi Z, Pahlman C, Veress B, Bundick RV, Craggs RI, et al. (2007). The 
Specific Monocarboxylate Transporter-1 (MCT-1) Inhibitor, AR-C117977, Induces 
Donor-Specific Suppression, Reducing Acute and Chronic Allograft Rejection in the 
Rat. Transplantation 84(9): 1191-1199. 
 
Elger CE, Schmidt D (2008). Modern management of epilepsy: A practical approach. 
Epilepsy & Behaviour 12(4): 501-539 
 
Elmorsi YM, El-Haggar SM, Ibrahim OM, Mabrouk MM (2013). Effect of ketoprofen 
and indomethacin on methotrexate pharmacokinetics in mice plasma and tumor tissues. 
European Journal Of Drug Metabolism And Pharmacokinetics 38: 27–32. 
 
Enerson BE, Drewes LR (2003). Molecular Features, Regulation, and Function of 
Monocarboxylate Transporters: Implications for Drug Delivery. Journal of 
Pharmaceutical Sciences 92(8): 1531-1544. 
 
Enomoto A, Takeda M, Shimoda M, Narikawa S, Kobayashi Y, Kobayashi Y, et al. 
(2002). Interaction of Human Organic Anion Transporters 2 and 4 with Organic Anion 
Transport Inhibitors. Pharmacology and Experimental Theraputics 301: 797–802. 
 
Eraly SA, Hamilton BA, Nigam SK (2003). Organic anion and cation transporters occur 
in pairs of similar and similarly expressed genes. Biochemical and Biophysical 
Research Communications 300: 333–342. 
 
Estudante M, Morais JG, Soveral G, Benet LZ (2013). Intestinal drug transporters: An 
overview. Advanced Drug Delivery Reviews 65: 1340-1356. 
 
Feldmann M, Asselin M-C, Liu J, Wang S, McMahon A, Anton-Rodriguez J, et al. 
(2013). P-glycoprotein expression and function in patients with temporal lobe epilepsy: 
a case-control study. Lancet Neurology 12: 777-785. 
 
Fischer W, Praetor K, Metzner L, Neubert RHH, Brandsch M (2008). Transport of 
valproate at intestinal epithelial (Caco-2) and brain endothelial (RBE4) cells: 
Mechanism and substrate specificity. European Journal of Pharmaceutics and 
Biopharmaceutics 70(2): 486-492. 
 
Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P, et al. (2005). 
Epileptic Seizures and Epilepsy: Definitions Proposed by the International League 
Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 
46(4): 470–472. 
 
Forman SA, Verkman AS, Dix JA, Solomon AK (1982). Interaction of phloretin with 
the anion transport protein of the red blood cell membrane. Biochimica et Biophysica 
Acta (BBA) - Biomembranes 689(3): 531-538.   
 
225 
 
    
Fotiadisa D, Kanaib Y, Palacínc M (2013). The SLC3 and SLC7 families of amino acid 
transporters. Molecular Aspects of Medicine 34(2-3): 139-158. 
 
Franke D, Diletti E, Hoffmann C (1995). Relative bioavailability of different valproic 
acid formulations. International Journal of Clinical Pharmacology and Therapeutics 
33: 653-657. 
 
French JA, Tonner F (2009). Levetiracetam. In: The Treatment of Epilepsy, Shorvon S, 
Perucca E, Engel J (eds), 3 edn: Blackwell Publishing LTD. 
 
Friesema ECH, Ganguly S, Abdalla A, Manning Fox JE, Halestrap AP, Visser TJ 
(2003). Identification of monocarboxylate transporter 8 as a specific thyroid hormone 
transporter. Journal of Biological Chemistry 278(41): 40128-40135. 
 
Fujiwara K, Adachi H, Nishio T, Unno M, Tokui T, Okabe M, et al. (2001). 
Identification of thyroid hormone transporters in humans: Different molecules are 
involved in a tissue-specific manner. Endocrinology 142(5): 2005-2012. 
 
Gallegos TF, Martovetsky G, Kouznetsova V, Bush KT, Nigam SK (2012). Organic 
Anion and Cation SLC22 ‘‘Drug’’ Transporter (Oat1, Oat3, and Oct1) Regulation 
during Development and Maturation of the Kidney Proximal Tubule. PLOS One 7(7): 
1-13. 
 
Garcia CK, Goldstein JL, Pathak RK, Anderson RGW, Brown MS (1994). Molecular 
characterization of a membrane transporter for lactate, pyruvate, and other 
monocarboxylates: Further study of the effect implications for the Cori cycle. Cell 76: 
865-873. 
 
Geier EG, Chen EC, Webb A, Papp AC, Yee SW, Sadee W, et al. (2013). Profiling 
Solute Carrier Transporters in the Human Blood-Brain Barrier. Clinical Pharmacology 
and Therapeutics 94(6): 636-639. 
 
Genton P, Vleymen BV (2000). Piracetam and levetiracetam: close structural 
similarities but different pharmacological and clinical profiles. Epileptic Disorders 2: 
99-105. 
 
Gerhart DZ, Enerson BE, O Y Zhdankina, Leino RL, Drewes LR (1997). Expression of 
monocarboxylate transporter MCT1 by brain endothelium and glia in adult and suckling 
rats. american Journal of Physiology - Endocrinology and Metabolism 273(1): 207-213. 
 
Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KLR, Chu X, et al. 
(2010). Membrane transporters in drug development. Nature Reviews Drug Discovery 
9(3): 215-236. 
 
UK Gabapentin Study Group (1990). Gabapentin in partial epilepsy. Lancet 335: 1114-
1117. 
 
Guile SD, Bantick JR, Cheshire DR, Cooper ME, Davis AM, Donald DK, et al. (2006). 
Potent blockers of the monocarboxylate transporter MCT1: Novel immunomodulatory 
compounds. Bioorganic & Medicinal Chemistry Letters 16: 2260–2265. 
226 
 
 
Hagenbuch B, Gui C (2008). Xenobiotic transporters of the human organic anion 
transporting polypeptides (OATP) family. Xenobiotica 38(7-8): 778-801. 
 
Hagenbuch B, Meier PJ (2003). The superfamily of organic anion transporting 
polypeptides. Biochimica et Biophysica Acta - Biomembranes 1609(1): 1-18. 
 
Hagenbuch B, Meier PJ (2004). Organic anion transporting polypeptides of the 
OATP/SLC21 family: Phylogenetic classification as OATP/SLCO super-family, new 
nomenclature and molecular/functional properties. Pflugers Archiv European Journal of 
Physiology 447(5): 653-665. 
 
Hagos Y, Bahn A, Vormfelde SV, Brockmöller J, Burckhardt G (2007). Torasemide 
Transport by Organic Anion Transporters Contributes to Hyperuricemia. Journal of the 
American Society of Nephrology 18: 3101–3109. 
 
Hagos Y, Wolff NA (2010). Assessment of the Role of Renal Organic Anion 
Transporters in Drug-Induced Nephrotoxicity. Toxins 2: 2055-2082. 
 
Halestrap AP (2013). The SLC16 gene family - Structure, role and regulation in health 
and disease. Molecular Aspects of Medicine 34: 337-349. 
 
Halestrap AP, Meredith D (2004). The SLC16 gene family -from monocarboxylate 
trasnporters (MCTs) to aromatic amino acid transporters and beyond. European Journal 
of Physiology 447: 619-628. 
 
Halestrap AP, Poole RC, Cranmer SL (1990). Mechanisms and regulation of lactate, 
pyruvate and ketone body transport across the plasma membrane of mammalian cells 
and their metabolic consequences. Biochemical Society Transactions 18(6): 1132-1135. 
 
Halestrap AP, Price NT (1999). The proton-linked monocarboxylate transporter (MCT) 
family: structure, function and regulation. Biochemical Journal 343: 281-299. 
 
Hansch C, Leo A (1979). Substituent constant for correlation analysis in chemistry and 
biology. edn. Wiley: New York. 
 
Hartkoorn RC, Kwan WS, Shallcross V, Chaikan A, Liptrott N, Egan D, et al. (2010). 
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and 
lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. 
Pharmacogenetics and Genomics 20(2): 112-120. 
 
Hauptmann A (1912). Luminal bei Epilepsie. Munch Med Wochenschr 59: 1907-1909. 
 
He L, Vasiliou K, Nebert DW (2009). Analysis and update of the human solute carrier 
(SLC) gene superfamily. Human genomics 3(2): 195-206. 
 
Hertz L, Dienel GA (2004). Lactate Transport and Transporters: General Principles and 
Functional Roles in Brain Cells. Journal of Neuroscience Research 79: 11-18. 
 
Heuer H, Visser TJ (2009). Minireview: Pathophysiological Importance of Thyroid 
Hormone Transporters. Endocrinology 150(3): 1078-1083. 
227 
 
 
Hirano M, Maeda K, Shitara Y, Sugiyama Y (2004). Contribution of OATP2 
(OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. 
The Journal of Pharmacology and Experimental Therapeutics 311: 139-146.   
 
Hirano M, Maeda K, Shitara Y, Sugiyama Y (2006). Drug-drug interaction between 
pitavastatin and various drugs via oatp1b1. Drug Metabolism and Disposition 34: 1229-
1236.  
 
Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ et al. (2006). Drug and 
bile acid transporters in rosuvastatin hepatic uptake: function, expression, and 
pharmacogenetics. Gastroenterology 130: 1793-1806.     
  
Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, Bruijn EAd, et al. (2008). Interaction 
of Imatinib with Human Organic Ion Carriers. Clinical Cancer Research 14: 3141-
3148. 
 
Huber RD, Gao B, Pfändler MAS, Zhang-Fu W, Leuthold S, Hagenbuch B, et al. 
(2007). Characterization of two splice variants of human organic anion transporting 
polypeptide 3A1 isolated from human brain. American Journal of Physiology - Cell 
Physiology 292(2): 795-806. 
 
Inui K, Masuda S, Saito H (2000). Cellular and molecular aspects of drug transport in 
the kidney. Kidney International 58: 944–958.  
 
Ishikawa T (1992). The ATP-dependent glutathione S-conjugate export pump. Trends 
in Biochemical Sciences 17: 463-468. 
 
Joost H-G, Thorens B (2001). The extended GLUT-family of sugar/polyol transport 
facilitators: nomenclature, sequence characteristics, and potential function of its novel 
members. Molecular Membrane Biology 18: 247-256. 
 
Juhász V, Beéry E, Nagy Z, Bui A, Molnár É, Zolnerciks JK, et al. (2013). 
Chlorothiazide is a Substrate for the Human Uptake Transporters OAT1 and OAT3. 
Journal of Pharmaceutical Sciences 102(5): 1683-1687. 
 
Juliano R, Ling V (1976). A surface glycoprotein modulating drug permeability in 
chinese hamster ovary cell mutants. Biochimica et Biophysica Acta (BBA) 455: 152-
162. 
 
Kalliokoski A, Niemi M (2009). Impact of OATP transporters on pharmacokinetics. 
British Journal of Pharmacology 158(3): 693-705. 
 
Kamiie J, Ohtsuki S, Iwase R, Ohmine K, Katsukura Y, Yanai K, et al. (2008). 
Quantitative atlas of membrane transporter proteins: development and application of a 
highly sensitive simultaneous LC/MS/MS method combined with novel in-silico 
peptide selection criteria. Pharmaceutical Research 25(6): 1469-1483. 
 
Kanner AM, Frey M (2000). Adding valproate to lamotrigine: a study of their 
pharmacokinetic interaction. Neurology 55: 588-591. 
 
228 
 
Karasinska JM, Haan Wd, Franciosi S, Ruddle P, Fan J, Kruit JK, et al. (2013). ABCA1 
influences neuroinflammation and neuronal death. Neurobiology of Disease 54: 445–
455. 
 
Katano K, Kondo A, Safaei R, A Holzer, Samimi G, Mishima M, et al. (2002). 
Acquisition of resistance to cisplatin is accompanied by changes in the cellular 
pharmacology of copper. Cancer Research 62(22): 6559–6565. 
 
Kikuchi R, Kusuhara H, Sugiyama D, Sugiyama Y (2003). Contribution of Organic 
Anion Transporter 3 (SLC22A8) to the Elimination of p-Aminohippuric acid and 
Benzylpenicillin across the Blood Brain Barrier. The Journal of Pharmacology and 
Experimental Theraputics 306: 51-58. 
 
Kim TK, Eberwine JH (2010). Mammalian cell transfection: the present and the future. 
Analytical and Bioanalytical Chemistry 397: 3173–3178. 
 
Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN, Halestrap AP (2000). CD147 
is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell 
surface expression. EMBO Journal 19(15): 3896-3904. 
 
Klaassen CD, Aleksunes LM (2010). Xenobiotic, bile acid, and cholesterol transporters: 
Function and regulation. Pharmacological Reviews 62(1): 1-96. 
 
 
Kobayashi M, Otsuka Y, Itagaki S, Hirano T, Iseki K (2006). Inhibitory effects of 
statins on human monocarboxylate transporter 4 International Journal of 
Pharmaceutics 317: 19-25. 
 
Kobayashi Y, Ohshiro N, Sakai R, Ohbayashi M, Kohyama N, Yamamoto T (2005). 
Transport mechanism and substrate specificity of human organic anion transporter 2 
(hOat2 [SLC22A7]). Journal of Pharmacy and Pharmacology 57: 573–578. 
 
Kobow K, El-Osta A, Blümcke I (2013). The methylation hypothesis of 
pharmacoresistance in epilepsy Epilepsia 54(Supplement 2): 41-47. 
 
Koepsell H, Lips K, Volk C (2007). Polyspecific Organic Cation Transporters: 
Structure, Function, Physiological Roles, and Biopharmaceutical Implications. 
Pharmaceutical Research 24(7): 1227-1251. 
 
Komatsu T, Hiasa M, Miyaji T, Kanamoto T, Matsumoto T, Otsuka M (2011). 
Characterization of the human MATE2 proton-coupled polyspecific organic cation 
exporter. International Journal of Biochemistry and Cell Biology 43: 913-918. 
 
König J, Müller F, Fromm MF (2013). Transporters and Drug-Drug Interactios: 
Important Determinants of Drug Disposition and Effects. Pharmacological Reviews 65: 
944-966. 
 
Kooijmans SAA, Senyschyn D, Mezhiselvam MM, Morizzi J, Charman SA, Weksler B, 
et al. (2012). The Involvement of a Na+- and Cl−-Dependent Transporter in the Brain 
Uptake of Amantadine and Rimantadine. Molecular Pharmaceutics 9: 883-893. 
 
229 
 
Kopplow K, Letschert K, Konig J, Walter B, Keppler D (2005). Human hepatobiliary 
transport of organic anions analysed by quadruple-transfected cells. Molecular 
Pharmacology 68: 1031-1038.   
 
Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, et al. 
(2001). Organic anion-transporting polypeptide B (OATP-B) and its functional 
comparison with three other OATPs of human liver. Gastroenterology 120(2): 525-533. 
 
Kuo CC (1998). A common anticonvulsant binding site for phenytoin, carbamazepine, 
and lamotrigine in neuronal Na+ channels. Molecular Pharmacology 54: 712-721. 
 
Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, et al. (1999). 
Transporter from Rat Brain a New Multispecific Organic Anion Molecular Cloning and 
Characterization of a New Multispecific Organic Anion Transporter from Rat Brain. 
The Journal of Biological Chemistry 274: 13675-13680. 
 
Kusuhara H, Sugiyama Y (2005). Active efflux across the blood-brain barrier: Role of 
the solute carrier family. NeuroRx 2(1): 73-85. 
 
Kutt H, Winters W, Kokenge R, McDowell F (1964). Diphenylhydantoin metabolism, 
blood levels, and toxicity. Archives of  Neurology 11: 642-648. 
 
Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Hauser WA, Mathern G, et al. (2010). 
Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of 
the ILAE Commission on Therapeutic Strategies. Epilepsia 51(6): 1069-1077. 
 
Kwan P, Brodie MJ (2000). Early identification of refractory epilepsy. New England 
Journal of Medicine 342: 314-319. 
 
Kwan P, Brodie MJ (2004). Phenobarbital for the treatment of epilepsy in the 21st 
cetury: a critical review. Epilepsia 45(9): 1141-1149. 
 
Lal R, Sukbuntherng J, Luo W, Virna VV, Blumenthal R, Ho J, et al. (2010). Clinical 
pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported 
prodrug of gabapentin, with naproxen and cimetidine. British Journal of Clinical 
Pharmacology 69(5): 498-507. 
 
Lamb RJ, Leach MJ, Miller AA, Hardenberg PJ (1985). Anticonvulsant profile in mice 
of lamotrigine, a novel anticonvulsant. British Journal of Pharmacology 85. 
 
Lauritzen F, de Lanerolle NC, Lee TSW, Spencer DD, Kim JH, Bergersen LH, et al. 
(2011). Monocarboxylate transporter 1 is deficient on microvessels in the human 
epileptogenic hippocampus. Neurobiology of Disease 41(2): 577-584. 
 
Lauritzen F, Perez EL, Melillo ER, Roh JM, Zaveri HP, Lee TSW, et al. (2012). Altered 
expression of brain monocarboxylate transporter 1 in models of temporal lobe epilepsy. 
Neurobiology of Disease 45(1): 165-176. 
 
Leach MJ, Marden CM, Miller AA (1986). Pharmacological studies on lamotrigine, a 
novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of 
action. Epilepsia 27: 490-497. 
230 
 
 
Lee SY, Williamson B, Caballero OL, Chen YT, Scanlan MJ, Ritter G, et al. (2004). 
Identification of the gonad-specific anion transporter SLCO6A1 as a cancer/testis (CT) 
antigen expressed in human lung cancer. Cancer Immunity 4. 
 
Leen WG, Klepper J, Verbeek MM, Leferink M, Hofste T, Engelen BGv, et al. (2010). 
Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum 
of a treatable disorder. Brain 133: 655–670. 
 
Leeson PD, Davis AM (2004). Time-related differences in the physical property profiles 
of oral drugs. Journal of Medicinal Chemistry 47(25): 6338-6348. 
 
Leighton B, Atkinson A, Coghla MP (2005).  Small molecule glucokinase activators as 
novel anti-diabetic agents. Biochemical Society Transactions 33 (2): 371-374.   
 
Leroy C, Pierre K, Simpson IA, Pellerin L, Vannucci SJ, Nehlig A (2011). Temporal 
changes in mRNA expression of the brain nutrient transporters in the lithium-
pilocarpine model of epilepsy in the immature and adult rat. Neurobiology of Disease 
43: 588–597. 
 
Leslie EM, Mao Q, Oleschuk CJ, Deeley RG, Cole SP (2001). Modulation of multidrug 
resistance protein 1 (MRP1/ABCC1) transport and atpase activities by interaction with 
dietary flavonoids. Molecular Pharmacology 59: 1171-1180.  
 
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997). Experimental and 
computational approaches to estimate solubility and permeability in drug discovery and 
development settings. Advanced Drug Delivery Reviews 23: 3-25. 
 
Liu J, Thom M, Catarino C (2012). Neuropathology of the blood-brain barrier and 
pharmaco-resistance in human epilepsy. Brain 135: 3115-3133. 
 
Löscher W (2002). Basic pharmacology of valproate. A review after 35 years of clinical 
use for the treatment of epilepsy. CNS Drugs 16: 669-694. 
 
Loscher W, Frey H-H (1984). Kinetics of Penetration of Common Antiepileptic Drugs 
into Cerebrospinal Fluid. Epilepsia 25(3): 346-352. 
 
Löscher W, Potschka H (2005a). Blood-Brain Barrier Active Efflux Transporters: ATP-
Binding Cassette Gene Family. NeuroRX 2(1): 86-98. 
 
Löscher W, Potschka H (2005b). Drug resistance in brain diseases and the role of drug 
efflux transporters Nature Reviews Neuroscience 6: 591-602. 
 
Luna-Toetos C, Fedrowitz M, Löscher W (2008). Several major antiepileptic drugs are 
substrates for human p-glycoprotein Neuropharmacology 55(8): 1364-1375. 
 
Macdonald RL (1999). Cellular actions of antiepileptic drugs. In: Eadie MJ, Vajda F 
(eds). Antiepileptic Drugs: Pharmacology and Therapeutics, edn. Berlin: Springer. 
p^pp 123-150. 
 
231 
 
Maeda T, Takahashi K, Ohtsu N, Oguma T, Ohnishi T, Atsumi R, et al. (2007). 
Identification of influx transporter for the quinolone antibacterial agent levofloxacin. 
Molecular Pharmaceutics 4(1): 85-94. 
 
Maiche AG (1986). Acute renal failure due to concomitant action of methotrexate and 
indomethacin. The Lancet 327(8494). 
 
Majumdar S, Duvvuri S, Mitra AK (2004). Membrane transporter/receptor-targeted 
prodrug design: strategies for human and vetinary drug development. Advanced Drug 
Delivery Reviews 56: 1437-1452.   
 
Manning Fox JE, Meredith D, Halestrap AP (2000). Characterisation of human 
monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal 
muscle. Journal of Physiology 529(2): 285-293. 
 
Manoharan C, Wilson MC, Sessions RB, Halestrap AP (2006). The role of charged 
residues in the transmembrane helices of monocarboxylate transporter 1 and its 
ancillary protein basigin in determining plasma membrane expression and catalytic 
activity. Molecular Membrane Biology 23(6): 486-498. 
 
Margineanu DG, Klitgaard H (2009). Mechanisms of drug resistance in epilepsy: 
Relevance for antiepileptic drug discovery. Expert Opinion on Drug Discovery 4(1): 
23-32. 
 
Markovich D (2008). Expression cloning and radiotracer uptakes in Xenopus laevis 
oocytes. Nature Protocols 3(12): 1975-1980. 
 
Martin H-J, Kornmann F, Fuhrmann GF (2003). The inhibitory effects of flavonoids 
and antiestrogens on the Glut1 glucose transporter in human erythrocytes. Chemico-
Biological Interactions 146: 225–235. 
 
Maryanoff BE, Nortey S, Gardocki JF, Shank RP, Dodgson SP (1987). Anticonvulsant 
O-Alkyl Sulfamates. 2,3:4,5-Bis-O-(l-methylethy1idene)-6-D-fructopyranose Sulfamate 
and Related Compounds. Journal of Medicinal Chemistry 30(5): 880-887. 
 
Masino SA, Rho JM (2012). Mechanisms of Ketogenic Diet Action. In: Jasper's Basic 
Mechanisms of the Epilepsies, Noebels JL, Avoli M, Rogawski MA (eds), 4th edn. 
Bethesda (MD): National Center for Biotechnology Information (US)  
 
Matsuo F, Riaz A (2009). Lamotrigine. In: Shorvon S, Perucca E, Engel J (eds). The 
Treatment of Epilepsy, edn: Blackwell Publishing LTD. p^pp 535-558. 
 
Merritt HH, Putnam TJ (1938a). A new series of anticonvulsant drugs tested by 
experiments in animals. Archives of Neurology and Psychiatry 39: 1003-1015. 
 
Merritt HH, Putnam TJ (1938b). Sodium diphenyl hydantoinate in the treatment of 
convulsive disorders. The Journal of the American Medical Association 111: 1068-
1073. 
 
Meunier H, Carraz G, Meunier Y, Eymard P, Almarro M (1963). Pharmacodynamic 
properties of dipropylactic acid 1. Anticonvulsive action. Therapie 18: 435-438. 
232 
 
 
Middleton E, Kandaswami C, Theoharides TC (2000). The Effects of Plant Flavonoids 
on Mammalian Cells: Implications for Inflammation, Heart Disease, and Cancer. 
Pharmalogical Reviews 52: 673-751.   
 
Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, et al. 
(2004). Isolation and characterization of a digoxin transporter and its rat homologue 
expressed in the kidney. Proceedings of the National Academy of Sciences of the United 
States of America 101(10): 3569-3574. 
 
Moermana L, Wyffelsa L, Slaets D, Raedt R, Boonb P, Vos FD (2011). Antiepileptic 
drugs modulate P-glycoproteins in the brain: A mice study with 11C-
desmethylloperamide. Epilepsy Research 94: 18-25. 
 
Mori S, Takanaga H, Ohtsuki S, Deguchi T, Kang Y-S, Hosoya K-I, et al. (2003). Rat 
Organic Anion Transporter 3 (rOAT3) Is Responsible for Brain to Blood Efflux of 
Homovanillic Acid at the Abluminal Membrane of Brain Capillary Endothelial Cells. 
Journal of Cerebral Blood Flow and Metabolism 23: 432-440. 
 
Morris ME, Felmlee MA (2008). Overview of the Proton-coupled MCT (SLC16A) 
Family of Transporters: Characterization, Function and Role in the Transport of the 
Drug of Abuse γ-Hydroxybutyric Acid. The AAPS Journal 10(2): 311-321. 
 
Morselli PL (1995). Carbamazepine: absorption, distribution and excretion. 4th edn. 
New York: Raven Press. 
 
Mullen SA, Marini C, Suls A, Mei D, Giustina ED (2011). Glucose Transporter 1 
Deficiency as a Treatable Cause of Myoclonic Astatic Epilepsy. Archives of  Neurology 
68(9): 1152-1154. 
 
Müller F, König J, Hoier E, Kathrin Mandery K, Fromm MF (2013). Role of organic 
cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and 
MATE2-K for transport and drug interactions of the antiviral lamivudine. Biochemical 
Pharmacology 86: 808-815. 
 
Murray CM, Hutchinson R, Bantick JR, Belfield GP, Benjamin AD, Brazma D, et al. 
(2005). Monocarboxylate transporter MCT1 is a target for immunosuppression. Nature 
Chemical Biology 1(7): 371-376. 
 
Nakata K, Tanaka Y, Nakano T, Adachi T, Tanaka H, Kaminuma T, et al. (2006). 
Nuclear receptor-mediated transcriptional regulation in Phase I, II, and III xenobiotic 
metabolizing systems. Drug Metabolism and Pharmacokinetics 21: 437-457. 
 
Naora K, Shen DD (1995). Mechanism of valproic acid uptake by isolated rat brain 
microvessels. Epilepsy Research 22: 97-106. 
 
Neuhoff S, Ungell A-L, Zamora I, Artursson P (2005). pH-Dependent passive and 
active transport of acidic drugs across Caco-2 cell monolayers. European Journal of 
Pharmaceutical Sciences 25: 211-220. 
 
233 
 
Neurvonen PJ (1979). Bioavailability of phenytoin: clinical pharmacokinetic and 
therapeutic implications. Clinical Pharmacokinetics 4: 91-103. 
 
Nguyen LN, Ma D, Shui G, Wong P, Cazenave-Gassiot A, et al. (2014). MFSD2A is a 
transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature 509: 503-
506.  
 
Ohtsuki S, Asaba H, Takanaga H, Deguchi T, Hosoya K-i, Otagiri M, et al. (2002). 
Role of blood–brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl 
sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from 
the brain. Journal of Neurochemistry 83: 57-66. 
 
Ovens MJ, Davis AJ, Wilson MC, Murray CM, Halestrap AP (2010a). AR-C155858 is 
a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an 
intracellular site involving transmembrane helices 7-10. Biochemical Journal 425: 523-
530. 
 
Ovens MJ, Manoharan C, Wilson MC, Murray CM, Halestrap AP (2010b). The 
inhibition of monocarboxylate transporter 2 (MCT2) by AR-C155858 is modulated by 
the associated ancillary protein Biochemical Journal 431: 217-225. 
 
Owen A, Pirmohamed M, Tettey JN, Morgan P, Chadwick D, Park BK (2001). 
Carbamazepine is not a substrate for P-glycoprotein. British Journal of Clinical 
Pharmacology 51: 345-349. 
 
Pajouhesh H, Lenz GR (2005). Medicial Chemical Properties of Successful Central 
Nervous System Drugs. The Journal of the American Society for Experimental 
NeuroTherapeutics 2: 541-553. 
 
Palm K, Stenberg P, Luthman K, Arturson P (1997). Polar molecular surface properties 
predict the intestinal absorption of drugs in humas. Pharmaceutical Research 14: 568-
571. 
 
Pardridge WM (1986). Blood-Brain Barrier Transport of Nutrients. Nutrition reviews 
44(Supplement): 15-25. 
 
Pardridge WM (2005). The Blood-Brain Barrier: Bottleneck in Brain Drug 
Development. The Journal of the American Society for Experimental 
NeuroTherapeutics 2: 3-14. 
 
Pardridge WM, Oldendorf WH (1977). Transport of metabolic substrates through the 
blood brain barrier. Journal of Neurochemistry 28(1): 5-12. 
 
Patsalos PN (2005). Properties of Antielieptic Drugs in the Treatment of Idiopathic 
Generalised Epilepsies Epilepsia 46: 140-148. 
 
Pedley TA (2009). Major advances in epilepsy in the last century: A personal 
perspective. Epilepsia 50(3): 358-363. 
 
234 
 
Pellerin L, Halestrap AP, Pierre K (2005). Cellular and subcellular distribution of 
monocarboxylate transporters in cultured brain cells and in the adult brain. Journal of 
Neuroscience Research 79(1-2): 55-64. 
 
Pereira JNDS, Tadjerpisheh S, Abed MA, Saadatmand AR, Weksler B, Romero IA, et 
al. (2014). The Poorly Membrane Permeable Antipsychotic Drugs Amisulpride and 
Sulpiride Are Substrates of the Organic Cation Transporters from the SLC22 Family. 
The AAPS Journal. 
 
Pefferkorn JA, Guzman-Perez A, Litchfield J, Aiello R, Treadway JL (2012). Discovery 
of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic 
acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 
diabetes mellitus. Journal of Medicinal Chemistry 55 (3): 1318-1333.   
 
Pierre K, Pellerin L (2005). Monocarboxylate transporters in the central nervous 
system: Distribution, regulation and function. Journal of Neurochemistry 94(1): 1-14. 
 
Poller; B, Heike Gutmann, Krähenbühl S, Weksler B, IgnacioRomero, Couraud P-O, et 
al. (2008). The human brain endothelial cell line hCMEC/D3 as a human blood-brain 
barrier model for drug transport studies. Journal of Neurochemistry 107(5): 1358-1368. 
 
Poole RC, Halestrap AP (1997). Interaction of the erythrocyte lactate transporter 
(monocarboxylate transporter 1) with an integral 70-kDa membrane glycoprotein of the 
immunoglobulin superfamily. Journal of Biological Chemistry 272(23): 14624-14628. 
 
Potschka H, Fedrowitz M, Loscher W (2002). P-Glycoprotein-mediated efflux of 
phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from 
microdialysis experiments in rats. Neuroscience Letters 327: 173-176. 
 
Potschka H, Fedrowitz M, Löscher W (2001). P-glycoprotein and multidrug resistance-
associated protein are involved in the regulation of extracellular levels of the major 
antiepileptic drug carbamazepine in the brain. Neuropharmacology and 
Neurotoxicology 12(16): 3557-3560. 
 
Price NT, Jackson VN, Halestrap AP (1998). Cloning and sequencing of four new 
mammalian monocarboxylate transporter (MCT) homologues confirms the existence of 
a transporter family with an ancient past. Biochemical Journal 329: 321-328. 
 
Qian X, Cheng Y-H, Mruk DD, Cheng CY (2013). Breast cancer resistance protein 
(Bcrp) and the testis—an unexpected turn of events. Asian Journal of Andology 15: 
455-460. 
 
Race JE, Grassl SM, Williams WJ, Holtzman EJ (1999). Molecular Cloning and 
Characterization of Two Novel Human Renal Organic Anion Transporters (hOAT1 and 
hOAT3). Biochemical and Biophysical Research Communications 255: 508 –514. 
 
Redzic Z (2011). Molecular biology of the blood-brain and the blood-cerebrospinal 
fluid barriers: Similarities and differences. Fluids and Barriers of the CNS 8(1). 
 
235 
 
Reid G, Wolff NA, Dautzenberg FM, Burckhardt G (1998). Cloning of a Human Renal 
p-Aminohippurate Transporter, hROAT1. Kidney Blood Pressure Research 21: 233–
237. 
 
Remy S, Gabriel S, Urban BW, Dietrich D, Lehmann TN, Elger CE, et al. (2003). A 
Novel Mechanism Underlying Drug Resistance in Chronic Epilepsy. Annals of 
Neurology 53: 469-479. 
 
Riedmaier AE, Nies AT, Schaeffeler E, Schwab M (2012). Organic Anion Transporters 
and Their Implications in Pharmacotherapy. Pharmacological Reviews 64: 421-449. 
 
Rizwan AN, Burckhardt G (2007). Organic Anion Transporters of the SLC22 Family: 
Biopharmaceutical, Physiological, and Pathological Roles. Pharmaceutical Research 
24(3): 450-470. 
 
Roberts LM, Woodford K, Zhou M, Black DS, Haggerty JE, Tate EH, et al. (2008). 
Expression of the Thyroid Hormone Transporters Monocarboxylate Transporter-8 
(SLC16A2) and Organic Ion Transporter-14 (SLCO1C1) at the Blood-Brain Barrier. 
Endocrinology 149(12): 6251-6261. 
 
Rogawski MA (2013). The intrinsic severity hypothesis of pharmacoresistance to 
antiepileptic drugs. Epilepsia 54(Supplement 2): 33-40. 
 
Rogawski MA, Porter RJ (1990). Antiepileptic drugs: Pharmacological mechanisms and 
clinical efficacy with consideration of promising developmental stage compounds. 
Pharmacological Reviews 42(3): 223-286. 
 
Roth M, Obaidat A, Hagenbuch B (2012). OATPs, OATs and OCTs: the organic anion 
and cation transporters of the SLCO and SLC22A gene superfamilies. British Journal of 
Pharmacology 165: 1260-1287. 
 
Samrén EB, M vDC, Koch S, Hiilesmaa VK, Klepel H, Bardy AH, et al. (1997). 
Maternal Use of Antiepileptic Drugs and the Risk of Major Congenital Malformations: 
A Joint European Prospective Study of Human Teratogenesis Associated with Maternal 
Epilepsy. Epilepsia 38(9): 981-990. 
 
Sato M, Iwanaga T, Mamada H, Ogihara T, Yabuuchi H, Maeda T, et al. (2008). 
Involvement of Uric Acid Transporters in Alteration of Serum Uric Acid Level by 
Angiotensin II Receptor Blockers. Pharmaceutical Research 25(3): 639-646. 
 
Schindler W, Häfliger F (1954). Über Derivate des Iminodibenzyls Helvetica Chimica 
Acta 37: 472-483. 
 
Sekine T, Cha SH, Endou H (2000). The multispecific organic anion transporter (OAT) 
family. Pflugers Archiv European Journal of Physiology 440(3): 337-350. 
 
Sekine T, Watanabe N, Hosoyamada M, Kanai Y, Endou H (1997). Expression Cloning 
and Characterization of a Novel Multispecific Organic Anion Transporter. The Journal 
of Biological Chemistry 272: 18526-18529. 
 
236 
 
Shawahna R, Uchida Y, Declèves X, Ohtsuki S, Yousif S, Dauchy S et al (2011). 
Transcriptomic and Quantitative Proteomic Analysis of Transporters and Drug 
Metabolising Enzymes in Freshly Isolated Human Brain Microvessels. Molecular 
Pharmaceutics 8: 1332-1341.    
 
Shin HJ, Lee CH, Park S-J, Shin J-G, Song I-S (2010). Establishment and 
Characterization of Mardin-Darby Canine Kidney Cells Stably Expressing Human 
Organic Anion Transporters. Archives of Pharmacal Research 33(5): 709-716. 
 
Shirasaka Y, Shichiri M, Mori T, Nakanishi T, Tamai I (2012). Major Active 
Components in Grapefruit, Orange, and Apple Juices Responsible for OATP2B1-
Mediated Drug Interactions. Journal of Pharmaceutical Sciences 102(1): 280-288. 
 
Shorvon SD (2009a). Drug treatment of epilepsy in the century of the ILAE: The first 
50 years, 1909-1958. Epilepsia 50(Supplement 3): 69-92. 
 
Shorvon SD (2009b). Drug treatment of epilepsy in the century of the ILAE: The 
second 50 years, 1959-2009. Epilepsia 50(supplement 3): 93-130. 
 
Sillanpää M, Haataja L, Tomson T, Johannessen SI (2009). Carbamazepine. In: 
Shorvon S, Perucca E, Engel J (eds). The Treatment of Epilepsy, 3rd edn: Blackwell 
Publishing LTD. p^pp 459-474. 
 
Sills GJ (2006). The mechanisms of action of gabapentin and pregabalin. Current 
Opinion in Pharmacology 6: 108-113. 
 
Sills GJ, Kwan P, Butler E, C.M. dLE, Berg D-Jvd, Brodie MJ (2002). P-glycoprotein-
mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice 
Epilepsy & Behaviour 3: 427-432. 
 
Simonson GD, Vincent AC, Roberg KJ, Huang Y, Iwanij V (1994). Molecular cloning 
and characterization of a novel liver-specific transport protein. Journal of Cell Science 
107,: 1065-1072. 
 
Sisodiya SM, Heffernan J, Squier MV (1999). Over-expression of Pglycoprotein in 
malformations of cortical development. NeuroReport 10: 3437-3441. 
 
Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M (2002). Drug resistance in 
epilepsy: expression of drug resistance proteins in common causes of refractory 
epilepsy. Brain 125: 22-31. 
 
Smith DA, Allerton C, Kalgutkar AS, Waterbeemd Hvd, Walker DK (2012). 
Physicochemistry. In. Pharmacokinetics and Metabolism in Drug Design, Third edn: 
Wiley-VCH Verlag GmbH & Co. KGaA. p^pp 1-17. 
 
Somerville ER, Michell AW (2009). Gabapentin. In: The Treatment of Epilepsy, 
Shorvon S, Perucca E, Engel J (eds), 3 edn, pp 519-526: Blackwell Publishing LTD. 
 
Splinter MY (2005). Pharmacokinetic Properties of New Antiepileptic Drugs. Journal 
of Pharmacy Practice 18(6): 444-460. 
 
237 
 
Stanley LA, Horsburgh BC, Ross J, Scheer N, Wolf CR (2009). Drug transporters: 
Gatekeepers controlling access of xenobiotics to the cellular interior. Drug Metabolism 
Reviews 41(1): 27-65. 
 
Staud F, Cerveny L, Ahmadimoghaddam D, Ceckova M (2013). Multidrug and toxin 
extrusion proteins (MATE/SLC47); role in pharmacokinetics. The International Journal 
of Biochemistry & Cell Biology 45: 2007-2011. 
 
Stephen LJ, Kelly K, Parker P, Brodie MJ (2011). Levetiracetam monotherapy—
Outcomes from an epilepsy clinic. Seizure 20: 554-557. 
 
Stieger B, Gao B (2015). Drug Transporters in the Central Nervous System. Clinical 
Pharmacokinetics 54: 225-242.  
 
Sun W, Wu RR, van Poelje PD, Erion MD (2001). Isolation of a Family of Organic 
Anion Transporters from Human Liver and Kidney. Biochemical and Biophysical 
Research Communications 283: 417– 422  
 
Szakács G, Váradi A, Özvegy-Laczka C, Sarkadi B (2008). The role of ABC 
transporters in drug absorption, distribution, metabolism, excretion and toxicity 
(ADME–Tox). Drug Discovery Today 13(9-10): 379-393. 
 
Tai LM, Reddy PS, Lopez-Ramirez MA, Davies HA, Male ADK, Loughlin AJ, et al. 
(2009). Polarized P-glycoprotein expression by the immortalised human brain 
endothelial cell line, hCMEC/D3, restricts apical-to-basolateral permeability to 
rhodamine 123. Brain Research 1292: 14-24. 
 
Tamai I, Nezu JI, Uchino H, Sai Y, Oku A, Shimane M, et al. (2000). Molecular 
identification and characterization of novel members of the human organic anion 
transporter (OATP) family. Biochemical and Biophysical Research Communications 
273(1): 251-260. 
 
Temkin O (1945). The falling Sickness. edn. Baltimore: The John Hopkins University 
Press. 
 
Terbach N, Shah R, Kelemen R, Klein PS, Gordienko D, Brown NA, et al. (2011). 
Identifying an uptake mechanism for the antiepileptic and bipolar disorder treatment 
valproic acid using the simple biomedical model Dictyostelium. Cell Science 124: 2267-
2276. 
 
Theofilopoulos S, Wang Y, Kitambi SS, Sacchetti P, Sousa KM, Bodin K, et al. (2013). 
Brain endogenous liver X receptor ligands selectively promote midbrain neurogenesis. 
Nature Chemical Biology 9: 126-134. 
 
Thomas J, Wang L, Clark RE, Pirmohamed M (2004). Active transport of imatinib into 
and out of cells: implications for drug resistance. blood 104: 3739-3745. 
 
Thyss A, Kubar J, Milano G, Namer M, Schneider M (1986). Clinical and 
pharmacokinetic evidence of a life-threatening interaction between methotrexate and 
ketoprofen. The Lancet 327(8475): 256–258. 
 
238 
 
Tirona RG, Leake BF, Merino G, Kim RB (2001). Polymorphisms in OATP-C: 
Identification of multiple allelic variants associated with altered transport activity 
among European- and African-Americans. Journal of Biological Chemistry 276(38): 
35669-35675. 
 
Tishler DM, Weinburg KI, Hinton DR, Barbaro N, Annett GM, Raffel C (1995). MDR1 
gene expression in brain of patients with medically intractable epilepsy. Epilepsia 
36(1): 1-6. 
 
Tomson T, Bertilsson L, Andersson DH, Schlaifer D, Arlet P, Ollier S, et al. (1989). 
Carbamazepine update. Lancet 2(8669): 980-981. 
 
Toyoda Y, Hagiya Y, Adachi T, Hoshijima K, Kuo MT, Ishikawa T (2008). MRP class 
of human ATP binding cassette (ABC) transporters: historical background and new 
research directions. Xenobiotica 38(7-8): 833-862. 
 
Tsuji A, Terasaki T, Takabatake Y, Tenda Y, Tamaia I, Yamashima T, et al. (1992). P-
glycoprotein as the drug efflux pump in primary cultured bovine brain capillary 
endothelial cells. Life Sciences 51: 1427-1437. 
 
Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, et al. (2011). 
Quantitative targeted absolute proteomics of human blood-brain barrier transporters and 
receptors. Journal of Neurochemistry 117: 333–345. 
 
Uldry M, Thorens B (2004). The SLC2 family of facilitated hexose and polyol 
transporters. European Journal of Physiology 447: 480-489. 
 
Urquhart BL, Kim RB (2009). Blood-brain barrier transporters and response to CNS-
active drugs. European Journal of Clinical Pharmacology 65(11): 1063-1070. 
 
Utoguchi N, Audus KL (2000). Carrier-mediated transport of valproic acid in BeWo 
cells, a human trophoblast cell line. International Journal of Pharmaceutics 195(1-2): 
115-124. 
 
van Bree JB, Audus KL, Borchardt RT (1988). Carrier-mediated transport of baclofen 
across monolayers of bovine brain endothelial cells in primary culture. Pharmaceutical 
Research 5(6): 1369-1371. 
 
van Bree JB, Heijligers-Feijen CD, Boer AGd, Danhof M, Breimer DD (1991). 
Stereoselective transport of baclofen across the blood-brain barrier in rats as determined 
by the unit impulse response methodology. Pharmaceutical Research 8(2): 259-262. 
 
van der Bliek AM, Kooiman PM, Schneider C, P PB (1988). Sequence of mdr3 cDNA 
encoding a human P-glycoprotein. Gene 71: 401-411. 
 
van Vliet EA, van Schaik R, Edelbroek PM, Voskuyl RA, Redeker S, Aronica E, et al. 
(2007). Region-Specific Overexpression of P-glycoprotein at the Blood-Brain Barrier 
Affects Brain Uptake of Phenytoin in Epileptic Rats. Pharmacology and Experimental 
Theraputics 22: 141-147. 
 
239 
 
VanWert AL, Gionfriddo MR, Sweet DH (2010). Organic anion transporters: 
Discovery, pharmacology, regulation and roles in pathophysiology. Biopharmaceutics 
and Drug Disposition 31(1): 1-71. 
 
Verrey F, Closs E, Wagner CA, Palacin M, Endou H, Kanai Y (2003). CATs and 
HATs: the SLC7 family of amino acid transporters. Pflgers Archiv European Journal of 
Physiology 447(5): 532-542. 
 
Vittorio CC, Muglia JJ (1995). Anticonvulsant hypersensitivity syndrome. Archives of 
internal medicine 155(21): 2285-2290. 
 
Volk C (2014). OCTs, OATs, and OCTNs: structure and function of the polyspecific 
organic ion transporters of the SLC22 family. WIREs Membrane Transport and 
Signalling 3: 1-13. 
 
Volk HA, Löscher W (2005). Multidrug resistance in epilepsy: rats with drug-resistant 
seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with 
drug-responsive seizures. Brain 128: 1358-1368. 
 
Wagner CA, Friedrich B, Setiawan I, Lang F, Broer S (2000). The Use of Xenopus 
laevis Oocytes for the Functional Characterization of Heterologously Expressed 
Membrane Proteins. Cellular Physiology and Biochemistry 10: 1-12. 
 
Waldbaum S, Liang L-P, Patel M (2010). Persistent impairment of mitochondrial and 
tissue redox status during lithium-pilocarpine-induced epileptogenesis. Journal of 
Neurochemistry 115: 1172–1182. 
 
Wang L (2002). Liver X receptors in the central nervous system: from lipid homeostasis 
to neuronal degeneration. Proceedings of the National Academy of Sciences of the 
United States of America 99: 13878–13883.  
 
Wang Q, Darling IM, Morris ME (2006). Transport of gamma-hydroxybutyrate in rat 
kidney membrane vesicles: Role of monocarboxylic acid transporters. Journal of 
Experimental Pharmacology and Theraputics 318(2): 751-761. 
 
Watanabe K, Sawano T, Endo T, Sakata M, Sato J (2002). Studies on Intestinal 
Absorption of Sulpiride (2): Transepithelial Transport of Sulpiride Across the Human 
Intestinal Cell Line Caco-2. Biological and Pharmaceutical Bulletin 25(10): 1345-1350. 
 
Waterbeemd HVD, Camenisch G, Folkers G, Chretien JR, Raevsky OA (1998). 
Estimation of Blood-Brain Barrier Crossing of Drugs Using Molecular Size and Shape, 
and H-bonding Descriptors. Journal of Drug Targetting 6(2): 151-165. 
 
Wee NKY, Weinstein DC, Fraser ST, Assinder SJ (2013). The mammalian copper 
transporters CTR1 and CTR2 and their roles in development and disease. The 
International Journal of Biochemistry & Cell Biology 45(5): 960-963. 
 
Weksler B, Romero IA, Couraud P-O (2013). The hCMEC/D3 cell line as a model of 
the human blood brain barrier. Fluids and Barriers of the CNS 10(16). 
 
240 
 
Welty DF, Schielke GP, Vartanian MG, Taylor CP (1993). Gabapentin anticonvulsant 
action in rats: disequilibrium with peak drug concentrations in plasma and brain 
microdialysate. Epilepsy Research 16: 175-181. 
 
Wen T, Liu Y-C, Yang H-W, Liu H-Y, Liu X-D, Wang G-J, et al. (2008). Effect of 21-
day exposure of phenobarbital, carbamazepine and phenytoin on P-glycoprotein 
expression and activity in the rat brain. Journal of the Neurological Sciences 28: 99-
106. 
 
Westholm DE, Stenehjem DD, Rumbley JN, Drewes LR, Anderson GW (2009). 
Competitive inhibition of organic anion transporting polypeptide 1c1-mediated 
thyroxine transport by the fenamate class of nonsteroidal antiinflammatory drugs. 
Endocrinology 150(2): 1025-1032. 
 
WHO (2012). Epilepsy fact sheet: World Health Organisation. 
 
Widemann BC, Adamson PC (2006). Understanding and Managing Methotrexate 
Nephrotoxicity. The Oncologist 11: 694-703. 
 
Wilson MC, Jackson VN, Heddle C, Price NT, Pilegaard H, Juel C, et al. (1998). Lactic 
acid efflux from white skeletal muscle is catalyzed by the monocarboxylate transporter 
isoform MCT3. Journal of Biological Chemistry 273: 15920-15926. 
 
Wilson MC, Meredith D, Fox JEM, Manoharan C, Davies AJ, Halestrap AP (2005). 
Basigin (CD147) Is the Target for Organomercurial Inhibition of Monocarboxylate 
Transporter Isoforms 1 and 4. 280 29: 27213–27221. 
 
Wilson MC, Meredith D, Halestrap AP (2002). Fluorescence resonance energy transfer 
studies on the interaction between the lactate transporter MCT1 and CD147 provide 
information on the topology and stoichiometry of the complex in Situ. Journal of 
Biological Chemistry 277(5): 3666-3672. 
 
Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, et al. (1998). Identity of the 
organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) 
and evidence for the expression of the transporter in the brain. Journal of Biological 
Chemistry 273(49): 32776-32786. 
 
Xia CQ, Milton MN, Gan LS (2007). Evaluation of drug-transporter interactions using 
in vitro and in vivo models. Current Drug Metabolism 8(4): 341-363. 
 
Xue X, Gong L-K, Maeda K, Luan Y, Qi X-M, Sugiyama Y, et al. (2011). Critical Role 
of Organic Anion Transporters 1 and 3 in Kidney Accumulation and Toxicity of 
Aristolochic Acid I. Molecular Pharmaceutics 8: 2183–2192. 
 
Yamada A, Maeda K, Kamiyama E, Sugiyama D, Kondo T, Shiroyanagi Y, et al. 
(2007). Multiple Human Isoforms of Drug Transporters Contribute to the Hepatic and 
Renal Transport of Olmesartan, a Selective Antagonist of the Angiotensin II AT1-
Receptor. Drug Metabolism and Disposition 35(12): 2166-2176. 
 
241 
 
Yuan H, Feng B, Yu Y, Chupka J, Zheng JY, Heath TG, et al. (2009). Renal Organic 
Anion Transporter-Mediated Drug-Drug Interaction between Gemcabene and Quinapril. 
The Journal of Pharmacology and Experimental Theraputics 330(1): 191-197. 
 
Yuen AWC, Sander JW (2011). Impaired mitochodrial energy production: The basis of 
pharmacoresistance in epilepsy. Medical Hypotheses 77: 536-540. 
 
Zhang X, He X, Baker J, Tama F, Chang G, Wright SH, et al (2012). Twelve 
transmembrane helices form the functional core of mammalian MATE1 (multidrug and 
toxin extruder 1) protein. Journal of Biological Chemistry 287: 27971-27982. 
 
Zhang EY, Knipp GT, Ekins S, Swaan PW (2002). Structural biology and function of 
solute transporters: Implications for identifying and designing substrates. Drug 
Metabolism Reviews 34(4): 709-750. 
 
Zhang S, Morris ME (2003). Effects of flavonoids biochanin A, morin, phloretin and 
silymarin on P-glycoprotein-mediated transport. The Journal of Pharmacology and 
Experimental Theraputics 304: 1258-1267.   
 
Zhang L, Ong WY, Lee T (1999). Induction of P-glycoprotein expression in astrocytes 
following intracerebroventricular kainate injections. Experimental Brain Research 126: 
509-516. 
 
Zhang S, Yang X, Morris ME (2004). Flavonoids are inhibitors of Breast Cancer 
Resistance Protein (ABCG2)-mediated transport. Molecular Pharmacology 65: 1208-
1216.  
 
Zhou J, Xu J, Huang Z, Wang M (2015). Transporter-mediated tissue targeting of 
therapeutic molecules in drug discovery. Bioorganic & Medicinal Chemistry Letters 25: 
993-997.   
 
 
 
 
 
 
 
 
